
<html lang="en"     class="pb-page"  data-request-id="ca351b0a-fcc2-472c-a190-c8ca0d8bfd16"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-22;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.8b01096;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics" /></meta><meta name="dc.Creator" content="Xudong  Cao" /></meta><meta name="dc.Creator" content="Yifang  Zhang" /></meta><meta name="dc.Creator" content="Yin  Chen" /></meta><meta name="dc.Creator" content="Yinli  Qiu" /></meta><meta name="dc.Creator" content="Minquan  Yu" /></meta><meta name="dc.Creator" content="Xiangqing  Xu" /></meta><meta name="dc.Creator" content="Xin  Liu" /></meta><meta name="dc.Creator" content="Bi-Feng  Liu" /></meta><meta name="dc.Creator" content="Liangren  Zhang" /></meta><meta name="dc.Creator" content="Guisen  Zhang" /></meta><meta name="dc.Description" content="Herein, a novel series of multireceptor ligands was developed as polypharmacological antipsychotic agents using the designed multiple ligand approach between dopamine receptors and serotonin recept..." /></meta><meta name="Description" content="Herein, a novel series of multireceptor ligands was developed as polypharmacological antipsychotic agents using the designed multiple ligand approach between dopamine receptors and serotonin recept..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 1, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01096" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01096" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01096" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01096" /></link>
        
    
    

<title>Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01096" /></meta><meta property="og:title" content="Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0022.jpeg" /></meta><meta property="og:description" content="Herein, a novel series of multireceptor ligands was developed as polypharmacological antipsychotic agents using the designed multiple ligand approach between dopamine receptors and serotonin receptors. Among them, compound 47 possessed unique pharmacological features, exhibiting high affinities for D2, D3, 5-HT1A, 5-HT2A, and 5-HT6 receptors and low efficacy at the off-target receptors (5-HT2C, histamine H1, and adrenergic α1 receptor). Compound 47 showed dose-dependent inhibition of apomorphine- and MK-801-induced motor behavior, and the conditioned avoidance response with low cataleptic effect. Moreover, compound 47 resulted nonsignificantly serum prolactin levels and weight gain change compared with risperidone. Additionally, compound 47 possessed a favorable pharmacokinetic profile with oral bioavailability of 58.8% in rats. Furthermore, compound 47 displayed procognition properties in a novel object recognition task in rats. Taken together, compound 47 may constitute a novel class of atypical antipsychotic drugs for schizophrenia." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01096"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01096">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01096&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01096&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01096&amp;href=/doi/10.1021/acs.jmedchem.8b01096" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 10017-10039</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01087" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01120" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xudong Cao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xudong Cao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xudong++Cao">Xudong Cao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yifang Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yifang Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yifang++Zhang">Yifang Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yin Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yin Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Nhwa Pharmaceutical Co., Ltd. 69 Democratic South Road, Xuzhou, Jiangsu 221116, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yin++Chen">Yin Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yinli Qiu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yinli Qiu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Nhwa Pharmaceutical Co., Ltd. 69 Democratic South Road, Xuzhou, Jiangsu 221116, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yinli++Qiu">Yinli Qiu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Minquan Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Minquan Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Nhwa Pharmaceutical Co., Ltd. 69 Democratic South Road, Xuzhou, Jiangsu 221116, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Minquan++Yu">Minquan Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiangqing Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiangqing Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Nhwa Pharmaceutical Co., Ltd. 69 Democratic South Road, Xuzhou, Jiangsu 221116, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiangqing++Xu">Xiangqing Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xin Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xin Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Liu">Xin Liu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2464-6458" title="Orcid link">http://orcid.org/0000-0003-2464-6458</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bi-Feng Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bi-Feng Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bi-Feng++Liu">Bi-Feng Liu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2135-0873" title="Orcid link">http://orcid.org/0000-0002-2135-0873</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liangren Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liangren Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liangren++Zhang">Liangren Zhang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Guisen Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guisen Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China</div><div class="loa-info-affiliations-info">Jiangsu Nhwa Pharmaceutical Co., Ltd. 69 Democratic South Road, Xuzhou, Jiangsu 221116, China</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +86-27-87792235. Fax: +86-27-87792170. E-Mail: <a href="/cdn-cgi/l/email-protection#4e293d34262f20290e232f272260263b3d3a602b2a3b602d20"><span class="__cf_email__" data-cfemail="6e091d14060f00092e030f070240061b1d1a400b0a1b400d00">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guisen++Zhang">Guisen Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8746-4195" title="Orcid link">http://orcid.org/0000-0002-8746-4195</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01096&amp;href=/doi/10.1021%2Facs.jmedchem.8b01096" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 10017–10039</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 1, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 July 2018</li><li><span class="item_label"><b>Published</b> online</span>1 November 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 21 November 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01096" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01096</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10017%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXudong%2BCao%252C%2BYifang%2BZhang%252C%2BYin%2BChen%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D22%26contentID%3Dacs.jmedchem.8b01096%26title%3DSynthesis%2Band%2BBiological%2BEvaluation%2Bof%2BFused%2BTricyclic%2BHeterocycle%2BPiperazine%2B%2528Piperidine%2529%2BDerivatives%2BAs%2BPotential%2BMultireceptor%2BAtypical%2BAntipsychotics%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10039%26publicationDate%3DNovember%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01096"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1487</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01096" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xudong&quot;,&quot;last_name&quot;:&quot;Cao&quot;},{&quot;first_name&quot;:&quot;Yifang&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Yin&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Yinli&quot;,&quot;last_name&quot;:&quot;Qiu&quot;},{&quot;first_name&quot;:&quot;Minquan&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Xiangqing&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Bi-Feng&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Liangren&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Guisen&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;10017-10039&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01096&quot;},&quot;abstract&quot;:&quot;Herein, a novel series of multireceptor ligands was developed as polypharmacological antipsychotic agents using the designed multiple ligand approach between dopamine receptors and serotonin receptors. Among them, compound 47 possessed unique pharmacological features, exhibiting high affinities for D2, D3, 5-HT1A, 5-HT2A, and 5-HT6 receptors and low efficacy at the off-target receptors (5-HT2C, histamine H1, and adrenergic α1 receptor). Compound 47 showed dose-dependent inhibition of apomorphine- and MK-801-induced motor behavior, and the conditioned avoidance response with low cataleptic effect. Moreover, compound 47 resulted nonsignificantly serum prolactin levels and weight gain change compared with risperidone. Additionally, compound 47 possessed a favorable pharmacokinetic profile with oral bioavailability of 58.8% in rats. Furthermore, compound 47 displayed procognition properties in a novel object recognition task in rats. Taken together, compound 47 may constitute a novel class of atypical antipsychot&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01096&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01096" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01096&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01096" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01096&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01096" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01096&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01096&amp;href=/doi/10.1021/acs.jmedchem.8b01096" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01096" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01096" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01096%26sid%3Dliteratum%253Aachs%26pmid%3D30383372%26genre%3Darticle%26aulast%3DCao%26date%3D2018%26atitle%3DSynthesis%2Band%2BBiological%2BEvaluation%2Bof%2BFused%2BTricyclic%2BHeterocycle%2BPiperazine%2B%2528Piperidine%2529%2BDerivatives%2BAs%2BPotential%2BMultireceptor%2BAtypical%2BAntipsychotics%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D22%26spage%3D10017%26epage%3D10039%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291363" title="Schizophrenia">Schizophrenia</a>,</li><li><a href="/action/doSearch?ConceptID=290921" title="Heterocyclic compounds">Heterocyclic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/jmcmar.2018.61.issue-22/20181121/jmcmar.2018.61.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein, a novel series of multireceptor ligands was developed as polypharmacological antipsychotic agents using the designed multiple ligand approach between dopamine receptors and serotonin receptors. Among them, compound <b>47</b> possessed unique pharmacological features, exhibiting high affinities for D<sub>2</sub>, D<sub>3</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>6</sub> receptors and low efficacy at the off-target receptors (5-HT<sub>2C</sub>, histamine H<sub>1</sub>, and adrenergic α<sub>1</sub> receptor). Compound <b>47</b> showed dose-dependent inhibition of apomorphine- and MK-801-induced motor behavior, and the conditioned avoidance response with low cataleptic effect. Moreover, compound <b>47</b> resulted nonsignificantly serum prolactin levels and weight gain change compared with risperidone. Additionally, compound <b>47</b> possessed a favorable pharmacokinetic profile with oral bioavailability of 58.8% in rats. Furthermore, compound <b>47</b> displayed procognition properties in a novel object recognition task in rats. Taken together, compound <b>47</b> may constitute a novel class of atypical antipsychotic drugs for schizophrenia.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78661" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78661" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Schizophrenia is a chronic neuropsychiatric disorder affecting approximately 1% of the global population<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and is characterized by a combination of positive symptoms (such as hallucinations and delusions), negative symptoms (such as avolition and psychomotor poverty), disordered thoughts, and cognitive deficits.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> After nearly a century of research, the etiology and pathophysiology of schizophrenia remain largely unresolved.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Adequate treatment for schizophrenia remains a challenge due to the complex pathophysiology.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Yet, hyper- and hypo-function of the dopaminergic signal transduction system clearly contribute to some of the symptoms of this disorder. The structures of the dopamine D<sub>2</sub> receptors bound to risperidone have revealed distinct extended binding sites that could shed light on how to design or discover new drugs with fewer side effects than existing therapeutics.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Furthermore, all current antipsychotic medications act by blocking dopamine D<sub>2</sub> receptors, which drives their efficacy in treating the positive symptoms of the condition.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Despite tremendous progress in the management of schizophrenia since the introduction of current therapies, the so-called “typical” and “atypical” antipsychotics still suffer from several liabilities that limit their overall effectiveness in patients.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Chlorpromazine and haloperidol are typical antipsychotics with potential antagonistic activity to D<sub>2</sub> receptor (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Although these agents are effective for controlling some of the positive symptoms postulated to arise from hyperdopaminergia in the mesolimbic pathway of the brain, they are relatively ineffective and may exacerbate negative symptoms as well as cognitive dysfunction.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Use of these agents also causes extrapyramidal symptoms (EPSs), including tardive dyskinesia and hyperprolactinemia.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> This profile, along with unwanted side effects, has led to finding the new therapeutic strategies, such as favorable polypharmacology, including the development of multireceptor agents which targeting specific dopamine receptor subtypes or a range of receptors, and the discovery of new ligands with a selectivity between 5-hydroxytryptamine (5-HT; serotonin) receptors and D<sub>2</sub> receptors, with the aim to improve therapeutic profile.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Indeed, second-generation antipsychotics (SGAs) (also known as “atypical drugs”), such as clozapine and olanzapine, show favorable polypharmacology effects (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representaive antipyschotics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">All SGAs antagonize the dopamine D<sub>2</sub> receptor and are effective in alleviating the positive symptoms of schizophrenia.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Because of their high affinity for serotonin receptors, particularly the 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors, these agents have also been shown to treat the positive symptoms, such as hallucinations and delusions, with fewer EPSs.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> First, 5-HT<sub>1A</sub> receptor agonism alleviates the EPS side effects of antipsychotics by activating 5-HT<sub>1A</sub> receptors located in the primary motor cortex and dorsolateral striatum region.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Second, in the frontal cortex, dopamine release is increased by the activation of the postsynaptic 5-HT<sub>1A</sub> receptor, thus potentiating functions of the mesocortical dopamine pathway, which may inprove negative symptoms and cognitive deficits in schizophrenia patients.<a onclick="showRef(event, 'cit14c cit14d'); return false;" href="javascript:void(0);" class="ref cit14c cit14d">(14c,d)</a> Furthermore, multiple preclinical studies supported the hypothesis that 5-HT<sub>1A</sub> receptor antagonists may reverse cognitive deficits although its ability to both enhance stimulated glutamate efflux and stimulated acetylcholine levels.<a onclick="showRef(event, 'cit14a cit14b cit14c'); return false;" href="javascript:void(0);" class="ref cit14a cit14b cit14c">(14a,b,c)</a> The 5-HT<sub>2A</sub> receptor is widely expressed in the brain, interacts with neurotransmitter systems, and especially acts on dopaminergic neurotransmission. Blocking the serotonin 5-HT<sub>2A</sub> receptor counteracted the effect of D<sub>2</sub> receptor blockade in striatum, thus alleviates the EPS side effects.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Moreover, 5-HT<sub>2A</sub> receptor antagonism has been implicated in the enhanced efficacy against negative schizophrenic symptoms.<a onclick="showRef(event, 'cit12a cit12b'); return false;" href="javascript:void(0);" class="ref cit12a cit12b">(12a,b)</a> It is now apparent that these SGAs, including clozapine and olanzapine, are antagonists at both 5-HT<sub>2A</sub> and dopamine D<sub>2</sub> receptors and that activity at both of these receptors is necessary for the antipsychotic efficacy of this class of drugs.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> However, the favorable polypharmacology observed with many atypical antipsychotics was achieved through a serendipitous discovery rather than a rational drug design process.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Treatment with these atypical antipsychotics is accompanied by various other risks, such as excessive weight gain, hyperglycemia, and abnormal blood lipid,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> which are primarily caused by high affinity binding to other off-target receptors, such as the histamine H<sub>1</sub> receptor, the 5-HT<sub>2C</sub> receptor, and the α<sub>1</sub>-adrenoceptor.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a> Moreover, no current antipsychotic drug addresses the cognitive deficits associated with schizophrenia, which is an equally important component in the etiology of schizophrenia.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">Current hypotheses suggest that cognition-enhancing actions may be due to interactions with the 5-HT<sub>6</sub> or D<sub>3</sub> receptor.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The 5-HT<sub>6</sub> receptor modulates multiple neurotransmitter systems possibly linked with the cognitive dysfunction of schizophrenia.<a onclick="showRef(event, 'cit12a ref20'); return false;" href="javascript:void(0);" class="ref cit12a ref20">(12a,20)</a> Blocking the 5-HT<sub>6</sub> receptor not only enhances prefrontal cortical dopamine release but may also modulate glutamatergic systems by disinhibiting GABAergic neurons in the frontal cortex.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Given this ability of the 5-HT<sub>6</sub> receptor, a large amount of scientific data have indicated that 5-HT<sub>6</sub> receptor ligands are effective procognitive agents in preclinical studies.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Although the role of this receptor in the regulation of psychotic symptoms is currently unclear, it may result in cognitive improvements along the way: blockade of D<sub>3</sub> receptor in the frontal cortex may enhance acetylcholine release.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Preclinical studies suggest that the D<sub>3</sub> receptor may be proposed as a high pharmacotherapeutic target and D<sub>3</sub> receptor ligands may constitute a promising approach to treat the negative and cognitive symptoms in schizophrenia and drug abuse disorders.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">These observations encouraged us to design multitarget ligands that can precisely modulate the activity of several monoaminergic receptors (D<sub>2</sub>, D<sub>3</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>6</sub> receptors), expecting that this multifunctional profile will contribute to the therapeutic potential for patients with schizophrenia.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> This three receptors (D<sub>2</sub>, 5-HT<sub>1A</sub>, and 5-HT<sub>2A</sub>) have been identified as crucial molecular targets in the development of new potential antipsychotic agents because drugs acting via these targets effectively treat the positive and negative symptoms. The pharmacological profile of the newly designed molecules with high affinities for the D<sub>3</sub> and 5-HT<sub>6</sub> receptors is presumed to be improved and enhanced with procognitive activities. Herein, we present the design, synthesis, and bioevaluation of a series of heterocyclic piperazine (piperidine) analogues as multimodal agents. The most promising molecule in the whole series was further characterized in extended pharmacological studies.</div><div class="NLM_p">Tricyclic scaffolds containing an indole and indoline moiety have been barely explored in medicinal chemistry. Compounds based on the pyrano[2,3,4-<i>cd</i>]indole scaffold show high affinity for the 5-HT<sub>6</sub> receptor.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> A series of potent and selective CYP11B1 inhibitors based on the heteroaryl substituted 1,2,5,6-tetrahydro pyrrolo[3,2,1-<i>ij</i>]quinolin-4-ones have been reported to treat Cushing’s syndrome.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Ligands based on the fused tricyclics with substituted 3-(piperidin-4-yl)-1<i>H</i>-indole that show high binding to D<sub>2</sub>, 5-HT<sub>2A</sub>, and the human serotonin transporter (hSERT) have been reported by Pfizer.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The structure of compound <b>1</b> displays key pharmacophoric features of many D<sub>2</sub> receptor ligands shown in an earlier publication (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of <b>1</b> highlighting common dopaminergic D<sub>2</sub> structural characteristics: a motif containing features of common privileged structures, an aliphatic spacer/linker, and a heterocyclic group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Therefore, using the tricyclic heterocycle structure of compound <b>1</b> as the primary scaffold, the privileged structures from known antipsychotic drugs were introduced into new compounds that simultaneously modulate several receptors using the designed multiple ligand approach described by Morphy. This approach takes two separate pharmacophores with distinct pharmacology and integrates them into one molecule with the attributes of both parent molecules.<a onclick="showRef(event, 'cit10a ref29'); return false;" href="javascript:void(0);" class="ref cit10a ref29">(10a,29)</a> The privileged structures from known antipsychotic drugs were covered (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>): (1) phenylpiperazines, which are known to be important motifs for the functional activity of antipsychotics, the preclinical and clinical tests demonstrated that compounds incorporating the 2,3-dichlorophenylpiperazine and 2-methoxyphenylpiperazine scaffolds are useful in the design of atypical antipsychotics,<a onclick="showRef(event, 'cit28a'); return false;" href="javascript:void(0);" class="ref cit28a">(28a)</a> and (2) benzisoxazoles and benzoisothiazoles, which are important fragments, and some medications containing these moieties have been approved for human clinical use, including atypical antipsychotics (risperidone, paliperidone, ziprasidone, and lurasidone). The activities of the piperazine or piperidine moiety at D<sub>2</sub> and 5-HT<sub>2A</sub> receptors followed by similar structural heterocycles have proven useful for antipsychotic efficacy.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Moreover, the appropriate linker between the tricyclic heterocycles and the privileged structures is important for new compounds binding to the desired multireceptors (D<sub>2</sub>, D<sub>3</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>6</sub> receptors).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design of multifunctional ligands. On the basis of the compound <b>1</b>, the privileged structures (phenylpiperazines and heterocyclicpiperazines(piperidines)) were introduced by replacement of 3-(piperidin-4-yl)-1<i>H</i>-indole. The appropriate linker between the privileged structures and the fused tricyclic heterocycles and the substituent of fused tricyclic heterocycles for the new compounds were investigated for the binding to the multireceptors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A series of new compounds in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a> was prepared by this strategy, which were used to identify their pharmacological affinities and determine binding specificity for the multiple receptors in structure–activity relationship studies. Among the derivatives prepared, compound <b>47</b> not only exhibited high affinity for the desired multitarget but was also endowed with low to moderate activities on off-target receptors (5-HT<sub>2C</sub>, H<sub>1</sub>, and α<sub>1</sub> receptors) and low hERG channel inhibition. Furthermore, compound <b>47</b> reversed significantly apomorphine-induced and MK-801-induced motor behavior with a low propensity to induce catalepsy. In addition, compound <b>47</b> led to negligible weight gain and resulted in nonsignificant serum prolactin levels change compared with risperidone. Moreover, compound <b>47</b> displayed procognitive properties in a novel object recognition task in rats and showed favorable pharmacokinetic properties. Thus, compound <b>47</b> was developed as atypical antipsychotics to validate the novel approach to treat schizophrenia based on its unique polypharmacological antipsychotic profile.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24382" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24382" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The syntheses of <b>3</b>–<b>54</b> are shown in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. The new compounds <b>8</b>–<b>22</b>, <b>24</b>, <b>29</b>–<b>33</b>, and <b>37</b>–<b>54</b> were prepared by synthetic route shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Tricyclic heterocycle core <b>3</b> was synthesized as the initial building block from commercially available 1,2,3,4-tetrahydroquinoline or 2,3-dihydro-1<i>H</i>-indole via <i>N</i>-acylation with 3-chloropropionyl chloride and subsequent Friedel–Crafts cyclization with AlCl<sub>3</sub> under molten conditions. The central building blocks <b>4</b> and <b>6</b> were produced with the Friedel–Crafts acylation reaction and an appropriate amount of chloroalkyl chloride. As shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, compounds <b>8</b>–<b>22</b>, <b>24</b>, and <b>37</b>–<b>48</b> were prepared by coupling <b>4</b> or <b>6</b> with corresponding arylpiperazines or arylpiperidines in CH<sub>3</sub>CN. Compounds <b>29</b>–<b>33</b> and <b>49</b>–<b>51</b> were prepared though two method routes. The final compounds were obtained by catalytic reduction of their corresponding ketone precursors in the presence of triethylsilicon hydride (Et<sub>3</sub>SiH) and trifluoroacetic acid (TFA) from method A. According to method B, the intermediates <b>5</b> and <b>7</b> were obtained from the reduction reaction of the corresponding intermediates <b>4</b> and <b>6</b>, followed by a reaction with the corresponding arylpiperazines or arylpiperidines to afford the target compounds. Compounds <b>35</b>, <b>36</b>, and <b>52</b>–<b>54</b> were yielded after further reduction of their ketone precursors in the presence of NaBH<sub>4</sub>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 3-chloropropanoyl chloride, acetone, reflux; (ii) AlCl<sub>3</sub>, 110 °C; (iii) appropriate chloroalkyl chloride, AlCl<sub>3</sub>, DCE; (iv) appropriate phenylpiperazines or heterocyclicpiperazines (piperidines), K<sub>2</sub>CO<sub>3</sub>, KI, acetonitrile, reflux; (v) Et<sub>3</sub>SiH, TFA, room tempreture; (vi) NaBH<sub>4</sub>, MeOH, room tempreture.</p></p></figure><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) ethyl acetoacetate, toluene, reflux overnight; (ii) H<sub>2</sub>SO<sub>4</sub> (conc), 100 °C, 6 h; (iii) Pd/C, H<sub>2</sub>; (iv) 4-chlorobutanoyl chloride, AlCl<sub>3</sub>, DCE; (v) 6-fluoro-3-(piperidin-4-yl)benzo[<i>d</i>]isoxazole hydrochloride, K<sub>2</sub>CO<sub>3</sub>, KI, acetonitrile, reflux; (vi) Et<sub>3</sub>SiH, TFA, room temperature.</p></p></figure><div class="NLM_p last">The methyl group-substituted tricyclic heterocycle compounds <b>23</b> and <b>34</b> was prepared though the route depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Intermediate <b>25</b> was prepared starting from 1,2,3,4-tetrahydroquinoline and treatment with ethyl acetoacetate and subsequent sulfuric acid-mediated cyclization to afford the methyl group substituted tricyclic heterocycle <b>26</b>. The key building block <b>27</b> was obtained by reduction with Pd/C, which was subsequently coupled with 4-chlorobutanoyl to give the corresponding ketone <b>28</b>. Final compound <b>23</b> was prepared by coupling <b>28</b> with 6-fluoro-3-(piperidin-4-yl)benzo[<i>d</i>]isoxazole in CH<sub>3</sub>CN, and compound <b>34</b> was yielded after further reduction of compound <b>23</b>.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01227" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01227" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Structure–Activity Relationships</h3><div class="NLM_p">As previously noted, most of the presently approved atypical antipsychotic drugs exhibit polypharmacology, with appreciable affinities for a variety of biogenic amine receptors (such as D<sub>2</sub>, 5-HT<sub>1A</sub>, and 5-HT<sub>2A</sub> receptors). Because of their multireceptors affinities, ligands containing different chemical groups are of high pharmacotherapeutic interest in schizophrenia, which has been extensively developed as a potential strategy to find a novel antipsychotics. In this study, a class of new compounds by introducing different privileged structures were characterized the binding to the D<sub>2</sub>, 5-HT<sub>1A</sub>, and 5-HT<sub>2A</sub> receptors.</div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6"> Effect of the Tricyclic Heterocycle (Containing 1,2,3,4-Tetrahydroquinoline) on Different Privileged Structures</h4><div class="NLM_p">In this study, our starting point focused on the impact of various privileged structures (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, compounds <b>9</b>–<b>18</b>). Compound <b>9</b> bearing a phenylpiperazine exhibited weak binding to D<sub>2</sub> and 5-HT<sub>1A</sub> receptors at micromolar concentrations (D<sub>2</sub>, <i>K</i><sub>i</sub> = 1764.8 ± 212.4 nM; 5-HT<sub>1A</sub>, <i>K</i><sub>i</sub> = 1856.2 ± 208.1 nM), with low activity to 5-HT<sub>2A</sub> receptor (<i>K</i><sub>i</sub> = 752.3 ± 121.2 nM). Replacing the phenyl ring with its bioisostere, pyridine (<b>10</b>) and pyrimidine (<b>11</b>), resulted in similar affinities as shown for compound <b>9</b>, while a low 5-HT<sub>2A</sub> affinity for the two compounds was observed (<b>10</b>, <i>K</i><sub>i</sub> = 675.2 ± 102.4 nM; <b>11</b>, <i>K</i><sub>i</sub> = 557.4 ± 84.6 nM). Compound <b>12</b> showed decreased D<sub>2</sub> receptor binding affinity when the methoxy groups was introduced in the ortho position of phenylpiperazine, while 5-HT<sub>1A</sub> receptor binding affinity increased slightly (<i>K</i><sub>i</sub> = 964.8 ± 125.3 nM), and a good 5-HT<sub>2A</sub> receptor affinity with <i>K</i><sub>i</sub> values of 178.2 ± 28.5 nM was obtained compared to compound <b>9</b>. Compound <b>13</b> exhibited good 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors affinities with <i>K</i><sub>i</sub>s of 196.1 ± 21.3 and 207.3 ± 23.4 nM after replacing 2,3-dimethylphenylpiperazine, compared with risperidone, but weak binding to the D<sub>2</sub> receptor. Introducing a chlorine atom to the 4-position (<b>14</b>) of the phenyl ring did not change the receptor profile compared with that of compound <b>9</b>. Derivative <b>15</b> of the 2,3-di-Cl-substituted counterpart maintained potent activities on the 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors with <i>K</i><sub>i</sub>s of 268.6 ± 30.1 and 207.4 ± 28.3 nM, respectively. When the privileged structure phenylpiperazine was replaced with heterocyclic piperazine, compound <b>16</b> with 3-(piperazin-1-yl)benzo[<i>d</i>]isothiazole, a remarkable increase in activity for the D<sub>2</sub> receptor (<i>K</i><sub>i</sub> = 182.1 ± 14.2 nM), and good binding activities to the 5-HT<sub>1A</sub> (<i>K</i><sub>i</sub> = 128.7 ± 13.0 nM) and 5-HT<sub>2A</sub> (<i>K</i><sub>i</sub> = 72.0 ± 8.2 nM) were observed compared with compound <b>9</b>. Compounds <b>17</b> and <b>18</b> showed different affinities for the main targets when piperazine was replaced by piperidine. Compound <b>17</b> with piperidine resulted in a decrease in D<sub>2</sub> (<i>K</i><sub>i</sub> = 861.2 ± 54.6 nM), 5-HT<sub>1A</sub> (<i>K</i><sub>i</sub> = 392.0 ± 43.2 nM), and 5-HT<sub>2A</sub> (<i>K</i><sub>i</sub> = 173.0 ± 28.1 nM) receptor potency by 4-, 3-, and 2-fold, respectively, compared with compound <b>16</b>. Interestingly, transforming the benzo[<i>d</i>]thiazole moiety to an oxygen-containing benzoheterocycle, such as 6-fluorobenzo[<i>d</i>]isoxazole, in compound <b>18</b> resulted in an increase in D<sub>2</sub> (<i>K</i><sub>i</sub> = 58.2 ± 6.4 nM) and 5-HT<sub>1A</sub> (<i>K</i><sub>i</sub> = 62.9 ± 7.3 nM) receptor potency by 3- and 2-fold, while 5-HT<sub>2A</sub> (<i>K</i><sub>i</sub> = 52.3 ± 5.8 nM) receptor potency increased only slightly compared to compound <b>16</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Binding Affinities for D<sub>2</sub>, 5-HT<sub>1A</sub>, and 5-HT<sub>2A</sub> Receptors of Compounds <b>9</b>–<b>18</b> and Reference Antipsychotics</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0013.gif" alt="" id="GRAPHIC-d7e1212-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0014.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> values are taken from three experiments, expressed as means ± SEM.</p></div></div><div></div></div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8"> Effect of the Different Linkers between the Tricyclic Heterocycle (Containing 1,2,3,4-Tetrahydroquinoline) and Privileged Structures</h4><div class="NLM_p">The optimal linker between the tricyclic heterocycle containing 1,2,3,4-tetrahydroquinoline and the privileged structures was determined in compound <b>18</b>. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, when 4-chlorobutyryl chloride was introduced and the linker was changed to a longer (4-unit) alkyl chain, compound <b>19</b>, bearing 2,3-dimethylphenylpiperazine, and compound <b>20</b>, containing 2,3-dichlorophenyl piperazine, showed similar affinity for 5-HT<sub>1A</sub>, while D<sub>2</sub> and 5-HT<sub>1A</sub> receptor potency decreased slightly (D<sub>2</sub>, <i>K</i><sub>i</sub> = 185.2 ± 19.5 nM; 5-HT<sub>1A</sub>, <i>K</i><sub>i</sub> = 169.2 ± 17.6 nM for <b>19</b>; D<sub>2</sub>, <i>K</i><sub>i</sub> = 282.5 ± 30.6 nM; 5-HT<sub>1A</sub>, <i>K</i><sub>i</sub> = 149.4 ± 16.7 nM for <b>20</b>) compared to compound <b>18</b>. The privileged structures in ziprasidone and risperidone revealed slightly different heterocycles (benzoisothiazole vs benzoisoxazole), and compound <b>21</b> bearing benzoisothiazole showed increased affinity for the D<sub>2</sub> receptor (<i>K</i><sub>i</sub> = 91.4 ± 10.7 nM). In addition, both the replacement S with O atom for the heterocycles and the benzothiazole with a powerful electron-withdrawing substituent (fluorine atom) on the aromatic ring, while benzoisoxazole without F at the same position may have made compound <b>22</b> more favorable for the three receptors compared with compound <b>21</b>. Substituting a hydrogen atom at the R<sub>3</sub> position for a methyl group (<b>23</b>) led to an approximate 3-fold decrease in activity for the D<sub>2</sub> receptor (<i>K</i><sub>i</sub> = 62.1 ± 7.2 nM), while the efficacy for the 5-HT receptors remained the same compared with compound <b>22</b>. When a longer or shorter linker was introduced, the compounds displayed different affinities for the three receptors. The affinities remained the same as those of compound <b>22</b> when 4-chlorobutyryl chloride (<b>23</b>) was replaced with 5-chloropentanoyl chloride (<b>24</b>), indicating that the compound with a longer linker (5-unit) may fail to improve the affinities for the three receptors. Compound <b>8</b>, containing 2-chloroacetyl chloride, a shorter linker (2-unit) resulted in significantly reduced activities at all three receptors.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Binding Affinities for D<sub>2</sub>, 5-HT<sub>1A</sub>, and 5-HT<sub>2A</sub> Receptors of Compounds <b>8</b> and <b>19</b>–<b>24</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0015.gif" alt="" id="GRAPHIC-d7e1368-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0016.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> values are taken from three experiments, expressed as means ± SEM.</p></div></div><div></div></div><div class="NLM_p">Reducing the carbonyl groups and introducing more aliphatic linkers may affect physicochemical properties and drug-likeness. To evaluate the effects of these modifications, the carbonyl group of the linker was reduced to methylene and a hydroxymethyl group, and the affinities for these compounds were determined (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). When the carbonyl group was reduced by Et<sub>3</sub>SiH in the presence of TFA, compounds containing the benzisoxazolepiperidine moiety with chain lengths of three (<b>29</b>) or four (<b>33</b>) carbons showed slightly reduced affinities for the receptors compared with compound <b>22</b>. The same affinities were observed when the methyl group was substituted at the R<sub>3</sub> position (<b>34</b>). Introducing the privileged structures 2,3-dichlorophenylpiperazine (<b>30</b> and <b>31</b>) and 3-(piperazin-1-yl)benzo[<i>d</i>]isothiazole (<b>32</b>) led to a decrease in affinity for the D<sub>2</sub> receptor, while activity against the 5-HT<sub>2A</sub> receptor was retained (albeit less than that of compound <b>22</b>). When the carbonyl group was reduced by sodium borohydride (NaBH<sub>4</sub>), compounds <b>35</b> and <b>36</b> with OH on the carbon chain resulted in a slight change in the D<sub>2</sub> and 5-HT<sub>2A</sub> receptors affinities. These results indicate that introducing a carbonyl or hydroxymethyl group on the linker between the tricyclic heterocycle (containing 1,2,3,4-tetrahydroquinoline), and the privileged structure benzisoxazolepiperidine moiety moiety resulted in good activities for the three receptors.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Binding Affinities for D<sub>2</sub>, 5-HT<sub>1A</sub>, and 5-HT<sub>2A</sub> Receptors of Compounds <b>29</b>–<b>36</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0017.gif" alt="" id="GRAPHIC-d7e1463-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0018.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> values are taken from three experiments, expressed as means ± SEM.</p></div></div><div></div></div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> Effect of the Tricyclic Heterocycle (Containing Indoline) on Different Privileged Structures</h4><div class="NLM_p">We proceeded with our investigation by replacing 1,2,3,4-tetrahydroquinoline with different substituted indolines on the tricyclic heterocycles (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). First, when indoline was introduced, the compounds showed moderate affinities for the D<sub>2</sub> receptor regardless of whether the phenyl ring of the privileged structures was replaced by an electron-donating (<b>37</b>) or electron-withdrawing (<b>38</b>) group. Compound <b>39</b> with a cyano group on naked aromatic ring showed weaker affinities for the three receptors. Changing the phenyl ring to benzoisothiazole and benzoisoxazole resulted in increased affinity of the three receptors for compounds <b>40</b> and <b>41</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Binding Affinities for D<sub>2</sub>, 5-HT<sub>1A</sub>, and 5-HT<sub>2A</sub> Receptors of Compounds <b>37</b>–<b>48</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0019.gif" alt="" id="GRAPHIC-d7e1523-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0020.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> values are taken from three experiments, expressed as means ± SEM.</p></div></div><div></div></div></div><div id="sec3_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Effect of the Different Linkers between the Tricyclic Heterocycles (Containing Indoline) and the Privileged Structures</h4><div class="NLM_p">The change of the different sapcer between the tricyclic heterocycle (containing indoline) and privileged structures was also determined (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Introducing 4-chlorobutyryl chloride and the linker changed the compound into a longer (4-unit) alkyl chain. Compounds with the privileged structures of aripiprazole, risperidone, and ziprasidone had significantly increased affinities for the three receptors. The following order of the three receptors for the analogues with different modifications was observed: 2,3-dichlorophenylpiperazine (<b>42</b>) < 3-(piperazin-1-yl)benzo[<i>d</i>]isothiazole (<b>43</b>) < 6-fluoro-3-(4-piperidyl)-1,2-benzisoxazole (<b>44</b>). We then introduced fluorine substituents at different positions on the tricyclic heterocycle. The activities of the substitution of F at the seven (<b>45</b>) and nine (<b>46</b>) positions of the tricyclic heterocycle were retained, although it was little less than that of compound <b>44.</b> Notably, compound (<b>47</b>) bearing benzisoxazolepiperidine moiety, particularly those with a long (5-unit) linker, had significantly higher activties for D<sub>2</sub> receptor (<i>K</i><sub>i</sub> = 2.9 ± 0.3 nM), 5-HT<sub>1A</sub> receptor (<i>K</i><sub>i</sub> = 8.6 ± 1.1 nM), and 5-HT<sub>2A</sub> receptor (<i>K</i><sub>i</sub> = 0.72 ± 0.02 nM). In contrast, compound <b>48</b>, interposed with chain lengths of six carbons, showed significantly inactive to the three receptors.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Binding Affinities for D<sub>2</sub>, 5-HT<sub>1A</sub>, and 5-HT<sub>2A</sub> Receptors of Compounds <b>49</b>–<b>54</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0021.gif" alt="" id="GRAPHIC-d7e1618-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±"><b>Receptor affinity <i>K</i><sub>i</sub> ± SEM (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>Compd</b></th><th class="colsep0 rowsep0" align="center"><b><i>Z</i></b></th><th class="colsep0 rowsep0" align="center"><b><i>n</i></b></th><th class="colsep0 rowsep0" align="center" char="±"><b>D<sub>2</sub></b></th><th class="colsep0 rowsep0" align="center" char="±"><b>5-HT<sub>1A</sub></b></th><th class="colsep0 rowsep0" align="center" char="±"><b>5-HT<sub>2A</sub></b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="center">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="char" char="±">46.5 ± 4.9</td><td class="colsep0 rowsep0" align="char" char="±">38.7 ± 4.0</td><td class="colsep0 rowsep0" align="char" char="±">29.3 ± 3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="center">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char="±">9.9 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">11.7 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">19.3 ± 2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="center">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="char" char="±">43.2 ± 5.1</td><td class="colsep0 rowsep0" align="char" char="±">54.0 ± 6.1</td><td class="colsep0 rowsep0" align="char" char="±">58.3 ± 6.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="center">CHOH</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="char" char="±">19.6 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">29.3 ± 3.8</td><td class="colsep0 rowsep0" align="char" char="±">59.6 ± 6.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="center">CHOH</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char="±">13.4 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">22.5 ± 3.5</td><td class="colsep0 rowsep0" align="char" char="±">69.5 ± 7.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="center">CHOH</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="char" char="±">8.4 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">12.0 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 0.05</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> values are taken from three experiments, expressed as means ± SEM.</p></div></div></div><div class="NLM_p">To investigate further structure–activity relationships, the carbonyl group of the linker between the tricyclic heterocycle and benzisoxazolepiperidine moiety was reduced and the affinities for these compounds was investigated. When the carbonyl group was reduced to a methylene group, the 5-HT<sub>2A</sub> receptor affinity of compounds with different chain lengths led a decrease but not the other two receptors. Compounds with chain lengths of four carbons (<b>50</b>) showed good activities for D<sub>2</sub> and 5-HT<sub>1A</sub> receptor with <i>K</i><sub>i</sub> < 15 nM, whereas compounds with shorter (3-unit) (<b>49</b>) or longer (5-unit) (<b>51</b>) linker had slightly reduced affinities for the two receptors. When the carbonyl group was reduced by NaBH<sub>4</sub>, compound <b>54</b>, with a chain length of five carbons, exhibited good binding activitie to the three receptors with <i>K</i><sub>i</sub> < 15 nM. Affinity for the D<sub>2</sub> receptor following modification of the chain length resulted in analogues in the following order: chain lengths of three carbons (<b>52</b>) < four carbons (<b>53</b>) < five carbons (<b>54</b>). Compounds <b>52</b> and <b>53</b> had similar activties for the 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors but weaker affinities than those of compound <b>54</b>.</div><div class="NLM_p">Overall, compounds <b>44</b>, <b>47</b>, <b>50</b>, <b>53</b>, and <b>54</b> exhibited good activities for the three receptors. These five compounds, especially compound <b>47</b> (<i>K</i><sub>i</sub> = 8.6 ± 1.1 nM), showed higher 5-HT<sub>1A</sub> affinities than risperidone (<i>K</i><sub>i</sub> = 182 ± 15 nM). Moreover, compound <b>47</b> (<i>K</i><sub>i</sub> = 2.9 ± 0.3 nM) displayed a strong binding activity to D2 receptor compared with risperidone (<i>K</i><sub>i</sub> = 3.7 ± 0.3 nM). Compounds <b>47</b> (<i>K</i><sub>i</sub> = 0.72 ± 0.02 nM) showed similar 5-HT<sub>2A</sub> activity to risperidone (<i>K</i><sub>i</sub> = 0.18 ± 0.02 nM). These relationships are summarized in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Summary of the results of SAR studies performed on different regions of the synthesized derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The atypical antipsychotics are less potent D<sub>2</sub> receptor antagonists than conventional antipsychotics and have the distinctive feature of being 5-HT<sub>2A</sub> receptor antagonists, which improves their neurological safety.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Thus, the atypical antipsychotics have demonstrated superior effectiveness, with a diminished incidence of EPSs, but are associated with the development of metabolic disturbances.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> They trigger many adverse events, such as excessive weight gain, which is primarily a result of treatment with clozapine and olanzapine and to a lesser extent risperidone; the synergistic effects of histamine H<sub>1</sub> and serotonin 5-HT<sub>2C</sub> antagonism have been postulated as the reason for the antipsychotic-induced weight gain. Many other adverse events may be induced by the administration of atypical antipsychotics. Glucose and lipid abnormalities may be caused by the treatment of clozapine and olanzapine, while the strong risk of QTc prolongation was tiggered by sertindole and ziprasidone.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Treating schizophrenia with antipsychotic drugs may trigger orthostatic hypotension related to the antagonistic effect of the adrenergic α<sub>1</sub> receptor.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> These adverse events have been suggested to be closely related to the three off-target receptors (5-HT<sub>2C</sub>, histamine H<sub>1</sub>, and adrenergic α<sub>1</sub>). As shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, compound <b>54</b> exhibited high binding activity to the two receptors compared to risperidone (<b>54</b>: 5-HT<sub>2C</sub>, <i>K</i><sub>i</sub> = 33.7 ± 4.1 nM; H<sub>1</sub>, <i>K</i><sub>i</sub> = 43.5 ± 5.2 nM; risperidone: 5-HT<sub>2C</sub>, <i>K</i><sub>i</sub> = 28.2 ± 3.3 nM; H<sub>1</sub>, <i>K</i><sub>i</sub> = 46.2 ± 5.1 nM). The other compounds may cause no or little treatment-associated weight gain because they have lower 5-HT<sub>2C</sub> and histamine H<sub>1</sub> receptor affinities compared with risperidone. Because of their inactivity to the adrenergic α<sub>1</sub> receptor (<i>K</i><sub>i</sub> > 300 nM), the selected compounds except compound <b>50</b> (<i>K</i><sub>i</sub> = 99.3 ± 12.1 nM) may not cause orthostatic hypotension.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Binding Affinities for the 5-HT<sub>2C</sub>, H<sub>1</sub>, and α<sub>1</sub> Receptors (<i>K</i><sub>i</sub> nM) and hERG Channels (IC<sub>50</sub> (nM)) of Selected Compounds and Reference Antipsychotics</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char="±"><b>Receptor affinity <i>K</i><sub>i</sub> ± SEM (nM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></b></th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>Compd</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>5-HT<sub>2C</sub></b></th><th class="colsep0 rowsep0" align="center" char="±"><b>H<sub>1</sub></b></th><th class="colsep0 rowsep0" align="center" char="±"><b>α<sub>1</sub></b></th><th class="colsep0 rowsep0" align="center" char="±"><b>5-HT<sub>6</sub></b></th><th class="colsep0 rowsep0" align="center" char="±"><b>D<sub>3</sub></b></th><th class="colsep0 rowsep0" align="center" char="."><b>hERG IC<sub>50</sub> (nM)</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="char" char="±">610.3 ± 61.3</td><td class="colsep0 rowsep0" align="char" char="±">421.0 ± 45.7</td><td class="colsep0 rowsep0" align="char" char="±">491.3 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">241.0 ± 25.2</td><td class="colsep0 rowsep0" align="char" char="±">61.3 ± 6.3</td><td class="colsep0 rowsep0" align="char" char=".">823.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="char" char="±">616.0 ± 65.1</td><td class="colsep0 rowsep0" align="char" char="±">630.3 ± 5.5</td><td class="colsep0 rowsep0" align="char" char="±">431.0 ± 62.2</td><td class="colsep0 rowsep0" align="char" char="±">5.55 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">1.66 ± 0.3</td><td class="colsep0 rowsep0" align="char" char=".">2905.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="char" char="±">539.9 ± 54.7</td><td class="colsep0 rowsep0" align="char" char="±">711.7 ± 81.2</td><td class="colsep0 rowsep0" align="char" char="±">99.3 ± 12.1</td><td class="colsep0 rowsep0" align="char" char="±">17.7 ± 1. 8</td><td class="colsep0 rowsep0" align="char" char="±">54.9 ± 5.7</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="char" char="±">742.0 ± 78.0</td><td class="colsep0 rowsep0" align="char" char="±">339.0 ± 35.4</td><td class="colsep0 rowsep0" align="char" char="±">339 ± 34.8</td><td class="colsep0 rowsep0" align="char" char="±">6.36 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">45.37 ± 5.4</td><td class="colsep0 rowsep0" align="char" char=".">1899.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="char" char="±">33.7 ± 4.1</td><td class="colsep0 rowsep0" align="char" char="±">43.5 ± 5.2</td><td class="colsep0 rowsep0" align="char" char="±">596 ± 60.2</td><td class="colsep0 rowsep0" align="char" char="±">29.46 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">116.32 ± 12.8</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">risperidone</td><td class="colsep0 rowsep0" align="char" char="±">28.2 ± 3.3</td><td class="colsep0 rowsep0" align="char" char="±">46.2 ± 5.1</td><td class="colsep0 rowsep0" align="char" char="±">54.7 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">1260 ± 150</td><td class="colsep0 rowsep0" align="char" char="±">31.9 ± 3.3</td><td class="colsep0 rowsep0" align="char" char=".">167.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> values are taken from three experiments, expressed as means ± SEM.</p></div></div></div><div class="NLM_p">Furthermore, the 5-HT<sub>6</sub> receptor has high density in brain areas associated with learning and memory, predominantly in the hippocampus, striatum, nucleus accumbens, and prefrontal cortex. Its enrichment in those brain regions suggests an important role in memory and cognitive processes.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Given that blockade of the 5-HT<sub>6</sub> receptor induces glutamatergic and monoaminergic (e.g., dopaminergic and adrenergic) neurotransmitter release, it was reasonable to consider that 5-HT<sub>6</sub> receptor antagonism could be a promising approach for the improvement of cognitive abilities.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The dopamine D<sub>3</sub> receptor plays an important role in regulating cortical DA neurotransmission related to cognitive and motivational behaviors due to its selective expression in the striatum and mesolimbic system.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Overall, the two desired target receptors (5-HT<sub>6</sub> and D<sub>3</sub> receptors) have been suggested to help improve cognitive abilities. In <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, the 5-HT<sub>6</sub> receptor affinities of compounds <b>47</b>, <b>50</b>, <b>53</b>, and <b>54</b> are higher than risperidone (<i>K</i><sub>i</sub> = 1260 ± 150 nM). In particular, compounds <b>47</b> (<i>K</i><sub>i</sub> = 5.55 ± 0.6 nM) and <b>53</b> (<i>K</i><sub>i</sub> = 6.36 ± 0.8 nM) displayed significantly higher binding activities to the 5-HT<sub>6</sub> receptor than risperidone. According to <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, compound <b>47</b> (<i>K</i><sub>i</sub> = 1.66 ± 0.3 nM) showed higher binding activity to the D<sub>3</sub> receptor than risperidone (<i>K</i><sub>i</sub> = 31.9 ± 3.3 nM), while the other selected compounds had weak affinities for the D<sub>3</sub> receptor. Thus, these results suggest that compound <b>47</b> may alleviate cognitive impairment in patients.</div><div class="NLM_p last">Taken together, compounds <b>44</b>, <b>47</b>, and <b>53</b> showed low binding activity to the off-target receptors (5-HT<sub>2C</sub>, histamine H<sub>1</sub>, and adrenergic α<sub>1</sub> receptors [<i>K</i><sub>i</sub> > 300 nM]), while compound <b>47</b> exhibited excellent affinities for the desired target receptors (5-HT<sub>6</sub>, <i>K</i><sub>i</sub> = 5.55 ± 0.6 nM; D<sub>3</sub>, <i>K</i><sub>i</sub> = 1.66 ± 0.3 nM). Therefore, the three compounds were selected to evluate their safety profile.</div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> hERG Channel Blockade</h3><div class="NLM_p">Cardiotoxicity is a serious side effect often caused by off-target interactions between drugs and various voltage-gated ion channels in the heart, particularly the hERG channel.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Unwanted interactions of drugs with this channel can trigger serious cardiac arrhythmias, such as long QT syndrome, which is characterized by prolongation of the QT interval and Torsades de pointes.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The possible lethal aftermath of drug-induced hERG blockade has significantly affected screening strategies, drug development, regulation, and approval procedures. Compounds <b>44</b>, <b>47</b>, and <b>53</b> were evaluated for their ability to block hERG in a patch-clamp assay. Compound <b>47</b> (IC<sub>50</sub> > 2000 nM) exhibited a lower hERG inhibition than the others.</div><div class="NLM_p last">Taken together, compound <b>47</b> exhibited excellent in vitro profiles with a higher affinity for the five desired targets and a lower affinity for the three off-target receptors and hERG.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Acute Toxicity</h3><div class="NLM_p last">The acute toxicity was investigated in terms of LD<sub>50</sub> values. Compound <b>47</b> even at the highest tested dose (2000 mg/kg) was not lethal in more than half of the mice. It suggested that compound <b>47</b> displayed a good safety profile with a very low acute toxicity (LD<sub>50</sub> > 2000 mg/kg).</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Intrinsic Activity of New Multireceptor Compound <b>47</b></h3><div class="NLM_p">Compound <b>47</b> was selected for further functional characterization based on its excellent in vitro profiles and good safety properties. In <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, compound <b>47</b> stimulated the five receptors in an agonist assay and showed minimal agonist activity, displaying <20% of the efficacy of the reference compounds, respectively. Compound <b>47</b> blocked five receptors by greater than 90% in an antagonist assay. Compound <b>47</b> functioned as an antagonist at the D<sub>2L</sub> (IC<sub>50</sub> = 9.20 nM), D<sub>3</sub> (IC<sub>50</sub> = 25.6 nM), 5-HT<sub>1A</sub> (IC<sub>50</sub> = 587.8 nM), 5-HT<sub>2A</sub> (IC<sub>50</sub> = 257.4 nM), and 5-HT<sub>6</sub> (IC<sub>50</sub> = 177.6 nM) receptors.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Activities of Compound <b>47</b> and Reference Compounds to D<sub>2L</sub>, D<sub>3</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>6</sub> Receptors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>Receptor</b></th><th class="colsep0 rowsep0" align="center"><b>Compd</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>Activation (10 μM, %) (<i>n</i> = 3)</b></th><th class="colsep0 rowsep0" align="center" char="."><b>EC<sub>50</sub> (nM)</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>Inhibition (10 μM, %) (<i>n</i> = 3)</b></th><th class="colsep0 rowsep0" align="center" char="."><b>IC<sub>50</sub> (nM)</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>2L</sub></td><td class="colsep0 rowsep0" align="left">dopamine</td><td class="colsep0 rowsep0" align="char" char="±">101.1 ± 3.1</td><td class="colsep0 rowsep0" align="char" char=".">19.0</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">SCH23390</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±">99.0 ± 1.0</td><td class="colsep0 rowsep0" align="char" char=".">31.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="char" char="±">9.8 ± 8.4</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±">93.3 ± 1.3</td><td class="colsep0 rowsep0" align="char" char=".">9.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>3</sub></td><td class="colsep0 rowsep0" align="left">dopamine</td><td class="colsep0 rowsep0" align="char" char="±">100.1 ± 8.5</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">spiperone</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±">99.2 ± 2.4</td><td class="colsep0 rowsep0" align="char" char=".">93.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="char" char="±">5.2 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±">100.6 ± 3.3</td><td class="colsep0 rowsep0" align="char" char=".">25.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1A</sub></td><td class="colsep0 rowsep0" align="left">5-HT</td><td class="colsep0 rowsep0" align="char" char="±">102.5 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">19.0</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">WAY-100635</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±">95.5 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">11.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="char" char="±">8.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±">94 ± 3.2</td><td class="colsep0 rowsep0" align="char" char=".">587.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>2A</sub></td><td class="colsep0 rowsep0" align="left">5-HT</td><td class="colsep0 rowsep0" align="char" char="±">94.5 ± 2.3</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ketanserin</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±">100 ± 2.1</td><td class="colsep0 rowsep0" align="char" char=".">83.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±">100 ± 3.2</td><td class="colsep0 rowsep0" align="char" char=".">257.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>6</sub></td><td class="colsep0 rowsep0" align="left">5-HT</td><td class="colsep0 rowsep0" align="char" char="±">98.0 ± 1.6</td><td class="colsep0 rowsep0" align="char" char=".">43.6</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">clozapine</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±">103.5 ± 2.1</td><td class="colsep0 rowsep0" align="char" char=".">20.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="char" char="±">6.0 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±">91.3 ± 3.5</td><td class="colsep0 rowsep0" align="char" char=".">177.6</td></tr></tbody></table></div></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> In Vivo Behavioral Studies on Selected Analogues of Compound <b>47</b></h3><div class="NLM_p">Analysis of the data obtained from the receptor binding assays allowed compound <b>47</b> to be selected for testing in several mouse models sensitive to mesolimbic-mediated antipsychotic-like activity.</div><div class="NLM_p">The antagonism of hyperlocomotion induced by dopamine receptor direct agonists (e.g., apomorphine) or compounds that facilitate dopaminergic tone (e.g., amphetamines and AMP) are used in murine models to assess antipsychotic efficacy.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The effects of apomorphine decrease significantly in response to D<sub>2</sub> receptor antagonists. Many of these compounds demonstrate a potent ability to attenuate climbing behavior induced by apomorphine in mice, which has been used as a model for identifying potential antipsychotic activity linked to behavioral agitation, one positive psychotic symptom.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Treatment with compound <b>47</b> can dose dependently inhibit the apomorphine induced climbing behavior (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), with an ED<sub>50</sub> value of 0.61 mg/kg (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). In comparison, the apomorphine-induced climbing behavior was also attenuated by risperidone (ED<sub>50</sub>, 0.028 mg/kg) and haloperidol (ED<sub>50</sub>, 0.11 mg/kg), respectively. It indicate that compound <b>47</b> is a potent blocker of the D<sub>2</sub> receptor, which was also consistent with its potent D<sub>2</sub> receptor antagonistic activity.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of compound <b>47</b> administered po on APO (apomorphine)-induced climbing in mice (10/group). Results are expressed as means ± SEM of the score. Statistical significances of drug effects were analyzed by the nonparametric two-tailed Mann–Whitney U-test: #, <i>p</i> < 0.05 versus vehicle treatment; **, <i>p</i> < 0.01 and *, <i>p</i> < 0.05 versus apomorphine treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. In Vivo Pharmacological Profile of Compound <b>47</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>Compd</b></th><th class="colsep0 rowsep0" align="center"><b>APO<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></b></th><th class="colsep0 rowsep0" align="center"><b>MK-801<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></b></th><th class="colsep0 rowsep0" align="center"><b>CAT<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></b></th><th class="colsep0 rowsep0" align="center"><b>CAR<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></b></th><th class="colsep0 rowsep0" align="center" char="."><b>CAT/APO</b></th><th class="colsep0 rowsep0" align="center" char="."><b>CAT/MK-801</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="center">0.61 (0.34–1.08)<a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">0.26 (0.14–0.51)</td><td class="colsep0 rowsep0" align="center">78.62 (35.65–189.74)</td><td class="colsep0 rowsep0" align="center">1.46 (1.15–3.94)</td><td class="colsep0 rowsep0" align="char" char=".">128.88</td><td class="colsep0 rowsep0" align="char" char=".">302.38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">risperidone</td><td class="colsep0 rowsep0" align="center">0.028 (0.017–0.048)</td><td class="colsep0 rowsep0" align="center">0.011 (0.003–0.051)</td><td class="colsep0 rowsep0" align="center">0.51 (0.26–2.04)</td><td class="colsep0 rowsep0" align="center">0.52 (0.28–0.66)</td><td class="colsep0 rowsep0" align="char" char=".">18.21</td><td class="colsep0 rowsep0" align="char" char=".">46.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">haloperidol</td><td class="colsep0 rowsep0" align="center">0.11 (0.084–0.13)</td><td class="colsep0 rowsep0" align="center">0.16 (0.064–0.37)</td><td class="colsep0 rowsep0" align="center">0.12 (0.030–1.03)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">1.09</td><td class="colsep0 rowsep0" align="char" char=".">0.75</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">APO: apomorphine-induced climbing (ED<sub>50</sub>, mg/kg, po).</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">MK-801: MK-801-induced hyperactivity (ED<sub>50</sub>, mg/kg, po).</p></div><div class="footnote" id="t8fn3"><sup><sup>c</sup></sup><p class="last">CAT: catalepsy (ED<sub>50</sub>, mg/kg, po).</p></div><div class="footnote" id="t8fn4"><sup><sup>d</sup></sup><p class="last">CAR: conditioned avoidance response (ED<sub>50</sub>, mg/kg, po).</p></div><div class="footnote" id="t8fn5"><sup><sup>e</sup></sup><p class="last">95% confidence limits.</p></div></div></div><div class="NLM_p">It is well-known that systemic administration of PCP or MK-801 increases the dopaminergic cell-firing rate in the brain.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The observation that uncompetitive NMDA receptor antagonists (e.g., PCP, MK801, and ketamine) induce schizophrenic symptoms (negative and cognitive symptoms) in healthy subjects and exacerbate existing psychoses in patients with schizophrenia suggests that endogenous dysfunction of NMDA receptor-mediated neurotransmission might play an important role in the pathophysiology of schizophrenia.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The compounds were also tested in the MK801-induced hyperactivity model. In this test, compound <b>47</b> significantly dose dependently decreased the increased locomotor activity induced by MK-801 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) with an ED<sub>50</sub> of 0.26 mg/kg (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). In comparison, risperidone and haloperidol reversed the MK801-induced hyperactivity with an ED<sub>50</sub> values of 0.011 and 0.16 mg/kg, respectively.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of compound <b>47</b> administered po on MK-801-induced hyperactivity in mice (10/group). Results are expressed as the means ± SEM of distance traveled. Statistical evaluation was performed by two-way ANOVA followed by Tukey’s test for multiple comparisons. #, <i>p</i> < 0.05 versus vehicle treatment; **, <i>p</i> < 0.01 and *, <i>p</i> < 0.05 versus MK-801 treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">One of the major obstacles of the use of antipsychotics is their propensity to produce EPSs. The rodent catalepsy test has been often used to predict the incidence of EPSs in the antipsychotic drug discovery process.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Selected compounds were tested in mice using the horizontal bar test to evaluate the liability for striatal-mediated side effects and for cataleptogenic potential. This test is sensitive to catalepsy induced by D<sub>2</sub> receptor antagonist. In <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>, haloperidol induced significant cataleptic effect (ED<sub>50</sub>, 0.12 mg/kg), consistent with its strong antagonistic effect on D<sub>2</sub> receptor. In contrast, compound <b>47</b> produced a low potential cataleptogenic effect (ED<sub>50</sub>, 78.62 mg/kg), while the ED<sub>50</sub> of catalepsy induced by risperidone is 0.51 mg/kg. Compound <b>47</b> with a higher threshold for catalepsy might induce a lower incidence of extrapyramidal motor side effects, compared with risperidone. Compound <b>47</b> exhibited a wider range of the therapeutic indices (128.88–302.38) based on its efficacy (apomorphine or MK-801 models) and its side effects (catalepsy), while the therapeutic index of risperidone was approximately 18.21–46.36.</div><div class="NLM_p">The conditioned avoidance response (CAR) test has significant predictive validity, some construct validity, but little face validity. The CAR test has been used to assess the antipsychotic activity of potential agents that display high affinities for dopamine receptors.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> This test has long been considered an important preclinical animal model for the study of antipsychotic drugs.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Both compound <b>47</b> and risperidone effectively inhibited the avoidance response in the rat CAR model (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). A nonlinear regression analysis indicating risperidone’s ED<sub>50</sub> was 0.52 mg/kg, while treatment of compound <b>47</b> resulted an ED<sub>50</sub> of 1.46 mg/kg (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of risperidone (10/group) and compound <b>47</b> (10/group) on the performance of conditioned avoidance response in rats 90 min after single oral administration. The animals served as their own controls using a within-subject design. Values of percentage inhibition of avoidance are expressed as mean ± SEM. The avoidance values were analyzed in a repeated measures analysis of variance with dose (resperidone and compound <b>47</b>) as a within-subject factor for each drug separately. Post hoc comparisons were performed using the Bonferroni adjustment for multiple comparisons, and the level of significance indicated in the figure is that with respect to vehicle treatment (**, <i>P</i> < 0.05) and all statistical analysis were carried out using SPSS software.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Weight Gain and Serum Prolactin</h3><div class="NLM_p">The potential adverse effect profile of compound <b>47</b> was also assessed in terms of its ability to induce weight gain and high prolactin levels.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Negligible weight gain was detected by administering compound <b>47</b> in mice that experienced chronic dosing (28 days), whereas risperidone was associated with significantly more weight gain in the experienced chronic dosing (28 days) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The discrepancies was also consistent with their different affinities for the histamine H<sub>1</sub> (risperidone, <i>K</i><sub>i</sub> = 46.2 ± 5.1 nM; <b>47</b>, <i>K</i><sub>i</sub> = 630.3 ± 5.5 nM) and 5-HT<sub>2C</sub> (risperidone, <i>K</i><sub>i</sub> = 28.2 ± 3.3 nM; <b>47</b>, <i>K</i><sub>i</sub> = 616.0 ± 65.1 nM) receptors. Moreover, compound <b>47</b> resulted nonsignificantly serum prolactin levels change compared with risperidone (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Influence of <b>47</b> and risperidone on weight gain. Each value is the mean ± SEM of 10 mice per group. Student’s <i>t</i> test: ##, <i>p</i> < 0.01 versus vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Serum prolactin (PRL) multiple (28 days) administration of compound <b>47</b> and risperidone in mice. Each value is the mean ± SEM of 10 mice per group. Student’s <i>t</i> test: ##, <i>p</i> < 0.01 versus vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Besides the aforementioned functional profile, extended pharmacological in vitro profiling was conducted with compound <b>47</b> to investigate its potential off-target activity (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). The results indicated that compound <b>47</b> behaved as an antagonist of the five receptors (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>) and showed weak affinities for off-target receptors (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Consequently, similar to other atypical antipsychotics, compound <b>47</b> displayed a complex pharmacology with the desired profile but appeared to produce some potentially unwanted off-target effects. These effects, resulting from off-target receptors (adrenergic α<sub>1</sub>, histamine H<sub>1</sub>, and 5-HT<sub>2C</sub> receptors), suggest factors related to metabolic disturbances (weight gain), hypotension, and sedation; however, these states were not observed in this study. The pharmacokinetic properties of compound <b>47</b> have been extensively studied in rats, and good pharmacokinetic characteristics have been demonstrated.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Pharmacokinetic Profile of Compound <b>47</b></h3><div class="NLM_p">The pharmacokinetic properties of compound <b>47</b> have been extensively studied in rats, and the good pharmacokinetic characteristics are demonstrated in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>. Interestingly, two ways of administration showed similar half-life (<i>t</i><sub>1/2</sub>), <i>t</i><sub>1/2</sub> of intravenous administration (1 mg/kg) was 2.15 ± 0.50 h, while oral administration (10 mg/kg) was associated with a <i>t</i><sub>1/2</sub> of 2.02 ± 0.19 h. Compound <b>47</b> showed intravenous AUC (area under the curve) of 3151.2 ± 402.9 ng·h/mL and oral AUC of 18539.5 ± 1584.6 ng·h/mL, respectively. Clearance was 15.4 mL/min/kg following intravenous administration. The <i>T</i><sub>max</sub> value was 1.00 ± 0.00 h and the peak serum concentration was 3733 ± 1635 ng/mL when dosed orally at 10 mg/kg. In sum, compound <b>47</b> exhibited a favorable drug-like pharmacokinetic properties with an oral bioavailability of 58.8%.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Pharmacokinetic Profile of Compound <b>47</b> in Rats (<i>n</i> = 6/Group)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>Dose (mg/kg)</b></th><th class="colsep0 rowsep0" align="center" char="±"><b><i>C</i><sub>max</sub> (ng/mL)</b></th><th class="colsep0 rowsep0" align="center" char="±"><b><i>t</i><sub>1/2</sub> (h)</b></th><th class="colsep0 rowsep0" align="center" char="±"><b><i>T</i><sub>max</sub> (h)</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>CL(mL/min/kg)</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>AUC(0–<i>t</i>) (ng·h/mL)</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>AUC(0–∞) (ng·h/mL)</b></th><th class="colsep0 rowsep0" align="center" char="."><b><i>F</i>(%)</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1 (iv)</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">2.15 ± 0.50</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">15.4 ± 0.74</td><td class="colsep0 rowsep0" align="char" char="±">3141.3 ± 397.6</td><td class="colsep0 rowsep0" align="char" char="±">3151.2 ± 402.9</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10 (po)</td><td class="colsep0 rowsep0" align="char" char="±">3733 ± 1635</td><td class="colsep0 rowsep0" align="char" char="±">2.02 ± 0.19</td><td class="colsep0 rowsep0" align="char" char="±">1.00 ± 0.00</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">18532.7 ± 1588.6</td><td class="colsep0 rowsep0" align="char" char="±">18539.5 ± 1584.6</td><td class="colsep0 rowsep0" align="char" char=".">58.8</td></tr></tbody></table></div></div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Memory Study</h3><div class="NLM_p">Given its promising profile, compound <b>47</b> exhibited excellent affinities for 5-HT<sub>6</sub> (<i>K</i><sub>i</sub> = 5.55 ± 0.6 nM) and D<sub>3</sub> (<i>K</i><sub>i</sub> = 1.66 ± 0.3 nM) receptors, so the effect of compound <b>47</b> on cognitive performance was evaluated in a novel object recognition (NOR) task in rats, predictive of potential procognitive activity of the drug.<a onclick="showRef(event, 'cit22b ref44'); return false;" href="javascript:void(0);" class="ref cit22b ref44">(22b,44)</a> The NOR task is a widely used behavioral task to assess visual recognition memory and is based on an animal’s innate preference for novelty.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The task consists of a training phase, where rats are presented with two identical objects to explore. Following a delay interval, memory was assessed by presenting the rats with a trained object and a novel object. Rats with a memory of the previously presented object will preferentially explore the novel object. Rats that receive a memory enhancing drug in conjunction with submaximal training are expected to exhibit improved memory performance similar to that of untreated animals that received stronger training (i.e., more exposure to objects during the training phase). In this study, compound <b>47</b> was orally administered 1 h prior to the acquisition trial and the exploration times for the two identical objects were recorded (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A). After a 24 h acquisition trial, one of the familiar objects was replaced with a novel object, the time spent investigating each of the objects was recorded (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B), and the novelty discrimination index (NDI) was calculated as the percentage of novel object interaction time relative to total interaction time during the retention trial (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>C). As shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A, oral administration of compound <b>47</b> (0.03–0.3 mg/kg) did not significantly affect total exploration time during the acquisition trial. As shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B, risperidone (0.2 mg/kg) failed to improve cognitive ability, while rivastigmine can enhance recognition memory at 0.3 mg/kg. In contrast, rats treated with 0.1 or 0.3 mg/kg of compound <b>47</b> during the retention trial explored the novel object for a longer time, indicative of preserved memory for the familiar object presented during the acquisition trial, whereas rats under the vehicle condition or dosed with 0.03 mg/kg of compound <b>47</b> did not exhibit differences between exploration times for the familiar and novel objects, indicating deterioration or loss of memory for the familiar object. In addition, a 0.3 mg/kg oral dose of compound <b>47</b> significantly increased the NDI (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>C). These results suggest that compound <b>47</b> enhanced recognition memory during the NOR task in rats.</div><figure id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effects of <b>47</b> on a novel object recognition task in rats. Vehicle or <b>47</b> (0.03, 0.1, and 0.3 mg/kg), rivastigmine (0.3 mg/kg), and risperidone (0.2 mg/kg) was orally administered 1 h prior to the acquisition trials. (A) Exploration times in the acquisition trial and (B) the retention trial (performed 24 h after the acquisition trial) were scored. (C) Novelty discrimination index (NDI) in the retention trial was calculated as novel object interaction time/total interaction time ×100 (%). Data are presented as the mean ± SEM, <i>n</i> = 9 for 0.03 mg/kg, <i>n</i> = 10 for the other groups; **, <i>p</i> < 0.01 vs familiar object by paired <i>t</i> test; #, <i>p</i> < 0.025 vs vehicle by one-tailed Williams’ test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Selectivity Profile of Compound <b>47</b></h3><div class="NLM_p last">The interactions between compound <b>47</b> and other receptors related to central nervous system (CNS) disorders were evaluated, a selectivity profile was created using additional receptors (including the D<sub>1</sub>, 5-HT<sub>7</sub>, α<sub>2</sub>, H<sub>3</sub>, SERT, NET, DAT, sigma-1 [σ<sub>1</sub>] and sigma-2 [σ<sub>2</sub>], muscarinic M<sub>1</sub>, and NMDA receptors). Moreover, anticholinergic side effects such as dry mouth, constipation, and blurred vision were induced by the antitargeting muscarinic M<sub>1</sub> receptors.<a onclick="showRef(event, 'cit12c'); return false;" href="javascript:void(0);" class="ref cit12c">(12c)</a> Compound <b>47</b> showed moderate affinities for D<sub>1</sub> and 5-HT<sub>7</sub> receptors (D<sub>1</sub>, <i>K</i><sub>i</sub> = 76.9 ± 10.3 nM; 5-HT<sub>7</sub>, <i>K</i><sub>i</sub> = 226.0 ± 33.2 nM), with no significant affinity (<i>K</i><sub>i</sub> > 1000 nM) for any other putative target. Futhurmore, Compound <b>47</b> inhibited D<sub>1</sub> receptor by greater than 90% in an antagonist assay and functioned as an antagonist at the D<sub>1</sub> receptor (IC<sub>50</sub> = 366 nM) (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01096/suppl_file/jm8b01096_si_002.pdf" class="ext-link">Supporting Information</a>).</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20656" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20656" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A new series of fused tricyclic heterocycle piperazine (piperidine) derivatives was synthesized, and selected candidates were evaluated as potential new antipsychotic agents. Among this series, compound <b>47</b> was favorable for the binding to the five (D<sub>2</sub>, D<sub>3</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>6</sub>) receptors. This compound has a desirable selectivity profile against other receptors, including 5-HT<sub>2C</sub>, histamine H<sub>1</sub>, and adrenergic α<sub>1</sub> receptors, which are known to be associated with the adverse effects of marketed antipsychotics. Compound <b>47</b> was a potent antagonist for those five receptors and was efficacious in animal models of psychoses. Because it reversed apomorphine- and MK-801-induced motor behavior, and avoidance behavior in the CAR test, compound <b>47</b> appears to be useful for addressing the positive symptoms of schizophrenia. Additionally, compound <b>47</b> displayed low hERG inhibitory activity and no tendency to induce catalepsy. Furthermore, compound <b>47</b> was evaluated in the rat NOR test, and improved visual recognition memory was observed 24 h after training. Compound <b>47</b> may promote the development of a unique CNS-active drug candidate due to its suitable physicochemical, biophysical, and pharmacokinetic properties. A thorough preclinical profiling of compound <b>47</b> and its analogues is currently ongoing in our lab, and further pharmacological details will be reported soon.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34812" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34812" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Chemistry</h3><div class="NLM_p last">All commercially available chemicals and reagents were used without further purification. Reagents were all of analytical grade or of chemical purity (>95%). Melting points were determined in open capillary tubes and uncorrected. <sup>1</sup>H NMR spectra was recorded on a Bruker Avance III 600 spectrometer at 600 MHz (<sup>1</sup>H) using CDCl<sub>3</sub> or DMSO-<i>d</i><sub>6</sub> as solvent. Chemical shifts are given in δ values (ppm), using tetramethylsilane (TMS) as the internal standard; coupling constants (<i>J</i>) are given in Hz. Signal multiplicities are characterized as s (singlet), d (doublet), t(triplet), q (quartet), m (multiplet), and br (broad signal). Analytical thin layer chromatography (TLC) was performed on silica gel GF254. Column chromatographic purification was carried out using silica gel. Compound purity is determined by high performance liquid chromatography (HPLC), and all final test compounds display purity higher than 95%. HPLC methods used the following: Shimadzu LC-20AD spectrometer; column, Waters XBridge Shield RP18 (150 mm × 4.6 mm, 3.5 μm); mobile phase, 0.01 mol/L KH<sub>2</sub>PO<sub>4</sub> (0.2% Et<sub>3</sub>N, pH = 3.5) aq/acetonitrile (Merck Company, Germany) 20/80; flow rate, 1.0 mL/min; column temperature, 35 °C. UV detection was performed at 210 nm.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> General Procedures for the Preparation of Intermediates <b>3</b></h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 1,2,6,7-Tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>3a</b>)</h4><div class="NLM_p last">Conpound <b>3a</b> was synthesized by the followed two-step reactions according the literature with modifications.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Step 1: To 1,2,3,4-tetrahydroquinoline (5.0 g, 37.5 mmol) was added acetone (50 mL), and then 3-chloropropionyl chloride (5.1 g, 40.5 mmol) was added slowly. The mixture was heated to reflux for 4 h. Then, it was cooled down and concentrated. The residue was diluted with water (50 mL) and extracted with 75 mL of ethyl acetate by three times. The ethyl acetate layer was dried with anhydrous MgSO<sub>4</sub>, and the filtrate was removed under reduced pressure. The obtained crude product was recrystallized from ethyl acetate to give 3-chloro-1-(3,4-dihydroquinolin-1(2<i>H</i>)-yl)propan-1-one as pale-white solid; mp 79–80 °C; yield 96.4%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.24–7.05 (m, 4H), 3.87 (t, <i>J</i> = 6.7 Hz, 4H), 3.00 (t, <i>J</i> = 6.7 Hz, 2H), 2.74 (s, 2H), 2.00 (p, <i>J</i> = 6.6 Hz, 2H). MS (ESI) <i>m</i>/<i>z</i> 224.2 (calcd 224.1 for C<sub>12</sub>H<sub>15</sub>ClNO<sup>+</sup> [M + H]<sup>+</sup>). Step 2: The product (8 g, 35.8 mmol) from the first step was heated at 100 °C to melt, and then anhydrous aluminum chloride (7.2 g, 54.1 mmol) was added by partions. The reaction was then stirred at 100 °C for 3 h. Then 100 mL of ice–water was added to quench the reaction until the reaction temperature was cooled down. The reaction mixture was extracted with 75 mL of ethyl acetate three times. The ethyl acetate layer was dried with anhydrous MgSO<sub>4</sub> and then removed under reduced pressure after filtration. The crude product was purified via chromatography (petroleum ether/EtOAc = 6/1) to afford 1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>3a</b>) as a pale-white solid; mp 68–70 °C; yield 80.0%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.02 (t, <i>J</i> = 6.9 Hz, 2H), 6.93 (t, <i>J</i> = 7.5 Hz, 1H), 3.95–3.84 (m, 2H), 2.94–2.86 (m, 2H), 2.81 (t, <i>J</i> = 6.3 Hz, 2H), 2.67 (dd, <i>J</i> = 8.4, 6.5 Hz, 2H), 2.02–1.91 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> 188.2 (calcd 188.1 for C<sub>12</sub>H<sub>14</sub>NO<sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 5,6-Dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>3b</b>)</h4><div class="NLM_p last">Pale-white solid; mp 74–76 °C; yield 75.0%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.09 (d, <i>J</i> = 6.9 Hz, 1H), 7.00 (dd, <i>J</i> = 7.4, 0.7 Hz, 1H), 6.93 (td, <i>J</i> = 7.4, 1.7 Hz, 1H), 4.09 (dd, <i>J</i> = 11.5, 5.3 Hz, 2H), 3.20 (t, <i>J</i> = 8.4 Hz, 2H), 2.98 (t, <i>J</i> = 7.7 Hz, 2H), 2.69 (dd, <i>J</i> = 10.6, 4.9 Hz, 2H). MS (ESI) <i>m</i>/<i>z</i> 174.2 (calcd 174.1 for C<sub>11</sub>H<sub>12</sub>NO<sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 7-Fluoro-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-2(4<i>H</i>)-one (<b>3c</b>)</h4><div class="NLM_p last">Pale-white solid; mp 72–73 °C; yield 72.1%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.00 (d, <i>J</i> = 7.4, 1H), 6.63 (d, <i>J</i> = 7.4, 1H), 4.11 (t, <i>J</i> = 8.4 Hz, 2H), 3.20 (t, <i>J</i> = 8.4 Hz, 2H), 2.98 (t, <i>J</i> = 7.7 Hz, 2H), 2.69 (dd, <i>J</i> = 10.6, 4.9 Hz, 2H). MS (ESI) <i>m</i>/<i>z</i> 192.2 (calcd 192.1 for C<sub>11</sub>H<sub>11</sub>FNO<sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 9-Fluoro-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-2(4<i>H</i>)-one (<b>3d</b>)</h4><div class="NLM_p last">Pale-white solid; mp 80–81 °C; yield 70.3%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.09 (d, <i>J</i> = 6.9 Hz, 1H), 6.65 (d, <i>J</i> = 7.4, 1H), 4.12 (t, <i>J</i> = 8.4 Hz, 2H), 3.18 (t, <i>J</i> = 8.4 Hz, 2H), 2.98 (t, <i>J</i> = 7.7 Hz, 2H), 2.69 (dd, <i>J</i> = 10.6, 4.9 Hz, 2H). MS (ESI) <i>m</i>/<i>z</i> 192.2 (calcd 192.1 for C<sub>11</sub>H<sub>11</sub>FNO<sup>+</sup> [M + H]<sup>+</sup>).</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> General Procedures for the Preparation of Intermediates <b>4</b>, <b>6</b>, and <b>7</b></h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 9-(2-Chloroacetyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>4a</b>)<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></h4><div class="NLM_p last">To a suspension of 1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>3a</b>) (5.0 g, 26.7 mmol) in 25 mL of 1,2-dichloroethane was added 2-chloroacetyl chloride (3.5 g, 23.9 mmol). Anhydrous aluminum trichloride (7.2 g, 54.1 mmol) was added by portions under ice-cooling. The reaction mixture was kept at 0–5 °C for 30 min after all AlCl<sub>3</sub> addition, and then the reaction was performed at room temperature for 2 h. Then the reaction was quenched with 100 mL of ice–water. The mixture was extracted with 75 mLof dichloromethane by three times. After being dried over MgSO<sub>4</sub>, dichloromethane was removed by evaporation. The crude mixture was purified by chromatography (petroleum ether:EtOAc = 4:1) to yield 9-(2-chloroacetyl)-1,2,6,7-tetrahydro pyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>4a</b>); pale-white solid; mp 68–70 °C; yield 70.3%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.65 (s, 1H), 7.64 (s, 1H), 4.66 (s, 2H), 4.03–3.81 (m, 2H), 3.06–2.94 (m, 2H), 2.87 (t, <i>J</i> = 6.2 Hz, 2H), 2.71 (dd, <i>J</i> = 8.5, 6.6 Hz, 2H), 1.99 (dt, <i>J</i> = 12.2, 6.1 Hz, 2H). MS (ESI) <i>m</i>/<i>z</i> 264.2 (calcd 264.1 for C<sub>14</sub>H<sub>15</sub>ClNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 9-(3-Chloropropanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>4b</b>)</h4><div class="NLM_p last">Pale-white solid; mp 67–68 °C; yield 73.5%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.65 (s, 1H), 7.64 (s, 1H), 3.93 (dt, <i>J</i> = 12.9, 6.4 Hz, 4H), 3.42 (t, <i>J</i> = 6.8 Hz, 2H), 3.05–2.89 (m, 2H), 2.87 (d, <i>J</i> = 6.2 Hz, 2H), 2.79–2.65 (m, 2H), 2.05–1.92 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> 278.1 (calcd 278.1 for C<sub>15</sub>H<sub>17</sub>ClNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 9-(4-Chlorobutanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>4c</b>)</h4><div class="NLM_p last">Pale-white solid; mp 70–71 °C; yield 73.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.67 (s, 1H), 7.64 (s, 1H), 3.97–3.86 (m, 2H), 3.69 (t, <i>J</i> = 6.2 Hz, 2H), 3.14 (t, <i>J</i> = 7.0 Hz, 2H), 2.98–2.93 (m, 2H), 2.86 (t, <i>J</i> = 6.2 Hz, 2H), 2.70 (dd, <i>J</i> = 8.4, 6.7 Hz, 2H), 2.23 (p, <i>J</i> = 6.7 Hz, 2H), 1.98 (dt, <i>J</i> = 12.2, 6.1 Hz, 2H). MS (ESI) <i>m</i>/<i>z</i> 292.2 (calcd 292.1 for C<sub>16</sub>H<sub>19</sub>ClNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 9-(5-Chloropentanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>4d</b>)</h4><div class="NLM_p last">Pale-white solid; mp 71–72 °C; yield 71.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.64 (s, 1H), 7.63 (s, 1H), 4.03–3.93 (m, 2H), 3.91–3.81 (m, 2H), 3.70 (t, <i>J</i> = 6.2 Hz, 2H), 3.27–3.11 (m, 2H), 2.94–2.82 (m, 2H), 2.78 (dd, <i>J</i> = 15.9, 5.6 Hz, 2H), 2.57–2.44 (m, 2H), 2.31–2.15 (m, 2H), 2.06–1.95 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> 306.2 (calcd 306.1 for C<sub>17</sub>H<sub>21</sub>ClNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 8-(3-Chloropropanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>6a</b>)</h4><div class="NLM_p last">Pale-white solid; mp 74–76 °C; yield 83.4%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.74 (s, 1H), 7.70 (s, 1H), 4.16 (t, <i>J</i> = 8.5 Hz, 2H), 3.66 (t, <i>J</i> = 6.2 Hz, 2H), 3.25 (t, <i>J</i> = 8.5 Hz, 2H), 3.05 (t, <i>J</i> = 7.8 Hz, 2H), 2.98 (t, <i>J</i> = 6.8 Hz, 2H), 2.74 (t, <i>J</i> = 7.8 Hz, 2H). MS (ESI) <i>m</i>/<i>z</i> 264.2 (calcd 264.1 for C<sub>14</sub>H<sub>15</sub>ClNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 8-(4-Chlorobutanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>6b</b>)</h4><div class="NLM_p last">Pale-white solid; mp 75–76 °C; yield 80.3%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.74 (s, 1H), 7.70 (s, 1H), 4.16 (t, <i>J</i> = 8.5 Hz, 2H), 3.71 (t, <i>J</i> = 6.2 Hz, 2H), 3.32–3.22 (m, 2H), 3.20–3.11 (m, 2H), 2.82–2.78 (m, 2H), 2.56–2.42 (m, 2H), 2.32–2.20 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> 278.2 (calcd 278.1 for C<sub>15</sub>H<sub>17</sub>ClNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 8-(5-Chloropentanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>6c</b>)</h4><div class="NLM_p last">Pale-white solid; mp 72–75 °C; yield 65.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.74 (s, 1H), 7.70 (s, 1H), 4.16 (t, <i>J</i> = 8.4 Hz, 2H), 3.61 (t, <i>J</i> = 6.0 Hz, 2H), 3.25 (t, <i>J</i> = 8.0 Hz, 2H), 3.05 (t, <i>J</i> = 7.8 Hz, 2H), 3.05–2.98 (m, 2H), 2.74–2.67 (m, 2H), 1.95–1.83 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 292.2 (calcd 292.1 for C<sub>16</sub>H<sub>19</sub>ClNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 8-(6-Chlorohexanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>6d</b>)</h4><div class="NLM_p last">Pale-white solid; mp 69–71 °C; yield 45.9%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.75 (s, 1H), 7.72 (s, 1H), 4.17–4.13 (m, 2H), 3.64 (t, <i>J</i> = 6.2 Hz, 2H), 3.20 (t, <i>J</i> = 8.4 Hz, 2H), 2.98 (t, <i>J</i> = 7.7 Hz, 4H), 2.69 (dd, <i>J</i> = 10.6, 4.9 Hz, 2H), 1.86–1.73 (m, 4H), 1.59–1.46 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> 306.20 (calcd 306.13 for C<sub>17</sub>H<sub>21</sub>ClNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 8-(4-Chlorobutanoyl)-7-fluoro-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>6e</b>)</h4><div class="NLM_p last">Pale-white solid; mp 70–72 °C; yield 64.9%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.75 (s, 1H), 4.16 (t, <i>J</i> = 8.0 Hz, 2H), 3.72–3.67 (m, 2H), 3.25 (t, <i>J</i> = 8.5 Hz, 2H), 3.18–3.14 (m, 2H), 3.08–3.02 (m, 2H), 2.74 (t, <i>J</i> = 7.8 Hz, 2H), 2.25–2.20 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> 296.2 (calcd 296.1 for C<sub>15</sub>H<sub>16</sub>ClFNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 8-(4-Chlorobutanoyl)-9-fluoro-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>6f</b>)</h4><div class="NLM_p last">Pale-white solid; mp 72–74 °C; yield 63.4%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.69 (s, 1H), 4.15 (t, <i>J</i> = 8.5 Hz, 2H), 3.69 (t, <i>J</i> = 6.0 Hz, 2H), 3.27–3.21 (m, 2H), 3.15 (t, <i>J</i> = 6.8 Hz, 2H), 3.00 (t, <i>J</i> = 7.8 Hz, 2H), 2.73 (t, <i>J</i> = 7.8 Hz, 2H), 2.26–2.20 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> 296.2 (calcd 296.1 for C<sub>15</sub>H<sub>16</sub>ClFNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 8-(4-Chlorobutyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>7a</b>)</h4><div class="NLM_p last">To a suspension of <b>6b</b> (3.2 g, 11 mmol) in 60 mL of CF<sub>3</sub>COOH was added Et<sub>3</sub>SiH (3.82 g, 33 mmol). After reaction at room temperature overnight, the mixture solvent was removed under reduced pressure and the residue was dissolved in 100 mL of dichloromethane and then washed by saturated NaHCO<sub>3</sub> and brine. The dichloromethane layer was dried with anhydrous MgSO<sub>4</sub> and then removed by evaporation, and the crude product was purified by chromatography (petroleum ether:EtOAc = 4:1) to give <b>7a</b>. Pale-yellow oil; yield 81.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 6.92 (s, 1H), 6.83 (s, 1H), 4.09 (dd, <i>J</i> = 11.1, 5.8 Hz, 2H), 3.57 (t, <i>J</i> = 6.5 Hz, 2H), 3.18 (t, <i>J</i> = 8.4 Hz, 2H), 2.96 (t, <i>J</i> = 7.8 Hz, 2H), 2.69 (t, <i>J</i> = 7.8 Hz, 2H), 2.60 (t, <i>J</i> = 7.5 Hz, 2H), 1.90–1.71 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 264.2 (calcd 264.1 for C<sub>15</sub>H<sub>19</sub>ClNO<sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 8-(5-Chloropentyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>7b</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 80.5%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.74 (s, 1H), 7.70 (s, 1H), 4.16 (t, <i>J</i> = 8.5 Hz, 2H), 3.61 (t, <i>J</i> = 6.2 Hz, 2H), 3.25 (t, <i>J</i> = 8.5 Hz, 2H), 3.05 (t, <i>J</i> = 7.8 Hz, 2H), 2.98 (t, <i>J</i> = 6.8 Hz, 2H), 2.74 (t, <i>J</i> = 7.8 Hz, 2H), 1.95–1.83 (m, 4H), 1.63 (s, 2H). MS (ESI) <i>m</i>/<i>z</i> 278.2 (calcd 278.1 for C<sub>16</sub>H<sub>21</sub>ClNO<sup>+</sup> [M + H]<sup>+</sup>).</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> General Procedures for the Preparation of Compounds <b>8</b>–<b>22</b> and <b>24</b></h3><div class="NLM_p">Arylpiperazine (piperidine) (0.32 mmol) and a catalytic amount of KI were added to the suspension of compounds <b>4</b> (1 equiv) and K<sub>2</sub>CO<sub>3</sub> (4 equiv) in CH<sub>3</sub>CN (5.0 mL), and then the mixture was refluxed for 7–9 h. After filtering, CH<sub>3</sub>CN was evaporated to dryness under reduced pressure. The residue was extracted with 75 mL of dichloromethane by three times after it was diluted with 10.0 mL of water. After drying over MgSO<sub>4</sub>, dichloromethane was removed under reduced pressure and the crude product was purified by chromatography (MeOH:CHCl<sub>3</sub> = 10:1) to yield target compounds.</div><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 9-(2-(4-(6-Fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)acetyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>8</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 72.3%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.81 (s, 1H), 7.77 (s, 1H), 7.72 (dd, <i>J</i> = 8.7, 5.1 Hz, 1H), 7.25–7.22 (m, 1H), 7.05 (ddd, <i>J</i> = 9.0, 7.9, 2.0 Hz, 1H), 5.31 (s, 2H), 4.14 (t, <i>J</i> = 8.5 Hz, 3H), 3.84 (s, 2H), 3.24 (t, <i>J</i> = 8.5 Hz, 2H), 3.16 (d, <i>J</i> = 11.5 Hz, 2H), 3.04 (t, <i>J</i> = 7.8 Hz, 2H), 2.73 (t, <i>J</i> = 7.8 Hz, 2H), 2.45–2.38 (m, 2H), 2.24–2.15 (m, 2H), 2.09 (d, <i>J</i> = 12.6 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 448.2023 (calcd 448.2031 for C<sub>26</sub>H<sub>27</sub>FN<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 9-(3-(4-Phenylpiperazin-1-yl)propanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>9</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 73.6%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.67 (s, 1H), 7.66 (s, 1H), 7.33–7.26 (m, 2H), 6.96 (d, <i>J</i> = 7.9 Hz, 2H), 6.88 (t, <i>J</i> = 7.3 Hz, 1H), 3.95–3.88 (m, 2H), 3.26–3.22 (m, 4H), 3.20 (dd, <i>J</i> = 9.4, 5.4 Hz, 2H), 2.99–2.95 (m, 2H), 2.92 (t, <i>J</i> = 7.4 Hz, 2H), 2.87 (t, <i>J</i> = 6.2 Hz, 2H), 2.76–2.64 (m, 6H), 1.99 (dt, <i>J</i> = 12.2, 6.1 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 404.2342 (calcd 404.2333 for C<sub>25</sub>H<sub>30</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 9-(3-(4-(Pyridin-2-yl)piperazin-1-yl)propanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>10</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 70.3%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.23 (d, <i>J</i> = 4.0 Hz, 1H), 7.73 (s, 1H), 7.71 (s, 1H), 7.58 (t, <i>J</i> = 7.8 Hz, 1H), 6.79 (dd, <i>J</i> = 6.8, 5.2 Hz, 1H), 6.71 (d, <i>J</i> = 8.5 Hz, 1H), 4.26–3.99 (m, 4H), 3.95–3.84 (m, 4H), 3.57 (t, <i>J</i> = 6.4 Hz, 2H), 3.46–3.26 (m, 4H), 3.05–2.94 (m, 2H), 2.87 (t, <i>J</i> = 6.0 Hz, 2H), 2.75–2.65 (m, 2H), 2.03–1.93 (m, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 405.2272 (calcd 405.2285 for C<sub>24</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 9-(3-(4-(Pyrimidin-2-yl)piperazin-1-yl)propanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>11</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 65.3%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.32 (d, <i>J</i> = 4.7 Hz, 2H), 7.66 (s, 1H), 7.65 (s, 1H), 6.51 (t, <i>J</i> = 4.7 Hz, 1H), 4.08–3.78 (m, 6H), 3.23 (t, <i>J</i> = 7.3 Hz, 2H), 2.97–2.92 (m, 4H), 2.86 (t, <i>J</i> = 6.2 Hz, 2H), 2.73–2.67 (m, 2H), 2.66–2.62 (m, 4H), 2.00–1.96 (m, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 406.2246 (calcd 406.2238 for C<sub>23</sub>H<sub>28</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 9-(3-(4-(2-Methoxyphenyl)piperazin-1-yl)propanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>12</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 62.5%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.67 (s, 1H), 7.66 (s, 1H), 7.33–7.26 (m, 1H), 6.96 (d, <i>J</i> = 7.9 Hz, 2H), 6.88 (t, <i>J</i> = 7.3 Hz, 1H), 3.95–3.88 (m, 5H), 3.26–3.22 (m, 4H), 3.20 (dd, <i>J</i> = 9.4, 5.4 Hz, 2H), 2.99–2.95 (m, 2H), 2.92 (t, <i>J</i> = 7.4 Hz, 2H), 2.87 (t, <i>J</i> = 6.2 Hz, 2H), 2.76–2.64 (m, 6H), 1.99 (dt, <i>J</i> = 12.2, 6.1 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 434.2430 (calcd 434.2438 for C<sub>26</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>)</div></div><div id="sec5_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 9-(3-(4-(2,3-Dimethylphenyl)piperazin-1-yl)propanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>13</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 67.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.68 (s, 1H), 7.67 (s, 1H), 7.10 (t, <i>J</i> = 7.7 Hz, 1H), 6.97–6.91 (m, 2H), 3.95–3.89 (m, 2H), 3.23 (t, <i>J</i> = 7.4 Hz, 2H), 3.02–2.91 (m, 8H), 2.87 (t, <i>J</i> = 6.2 Hz, 2H), 2.80–2.67 (m, 6H), 2.29 (s, 3H), 2.24 (s, 3H), 1.99 (dt, <i>J</i> = 12.1, 6.1 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 432.3653 (calcd 432.2646 for C<sub>27</sub>H<sub>34</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 9-(3-(4-(4-Chlorophenyl)piperazin-1-yl)propanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>14</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 68.8%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.66 (s, 1H), 7.65 (s, 1H), 7.21 (d, <i>J</i> = 9.0 Hz, 2H), 6.91–6.81 (d, <i>J</i> = 9.0 Hz, 2H), 3.95–3.85 (m, 2H), 3.19 (dd, <i>J</i> = 8.9, 4.2 Hz, 6H), 2.98–2.94 (m, 2H), 2.92 (t, <i>J</i> = 7.4 Hz, 2H), 2.86 (t, <i>J</i> = 6.2 Hz, 2H), 2.75–2.66 (m, 6H), 1.98 (m, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 438.1957 (calcd 438.1943 for C<sub>25</sub>H<sub>29</sub>ClN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 9-(3-(4-(2,3-Dichlorophenyl)piperazin-1-yl)propanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>15</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 76.1%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.67 (s, 1H), 7.65 (s, 1H), 7.21–7.10 (m, 2H), 6.98 (dd, <i>J</i> = 7.3, 2.3 Hz, 1H), 4.01–3.83 (m, 2H), 3.20 (t, <i>J</i> = 7.4 Hz, 2H), 3.11 (s, 4H), 2.96 (dt, <i>J</i> = 10.5, 7.2 Hz, 4H), 2.87 (t, <i>J</i> = 6.2 Hz, 2H), 2.79–2.66 (m, 6H), 1.99 (dt, <i>J</i> = 12.2, 6.1 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 472.1562 (calcd 472.1553 for C<sub>25</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 9-(3-(4-(Benzo[<i>d</i>]isothiazol-3-yl)piperazin-1-yl)propanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>16</b>)</h4><div class="NLM_p last">Pale-yellow solid; mp 145–147 °C; yield 72.3%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.91 (d, <i>J</i> = 8.2 Hz, 1H), 7.81 (d, <i>J</i> = 8.1 Hz, 1H), 7.66 (d, <i>J</i> = 9.5 Hz, 2H), 7.49–7.45 (m, 1H), 7.38–7.32 (m, 1H), 3.93–3.87 (m, 2H), 3.63–3.53 (m, 4H), 3.21 (t, <i>J</i> = 7.4 Hz, 2H), 2.95 (q, <i>J</i> = 7.1 Hz, 4H), 2.85 (t, <i>J</i> = 6.2 Hz, 2H), 2.79–2.75 (m, 4H), 2.72–2.65 (m, 2H), 1.97 (dt, <i>J</i> = 12.2, 6.1 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 461.2012 (calcd 461.2006 for C<sub>26</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub>S <sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 9-(3-(4-(Benzo[<i>d</i>]thiazol-2-yl)piperidin-1-yl)propanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>17</b>)</h4><div class="NLM_p last">Pale-yellow solid; mp 165–166 °C; yield 75.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.98 (d, <i>J</i> = 8.1 Hz, 1H), 7.87 (d, <i>J</i> = 7.9 Hz, 1H), 7.66 (d, <i>J</i> = 9.6 Hz, 2H), 7.51–7.42 (m, 1H), 7.40–7.32 (m, 1H), 3.96–3.83 (m, 2H), 3.31–3.04 (m, 5H), 3.00–2.81 (m, 6H), 2.78–2.63 (m, 2H), 2.37–2.18 (m, 4H), 2.10–1.91 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i> 460.2060 (calcd 460.2053 for C<sub>27</sub>H<sub>30</sub>N<sub>3</sub>O<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 9-(3-(4-(6-Fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)propanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>18</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 78.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.76 (s, 1H), 7.72 (s, 1H), 7.21–7.11 (m, 2H), 7.03–6.86 (m, 1H), 3.93 (dt, <i>J</i> = 12.9, 6.4 Hz, 3H), 3.42 (t, <i>J</i> = 6.8 Hz, 2H), 3.20 (t, <i>J</i> = 7.3 Hz, 2H), 3.11 (s, 4H), 3.05–2.89 (m, 2H), 2.87 (d, <i>J</i> = 6.2 Hz, 2H), 2.79–2.65 (m, 2H), 2.05–1.92 (m, 6H). HRMS (ESI) <i>m</i>/<i>z</i> 462.2188 (calcd 462.2187 for C<sub>27</sub>H<sub>29</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 9-(4-(4-(2,3-Dimethylphenyl)piperazin-1-yl)butanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>19</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 60.8%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.68 (s, 1H), 7.67 (s, 1H), 7.09 (t, <i>J</i> = 7.7 Hz, 1H), 6.92 (d, <i>J</i> = 7.7 Hz, 2H), 3.95–3.88 (m, 2H), 3.01 (t, <i>J</i> = 7.2 Hz, 4H), 2.98–2.95 (m, 2H), 2.91 (s, 2H), 2.87 (t, <i>J</i> = 6.2 Hz, 2H), 2.69 (dd, <i>J</i> = 17.7, 10.5 Hz, 6H), 2.53 (t, <i>J</i> = 7.2 Hz, 2H), 2.28 (s, 3H), 2.23 (s, 3H), 2.06–1.95 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i> 446.2813 (calcd 462.2802 for C<sub>28</sub>H<sub>36</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 9-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>20</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 58.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.67 (s, 1H), 7.65 (s, 1H), 7.20–7.13 (m, 2H), 6.95 (dd, <i>J</i> = 7.1, 2.4 Hz, 1H), 3.95–3.88 (m, 2H), 3.03 (d, <i>J</i> = 27.0 Hz, 4H), 3.00 (t, <i>J</i> = 7.2 Hz, 2H), 2.98–2.94 (m, 2H), 2.86 (t, <i>J</i> = 6.2 Hz, 2H), 2.69 (dd, <i>J</i> = 15.4, 8.2 Hz, 6H), 2.52 (t, <i>J</i> = 7.2 Hz, 2H), 2.07–1.89 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i> 486.1723 (calcd 486.1710 for C<sub>26</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 9-(4-(4-(Benzo[<i>d</i>]isothiazol-3-yl)piperazin-1-yl)butanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>21</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 62.1%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.92 (d, <i>J</i> = 8.2 Hz, 1H), 7.83 (d, <i>J</i> = 8.1 Hz, 1H), 7.67 (s, 1H), 7.66 (s, 1H), 7.51–7.46 (m, 1H), 7.41–7.34 (m, 1H), 3.95–3.87 (m, 2H), 3.56 (d, <i>J</i> = 4.0 Hz, 4H), 3.02 (t, <i>J</i> = 7.1 Hz, 2H), 2.98–2.94 (m, 2H), 2.86 (t, <i>J</i> = 6.2 Hz, 2H), 2.75–2.68 (m, 6H), 2.55 (t, <i>J</i> = 7.1 Hz, 2H), 2.08–1.95 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i> 475.2168 (calcd 475.2162 for C<sub>27</sub>H<sub>31</sub>N<sub>4</sub>O<sub>2</sub>S <sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 9-(4-(4-(6-Fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)butanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>22</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 63.8%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.66 (s, 1H), 7.65 (s, 1H), 7.29 (s, 1H), 7.27 (d, <i>J</i> = 7.9 Hz, 1H), 7.14 (tt, <i>J</i> = 12.4, 6.2 Hz, 1H), 3.95–3.87 (m, 2H), 3.49–3.40 (m, 3H), 3.21 (t, <i>J</i> = 6.2 Hz, 2H), 3.07–3.00 (m, 2H), 3.00–2.92 (m, 4H), 2.86 (t, <i>J</i> = 6.1 Hz, 2H), 2.72–2.65 (m, 4H), 2.33–2.30 (m, 4H), 1.98–19.5 (m, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 476.2353 (calcd 476.2344 for C<sub>28</sub>H<sub>31</sub>FN<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 9-(5-(4-(6-Fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)pentanoyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>24</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 65.5%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.71 (dd, <i>J</i> = 8.7, 5.1 Hz, 1H), 7.64 (s, 1H), 7.63 (s, 1H), 7.24 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 7.10–7.02 (m, 1H), 3.99–3.84 (m, 2H), 3.50–3.42 (m, 3H), 3.26–3.23 (m, 2H), 3.08 (d, <i>J</i> = 10.0 Hz, 2H), 3.01–2.93 (m, 4H), 2.85 (t, <i>J</i> = 6.2 Hz, 2H), 2.72–2.66 (m, 2H), 2.49–2.43 (m, 2H), 2.14 (dt, <i>J</i> = 21.2, 8.7 Hz, 2H), 2.10–2.03 (m, 4H), 1.97 (dt, <i>J</i> = 12.1, 6.1 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 490.2510 (calcd 490.2500 for C<sub>29</sub>H<sub>33</sub>FN<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> General Procedure for the Preparation of Compounds <b>23</b> and <b>34</b></h3><div class="NLM_p">Ethyl acetoacetate (13.0 g, 100 mmol) was added to 1,2,3,4-tetrahydroquinoline (14.6 g, 110 mmol) in toluene (150 mL), and it was heated at 100 °C overnight. After the reaction completion, the solutions were removed under reduced pressure and the residues were purified by chromatography (petroleum ether:EtOAc = 1:1) to yield 1-(3,4-dihydroquinolin-1(2<i>H</i>)-yl)butane-1,3-dione (<b>25</b>).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Pale-yellow oil; yield 89.5%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.23 (d, <i>J</i> = 8.1 Hz, 1H), 7.23 (dd, <i>J</i> = 14.5, 7.2 Hz, 2H), 7.08–7.02 (m, 1H), 4.08 (t, <i>J</i> = 8.5 Hz, 2H), 3.23 (t, <i>J</i> = 8.4 Hz, 2H), 2.38 (s, 2H), 2.10 (dt, <i>J</i> = 12.1, 6.1 Hz, 2H), 2.04 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 218.2 (calcd 218.1 for C<sub>13</sub>H<sub>16</sub>NO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div><div class="NLM_p">Concentrated sulfuric acid (20 mL) was added to <b>25</b> (10 g, 46.1 mmol) and then it was heated at 100 °C for 6 h. After its cooling, the mixture was poured into 100 mL of ice–water. The precipitate thus formed was neutralized to pH = 8 with saturated NaHCO<sub>3</sub> after filtering and washing with water, resulting 1-methyl-6,7-dihydro pyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>26</b>). Pale-white solid; mp 82–84 °C; yield 69.3%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.57 (d, <i>J</i> = 8.0 Hz, 1H), 7.34 (d, <i>J</i> = 7.3 Hz, 1H), 7.17 (t, <i>J</i> = 7.7 Hz, 1H), 6.61 (s, 1H), 4.67–3.92 (m, 2H), 3.02 (t, <i>J</i> = 6.2 Hz, 2H), 2.48 (d, <i>J</i> = 0.7 Hz, 3H), 2.13 (dt, <i>J</i> = 12.1, 6.1 Hz, 2H). MS (ESI) <i>m</i>/<i>z</i> 200.2 (calcd 200.1 for C<sub>13</sub>H<sub>14</sub>NO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div><div class="NLM_p">A suspension of <b>26</b> (6.0 g, 30.1 mmol) in 50 mL of MeOH was hydrogenated at room temperature under 3 MPa in the presence of 10% palladized charcoal (0.12 g) for 6 h. The mixture was filtered, and MeOH was evaporated. The residue was purified by chromatography (petroleum ether:EtOAc = 6:1) to yield 1-methyl-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>27</b>).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Pale-white solid; mp 71–72 °C; yield 94.3%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.61 (d, <i>J</i> = 7.4 Hz, 1H), 7.36 (d, <i>J</i> = 7.5 Hz, 1H), 7.10 (t, <i>J</i> = 7.5 Hz, 1H), 4.17–4.01 (m, 2H), 3.21 (ddd, <i>J</i> = 18.4, 12.6, 5.0 Hz, 1H), 2.76 (dd, <i>J</i> = 16.5, 6.4 Hz, 2H), 2.44–2.40 (m, 2H), 2.13 (dt, <i>J</i> = 12.1, 6.1 Hz, 2H), 1.34 (d, <i>J</i> = 7.0 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i> 202.2 (calcd 202.1 for C<sub>13</sub>H<sub>16</sub>NO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div><div class="NLM_p">To a suspension of <b>27</b> (5.0 g, 24.9 mmol) in 25 mL of 1,2-dichloroethane was added 4-chlorobutanoyl chloride (3.2 g, 22.3 mmol). Anhydrous aluminum trichloride (6.7 g, 50.5 mmol) was added by portions under ice-cooling. The mixture was kept at 0–5 °C for 30 min after all AlCl<sub>3</sub> addition, and then the reaction was performed at room temperature for 2 h. Then the reaction was quenched with 100 mL of ice–water. The mixture was extracted with 75 mL of dichloromethane three times. After the dichloromethane layer was dried over MgSO<sub>4</sub>, it was removed by evaporation. The crude product was purified by chromatography (petroleum ether:EtOAc = 4:1) to yield 9-(4-chlorobutanoyl)-1-methyl-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>28</b>). Pale-white solid; mp 71–72 °C. Yield 80.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.69 (s, 1H), 7.68 (s, 1H), 3.97–3.86 (m, 2H), 3.70 (t, <i>J</i> = 6.2 Hz, 2H), 3.22–3.09 (m, 3H), 2.88 (t, <i>J</i> = 6.2 Hz, 2H), 2.52 (dd, <i>J</i> = 15.9, 7.3 Hz, 2H), 2.27–2.19 (m, 2H), 2.04–1.95 (m, 2H), 1.33 (d, <i>J</i> = 7.0 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i> 306.2 (calcd 306.1 for C<sub>17</sub>H<sub>21</sub>ClNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div><div class="NLM_p last">6-Fluoro-3-(piperidin-4-yl)benzo[<i>d</i>]isoxazole hydrochloride (0.32 mmol) and a catalytic amount of KI were added to the mixture of compounds <b>28</b> (1 equiv) and K<sub>2</sub>CO<sub>3</sub> (4 equiv) in CH<sub>3</sub>CN (5.0 mL) and then was refluxed for 7–9 h. After cooling, the filtrate was evaporated to dryness under reduced pressure. The residue was extracted with 75 mL of dichloromethane three times after it was diluted with 10.0 mL of water. After drying, dichloromethane was removed under reduced pressure and the crude product was purified by (MeOH:CHCl<sub>3</sub> = 10:1) to afford 9-(4-(4-(6-fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)butanoyl)-1-methyl-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>23</b>). Pale-yellow oil; yield 60.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.73–7.64 (m, 3H), 7.26 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 7.06 (td, <i>J</i> = 8.8, 2.1 Hz, 1H), 4.06–3.93 (m, 1H), 3.92–3.83 (m, 1H), 3.18–3.03 (m, 4H), 3.01 (t, <i>J</i> = 7.1 Hz, 2H), 2.88 (t, <i>J</i> = 6.2 Hz, 2H), 2.55–2.46 (m, 4H), 2.18 (t, <i>J</i> = 10.9 Hz, 2H), 2.10–1.96 (m, 8H), 1.32 (d, <i>J</i> = 7.0 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i> 490.2508 (calcd 490.2500 for C<sub>29</sub>H<sub>33</sub>FN<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> General Procedure for the Preparation of Compounds <b>29</b>, <b>30</b>, and <b>34</b></h3><div class="NLM_p">According method A, 9-(3-(4-(6-fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl) propyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>29</b>). To a suspension of <b>22</b> (0.5 g, 1.1 mmol) in 20 mL of CF<sub>3</sub>COOH was added Et<sub>3</sub>SiH (0.38 g, 3 equiv). After reacting at room temperature overnight, the mixture was evaporated and the residue was dissolved in 100 mL of dichloromethane and then washed by saturated NaHCO<sub>3</sub> and brine. The dichloromethane layer was dried with anhydrous MgSO<sub>4</sub> and then removed under reduced pressure. The crude product was purified by chromatography (MeOH:CHCl<sub>3</sub> = 10:1) to afford <b>29</b>. Pale-yellow oil; yield 81.3%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.71 (dt, <i>J</i> = 11.6, 5.8 Hz, 1H), 7.68 (s, 1H), 7.66 (s, 1H), 7.26 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.12–7.02 (m, 1H), 3.94–3.88 (m, 2H), 3.20 (t, <i>J</i> = 7.3 Hz, 2H), 3.10 (dd, <i>J</i> = 15.3, 7.3 Hz, 3H), 3.00–2.95 (m, 2H), 2.92 (t, <i>J</i> = 7.3 Hz, 2H), 2.87 (t, <i>J</i> = 6.2 Hz, 2H), 2.73–2.69 (m, 2H), 2.30 (t, <i>J</i> = 12.5 Hz, 2H), 2.14–2.05 (m, 4H), 1.99 (dt, <i>J</i> = 12.1, 6.1 Hz, 2H),1.86–1.80(m, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 448.2401 (calcd 448.2395 for C<sub>27</sub>H<sub>31</sub>FN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div><div id="sec5_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 9-(3-(4-(2,3-Dichlorophenyl)piperazin-1-yl)propyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>30</b>)</h4><div class="NLM_p">Pale-yellow oil; yield 83.1%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.65 (s, 1H), 7.63 (s, 1H), 7.18–7.11 (m, 2H), 6.98–6.93 (m, 1H), 3.93–3.87 (m, 2H), 3.26–3.17 (m, 2H), 3.10 (s, 2H), 2.99–2.91 (m, 4H), 2.83 (dd, <i>J</i> = 16.6, 10.0 Hz, 4H), 2.76 (dd, <i>J</i> = 13.5, 7.0 Hz, 4H), 2.67 (dd, <i>J</i> = 15.4, 8.1 Hz, 2H), 1.99–1.86 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i> 458.1751 (calcd 458.1760 for C<sub>29</sub>H<sub>30</sub>FN<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div><div class="NLM_p">According method B, 9-(4-chlorobutyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>] quinolin-3(5<i>H</i>)-one (<b>5</b>). To a suspension of <b>4c</b> (3.2 g, 11 mmol) in 60 mL of CF<sub>3</sub>COOH was added Et<sub>3</sub>SiH (3.82 g, 3 equiv). After reacting at room temperature overnight, the mixture solvent was removed under reduced pressure and the residue was dissolved in 150 mL of dichloromethane and then washed by saturated NaHCO<sub>3</sub> and brine. The dichloromethane layer was dried with anhydrous MgSO<sub>4</sub> and then removed by evaporation, and the crude product was purified by (petroleum ether:EtOAc = 4:1) to give <b>5</b>. Pale-yellow oil; yield 79.7%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 6.83 (d, <i>J</i> = 2.5 Hz, 2H), 3.92–3.85 (m, 2H), 3.58 (t, <i>J</i> = 6.5 Hz, 2H), 2.89–2.82 (m, 2H), 2.78 (t, <i>J</i> = 6.3 Hz, 2H), 2.66 (dd, <i>J</i> = 8.4, 6.5 Hz, 2H), 2.57 (t, <i>J</i> = 7.5 Hz, 2H), 1.95 (dt, <i>J</i> = 12.2, 6.1 Hz, 2H), 1.87–1.81 (m, 2H), 1.79–1.73 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> 278.2 (calcd 278.1 for C<sub>16</sub>H<sub>21</sub>ClNO<sup>+</sup> [M + H]<sup>+</sup>).</div><div class="NLM_p last">Compounds <b>5</b> (0.32 mmol), K<sub>2</sub>CO<sub>3</sub> (1.28 mmol) in acetonitrile (5.0 mL), arylpiperazine (piperidine) (0.32 mmol), and a catalytic amount of KI were added in CH<sub>3</sub>CN (5.0 mL) and then refluxed for 27–30 h. After cooling, the filtrate was evaporated to dryness under reduced pressure. Then 75 mL of dichloromethane was used and extracted three times, after which the residue was diluted with 10.0 mL of water. After drying over MgSO<sub>4</sub>, dichloromethane were removed by evaporation. The crude product was purified by chromatography (MeOH:CHCl<sub>3</sub> = 50:1) to give target compounds 9-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>31</b>). Pale-yellow oil; yield 71.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.21–7.12 (m, 2H), 7.02–6.95 (m, 1H), 6.84 (d, <i>J</i> = 2.3 Hz, 2H), 3.93–3.83 (m, 2H), 3.18–3.07 (m, 4H), 2.92–2.85 (m, 2H), 2.78 (t, <i>J</i> = 6.2 Hz, 2H), 2.66 (dd, <i>J</i> = 8.4, 6.5 Hz, 6H), 2.58 (t, <i>J</i> = 7.4 Hz, 2H), 2.50–2.45 (m, 2H), 1.97–1.93 (m, 2H), 1.69–1.56 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i> 472.1926 (calcd 472.1917 for C<sub>26</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 9-(4-(4-(Benzo[<i>d</i>]isothiazol-3-yl)piperazin-1-yl)butyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>32</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 72.5%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.93 (d, <i>J</i> = 8.2 Hz, 1H), 7.83 (d, <i>J</i> = 8.1 Hz, 1H), 7.53–7.45 (m, 1H), 7.41–7.34 (m, 1H), 6.85 (d, <i>J</i> = 2.6 Hz, 2H), 3.94–3.82 (m, 2H), 3.69–3.54 (m, 4H), 2.91–2.83 (m, 2H), 2.79 (t, <i>J</i> = 6.2 Hz, 2H), 2.73–2.68 (m, 4H), 2.66 (dd, <i>J</i> = 8.4, 6.5 Hz, 2H), 2.59 (t, <i>J</i> = 7.5 Hz, 2H), 2.51–2.46 (m, 2H), 1.95 (dt, <i>J</i> = 12.2, 6.1 Hz, 2H), 1.71–1.57 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i> 461.2378 (calcd 461.2370 for C<sub>27</sub>H<sub>33</sub>N<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 9-(4-(4-(6-Fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)butyl)-1,2,6,7-tetrahydro pyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>33</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 71.1%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.72 (dd, <i>J</i> = 8.5, 5.1 Hz, 1H), 7.26 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 7.07 (td, <i>J</i> = 8.8, 1.7 Hz, 1H), 6.84 (d, <i>J</i> = 1.9 Hz, 2H), 3.91–3.85 (m, 2H), 3.09 (d, <i>J</i> = 9.2 Hz, 3H), 2.90–2.84 (m, 2H), 2.78 (t, <i>J</i> = 6.2 Hz, 2H), 2.68–2.64 (m, 2H), 2.58 (t, <i>J</i> = 7.4 Hz, 2H), 2.46–2.41 (m, 2H), 2.19–2.03 (m, 6H), 1.95 (dt, <i>J</i> = 12.1, 6.2 Hz, 2H), 1.66–1.60 (m, 19.0 Hz, 4H). HRMS (ESI) <i>m</i>/<i>z</i> 462.2541 (calcd 462.2551 for C<sub>28</sub>H<sub>33</sub>FN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 9-(4-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butyl)-1-methyl-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>34</b>)</h4><div class="NLM_p last">According to method A. Pale-yellow oil; yield 83.3%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.74 (dd, <i>J</i> = 8.6, 5.1 Hz, 1H), 7.26 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 7.08 (td, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.84 (d, <i>J</i> = 2.4 Hz, 2H), 3.89–3.87 (m, 2H), 3.16 (d, <i>J</i> = 10.8 Hz, 3H), 2.89–2.84 (m, 2H), 2.78 (t, <i>J</i> = 6.2 Hz, 2H), 2.67–2.63 (m, 2H), 2.57 (dd, <i>J</i> = 19.0, 12.1 Hz, 6H), 2.24–2.07 (m, 4H), 1.94 (dt, <i>J</i> = 12.1, 6.1 Hz, 2H), 1.65 (s, 6H). HRMS (ESI) <i>m</i>/<i>z</i> 476.2715 (calcd 476.2708 for C<sub>29</sub>H<sub>35</sub>FN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> General Procedure for the Preparation of Compound <b>35</b> and <b>36</b></h3><div class="NLM_p">To a suspension of <b>22</b> (3 mmol) in 30 mL of methanol, NaBH<sub>4</sub> (3.1 mmol) was added by portions under the room temperature. After being stirred for 6–8 h, the reaction was quenched by 100 mL of ice–water, 75 mLof dichloromethane was used to extracte the mixture by three times. The dichloromethane layer was dried with anhydrous MgSO<sub>4</sub> and evaporated under reduced pressure. The crude product was purified chromatography (MeOH:CHCl<sub>3</sub> = 10:1) to give 9-(3-(4-(6-fluoro benzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)-1-hydroxypropyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one <b>35</b>. Pale-yellow oil; yield 92.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.71 (dt, <i>J</i> = 11.6, 5.8 Hz, 1H), 7.68 (s, 1H), 7.66 (s, 1H), 7.26 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.12–7.02 (m, 1H), 3.94–3.88 (m, 2H), 3.20 (t, <i>J</i> = 7.3 Hz, 2H), 3.10 (dd, <i>J</i> = 15.3, 7.3 Hz, 3H), 3.00–2.95 (m, 2H), 2.92 (t, <i>J</i> = 7.3 Hz, 2H), 2.87 (t, <i>J</i> = 6.2 Hz, 2H), 2.73–2.69 (m, 2H), 2.30 (t, <i>J</i> = 12.5 Hz, 2H), 2.14–2.05 (m, 4H), 1.99 (dt, <i>J</i> = 12.1, 6.1 Hz, 2H), 1.86–1.80 (m, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 464.2344 (calcd 464.2344 for C<sub>27</sub>H<sub>31</sub>FN<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div><div id="sec5_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 9-(4-(4-(6-Fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)-1-hydroxybutyl)-1,2,6,7-tetrahydropyrido[3,2,1-<i>ij</i>]quinolin-3(5<i>H</i>)-one (<b>36</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 93.8%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.72 (dd, <i>J</i> = 8.5, 5.1 Hz, 1H), 7.26 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 7.07 (td, <i>J</i> = 8.8, 1.7 Hz, 1H), 6.84 (d, <i>J</i> = 1.9 Hz, 2H), 3.94–3.82 (m, 2H), 3.09 (d, <i>J</i> = 9.2 Hz, 3H), 2.93–2.84 (m, 2H), 2.78 (t, <i>J</i> = 6.2 Hz, 2H), 2.69–2.62 (m, 2H), 2.58 (t, <i>J</i> = 7.4 Hz, 2H), 2.52–2.41 (m, 2H), 2.23–2.04 (m, 6H), 1.95 (dt, <i>J</i> = 12.1, 6.2 Hz, 2H), 1.69–1.57 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i> 478.2505 (calcd 478.2500 for C<sub>28</sub>H<sub>33</sub>FN<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> General Procedures for the Preparation of Compounds <b>37</b>–<b>48</b></h3><div class="NLM_p">Compounds <b>6</b> (0.32 mmol), K<sub>2</sub>CO<sub>3</sub> (3 equiv), arylpiperazine (piperidine) (1 equiv), and a catalytic amount of KI were added in 5.0 mL of CH<sub>3</sub>CN and then refluxed for 7–9 h. After reaction, the filtrate was evaporated to dryness under reduced pressure. The residue was extracted with 75 mL of dichloromethane three times, after which it was diluted with 10.0 mL of water. After dried over MgSO<sub>4</sub>, dichloromethane were removed by evaporation. The crude product was purified by chromatography (MeOH:CHCl<sub>3</sub> = 10:1) to give target compounds.</div><div id="sec5_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 8-(3-(4-(2,3-Dimethylphenyl)piperazin-1-yl)propanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>37</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 88.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.77 (s, 1H), 7.73 (s, 1H), 7.09 (t, <i>J</i> = 7.7 Hz, 1H), 6.93 (dd, <i>J</i> = 10.1, 8.1 Hz, 2H), 4.15 (t, <i>J</i> = 8.5 Hz, 2H), 3.25 (t, <i>J</i> = 8.5 Hz, 2H), 3.21 (t, <i>J</i> = 7.4 Hz, 2H), 3.05 (t, <i>J</i> = 7.8 Hz, 2H), 3.00–2.90 (m, 6H), 2.74 (t, <i>J</i> = 7.8 Hz, 6H), 2.28 (s, 3H), 2.24 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> 418.2478 (calcd 418.2489 for C<sub>26</sub>H<sub>32</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 8-(3-(4-(2,3-Dichlorophenyl)piperazin-1-yl)propanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>38</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 89.1%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.76 (s, 1H), 7.71 (s, 1H), 7.21–7.14 (m, 2H), 7.02–6.95 (m, 1H), 4.15 (t, <i>J</i> = 8.5 Hz, 2H), 3.27–3.20 (m, 4H), 3.12 (s, 2H), 3.04 (t, <i>J</i> = 7.8 Hz, 2H), 2.99 (t, <i>J</i> = 7.3 Hz, 2H), 2.77 (d, <i>J</i> = 21.4 Hz, 4H), 2.74 (t, <i>J</i> = 7.8 Hz, 4H). HRMS (ESI) <i>m</i>/<i>z</i> 458.1388 (calcd 458.1397 for C<sub>24</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 3-Fluoro-4-(4-(3-oxo-3-(4-oxo-2,4,5,6-tetrahydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-8-yl)propyl)piperazin-1-yl)benzonitrile (<b>39</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 91.1%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.75 (s, 1H), 7.71 (s, 1H), 7.39–7.35 (m, <i>J</i> = 8.4, 1.4 Hz, 1H), 7.32–7.25 (m, 1H), 6.93 (t, <i>J</i> = 8.5 Hz, 1H), 4.15 (t, <i>J</i> = 8.4 Hz, 2H), 3.25 (dd, <i>J</i> = 9.3, 5.5 Hz, 6H), 3.17 (t, <i>J</i> = 7.3 Hz, 2H), 3.04 (t, <i>J</i> = 7.8 Hz, 2H), 2.92 (t, <i>J</i> = 7.3 Hz, 2H), 2.74 (t, <i>J</i> = 7.8 Hz, 2H), 2.72–2.70 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i> 433.2030 (calcd 433.2034 for C<sub>25</sub>H<sub>26</sub>FN<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 8-(3-(4-(Benzo[<i>d</i>]isothiazol-3-yl)piperazin-1-yl)propanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>40</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 92.3%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.92 (d, <i>J</i> = 8.2 Hz, 1H), 7.82 (d, <i>J</i> = 8.1 Hz, 1H), 7.77 (s, 1H), 7.72 (s, 1H), 7.48 (t, <i>J</i> = 7.5 Hz, 1H), 7.37 (t, <i>J</i> = 7.5 Hz, 1H), 4.15 (t, <i>J</i> = 8.5 Hz, 2H), 3.63–3.55 (m, 4H), 3.25 (t, <i>J</i> = 8.5 Hz, 2H), 3.21 (t, <i>J</i> = 7.4 Hz, 2H), 3.04 (t, <i>J</i> = 7.8 Hz, 2H), 2.95 (t, <i>J</i> = 7.4 Hz, 2H), 2.79–2.76 (m, 4H), 2.74 (t, <i>J</i> = 7.8 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 477.1856 (calcd 447.1849 for C<sub>25</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_8_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 8-(3-(4-(6-Fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)propanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>41</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 89.9%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.77 (s, 1H), 7.74–7.69 (m, 2H), 7.26 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.07 (td, <i>J</i> = 8.8, 2.1 Hz, 1H), 4.16 (t, <i>J</i> = 8.5 Hz, 2H), 3.26 (t, <i>J</i> = 8.5 Hz, 2H), 3.20 (t, <i>J</i> = 7.4 Hz, 2H), 3.13 (d, <i>J</i> = 11.4 Hz, 3H), 3.05 (t, <i>J</i> = 7.8 Hz, 2H), 2.92 (t, <i>J</i> = 7.4 Hz, 2H), 2.74 (t, <i>J</i> = 7.8 Hz, 2H), 2.29 (dd, <i>J</i> = 14.0, 11.4 Hz, 2H), 2.18–2.04 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i> 448.2030 (calcd 448.2031 for C<sub>26</sub>H<sub>27</sub>FN<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_8_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 8-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>42</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 75.3%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.77 (s, 1H), 7.71 (d, <i>J</i> = 12.1 Hz, 1H), 7.22–7.12 (m, 2H), 7.01–6.91 (m, 1H), 4.51 (t, <i>J</i> = 8.5 Hz, 2H), 4.15 (t, <i>J</i> = 8.5 Hz, 2H), 3.78 (t, <i>J</i> = 8.5 Hz, 2H), 3.25 (t, <i>J</i> = 8.5 Hz, 2H), 3.13–3.06 (m, 4H), 3.03 (m, 4H), 2.75 (t, <i>J</i> = 8.5 Hz, 4H), 2.10–1.95 (m, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 472.1559 (calcd 472.1553 for C<sub>25</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_8_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 8-(4-(4-(Benzo[<i>d</i>]isothiazol-3-yl)piperazin-1-yl)butanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>43</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 72.5%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.87 (d, <i>J</i> = 8.2 Hz, 1H), 7.84 (d, <i>J</i> = 8.1 Hz, 1H), 7.75 (s, 1H), 7.71 (s, 1H), 7.51 (t, <i>J</i> = 7.4 Hz, 1H), 7.39 (t, <i>J</i> = 7.5 Hz, 1H), 4.14 (td, <i>J</i> = 8.5, 3.8 Hz, 2H), 3.89 (d, <i>J</i> = 12.5 Hz, 2H), 3.75 (dd, <i>J</i> = 10.8, 4.8 Hz, 2H), 3.47 (t, <i>J</i> = 6.1 Hz, 2H), 3.23 (dt, <i>J</i> = 23.0, 11.6 Hz, 2H), 3.13 (t, <i>J</i> = 7.0 Hz, 2H), 3.03 (dd, <i>J</i> = 14.7, 7.5 Hz, 4H), 2.73 (td, <i>J</i> = 7.8, 3.5 Hz, 2H), 2.23 (dt, <i>J</i> = 13.2, 6.7 Hz, 2H), 2.06–1.98 (m, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 461.2018 (calcd 461.2006 for C<sub>26</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_8_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 8-(4-(4-(6-Fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)butanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>44</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 71.4%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.70 (d, <i>J</i> = 17.1 Hz, 1H), 7.67 (s, 1H), 7.62 (dt, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.17 (dt, <i>J</i> = 8.3, 4.1 Hz, 1H), 7.00 (ddd, <i>J</i> = 8.6, 6.4, 1.8 Hz, 1H), 4.08 (t, <i>J</i> = 8.2 Hz, 2H), 3.19 (t, <i>J</i> = 8.0 Hz, 2H), 3.05–2.90 (m, 7H), 2.67 (t, <i>J</i> = 7.5 Hz, 2H), 2.44 (t, <i>J</i> = 6.5 Hz, 2H), 2.12 (t, <i>J</i> = 10.3 Hz, 2H), 2.04–1.89 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 198.84, 167.84, 165.28, 163.83, 163.69, 162.79, 161.14, 145.46, 133.08, 129.15, 126.66, 123.96, 122.55, 122.44, 119.61, 117.33, 117.32, 112.38, 112.13, 97.51, 97.25, 57.93, 53.45, 45.70, 36.16, 34.52, 31.44, 30.51, 27.33, 24.24, 21.97. HRMS (ESI) <i>m</i>/<i>z</i> 462.2188 (calcd 462.2187 for C<sub>27</sub>H<sub>29</sub>FN<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_8_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 7-Fluoro-8-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>45</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 73.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.65 (s, 1H), 7.64–7.60 (m, 1H), 7.19–7.10 (m, 1H), 7.06–6.98 (m, 1H), 4.10 (t, <i>J</i> = 8.2 Hz, 2H), 3.18 (t, <i>J</i> = 8.0 Hz, 2H), 3.05–2.90 (m, 7H), 2.66 (t, <i>J</i> = 7.5 Hz, 2H), 2.45 (t, <i>J</i> = 6.5 Hz, 2H), 2.13 (t, <i>J</i> = 10.3 Hz, 2H), 2.05–1.89 (m, 6H). HRMS (ESI) <i>m</i>/<i>z</i> 480.2099 (calcd 480.2093 for C<sub>27</sub>H<sub>28</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_8_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 9-Fluoro-8-(4-(4-(6-fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)butanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>46</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 72.6%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.72 (s, 1H), 7.62 (dt, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.17 (dt, <i>J</i> = 8.3, 4.1 Hz, 1H), 7.00 (ddd, <i>J</i> = 8.6, 6.4, 1.8 Hz, 1H), 4.08 (t, <i>J</i> = 8.2 Hz, 2H), 3.19 (t, <i>J</i> = 8.0 Hz, 2H), 3.05–2.90 (m, 7H), 2.67 (t, <i>J</i> = 7.5 Hz, 2H), 2.44 (t, <i>J</i> = 6.5 Hz, 2H), 2.12 (t, <i>J</i> = 10.3 Hz, 2H), 2.04–1.89 (m, 6H). HRMS (ESI) <i>m</i>/<i>z</i> 480.2100 (calcd 480.2093 for C<sub>27</sub>H<sub>28</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_8_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 8-(5-(4-(6-Fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)pentanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>47</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 70.4%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.72–7.67 (m, 3H), 7.21–7.18 (m, 1H), 7.05–7.00 (m, 1H), 4.13–4.10 (m, 2H), 3.21 (dd, <i>J</i> = 10.9, 5.4 Hz, 2H), 3.06–2.93 (m, 7H), 2.69 (dd, <i>J</i> = 11.3, 7.5 Hz, 2H), 2.43 (d, <i>J</i> = 7.5 Hz, 2H), 2.11–2.03 (m, 6H), 1.76 (s, 2H), 1.61 (d, <i>J</i> = 6.4 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 198.90, 167.81, 165.25, 163.84, 163.71, 162.76, 161.09, 145.50, 132.86, 129.17, 126.62, 123.92, 122.64, 122.53, 119.62, 117.29, 117.28, 112.37, 112.12, 97.49, 97.22, 58.57, 53.56, 45.68, 38.27, 34.60, 31.42, 30.55, 27.32, 26.63, 24.22, 22.65. HRMS (ESI) <i>m</i>/<i>z</i> 476.2348 (calcd 476.2344 for C<sub>28</sub>H<sub>31</sub>FN<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_8_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 8-(6-(4-(6-Fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)hexanoyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>48</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 66.1%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.78–7.68 (m, 3H), 7.26–7.18 (m, 1H), 7.10–7.00 (m, 1H), 4.20–4.10 (m, 2H), 3.44 (t, <i>J</i> = 6.2 Hz, 2H), 3.20–2.90 (m, 9H), 2.72–2.66 (m, 2H), 2.20–1.95 (m, 6H), 1.86–1.73 (m, 4H), 1.59–1.46 (m, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 490.2506 (calcd 490.2500 for C<sub>29</sub>H<sub>33</sub>FN<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> General Procedure for the Preparation of Compounds <b>49</b>–<b>51</b></h3><div class="NLM_p">According method A, 8-(3-(4-(6-Fuorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl) propyl)-5,6-dihydro-1<i>H</i>-pyrrolo [3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>49</b>). To a suspension of <b>41</b> (0.5 g, 1.1 mmol) in 20 mL of CF<sub>3</sub>COOH was added Et<sub>3</sub>SiH (0.38 g, 3 equiv). After reaction at room temperature overnight, the mixture solvent was removed under reduced pressure and the residue was dissolved in 100 mL of dichloromethane and then washed by saturated NaHCO<sub>3</sub> and brine. The dichloromethane layer was dried with anhydrous MgSO<sub>4</sub> and then removed by evaporation, and the crude product was purified by chromatography (MeOH:CHCl<sub>3</sub> = 10:1) to give <b>49</b>. Pale-yellow oil; yield 92.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.76 (s, 1H), 7.72 (s, 1H), 7.71–7.68 (m, 1H), 7.29–7.20 (m, 1H), 7.06 (td, <i>J</i> = 8.8, 1.9 Hz, 1H), 4.15 (t, <i>J</i> = 8.5 Hz, 2H), 3.25 (t, <i>J</i> = 8.5 Hz, 2H), 3.18 (dt, <i>J</i> = 13.1, 7.8 Hz, 3H), 3.09 (dt, <i>J</i> = 22.0, 9.4 Hz, 4H), 3.04 (t, <i>J</i> = 7.8 Hz, 2H), 2.91 (t, <i>J</i> = 7.4 Hz, 2H), 2.74 (t, <i>J</i> = 7.8 Hz, 2H), 2.30–2.26 (m, 2H), 2.15–2.06 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i> 434.2230 (calcd 434.2238 for C<sub>26</sub>H<sub>29</sub>FN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div><div class="NLM_p">According method B, Compounds <b>7</b> (0.32 mmol), K<sub>2</sub>CO<sub>3</sub> (4 equiv), arylpiperazine (piperidine) (1 equiv), and a catalytic amount of KI were added in 5.0 mL of CH<sub>3</sub>CN and then refluxed for 27–30 h. After reaction, the filtrate was evaporated to dryness under reduced pressure. The residue was extracted with 75 mL of dichloromethane three times, after which it was diluted with 10.0 mL of water. After drying over MgSO<sub>4</sub>, dichloromethane was removed by evaporation. The crude product was purified by chromatography (MeOH:CHCl<sub>3</sub> = 50:1) to give target compounds.</div><div id="sec5_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 8-(4-(4-(6-Fuorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)butyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>50</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 70.2%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.83 (d, <i>J</i> = 7.2 Hz, 1H), 7.26 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 7.10 (td, <i>J</i> = 8.8, 2.0 Hz, 1H), 6.92 (s, 1H), 6.83 (s, 1H), 4.08 (t, <i>J</i> = 8.4 Hz, 2H), 3.42–3.23 (m, 3H), 3.18 (t, <i>J</i> = 8.4 Hz, 2H), 2.96 (t, <i>J</i> = 7.7 Hz, 2H), 2.68 (t, <i>J</i> = 7.7 Hz, 4H), 2.62 (t, <i>J</i> = 7.5 Hz, 4H), 2.33 (s, 4H), 1.76 (s, 2H), 1.71–1.57 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.46, 165.30, 163.91, 163.78, 162.81, 161.09, 139.32, 137.97, 128.91, 125.39, 123.25, 122.64, 122.53, 119.87, 117.29, 112.42, 112.17, 97.55, 97.28, 58.82, 53.61, 45.28, 35.70, 34.61, 31.71, 30.52, 30.03, 27.78, 26.64, 24.44. HRMS (ESI) <i>m</i>/<i>z</i> 448.2383 (calcd 448.2395 for C<sub>27</sub>H<sub>31</sub>FN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 8-(5-(4-(6-Fuorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)pentyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>51</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 69.8%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.74 (dd, <i>J</i> = 8.6, 5.1 Hz, 1H), 7.26 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 7.15–7.00 (m, 1H), 6.92 (s, 1H), 6.83 (s, 1H), 4.09 (t, <i>J</i> = 8.4 Hz, 2H), 3.29–3.09 (m, 5<i>H</i>), 2.96 (t, <i>J</i> = 7.8 Hz, 2H), 2.69 (t, <i>J</i> = 7.7 Hz, 2H), 2.64–2.54 (m, 2H), 2.49 (s, 2H), 2.19 (dd, <i>J</i> = 43.3, 32.1 Hz, 6H), 1.64 (dt, <i>J</i> = 15.2, 7.7 Hz, 4H), 1.39 (dt, <i>J</i> = 15.3, 7.7 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i> 462.2537 (calcd 462.2551 for C<sub>28</sub>H<sub>33</sub>FN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> General Procedure for the Preparation of Compounds <b>52</b>–<b>54</b></h3><div class="NLM_p">To a suspension of <b>41</b> (3 mmol) in 30 mL of methanol, NaBH<sub>4</sub> (3.1 mmol) was added by portions under the room temperature. After stirring for 6–8 h, the reaction was quenched by 100 mL of ice–water, then 75 mLof dichloromethane was used to extracte the mixture by three times. The organic layer was dried with anhydrous MgSO<sub>4</sub>, and dichloromethane was evaporated under reduced pressure. The crude product was purified by means of chromatography (MeOH:CHCl<sub>3</sub> = 10:1) to yield 8-(3-(4-(6-fluorobenzo[<i>d</i>]isoxazol-3-yl)pperidin-1-yl)-1-hydroxypropyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>52</b>). Pale-yellow oil; yield 93.1%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.69 (dd, <i>J</i> = 8.7, 5.1 Hz, 1H), 7.27 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 7.14 (s, 1H), 7.11–7.04 (m, 2H), 4.91 (dd, <i>J</i> = 9.1, 2.3 Hz, 1H), 4.10 (t, <i>J</i> = 8.4 Hz, 2H), 3.34 (s, 1H), 3.19 (dd, <i>J</i> = 16.2, 7.7 Hz, 4H), 2.98 (t, <i>J</i> = 7.8 Hz, 2H), 2.89–2.76 (m, 1H), 2.69 (t, <i>J</i> = 7.7 Hz, 3H), 2.40 (s, 1H), 2.22–2.07 (m, 6H), 1.99–1.87 (m, 1H), 1.87–1.78 (m, 1H). HRMS (ESI) <i>m</i>/<i>z</i> 450.2181 (calcd 450.2187 for C<sub>26</sub>H<sub>29</sub>FN<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div><div id="sec5_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 8-(4-(4-(6-Fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)-1-hydroxybutyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>53</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 92.5%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.76–7.74 (m, 1H), 7.2–7.24 (m, 1H), 7.14 (s, 1H), 7.08–7.04 (m,, 2H), 4.66–4.63 (m, 1H), 4.08 (t, <i>J</i> = 8.4 Hz, 2H), 3.18 (t, <i>J</i> = 8.4 Hz, 4H), 2.97 (t, <i>J</i> = 7.7 Hz, 4H), 2.68 (t, <i>J</i> = 7.8 Hz, 2H), 2.59 (d, <i>J</i> = 5.0 Hz, 2H), 2.29–2.18 (m, 2H), 2.21–2.09 (m, 4H), 2.03–1.91 (m, 2H), 1.87–1.72 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.66, 165.35, 163.98, 163.85, 162.86, 160.54, 141.55, 140.16, 128.84, 123.00, 122.82, 122.71, 120.80, 119.80, 117.05, 112.65, 112.40, 97.57, 97.31, 73.87, 58.90, 53.45, 52.48, 45.37, 40.07, 31.68, 29.66, 27.78, 24.47, 24.10. HRMS (ESI) <i>m</i>/<i>z</i> 464.2335 (calcd 464.2344 for C<sub>27</sub>H<sub>31</sub>FN<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div><div id="sec5_10_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 8-(5-(4-(6-Fluorobenzo[<i>d</i>]isoxazol-3-yl)piperidin-1-yl)-1-hydroxypentyl)-5,6-dihydro-1<i>H</i>-pyrrolo[3,2,1-<i>ij</i>]quinolin-4(2<i>H</i>)-one (<b>54</b>)</h4><div class="NLM_p last">Pale-yellow oil; yield 93.6%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.79–7.74 (m, 1H), 7.26 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.12 (s, 1H), 7.06 (td, <i>J</i> = 8.8, 2.1 Hz, 1H), 7.03 (s, 1H), 4.66 (dd, <i>J</i> = 7.9, 5.4 Hz, 1H), 4.11 (t, <i>J</i> = 8.4 Hz, 2H), 3.26–3.18 (m, 2H), 3.16–3.06 (m, 2H), 3.04–2.94 (m, 2H), 2.70 (t, <i>J</i> = 7.8 Hz, 2H), 2.47–2.39 (m, 2H), 2.28–1.97 (m, 6H), 1.90–1.72 (m, 2H), 1.57–1.49 (m, 4H), 1.46–1.38 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.65, 165.28, 163.86, 163.73, 162.79, 161.01, 141.16, 140.41, 128.94, 123.24, 122.82, 122.71, 120.99, 119.84, 117.19, 117.18, 112.45, 112.19, 97.49, 97.22, 73.99, 58.53, 53.53, 53.41, 45.36, 39.07, 34.42, 31.55, 30.17, 27.72, 26.39, 24.37, 23.76. HRMS (ESI) <i>m</i>/<i>z</i> 478.2512 (calcd 478.2500 for C<sub>28</sub>H<sub>33</sub>FN<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>).</div></div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Receptor Binding Studies</h3><div id="sec5_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> Materials</h4><div class="NLM_p last">The following specific radioligands and tissue sources were used: (a) the serotonin 5-HT<sub>1A</sub> receptor, [<sup>3</sup>H]8-OH-DPAT, from rat brain cortex, (b) the serotonin 5-HT<sub>2A</sub> receptor, [<sup>3</sup>H]ketanserin in the presence of 4-dione hydrochloride hydrate (35 nM) from rat brain cortex, (c) the serotonin 5-HT<sub>2C</sub> receptor, [<sup>3</sup>H]mesulergine, in the presence of spiperone (40 nM) from rat brain cortex, (d) the serotonin 5-HT<sub>6</sub> receptor, [<sup>3</sup>H]lysergic acid diethylamide, from 5-HT<sub>6</sub>-C3 cells (CHO-K1), (e) the dopamine D2 receptor, [<sup>3</sup>H]spiperone, from rat striatum, (f) the histamine H<sub>1</sub> receptor, [<sup>3</sup>H]mepyramine, from guinea pig cerebellum, (g) the adrenergic α<sub>1</sub> receptor, [<sup>3</sup>H]prazosin, from rat cerebral cortex, and (h) the dopaminergic D<sub>3</sub> receptor, [<sup>3</sup>H] 7-OH-DPAT, from rat olfactory tubercle.</div></div><div id="sec5_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> General Procedures for the Binding Assays</h4><div class="NLM_p">All of the new compounds were solved in 50% (v/v) DMSO, and the compound concentration was 2 × 10<sup>–3</sup> M; dilution to the initial concentration of the new compound, 2 × 10<sup>–4</sup> M, contained 5% DMSO. For 5-HT<sub>1A</sub> receptor binding assays, total binding (TB) was determined in the presence of the radioligand [<sup>3</sup>H]8-OH-DPAT. Nonspecific binding (NB) was determined in the presence of the radioligand [<sup>3</sup>H]8-OH-DPAT and serotonin, whereas compound binding (CB) was determined in the presence of the radioligand [<sup>3</sup>H]8-OH-DPAT and the compound of interest. Each specific binding (SB) was calculated as the total binding (TB) minus the nonspecific binding (NB) at a particular concentration of radioligand. Each percentage of inhibition (%) was calculated as follows: percentage of inhibition (%) = [(TB – CB)/(TB – NB)] × 100.</div><div class="NLM_p last">Blank binding experiments contained 0.25% (v/v) DMSO were performed; DMSO had no effect. All compounds were tested at least three times over a 6-fold concentration range (10<sup>–5</sup> M to 10<sup>–10</sup> M). IC<sub>50</sub> values were determined by nonlinear regression analysis with fitting to the Hill equation curve. <i>K</i><sub>i</sub> values were calculated using the Cheng and Prussoff equation, <i>K</i><sub>i</sub> = IC<sub>50</sub>/(1 + <i>C</i>/<i>K</i><sub>d</sub>), where <i>C</i> represents the concentration of the hot ligand used and <i>K</i><sub>d</sub> the receptor dissociation constant of each labeled ligand. The mean <i>K</i><sub>i</sub> values and SEM were derived in at least three independent experiments.</div></div><div id="sec5_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 5-HT<sub>1A</sub> Receptor<a onclick="showRef(event, 'cit28b cit28c'); return false;" href="javascript:void(0);" class="ref cit28b cit28c">(28b,c)</a></h4><div class="NLM_p last">Rat cerebral cortex was homogenized in 20 vol of of ice-cold Tris-HCl buffer (50 mM, pH 7.4) using an ULTRA TURAX homogenizer and was then centrifuged at 32000<i>g</i> for 10 min. The resulting pellet was then resuspended in the same buffer, incubated for 10 min at 37 °C, and centrifuged at 32000<i>g</i> for 10 min. The final pellet was resuspended in Tris-HCl buffer containing 10 mM pargyline, 4 mM CaCl<sub>2</sub>, and 0.1% ascorbic acid. Total binding each assay tube was added 900 μL of the tissue suspension, 50 μL of 0.5 nM [<sup>3</sup>H] 8-OH-DPAT (187.4 Ci/mmol, PerkinElmer Life Sciences, Boston, MA, USA), 50 μL of Tris-HCl buffer containing 10 mM pargyline, 4 mM CaCl<sub>2</sub>, and 0.1% ascorbic acid. For nonspecific binding each assay, to the tube was added 900 μL of the tissue suspension, 50 μL of [<sup>3</sup>H] 8-OH-DPAT, and 50 μL of 10 mM serotonin. Compound binding each assay tube was added 900 μL of the tissue suspension, 50 μL of [<sup>3</sup>H] 8-OH-DPAT, and 50 μL of new compounds or reference drug. The tubes were incubated at 37 °C for 30 min. The incubation was followed by a rapid vacuum filtration through Whatman GF/B glass filters, and the filtrates were washed twice with 5 mL of cold buffer and transferred to scintillation vials. Scintillation fluid (1.0 mL) was added, and the radioactivity bound was measured using a PE Microbeta 2450 liquid scintillation counter.</div></div><div id="sec5_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 5-HT<sub>2A</sub> Receptor.<a onclick="showRef(event, 'cit28b cit28c'); return false;" href="javascript:void(0);" class="ref cit28b cit28c">(28b,c)</a></h4><div class="NLM_p last">Rat cerebral cortex was homogenized in 20 vol of ice-cold Tris-HCl buffer (50 mM, pH 7.4) using an ULTRA TURAX homogenizer and centrifuged at 32000<i>g</i> for 20 min. The resulting pellet was resuspended in the same quantity of the buffer and centrifuged for 20 min. The final pellet was resuspended in 50 vol of the Tris-HCl buffer. For total binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of 0.6 nM [<sup>3</sup>H] ketanserine (60.0 Ci/mmol, PerkinElmer Life Sciences, Boston, MA, USA), 50 μL of 4-dione hydrochloride hydrate, and 50 μL of Tris-HCl buffer. For nonspecific binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of [<sup>3</sup>H] ketanserin, 50 μL of 4-dione hydrochloride hydrate, and 50 μL of 10 mM methisergide. For compound binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of [<sup>3</sup>H] ketanserin, 50 μL of 4-dione hydrochloride hydrate, and 50 μL of new compounds or reference drug. The tubes were incubated at 37 °C for 30 min. The incubation was followed by a rapid vacuum filtration through Whatman GF/B glass filters, and the filtrates were washed twice with 5 mL of cold buffer and transferred to scintillation vials. Scintillation fluid (1.0 mL) was added, and the radioactivity bound was measured using a PE Microbeta 2450 liquid scintillation counter.</div></div><div id="sec5_11_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> Dopamine D2 Receptor<a onclick="showRef(event, 'cit28b cit28c'); return false;" href="javascript:void(0);" class="ref cit28b cit28c">(28b,c)</a></h4><div class="NLM_p last">Rat striatum was homogenized in 20 vol of ice-cold 50 mM Tris-HCl buffer (pH 7.4) using an ULTRA TURAX homogenizer and centrifuged twice for 10 min at 48000<i>g</i> with resuspension of the pellet in fresh buffer. The final pellet was resuspended in 50 mM ice-cold Tris-HCl containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 0.1% ascorbic acid, and 5 mM pargyline. For total binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of 0.5 nM [3H] spiperone (16.2 Ci/mmol; PerkinElmer Life Sciences, Boston, MA, USA) and 50 μL Tris-HCl buffer containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 0.1% ascorbic acid, and 5 mM pargyline. For nonspecific binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of [<sup>3</sup>H]spiperone, and 50 μL of 10 mM (<i>t</i>)-butaclamol. For compound binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of [<sup>3</sup>H] spiperone, and 50 μL of new compounds or reference drug. The tubes were incubated at 37 °C for 30 min. The incubation was followed by a rapid vacuum filtration through Whatman GF/B glass filters, and the filtrates were washed twice with 5 mL of cold buffer and transferred to scintillation vials. Scintillation fluid (1.0 mL) was added, and the radioactivity bound was measured using a PE Microbeta 2450 liquid scintillation counter.</div></div><div id="sec5_11_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Histamine H<sub>1</sub> Receptor<a onclick="showRef(event, 'cit28b cit28c'); return false;" href="javascript:void(0);" class="ref cit28b cit28c">(28b,c)</a></h4><div class="NLM_p last">guinea pig cerebellum was homogenized in 20 vol of ice-cold 50 mM phosphate buffer (pH 7.7) using an ULTRA TURAX homogenizer and centrifuged twice for 10 min at 50000<i>g</i> with resuspension of the pellet in fresh buffer. The final pellet was resuspended in phosphate buffer. For total binding, to each assay tube was added 900 μL of membranes 50 μL of 1 nM [<sup>3</sup>H]mepyramine (20.0 Ci/mmol; PerkinElmer Life Sciences, Boston, MA, USA), and 50 μL of phosphate buffer. For nonspecific binding, to each assay tube was added 900 μL of membranes, 50 μL of [<sup>3</sup>H]mepyramine, and 50 μL of 1 mM promethazine. For compound binding, to each assay tube was added 900 μL of membranes, 50 μL of [<sup>3</sup>H]mepyramine, and 50 μL of new compounds or reference drug. The tubes were incubated at 30 °C for 60 min. The incubation was followed by a rapid vacuum filtration through Whatman GF/B glass filters, and the filtrates were washed twice with 5 mL of cold buffer and transferred to scintillation vials. Scintillation fluid (1.0 mL) was added, and the radioactivity bound was measured using a PE Microbeta 2450 liquid scintillation counter.</div></div><div id="sec5_11_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 5-HT<sub>2C</sub> Receptor<a onclick="showRef(event, 'cit28b cit28c'); return false;" href="javascript:void(0);" class="ref cit28b cit28c">(28b,c)</a></h4><div class="NLM_p last">Rat cerebral cortex was homogenized in 20 vol of ice-cold Tris-HCl buffer (50 mM, pH 7.4) using an ULTRA TURAX homogenizer and centrifuged at 32000<i>g</i> for 20 min. The resulting pellet was resuspended in the same quantity of the buffer centrifuged for 20 min. The final pellet was resuspended in 50 vol of the Tris-HCl buffer. For total binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of [<sup>3</sup>H]mesulergine, 50 mL of spiperone, and 50 μL of Tris-HCl buffer. For nonspecific binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of 1 nM [<sup>3</sup>H]mesulergine (85.4 Ci/mmol; PerkinElmer Life Sciences, Boston, MA, USA), 50 μL of spiperone, and 50 μL of 10 mM mianserin. For compound binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of [<sup>3</sup>H]mesulergine, 50 μL of spiperone, and 50 μL of new compounds or reference drug. The tubes were incubated at 37 °C for 15 min. The incubation was followed by rapid vacuum filtration through Whatman GF/B glass filters, and the filtrates were washed twice with 5 mL of cold buffer and transferred to scintillation vials. Scintillation fluid (1.0 mL) was added, and the radioactivity bound was measured using a PE Microbeta 2450 liquid scintillation counter.</div></div><div id="sec5_11_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> Adrenergic α<sub>1</sub> Receptor<a onclick="showRef(event, 'cit28b cit28c'); return false;" href="javascript:void(0);" class="ref cit28b cit28c">(28b,c)</a></h4><div class="NLM_p last">Rat cerebral cortex was homogenized in 20 vol of ice-cold Tris-HCl buffer containing 5 mM EDTA (50 mM, pH 7.4) using an ULTRA TURAX homogenizer and centrifuged at 44000<i>g</i> for 20 min at 4 °C. The resulting pellet was resuspended in the same quantity of the buffer centrifuged for 20 min. The final pellet was resuspended in 50 vol of the Tris-HCl buffer. For total binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of 1 nM [<sup>3</sup>H]prazosin (85.4 Ci/mmol; PerkinElmer Life Sciences, Boston, MA, USA), and 50 μL of Tris-HCl buffer. For nonspecific binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of 1 nM [<sup>3</sup>H]prazosin, and 50 μL of 10 mMprazosin. For compound binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of [<sup>3</sup>H]prazosin, and 50 μL of new compounds or reference drug. The tubes were incubated at 25 °C for 60 min. The incubation was followed by rapid vacuum filtration through Whatman GF/B glass filters, and the filtrates were washed twice with 5 mL of cold buffer and transferred to scintillation vials. Scintillation fluid (1.0 mL) was added, and the radioactivity bound was measured using a PE Microbeta 2450 liquid scintillation counter.</div></div><div id="sec5_11_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> 5-HT<sub>6</sub> Receptor<a onclick="showRef(event, 'cit28b cit28c'); return false;" href="javascript:void(0);" class="ref cit28b cit28c">(28b,c)</a></h4><div class="NLM_p last">Membranes were prepared from CHO-5-HT<sub>6</sub> cells stably transected with the human serotonin 5-HT<sub>6</sub> receptor cell. The harvested cells were suspended in 1 volume of fresh physiological phosphate buffered saline (PBS) solution and centrifuged at 1000 g. This homogenate was centrifuged at 100000<i>g</i> for 60 min, the resulting pellet was suspended in Tris-HCl (pH 7.4) to obtain a concentration corresponding to 4 × 10<sup>7</sup> cells/mL, and aliquots were stored at −80 °C. For total binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of 2 nM [<sup>3</sup>H]lysergic acid diethylamide (84.0 Ci/mmol, PerkinElmer Life Sciences, Boston, MA, USA), and 50 μL Tris-HCl buffer. For nonspecific binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of [<sup>3</sup>H]lysergic acid diethylamide, and 50 μL of 10 mM serotonin. For compound binding, to each assay tube was added 900 μL of the tissue suspension, 50 μL of [<sup>3</sup>H]lysergic acid diethylamide, and 50 μL of new compounds or reference drug. The tubes were incubated at 37 °C for 30 min. The incubation was followed by a rapid vacuum filtration through Whatman GF/B glass filters, and the filtrates were washed twice with 5 mL of cold buffer and transferred to scintillation vials. Scintillation fluid (1.0 mL) was added, and the radioactivity bound was measured using a PE Microbeta 2450 liquid scintillation counter.</div></div><div id="sec5_11_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> Dopaminergic D<sub>3</sub> Receptor<a onclick="showRef(event, 'cit28b cit28c'); return false;" href="javascript:void(0);" class="ref cit28b cit28c">(28b,c)</a></h4><div class="NLM_p last">A rat olfactory tubercle was homogenized in 20 volumes of ice-cold 50 mM Hepes Na (pH 7.5) using an ULTRA TURAX homogenizer and centrifuged twice for 10 min at 48000<i>g</i> with resuspension of the pellet in fresh buffer. The final pellet was resuspended in 50 mM Hepes Na, pH 7.5, containing 1 mM EDTA, 0.005% ascorbic acid, 0.1% albumin, and 200 nM eliprodil. For total binding, to each assay tube was added 900 μL of membranes, 50 μL of 0.6 nM [<sup>3</sup>H] 7-OH-DPAT (50 Ci/mmol; PerkinElmer Life Sciences, Boston, MA, USA), and 50 μL of 50 mM Hepes Na, pH 7.5, containing 1 mM EDTA, 0.005% ascorbic acid, 0.1% albumin, and 200 nM eliprodil. For nonspecific binding, to each assay tube was added 900 μL of membranes, 50 μL of [<sup>3</sup>H] 7-OH-DPAT (50 Ci/mmol; PerkinElmer Life Sciences, Boston, MA, USA), and 50 μL of 1 μM dopamine. For specific binding, to each assay tube was added 900 μL of membranes, 50 μL of [<sup>3</sup>H] 7-OH-DPAT (50 Ci/mmol; PerkinElmer Life Sciences, Boston, MA, USA), and 50 μL of new compounds or reference drug. The tubes were incubated at 25 °C for 60 min. The incubation was followed by rapid vacuum filtration through Whatman GF/B glass filters, and the filtrates were washed twice with 5 mL of cold buffer and transferred to scintillation vials. Scintillation fluid (1.0 mL) was added, and the radioactivity bound was measured using a PE Microbeta 2450 liquid scintillation counter.</div></div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> Experimental in Vitro Pharmacology for Intrinsic Activity Assessment<a onclick="showRef(event, 'ref22 cit28b'); return false;" href="javascript:void(0);" class="ref ref22 cit28b">(22,28b)</a></h3><div class="NLM_p">HEK cells expressing five receptors (HEK293/D<sub>2L</sub>, HEK293/ACTOne D<sub>3</sub>, HEK293/5-HT<sub>1A</sub>, HEK293/5-HT<sub>2A</sub>, and HEK293T/h5-HT<sub>6</sub>) were seeded in a 384-well black-walled, clear-bottom plate at a density of 1.5 × 10<sup>4</sup> cells/well in cell seeding medium (90% DMEM and 10% dialyzed serum) and incubated in CO<sub>2</sub> incubator for 16–24 h (at least overnight).</div><div class="NLM_p">For the D<sub>2L</sub> assay, all compounds were diluted with DMSO, 1/2 log dilution (3.162-fold), 11 points and triplicate to get the compounds dose, then  the assay buffer added to get the working concentration and do the test. Agonist mode: (1) Diluted the reference compound dopamine to 50 μM (11 points, 5×), (2) diluted the test compounds to working concentration (11 points, 5×). Antagonist mode: (1) Diluted the reference compound SCH23390 to 600 μM (11 points, 6×), (2) diluted the test compounds to working concentration (11 points, 6×). Assay buffer: 1× HBSS, 20 mM HEPES, 2.5 mM probenecid (probenecid is 400 mM stock in 1 M NaOH, add freshly). Assay buffer was used as dye loading buffer, compound dilution buffer, etc., and then gently discarded the medium, and 20 μL of calcium dye loading solution was added into each well. The plate at 37 °C and incubated in the dark for 60 min before calcium signal readout.</div><div class="NLM_p">For the agonist assay, 5 μL/well 5× working concentration of test compounds was added into cell plate using FLIPR and read with FLIPR (FLIPR Calcium 4, Molecular Devices) using the specified settings and saved data. The total assay volume was 25 μL including 20 μL/well dye loading buffer and 5 μL/well 5× working concentration of test compounds.</div><div class="NLM_p">For the antagonist assay, 6× working concentration of antagonist compound at 5 μL/wellwas added to cells and incubated plate at room temperature in the dark for 15 min, transferred to the assay plate to FLIPR, and 5 μL/well 6× working concentration of antagonist compound added was using FLIPR and read with FLIPR using the specified settings and saved data. The total assay volume was 30 μL including 20 μL/well dye loading buffer, 5 μL/well 6× work concentration of test compounds, and 5 μL/well 6× work concentration of agonist compound.</div><div class="NLM_p">Data analysis: FLIPR read the plate and got the maximal fluorescence signal data from the excitation light wavelength at 480 nm and emission light wavelength at 520 nm. All results for test compounds were test three times. According to the positive control (HPE) and negative control (ZPE) results, the effect (%) or inhibition (%) of reference and the test compounds was calculated by using GraphPad Prism 5 to analyze the data and obtained the dose response curve and the value of EC<sub>50</sub> and IC<sub>50</sub>.</div><div class="NLM_p">Effect (%) for agonist mode was calculated from the following equation:<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_m001.gif" alt="" id="_i104" /></img></span>The % effect was then plotted as a function of the log of the cumulative doses of compounds.</div><div class="NLM_p">Inhibition (%) for antagonist mode was calculated from the following equation:<span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_m002.gif" alt="" id="_i105" /></img></span></div><div class="NLM_p last">The % inhibition was then plotted as a function of the log of the cumulative doses of compounds.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> hERG Affinity</h3><div class="NLM_p">The Ability to block hERG potassium channels was determined using the whole-cell patch clamp method and cloned hERG potassium channels (expressed in HEK 293 cells) as biological material.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> For this purpose, the patch clamp amplifier (Axopatch 200B, Molecular Devices) and digital converter (Digidata 1440A, Molecular Devices) were used. Recording electrodes were made from borosilicate glass with filament (BF120-94-15, Sutter Instrument Company). Creation of voltage-clamp command pulse protocols and data acquisition were controlled by pCLAMP software (version 10.1, Molecular Devices). The bath solution consisted of 137 mM NaCl, 5.4 mM KCl, 10 mM glucose, 10 mM HEPES, and 2 mM CaCl<sub>2</sub>. The pH was adjusted to 7.5 by addition of NaOH. The pipet filling solution consisted of 140 mM KCl, 1 mM MgCl<sub>2</sub>, 5 mM EGTA, 10 mM HEPES, and 5 mM Na<sub>2</sub>ATP. The pH was adjusted to 7.2 by addition of KOH. The test compound <b>47</b> was dissolved in 50% (w/v) DMSO and the initial concentration was 1 mM, and the test concentration for compound <b>47</b> was diluted by the bath solution.</div><div class="NLM_p last">To study voltage dependence of steady-state block of hERG channels on different drug concentrations (0.3, 1, 3, and 10 μM) in HEK cells, the holding membrane potential was switched from −80 to +50 mV for 2 s, followed by return to −50 mV for 3 s (sampling rate of 4 kHz, low-pass filtered at 1 kHz) in intervals of 30 s. Tail currents were measured at −50 mV in control and in the presence of the drug at concentrations determined empirically. All raw measurements were performed using Clampfit (version 10.2), a part of pCLAMP software (version 10.1). The hERG inhibition experiments were tested for three independent experiments. Results were transferred to the program Statistical Package for the Social Sciences (SPSS) spreadsheets for further analysis.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> In Vivo Test</h3><div id="sec5_14_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> Animals</h4><div class="NLM_p last">Chinese Kun Ming (KM) mice (20 ± 2.0 g) and Sprague–Dawley (SD) rats (250 ± 5.0 g) were used as experimental animals in this study. All the animals were housed under standardized conditions for light, temperature, and humidity and received standard rat chow and tap water ad libitum. Animals were assigned to different experimental groups randomly, each kept in a separate cage. In the test, the drug was administered po in a vehicle of 10:90 PEG400/H<sub>2</sub>O at a volume of 0.1 mL/10 g. All studies involving animals in this research followed the guidelines of the bylaw of experiments on animals and have been approved by the Ethics and Experimental Animal Committee of Jiangsu Nhwa Pharmaceutical Co., Ltd.</div></div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> Acute Toxicity</h3><div class="NLM_p last">Mice (10 mice in each group) were orally dosed with increasing doses of the compound <b>47</b> (250, 500, 1000, 1500, and 2000 mg/kg). The number of surviving animals was recorded after 24 h of drug administration, and the percent mortality in each group was calculated. The LD<sub>50</sub> values were calculated by using the program SPSS (Statistical Package for the Social Sciences).</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> MK-801-Induced Hyperactivity<a onclick="showRef(event, 'cit28b cit28c'); return false;" href="javascript:void(0);" class="ref cit28b cit28c">(28b,c)</a></h3><div class="NLM_p last">Mice (10 mice in each group) were orally dosed with vehicle or increasing doses of the haloperidol (0.1, 0.3, 1, 3.0, and 10 mg/kg), risperidone (0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg), and compound <b>47</b> (0.03, 0.1, 0.3, and 1 mg/kg). Animals were placed in Plexiglas cages for evaluating locomotor activity. After 60 min, the animals were challenged with 0.3 mg/kg (sc) of MK-801 and the locomotor activity of each animal was recorded for 90 min. Statistical evaluation was performed by Two-Way ANOVA followed by Tukey test for multiple comparisons. #, <i>p</i> < 0.05 versus vehicle treatment; **, <i>p</i> < 0.01, *, <i>p</i> < 0.05 versus MK-801 treatment.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> Apomorphine-Induced Climbing<a onclick="showRef(event, 'cit28b cit28c'); return false;" href="javascript:void(0);" class="ref cit28b cit28c">(28b,c)</a></h3><div class="NLM_p last">Mice (10 mice in each group) were orally dosed with vehicle or increasing doses of the haloperidol (0.1, 0.3, 1, and 3 mg/kg), risperidone (0.01, 0.03, 0.1, and 0.3 mg/kg), and compound <b>47</b> (0.1, 0.3, 1, and 3 mg/kg). Animals were then challenged at 30 min postinjection with 1.0 mg/kg of the apomorphine in 0.9% NaCl + 0.1% ascorbic acid, placed in cylindrical wire cages (12 cm in diameter, 14 cm in height), and observed for climbing behavior at 10, 20, and 30 min post dose. The climbing behavior was scored as follows: 3 or 4 paws on the cage floor = 0 score; 2 and 3 paws on the cage = 1 score; 4 paws on the cage = 2 score. The statistical significances of drug effects were analyzed by the nonparametric two-tailed-Mann–Whitney U test: #, <i>p</i> < 0.05 versus vehicle treatment; **, <i>p</i> < 0.01, *, <i>p</i> < 0.05 versus apomorphine treatment.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> Catalepsy Test<a onclick="showRef(event, 'cit28b cit28c'); return false;" href="javascript:void(0);" class="ref cit28b cit28c">(28b,c)</a></h3><div class="NLM_p last">Mice (10 mice in each group) were orally dosed with vehicle or increasing doses of the haloperidol (0.1, 0.3, 1, 1.5, and 3.0 mg/kg), risperidone (0.1, 0.4, 0.75, 1.5, 3, and 6.0 mg/kg), and compound <b>47</b> (1, 5, 15, 45, and 100 mg/kg). Catalepsy was evaluated on a metal bar 0.3 cm in diameter positioned 4.5 cm above the tabletop. The test consisted in positioning the animal with its forepaws on the bar and recording how long it remained hanging onto the bar; the end point was 60 s and an all-or-none criterion was used. A mean immobility score of 30 s was used as the criterion for the presence of catalepsy.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> Conditioned Avoidance Response (CAR)<a onclick="showRef(event, 'cit28b cit28c ref48'); return false;" href="javascript:void(0);" class="ref cit28b cit28c ref48">(28b,c,48)</a></h3><div class="NLM_p last">Rats were trained daily and tested in a computer-assisted two-way active avoidance apparatus (shuttle box) equipped with a tilting grid floor with microswitch detection and connected to a high resistant power supply. These boxes were divided into two compartments of equal size by a partition with one opening. Upon presentation of the light-conditioned stimulus (CS), the animal had 3 s to move from one compartment of the shuttle box into the other. If the rat remained in the same compartment for more than 3 s, the unconditioned stimulus (UCS) was presented as an electric shock in the grid floor until the rat escaped. If it did not respond within 7 s, including the first 3 s, the trial was terminated (failure). The interval between trials was 45 s. The following variables were recorded: avoidance (response to CS within 3 s), escape (response to CS UCS), failure (failure to respond to CS and CS UCS), and intertrial crossing. The animals were trained on consecutive days until they achieved about 70% conditioned avoidance. The selected animals were given the different oral doses of either <b>47</b> (0.6, 1.2, and 2 mg/kg, po) or risperidone (0.06, 0.2, and 0.6 mg/kg, po). CAR was then tested 60 min later. While the training phase consisted of 40 trials each day (in one session), the testing phase consisted of 20 trials for each session (one session at each of the time points). The number of trials in which an avoidance response occurred was divided by the total number of trials per session to give the percentage avoidance response.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> Weight Gain and Serum Prolactin<a onclick="showRef(event, 'cit28b cit28c ref48'); return false;" href="javascript:void(0);" class="ref cit28b cit28c ref48">(28b,c,48)</a></h3><div class="NLM_p last">Mice (10 mice in each group) were orally dosed with vehicle or increasing doses as follows: risperidone (0.03, 0.09, and 0.27 mg/kg) and <b>47</b> (0.6, 1.8, and 5.4 mg/kg). The animals received multiple doses (28 day) of each compound. The weight of mice was tested every day. The mice were killed by decapitation 180 min after the last treatment. Blood samples (2 mL) were collected and centrifuged (300 g for 30 min), and the resulting serum samples were stored at −20 °C until being analyzed for prolactin (PRL). Serum PRL was determined by an EIA-kit from Amersham. Data were analyzed by Student’s <i>t</i> test (##, <i>p</i> < 0.01).</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> Pharmacokinetics Study in Rats</h3><div class="NLM_p last">The HPLC conditions were as follows: column, XSELECT CSH XP C18 (2.1 mm × 50 mm, 2.5 μm); mobile phase, 0.025% FA and 1 mM NH<sub>4</sub>OAc (Roe Scientific Inc., USA) in water/acetonitrile (Merck Company, Germany) (v/v, 45:55); flow rate, 0.6 mL/min; column temperature, 50 °C. UV detection was performed at 210 nm. For routine compound <b>47</b> screening, rats (<i>n</i> = 6/group) were dosed via the lateral tail vein at the indicated dose for iv administration (1 mg/kg, 100% saline) or via oral gavage (10 mg/kg, suspension in 0.5% methylcellulose). At 30 min and 1, 2, 3, 4, 5, 6, 8, and 24 h after administration, serial blood samples were collected from the lateral tail vein into heparinized collection tubes (approximately 0.25 mL). The plasma was separated by centrifugation, and the sample was prepared for LC/MS analysis by protein precipitation with acetonitrile. The plasma samples were analyzed for drug and internal standard via the LC–MS/MS protocol.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> Novel Object Recognition Training and Testing<a onclick="showRef(event, 'cit22b ref44 ref45'); return false;" href="javascript:void(0);" class="ref cit22b ref44 ref45">(22b,44,45)</a></h3><div class="NLM_p last">Rats were acclimated for 1 week prior to the experiment. The rats were housed in groups of two/cage in a light-controlled room (12 h light/dark cycles with lights on at 07:00). Food and water were provided ad libitum. Rats were habituated to handling and an empty test arena (a gray-colored polyvinyl chloride box (40 × 40 × 50 cm<sup>3</sup>)) for 7 min on each of 3 consecutive days. On the training day, the drug was administered po in a vehicle of physiological saline at a volume of 1 mL/kg. Then 1 h after dosing, each rat was placed in the test arena, which now contained two identical objects located centrally in the arena. Rats were given either 3 min explore the arena and objects. Memory retention was tested 24 h after training. Rats were placed back in the arena with one “familiar” (previously trained) and one “novel” object and given 5 min to explore. The spatial position of objects left–right position) and which object was novel (ball or cube) was counterbalanced across subjects. Objects and arenas were cleaned with diluted 75% alcohol solution between trials to remove rat feces and urine. To determine memory performance, the novelty discrimination index (NDI) was calculated using the following equation: (novel object interaction time/total interaction time) ×100 (%). Rats were excluded from the analysis if total exploration time in the acquisition trial was less than 10 s. Numbers of rats treated with vehicle and those treated with 0.03, 0.1, and 0.3 mg/kg of compound <b>47</b> were <i>n</i> = 9 for 0.03 mg/kg and <i>n</i> = 10 for the other groups.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> Statistics</h3><div class="NLM_p last">To estimate the potency of test and reference compounds, the ED<sub>50</sub> values and their 95% confidence limits were calculated by using the program SPSS (Statistical Package for the Social Sciences).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i118"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01096" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61504" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61504" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01096" class="ext-link">10.1021/acs.jmedchem.8b01096</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional receptors binding affinities of compound <b>47</b>; <sup>1</sup>H NMR, <sup>13</sup>C NMR, HRMS, and HPLC of compound <b>47</b>; <sup>13</sup>C NMR and HPLC of compound <b>44</b>, <b>50</b>, <b>53</b>, and <b>54</b>; LR-MS of the intermediates <b>3b</b>, <b>4b</b>, <b>5</b>, <b>6c</b>, and <b>7a</b>; D<sub>1</sub>, D<sub>2L</sub>, D<sub>3</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>6</sub> receptors functional activity of compound <b>47</b>; dose–response curve of hERG of compound <b>47</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01096/suppl_file/jm8b01096_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01096/suppl_file/jm8b01096_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01096/suppl_file/jm8b01096_si_001.csv">jm8b01096_si_001.csv (4.8 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01096/suppl_file/jm8b01096_si_002.pdf">jm8b01096_si_002.pdf (1.18 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01096" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guisen Zhang</span> - <span class="hlFld-Affiliation affiliation">Systems
Biology Theme, Department of Biomedical Engineering, College of Life
Science and Technology, Huazhong University
of Science and Technology, Wuhan 430074, China</span>; 
    <span class="hlFld-Affiliation affiliation">Jiangsu
Nhwa Pharmaceutical Co., Ltd. 69 Democratic South Road, Xuzhou, Jiangsu 221116, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8746-4195" title="Orcid link">http://orcid.org/0000-0002-8746-4195</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7017030a18111e17301d11191c5e180503045e1514055e131e"><span class="__cf_email__" data-cfemail="b3d4c0c9dbd2ddd4f3ded2dadf9ddbc6c0c79dd6d7c69dd0dd">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xudong Cao</span> - <span class="hlFld-Affiliation affiliation">Systems
Biology Theme, Department of Biomedical Engineering, College of Life
Science and Technology, Huazhong University
of Science and Technology, Wuhan 430074, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yifang Zhang</span> - <span class="hlFld-Affiliation affiliation">Systems
Biology Theme, Department of Biomedical Engineering, College of Life
Science and Technology, Huazhong University
of Science and Technology, Wuhan 430074, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yin Chen</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Nhwa Pharmaceutical Co., Ltd. 69 Democratic South Road, Xuzhou, Jiangsu 221116, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yinli Qiu</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Nhwa Pharmaceutical Co., Ltd. 69 Democratic South Road, Xuzhou, Jiangsu 221116, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minquan Yu</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Nhwa Pharmaceutical Co., Ltd. 69 Democratic South Road, Xuzhou, Jiangsu 221116, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiangqing Xu</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Nhwa Pharmaceutical Co., Ltd. 69 Democratic South Road, Xuzhou, Jiangsu 221116, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Liu</span> - <span class="hlFld-Affiliation affiliation">Systems
Biology Theme, Department of Biomedical Engineering, College of Life
Science and Technology, Huazhong University
of Science and Technology, Wuhan 430074, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2464-6458" title="Orcid link">http://orcid.org/0000-0003-2464-6458</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bi-Feng Liu</span> - <span class="hlFld-Affiliation affiliation">Systems
Biology Theme, Department of Biomedical Engineering, College of Life
Science and Technology, Huazhong University
of Science and Technology, Wuhan 430074, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2135-0873" title="Orcid link">http://orcid.org/0000-0002-2135-0873</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liangren Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical
Sciences, Peking University, Beijing 100191, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>X.C. and Y.Zh. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i120">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30581" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30581" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful for financial support from the China Postdoctoral Science Foundation funded project (2017M612473), the NSFC (grant 81573291), the National Science and Technology Major Project “Key New Drug Creation and Manufacturing Program” (grant 2018ZX09711002-013-004), and the National Major Scientific and Technological Special Project for “Significant New Drugs Development” (2018ZX9711002-013-004, 2018ZX09735001-003).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">D<sub>2</sub></td><td class="NLM_def"><p class="first last">dopamine-2;</p></td></tr><tr><td class="NLM_term">D<sub>3</sub></td><td class="NLM_def"><p class="first last">dopamine-3</p></td></tr><tr><td class="NLM_term">5-HT<sub>1A</sub></td><td class="NLM_def"><p class="first last">serotonin-1A</p></td></tr><tr><td class="NLM_term">5-HT<sub>2A</sub></td><td class="NLM_def"><p class="first last">serotonin-2A</p></td></tr><tr><td class="NLM_term">5-HT<sub>2C</sub></td><td class="NLM_def"><p class="first last">serotonin-2C</p></td></tr><tr><td class="NLM_term">H<sub>1</sub></td><td class="NLM_def"><p class="first last">histamine-1</p></td></tr><tr><td class="NLM_term">α<sub>1</sub></td><td class="NLM_def"><p class="first last">adrenergic-1</p></td></tr><tr><td class="NLM_term">EPS</td><td class="NLM_def"><p class="first last">extrapyramidal symptoms</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate</p></td></tr><tr><td class="NLM_term">ED<sub>50</sub></td><td class="NLM_def"><p class="first last">50% effective dose</p></td></tr><tr><td class="NLM_term">LD<sub>50</sub></td><td class="NLM_def"><p class="first last">median lethal dose</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i122">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73846" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73846" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 50 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, R.</span></span> <span> </span><span class="NLM_article-title">Schizophrenia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">1738</span>– <span class="NLM_lpage">1749</span>, <span class="refDoi"> DOI: 10.1056/NEJMra035458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1056%2FNEJMra035458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=14585943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Smsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2003&pages=1738-1749&author=R.+Freedman&title=Schizophrenia&doi=10.1056%2FNEJMra035458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia</span></div><div class="casAuthors">Freedman, Robert</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1738-1749</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on the clin. features, pathophysiol., and treatment of schizophrenia.  A new generation of medications and recent developments in neuropathol., brain imaging, and mol. genetics have led to a greater understanding of the pathophysiol. of schizophrenia and to improved treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmsEOcFuK4KLVg90H21EOLACvtfcHk0lg_poiX32GFNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Smsbc%253D&md5=9b6c07fce84e996e44820ee4b4531b59</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1056%2FNEJMra035458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra035458%26sid%3Dliteratum%253Aachs%26aulast%3DFreedman%26aufirst%3DR.%26atitle%3DSchizophrenia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D349%26spage%3D1738%26epage%3D1749%26doi%3D10.1056%2FNEJMra035458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Perala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvisaari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saarni, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuoppasalmi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isometsa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirkola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partonen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuulio-Henriksson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hintikka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieseppa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harkanen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koskinen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonnqvist, J.</span></span> <span> </span><span class="NLM_article-title">Lifetime prevalence of psychotic and bipolar I disorders in a general population</span>. <i>Arch. Gen. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1001/archpsyc.64.1.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1001%2Farchpsyc.64.1.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=17199051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FitVOjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2007&pages=19-28&author=J.+Peralaauthor=J.+Suvisaariauthor=S.+I.+Saarniauthor=K.+Kuoppasalmiauthor=E.+Isometsaauthor=S.+Pirkolaauthor=T.+Partonenauthor=A.+Tuulio-Henrikssonauthor=J.+Hintikkaauthor=T.+Kieseppaauthor=T.+Harkanenauthor=S.+Koskinenauthor=J.+Lonnqvist&title=Lifetime+prevalence+of+psychotic+and+bipolar+I+disorders+in+a+general+population&doi=10.1001%2Farchpsyc.64.1.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Lifetime prevalence of psychotic and bipolar I disorders in a general population</span></div><div class="casAuthors">Perala Jonna; Suvisaari Jaana; Saarni Samuli I; Kuoppasalmi Kimmo; Isometsa Erkki; Pirkola Sami; Partonen Timo; Tuulio-Henriksson Annamari; Hintikka Jukka; Kieseppa Tuula; Harkanen Tommi; Koskinen Seppo; Lonnqvist Jouko</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-28</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">CONTEXT:  Recent general population surveys of psychotic disorders have found low lifetime prevalences.  However, this may be owing to methodological problems.  Few studies have reported the prevalences of all specific psychotic disorders.  OBJECTIVE:  To provide reliable estimates of the lifetime prevalences of specific psychotic disorders.  DESIGN:  General population survey.  SETTING AND PARTICIPANTS:  A nationally representative sample of 8028 persons 30 years or older was screened for psychotic and bipolar I disorders using the Composite International Diagnostic Interview, self-reported diagnoses, medical examination, and national registers.  Those selected by the screens were then re-interviewed with the Structured Clinical Interview for DSM-IV.  Best-estimate DSM-IV diagnoses were formed by combining the interview and case note data.  Register diagnoses were used to estimate the effect of the nonresponders.  MAIN OUTCOME MEASURES:  Diagnosis of any psychotic or bipolar I disorder according to the DSM-IV criteria.  RESULTS:  The lifetime prevalence of all psychotic disorders was 3.06% and rose to 3.48% when register diagnoses of the nonresponder group were included.  Lifetime prevalences were as follows: 0.87% for schizophrenia, 0.32% for schizoaffective disorder, 0.07% for schizophreniform disorder, 0.18% for delusional disorder, 0.24% for bipolar I disorder, 0.35% for major depressive disorder with psychotic features, 0.42% for substance-induced psychotic disorders, and 0.21% for psychotic disorders due to a general medical condition.  The National Hospital Discharge Register was the most reliable of the screens (kappa = 0.80).  Case notes supplementing the interviews were essential for specific diagnoses of psychotic disorders.  CONCLUSIONS:  Multiple sources of information are essential for accurate estimation of lifetime prevalences of psychotic disorders.  The use of comprehensive methods reveals that their lifetime prevalence exceeds 3%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKNfedLYPE38ERNNga7KD-fW6udTcc2eYrvctaQuUmxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FitVOjtw%253D%253D&md5=c092fedf94e477bc7c329ef994ab8e8b</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.64.1.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.64.1.19%26sid%3Dliteratum%253Aachs%26aulast%3DPerala%26aufirst%3DJ.%26aulast%3DSuvisaari%26aufirst%3DJ.%26aulast%3DSaarni%26aufirst%3DS.%2BI.%26aulast%3DKuoppasalmi%26aufirst%3DK.%26aulast%3DIsometsa%26aufirst%3DE.%26aulast%3DPirkola%26aufirst%3DS.%26aulast%3DPartonen%26aufirst%3DT.%26aulast%3DTuulio-Henriksson%26aufirst%3DA.%26aulast%3DHintikka%26aufirst%3DJ.%26aulast%3DKieseppa%26aufirst%3DT.%26aulast%3DHarkanen%26aufirst%3DT.%26aulast%3DKoskinen%26aufirst%3DS.%26aulast%3DLonnqvist%26aufirst%3DJ.%26atitle%3DLifetime%2520prevalence%2520of%2520psychotic%2520and%2520bipolar%2520I%2520disorders%2520in%2520a%2520general%2520population%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2007%26volume%3D64%26spage%3D19%26epage%3D28%26doi%3D10.1001%2Farchpsyc.64.1.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasrallah, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keshavan, M. S.</span></span> <span> </span><span class="NLM_article-title">Schizophrenia, ″just the facts″ 4. Clinical features and conceptualization</span>. <i>Schizophr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.schres.2009.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.schres.2009.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19328655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BD1M3ps12mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2009&pages=1-23&author=R.+Tandonauthor=H.+A.+Nasrallahauthor=M.+S.+Keshavan&title=Schizophrenia%2C+%E2%80%B3just+the+facts%E2%80%B3+4.+Clinical+features+and+conceptualization&doi=10.1016%2Fj.schres.2009.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia, "just the facts" 4. Clinical features and conceptualization</span></div><div class="casAuthors">Tandon Rajiv; Nasrallah Henry A; Keshavan Matcheri S</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">1-23</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Although dementia praecox or schizophrenia has been considered a unique disease entity for the past century, its definitions and boundaries have continued to vary over this period.  At any given time, the changing concept of schizophrenia has been influenced by available diagnostic tools and treatments, related conditions from which it most needs to be distinguished, extant knowledge and scientific paradigms.  There is significant heterogeneity in the etiopathology, symptomatology, and course of schizophrenia.  It is characterized by an admixture of positive, negative, cognitive, mood, and motor symptoms whose severity varies across patients and through the course of the illness.  Positive symptoms usually first begin in adolescence or early adulthood, but are often preceded by varying degrees of negative and cognitive symptomatology.  Schizophrenia tends to be a chronic and relapsing disorder with generally incomplete remissions, variable degrees of functional impairment and social disability, frequent comorbid substance abuse, and decreased longevity.  Although schizophrenia may not represent a single disease with a unitary etiology or pathogenetic process, alternative approaches have thus far been unsuccessful in better defining this syndrome or its component entities.  The symptomatologic, course, and etio-pathological heterogeneity can usefully be addressed by a dimensional approach to psychopathology, a clinical staging approach to illness course, and by elucidating endophenotypes and markers of illness progression, respectively.  This will allow an approach to the deconstruction of schizophrenia into its multiple component parts and strategies to reconfigure these components in a more meaningful manner.  Possible implications for DSM-V and ICD-11 definitions of schizophrenia are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvnCea0e_JZZotVjB3IRIyfW6udTcc2eYrvctaQuUmxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3ps12mtw%253D%253D&md5=8ed68c03937fb30924537e7cbe9f624e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2009.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2009.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DTandon%26aufirst%3DR.%26aulast%3DNasrallah%26aufirst%3DH.%2BA.%26aulast%3DKeshavan%26aufirst%3DM.%2BS.%26atitle%3DSchizophrenia%252C%2520%25E2%2580%25B3just%2520the%2520facts%25E2%2580%25B3%25204.%2520Clinical%2520features%2520and%2520conceptualization%26jtitle%3DSchizophr.%2520Res.%26date%3D2009%26volume%3D110%26spage%3D1%26epage%3D23%26doi%3D10.1016%2Fj.schres.2009.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaebel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barch, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bustillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gur, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malaspina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Os, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, W.</span></span> <span> </span><span class="NLM_article-title">Definition and description of schizophrenia in the DSM-5</span>. <i>Schizophr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.schres.2013.05.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.schres.2013.05.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=23800613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BC3sjlsVKhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2013&pages=3-10&author=R.+Tandonauthor=W.+Gaebelauthor=D.+M.+Barchauthor=J.+Bustilloauthor=R.+E.+Gurauthor=S.+Heckersauthor=D.+Malaspinaauthor=M.+J.+Owenauthor=S.+Schultzauthor=M.+Tsuangauthor=J.+Van+Osauthor=W.+Carpenter&title=Definition+and+description+of+schizophrenia+in+the+DSM-5&doi=10.1016%2Fj.schres.2013.05.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Definition and description of schizophrenia in the DSM-5</span></div><div class="casAuthors">Tandon Rajiv; Gaebel Wolfgang; Barch Deanna M; Bustillo Juan; Gur Raquel E; Heckers Stephan; Malaspina Dolores; Owen Michael J; Schultz Susan; Tsuang Ming; Van Os Jim; Carpenter William</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although dementia praecox or schizophrenia has been considered a unique disease for over a century, its definitions and boundaries have changed over this period and its etiology and pathophysiology remain elusive.  Despite changing definitions, DSM-IV schizophrenia is reliably diagnosed, has fair validity and conveys useful clinical information.  Therefore, the essence of the broad DSM-IV definition of schizophrenia is retained in DSM-5.  The clinical manifestations are extremely diverse, however, with this heterogeneity being poorly explained by the DSM-IV clinical subtypes and course specifiers.  Additionally, the boundaries of schizophrenia are imprecisely demarcated from schizoaffective disorder and other diagnostic categories and its special emphasis on Schneiderian "first-rank" symptoms appears misplaced.  Changes in the definition of schizophrenia in DSM-5 seek to address these shortcomings and incorporate the new information about the nature of the disorder accumulated over the past two decades.  Specific changes in its definition include elimination of the classic subtypes, addition of unique psychopathological dimensions, clarification of cross-sectional and longitudinal course specifiers, elimination of special treatment of Schneiderian 'first-rank symptoms', better delineation of schizophrenia from schizoaffective disorder, and clarification of the relationship of schizophrenia to catatonia.  These changes should improve diagnosis and characterization of individuals with schizophrenia and facilitate measurement-based treatment and concurrently provide a more useful platform for research that will elucidate its nature and permit a more precise future delineation of the 'schizophrenias'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSl9hdo7Fq4FT0SWnHPWbmmfW6udTcc2eYrvctaQuUmxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjlsVKhsw%253D%253D&md5=7b84bfba8cb8e6882ae727f29947d6a2</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2013.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2013.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DTandon%26aufirst%3DR.%26aulast%3DGaebel%26aufirst%3DW.%26aulast%3DBarch%26aufirst%3DD.%2BM.%26aulast%3DBustillo%26aufirst%3DJ.%26aulast%3DGur%26aufirst%3DR.%2BE.%26aulast%3DHeckers%26aufirst%3DS.%26aulast%3DMalaspina%26aufirst%3DD.%26aulast%3DOwen%26aufirst%3DM.%2BJ.%26aulast%3DSchultz%26aufirst%3DS.%26aulast%3DTsuang%26aufirst%3DM.%26aulast%3DVan%2BOs%26aufirst%3DJ.%26aulast%3DCarpenter%26aufirst%3DW.%26atitle%3DDefinition%2520and%2520description%2520of%2520schizophrenia%2520in%2520the%2520DSM-5%26jtitle%3DSchizophr.%2520Res.%26date%3D2013%26volume%3D150%26spage%3D3%26epage%3D10%26doi%3D10.1016%2Fj.schres.2013.05.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peshin, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, docking and pharmacological evaluation of novel indole based potential atypical antipsychotics</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.09.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.ejmech.2013.09.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=477-490&author=A.+Baliauthor=U.+Senauthor=T.+Peshin&title=Synthesis%2C+docking+and+pharmacological+evaluation+of+novel+indole+based+potential+atypical+antipsychotics&doi=10.1016%2Fj.ejmech.2013.09.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.09.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.09.020%26sid%3Dliteratum%253Aachs%26aulast%3DBali%26aufirst%3DA.%26aulast%3DSen%26aufirst%3DU.%26aulast%3DPeshin%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520docking%2520and%2520pharmacological%2520evaluation%2520of%2520novel%2520indole%2520based%2520potential%2520atypical%2520antipsychotics%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D74%26spage%3D477%26epage%3D490%26doi%3D10.1016%2Fj.ejmech.2013.09.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beard, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrick, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanover, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mates, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennogle, L. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2670</span>– <span class="NLM_lpage">2682</span>, <span class="refDoi"> DOI: 10.1021/jm401958n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401958n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFOhu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2670-2682&author=P.+Liauthor=Q.+Zhangauthor=A.+J.+Robichaudauthor=T.+Leeauthor=J.+Tomeschauthor=W.+Yaoauthor=J.+D.+Beardauthor=G.+L.+Snyderauthor=H.+Zhuauthor=Y.+Pengauthor=J.+P.+Hendrickauthor=K.+E.+Vanoverauthor=R.+E.+Davisauthor=S.+Matesauthor=L.+P.+Wennogle&title=Discovery+of+a+tetracyclic+quinoxaline+derivative+as+a+potent+and+orally+active+multifunctional+drug+candidate+for+the+treatment+of+neuropsychiatric+and+neurological+disorders&doi=10.1021%2Fjm401958n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders</span></div><div class="casAuthors">Li, Peng; Zhang, Qiang; Robichaud, Albert J.; Lee, Taekyu; Tomesch, John; Yao, Wei; Beard, J. David; Snyder, Gretchen L.; Zhu, Hongwen; Peng, Youyi; Hendrick, Joseph P.; Vanover, Kimberly E.; Davis, Robert E.; Mates, Sharon; Wennogle, Lawrence P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2670-2682</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the synthesis and structure-activity relationships of a class of tetracyclic butyrophenones that exhibit potent binding affinities to serotonin 5-HT2A and dopamine D2 receptors.  This work has led to the discovery of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 4-methylbenzenesulfonate (ITI-007, I.TsOH), which is a potent 5-HT2A antagonist, postsynaptic D2 antagonist, and inhibitor of serotonin transporter.  This multifunctional drug candidate is orally bioavailable and exhibits good antipsychotic efficacy in vivo.  Currently, this investigational new drug is under clin. development for the treatment of neuropsychiatric and neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozLklhmBkFo7Vg90H21EOLACvtfcHk0lgbDpt6OowXTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFOhu7o%253D&md5=318c9a3df9d79a2ac593c40015021015</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm401958n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401958n%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DTomesch%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DBeard%26aufirst%3DJ.%2BD.%26aulast%3DSnyder%26aufirst%3DG.%2BL.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DHendrick%26aufirst%3DJ.%2BP.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DMates%26aufirst%3DS.%26aulast%3DWennogle%26aufirst%3DL.%2BP.%26atitle%3DDiscovery%2520of%2520a%2520tetracyclic%2520quinoxaline%2520derivative%2520as%2520a%2520potent%2520and%2520orally%2520active%2520multifunctional%2520drug%2520candidate%2520for%2520the%2520treatment%2520of%2520neuropsychiatric%2520and%2520neurological%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2670%26epage%3D2682%26doi%3D10.1021%2Fjm401958n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Remington, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foussias, G.</span></span> <span> </span><span class="NLM_article-title">Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1586/ern.10.191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1586%2Fern.10.191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=21469931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlyqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=589-607&author=G.+Remingtonauthor=O.+Agidauthor=G.+Foussias&title=Schizophrenia+as+a+disorder+of+too+little+dopamine%3A+implications+for+symptoms+and+treatment&doi=10.1586%2Fern.10.191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment</span></div><div class="casAuthors">Remington, Gary; Agid, Ofer; Foussias, George</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-607</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Antipsychotics represent the first effective therapy for schizophrenia, with their benefits linked to dopamine D2 blockade.  Schizophrenia was soon identified as a hyperdopaminergic disorder, and antipsychotics proved to be reasonably effective in controlling pos. symptoms.  However, over the years, schizophrenia has been reconceptualized more broadly, now defined as a heterogeneous disorder with multiple symptom domains.  Neg. and cognitive features, not particularly responsive to antipsychotic therapy, have taken on increased importance -- current thinking suggests that these domains predate the onset of pos. symptoms and are more closely tied to functional outcome.  That they are better understood in the context of decreased dopamine activity suggests that schizophrenia may fundamentally represent a hypodopaminergic disorder.  This shift in thinking has important theor. implications from the standpoint of etiol. and pathophysiol., but also clin. in terms of treatment and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKxDPNplr2yrVg90H21EOLACvtfcHk0lhSp446Hi9N2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlyqtbo%253D&md5=65a8003827406d9e7ba57f1a60222940</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1586%2Fern.10.191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fern.10.191%26sid%3Dliteratum%253Aachs%26aulast%3DRemington%26aufirst%3DG.%26aulast%3DAgid%26aufirst%3DO.%26aulast%3DFoussias%26aufirst%3DG.%26atitle%3DSchizophrenia%2520as%2520a%2520disorder%2520of%2520too%2520little%2520dopamine%253A%2520implications%2520for%2520symptoms%2520and%2520treatment%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2011%26volume%3D11%26spage%3D589%26epage%3D607%26doi%3D10.1586%2Fern.10.191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maneen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. M.</span></span> <span> </span><span class="NLM_article-title">Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.nurt.2008.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.nurt.2008.10.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=78-85&author=D.+H.+Kimauthor=M.+J.+Maneenauthor=S.+M.+Stahl&title=Building+a+better+antipsychotic%3A+receptor+targets+for+the+treatment+of+multiple+symptom+dimensions+of+schizophrenia&doi=10.1016%2Fj.nurt.2008.10.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2008.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2008.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DManeen%26aufirst%3DM.%2BJ.%26aulast%3DStahl%26aufirst%3DS.%2BM.%26atitle%3DBuilding%2520a%2520better%2520antipsychotic%253A%2520receptor%2520targets%2520for%2520the%2520treatment%2520of%2520multiple%2520symptom%2520dimensions%2520of%2520schizophrenia%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26spage%3D78%26epage%3D85%26doi%3D10.1016%2Fj.nurt.2008.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">A new era of rationally designed antipsychotics</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>555</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1038/d41586-018-02328-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1038%2Fd41586-018-02328-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2018&pages=170-172&author=D.+R.+Sibleyauthor=L.+Shi&title=A+new+era+of+rationally+designed+antipsychotics&doi=10.1038%2Fd41586-018-02328-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1038%2Fd41586-018-02328-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41586-018-02328-z%26sid%3Dliteratum%253Aachs%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DA%2520new%2520era%2520of%2520rationally%2520designed%2520antipsychotics%26jtitle%3DNature%26date%3D2018%26volume%3D555%26spage%3D170%26epage%3D172%26doi%3D10.1038%2Fd41586-018-02328-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure of the D<sub>2</sub> dopamine receptor bound to the atypical antipsychotic drug risperidone</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>555</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1038/nature25758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1038%2Fnature25758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=29466326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2018&pages=269-273&author=S.+Wangauthor=T.+Cheauthor=A.+Levitauthor=B.+K.+Shoichetauthor=D.+Wackerauthor=B.+L.+Roth&title=Structure+of+the+D2+dopamine+receptor+bound+to+the+atypical+antipsychotic+drug+risperidone&doi=10.1038%2Fnature25758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span></div><div class="casAuthors">Wang, Sheng; Che, Tao; Levit, Anat; Shoichet, Brian K.; Wacker, Daniel; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">555</span>
        (<span class="NLM_cas:issue">7695</span>),
    <span class="NLM_cas:pages">269-273</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metab. and hormonal secretion.  Correspondingly, dysregulation of the dopaminergic system has been implicated in diseases such as schizophrenia, Parkinson's disease, depression, attention deficit hyperactivity disorder, and nausea and vomiting.  The actions of dopamine are mediated by a family of five G-protein-coupled receptors.  The D2 dopamine receptor (DRD2) is the primary target for both typical and atypical antipsychotic drugs, and for drugs used to treat Parkinson's disease.  Unfortunately, many drugs that target DRD2 cause serious and potentially life-threatening side effects due to promiscuous activities against related receptors.  Accordingly, a mol. understanding of the structure and function of DRD2 could provide a template for the design of safer and more effective medications.  Here we report the crystal structure of DRD2 in complex with the widely prescribed atypical antipsychotic drug risperidone.  The DRD2-risperidone structure reveals an unexpected mode of antipsychotic drug binding to dopamine receptors, and highlights structural determinants that are essential for the actions of risperidone and related drugs at DRD2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeo4Ov49kft7Vg90H21EOLACvtfcHk0lhSp446Hi9N2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D&md5=2842adc1893293ea8dbf98ae3270a1b2</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1038%2Fnature25758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25758%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure%2520of%2520the%2520D2%2520dopamine%2520receptor%2520bound%2520to%2520the%2520atypical%2520antipsychotic%2520drug%2520risperidone%26jtitle%3DNature%26date%3D2018%26volume%3D555%26spage%3D269%26epage%3D273%26doi%3D10.1038%2Fnature25758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Seeman, P.</span></span> <span> </span><span class="NLM_article-title">Targeting the dopamine D<sub>2</sub> receptor in schizophrenia</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1517/14728222.10.4.515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1517%2F14728222.10.4.515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=16848689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1ahtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=515-531&author=P.+Seeman&title=Targeting+the+dopamine+D2+receptor+in+schizophrenia&doi=10.1517%2F14728222.10.4.515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dopamine D2 receptor in schizophrenia</span></div><div class="casAuthors">Seeman, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">515-531</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  After a 12-yr search for the antipsychotic receptor, the binding site was discovered and labeled by [3H]haloperidol in 1975.  Of the various neurotransmitters, dopamine was the most potent in inhibiting the binding of [3H]haloperidol, indicating that the antipsychotic receptor was a dopamine receptor, now named the dopamine D2 receptor, a major targeting site in schizophrenia.  All antipsychotic drugs, including traditional and newer antipsychotics, either bind to D2 in direct relation to their clin. potencies or hinder normal dopamine neurotransmission, as in the case of partial dopamine agonists.  In fact, the antipsychotic concns. found in the plasma water of treated patients closely match the predicted therapeutic abs. concns., adjusted for the 60-75% D2 occupancy needed for clin. efficacy.  Antipsychotics that elicit low or no Parkinsonism or prolactinemia are loosely attached to D2 and rapidly dissoc. from D2, whereas those eliciting Parkinsonism stay tightly attached to D2 for many hours.  Because animal models of psychosis (amfetamine sensitization, brain lesions) all show a marked elevation in the no. of high-affinity states of D2, the antipsychotics are thought to specifically target these D2High states in psychosis in general and schizophrenia in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGjVyTQvf6orVg90H21EOLACvtfcHk0lhSp446Hi9N2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1ahtro%253D&md5=4ac073cabc6f50e8d0e3a2ecc631e781</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1517%2F14728222.10.4.515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.10.4.515%26sid%3Dliteratum%253Aachs%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DTargeting%2520the%2520dopamine%2520D2%2520receptor%2520in%2520schizophrenia%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2006%26volume%3D10%26spage%3D515%26epage%3D531%26doi%3D10.1517%2F14728222.10.4.515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanover, K. E.</span></span> <span> </span><span class="NLM_article-title">Dopamine targeting drugs for the treatment of schizophrenia: past, present and future</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3385</span>– <span class="NLM_lpage">3403</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160608084834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.2174%2F1568026616666160608084834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=27291902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKksb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=3385-3403&author=P.+Liauthor=G.+L.+Snyderauthor=K.+E.+Vanover&title=Dopamine+targeting+drugs+for+the+treatment+of+schizophrenia%3A+past%2C+present+and+future&doi=10.2174%2F1568026616666160608084834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future</span></div><div class="casAuthors">Li, Peng; Snyder, Gretchen L.; Vanover, Kimberly E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3385-3403</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting approx. 1% of the world's population.  This disease is assocd. with considerable morbidity placing a major financial burden on society.  Antipsychotics have been the mainstay of the pharmacol. treatment of schizophrenia for decades.  The traditional typical and atypical antipsychotics demonstrate clin. efficacy in treating pos. symptoms, such as hallucinations and delusions, while are largely ineffective and may worsen neg. symptoms, such as blunted affect and social withdrawal, as well as cognitive function.  The inability to treat these latter symptoms may contribute to social function impairment assocd. with schizophrenia.  The dysfunction of multiple neurotransmitter systems in schizophrenia suggests that drugs selectively targeting one neurotransmission pathway are unlikely to meet all the therapeutic needs of this heterogeneous disorder.  Often, however, the unintentional engagement of multiple pharmacol. targets or even the excessive engagement of intended pharmacol. targets can lead to undesired consequences and poor tolerability.  In this article, we will review marketed typical and atypical antipsychotics and new therapeutic agents targeting dopamine receptors and other neurotransmitters for the treatment of schizophrenia.  Representative typical and atypical antipsychotic drugs and new investigational drug candidates will be systematically reviewed and compared by reviewing structure-activity relationships, pharmacokinetic properties, drug metab. and safety, pharmacol. properties, preclin. data in animal models, clin. outcomes and assocd. side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW2CSrOaezH7Vg90H21EOLACvtfcHk0liHiND6dmR1Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKksb3P&md5=50cf78381bcc8669642112f94fcc26e8</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160608084834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160608084834%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSnyder%26aufirst%3DG.%2BL.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26atitle%3DDopamine%2520targeting%2520drugs%2520for%2520the%2520treatment%2520of%2520schizophrenia%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D3385%26epage%3D3403%26doi%3D10.2174%2F1568026616666160608084834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartolome-Nebreda, J.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Martin, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Viturro, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iturrino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Megens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhoof, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde-Ceide, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4196</span>– <span class="NLM_lpage">4212</span>, <span class="refDoi"> DOI: 10.1021/jm500073h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500073h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4196-4212&author=J.%0AM.+Bartolome-Nebredaauthor=F.+Delgadoauthor=M.+L.+Martin-Martinauthor=C.+M.+Martinez-Viturroauthor=J.+Pastorauthor=H.+M.+Tongauthor=L.+Iturrinoauthor=G.+J.+Macdonaldauthor=W.+Sandersonauthor=A.+Megensauthor=X.+Langloisauthor=M.+Somersauthor=G.+Vanhoofauthor=S.+Conde-Ceide&title=Discovery+of+a+potent%2C+selective%2C+and+orally+active+phosphodiesterase+10A+inhibitor+for+the+potential+treatment+of+schizophrenia&doi=10.1021%2Fjm500073h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm500073h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500073h%26sid%3Dliteratum%253Aachs%26aulast%3DBartolome-Nebreda%26aufirst%3DJ.%2BM.%26aulast%3DDelgado%26aufirst%3DF.%26aulast%3DMartin-Martin%26aufirst%3DM.%2BL.%26aulast%3DMartinez-Viturro%26aufirst%3DC.%2BM.%26aulast%3DPastor%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DH.%2BM.%26aulast%3DIturrino%26aufirst%3DL.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DSanderson%26aufirst%3DW.%26aulast%3DMegens%26aufirst%3DA.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DSomers%26aufirst%3DM.%26aulast%3DVanhoof%26aufirst%3DG.%26aulast%3DConde-Ceide%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520active%2520phosphodiesterase%252010A%2520inhibitor%2520for%2520the%2520potential%2520treatment%2520of%2520schizophrenia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4196%26epage%3D4212%26doi%3D10.1021%2Fjm500073h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Seeman, P.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic drugs, dopamine receptors, and schizophrenia</span>. <i>Clin. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/S1566-2772(00)00007-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2FS1566-2772%2800%2900007-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntlartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=53-60&author=P.+Seeman&title=Antipsychotic+drugs%2C+dopamine+receptors%2C+and+schizophrenia&doi=10.1016%2FS1566-2772%2800%2900007-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic drugs, dopamine receptors, and schizophrenia</span></div><div class="casAuthors">Seeman, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Neuroscience Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">53-60</span>CODEN:
                <span class="NLM_cas:coden">CNRLBU</span>;
        ISSN:<span class="NLM_cas:issn">1566-2772</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The clin. potencies of antipsychotic drugs are directly related to their affinities for the dopamine D2 receptor.  In addn., the concns. of antipsychotic drugs (given at therapeutic maintenance doses) in the plasma water or in the spinal fluid are almost identical to the antipsychotic dissocn. consts. at the dopamine D2 receptor.  A consistent 70-75% of brain D2 receptors are occupied by antipsychotic drugs, as calcd. from the therapeutic concn. and the antipsychotic dissocn. const.  The D3 and D4 dopamine receptors, however, are not consistently occupied by antipsychotic drugs, the occupancies being 0-85% for D3, and 0-95% for D4.  Human brain imaging also reveals that therapeutic doses of antipsychotic drugs occupy ∼70% of D2 receptors.  Between 2 and 4 h after the daily oral dose, clozapine and quetiapine occupy high levels (∼70%) of the dopamine D2 receptors in schizophrenia patients, with lower occupancies at 6 and 12 h.  Although clozapine and quetiapine occupy low levels of D2 receptors many hours after the oral dose, the obsd. fraction of D2 receptors occupied by these drugs, however, depends on the radioligand used, with high occupancy seen when using [11C]raclopride, and low occupancy seen with [11C]methylspiperone (which is tightly bound to D2).  This dependence on the radioligand occurs because clozapine and quetiapine are loosely bound to D2.  The loose binding of clozapine and quetiapine to D2 permits endogenous dopamine to displace these antipsychotic drugs much more quickly than haloperidol.  In addn., the small dose of radioactive raclopride injected (in brain imaging) can displace a little of the D2-bound clozapine.  Hence, the obsd. low level of D2 occupancy by clozapine in patients may arise from a combination of the above three factors - the ligand dependency, the endogenous dopamine, and the displacement by the imaging dose.  Parkinsonism and extrapyramidal effects occur with antipsychotics which have a high affinity for D2 and which are, therefore, tightly bound to D2.  Clozapine and quetiapine have a low affinity for D2, and, being readily displaced by endogenous dopamine, do not give rise to extrapyramidal effects.  Because the loosely bound antipsychotics dissoc. from D2 more rapidly, clin. relapse may occur earlier than that found with the tightly bound traditional antipsychotics.  The dopamine hypothesis of schizophrenia is supported by the fact that D2 is the main target of antipsychotic action, that monomers of D2 appear elevated in schizophrenia, and that the synaptic levels of dopamine in schizophrenia are at least two-fold higher than in control subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQy-mJNj1fZbVg90H21EOLACvtfcHk0liHiND6dmR1Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntlartb0%253D&md5=228879acf06c63cc22c09435352b2be7</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2FS1566-2772%2800%2900007-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1566-2772%252800%252900007-4%26sid%3Dliteratum%253Aachs%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DAntipsychotic%2520drugs%252C%2520dopamine%2520receptors%252C%2520and%2520schizophrenia%26jtitle%3DClin.%2520Neurosci.%2520Res.%26date%3D2001%26volume%3D1%26spage%3D53%26epage%3D60%26doi%3D10.1016%2FS1566-2772%2800%2900007-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Strange, P. G.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">133</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2001&pages=119-133&author=P.+G.+Strange&title=Antipsychotic+drugs%3A+importance+of+dopamine+receptors+for+mechanisms+of+therapeutic+actions+and+side+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStrange%26aufirst%3DP.%2BG.%26atitle%3DAntipsychotic%2520drugs%253A%2520importance%2520of%2520dopamine%2520receptors%2520for%2520mechanisms%2520of%2520therapeutic%2520actions%2520and%2520side%2520effects%26jtitle%3DPharmacol.%2520Rev.%26date%3D2001%26volume%3D53%26spage%3D119%26epage%3D133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muench, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamer, A. M.</span></span> <span> </span><span class="NLM_article-title">Adverse effects of antipsychotic medications</span>. <i>Am. Fam. Physician</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">622</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=20187598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BC3c7ktlynsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2010&pages=617-622&author=J.+Muenchauthor=A.+M.+Hamer&title=Adverse+effects+of+antipsychotic+medications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse effects of antipsychotic medications</span></div><div class="casAuthors">Muench John; Hamer Ann M</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">617-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The use of antipsychotic medications entails a difficult trade-off between the benefit of alleviating psychotic symptoms and the risk of troubling, sometimes life-shortening adverse effects.  There is more variability among specific antipsychotic medications than there is between the first- and second-generation antipsychotic classes.  The newer second-generation antipsychotics, especially clozapine and olanzapine, generally tend to cause more problems relating to metabolic syndrome, such as obesity and type 2 diabetes mellitus.  Also, as a class, the older first-generation antipsychotics are more likely to be associated with movement disorders, but this is primarily true of medications that bind tightly to dopaminergic neuroreceptors, such as haloperidol, and less true of medications that bind weakly, such as chlorpromazine.  Anticholinergic effects are especially prominent with weaker-binding first-generation antipsychotics, as well as with the second-generation antipsychotic clozapine.  All antipsychotic medications are associated with an increased likelihood of sedation, sexual dysfunction, postural hypotension, cardiac arrhythmia, and sudden cardiac death.  Primary care physicians should understand the individual adverse effect profiles of these medications.  They should be vigilant for the occurrence of adverse effects, be willing to adjust or change medications as needed (or work with psychiatric colleagues to do so), and be prepared to treat any resulting medical sequelae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKTaXFsO12OOIHSmpohpd0fW6udTcc2eZXeCCSBH2rCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7ktlynsQ%253D%253D&md5=2bac8b3c75c7610f7d59f5a34b296723</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuench%26aufirst%3DJ.%26aulast%3DHamer%26aufirst%3DA.%2BM.%26atitle%3DAdverse%2520effects%2520of%2520antipsychotic%2520medications%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2010%26volume%3D81%26spage%3D617%26epage%3D622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designing multiple ligands - medicinal chemistry strategies and challenges</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.2174/138161209787315594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.2174%2F138161209787315594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19199984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=587-600&author=R.+Morphyauthor=Z.+Rankovic&title=Designing+multiple+ligands+-+medicinal+chemistry+strategies+and+challenges&doi=10.2174%2F138161209787315594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multiple ligands - medicinal chemistry strategies and challenges</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  It has been widely recognized over the recent years that parallel modulation of multiple biol. targets can be beneficial for treatment of diseases with complex etiologies such as cancer asthma, and psychiatric disease.  In this article, current strategies for the generation of ligands with a specific multi-target profile (designed multiple ligands or DMLs) are described and a no. of illustrative example are given.  Designing multiple ligands is frequently a challenging endeavor for medicinal chemists, with the need to appropriately balance affinity for 2 or more targets while obtaining physicochem. and pharmacokinetic properties that are consistent with the administration of an oral drug.  Given that the properties of DMLs are influenced to a large extent by the proteomic superfamily to which the targets belong and the lead generation strategy that is pursued, an early assessment of the feasibility of any given DML project is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUo6NjoK5D-LVg90H21EOLACvtfcHk0ljE-RW-6OMLIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D&md5=fa34039be6e9c3b489f530fc74fd0346</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.2174%2F138161209787315594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209787315594%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigning%2520multiple%2520ligands%2520-%2520medicinal%2520chemistry%2520strategies%2520and%2520challenges%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26spage%3D587%26epage%3D600%26doi%3D10.2174%2F138161209787315594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. an emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+an+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0ljE-RW-6OMLIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroeze, W. K.</span></span> <span> </span><span class="NLM_article-title">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1038/nrd1346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+shotguns+versus+magic+bullets%3A+selectively+non-selective+drugs+for+mood+disorders+and+schizophrenia&doi=10.1038%2Fnrd1346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0ljE-RW-6OMLIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520shotguns%2520versus%2520magic%2520bullets%253A%2520selectively%2520non-selective%2520drugs%2520for%2520mood%2520disorders%2520and%2520schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D353%26epage%3D359%26doi%3D10.1038%2Fnrd1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H.
Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. A.</span></span> <span> </span><span class="NLM_article-title">Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin 2 p<i>K</i><sub>i</sub> values</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>251</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">246</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=2571717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADyaL1MXmt1Cksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=251&publication_year=1989&pages=238-246&author=H.%0AY.+Meltzerauthor=S.+Matsubaraauthor=M.+A.+Lee&title=Classification+of+typical+and+atypical+antipsychotic+drugs+on+the+basis+of+dopamine+D-1%2C+D-2%2C+and+serotonin+2+pKi+values"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values</span></div><div class="casAuthors">Meltzer, Herbert Y.; Matsubara, Shigehiro; Lee, Jar Chi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">251</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-46</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The pKi values of 38 typical and atypical antipsychotic drugs (APD) for 5-HT2, D-1 and D-2 binding sites in rat brain have been detd.  Multivariate analytic techniques demonstrate the importance of the D-2 and 5-HT2 affinities for detg. whether a drug which can block the conditioned avoidance response will have atypical properties as an antipsychotic.  A 5-HT2/D-2 ratio ≥1.12 is characteristic of the atypical APD.  These results may be useful in drug screening programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqCUl6xIvXorVg90H21EOLACvtfcHk0lg0n8jdrL0Q9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmt1Cksb4%253D&md5=0f46fdcc98abf7d93d7ea102ac30df84</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DMatsubara%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.%2BA.%26atitle%3DClassification%2520of%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%2520on%2520the%2520basis%2520of%2520dopamine%2520D-1%252C%2520D-2%252C%2520and%2520serotonin%25202%2520pKi%2520values%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1989%26volume%3D251%26spage%3D238%26epage%3D246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Horacek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubenikova-Valesova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palenicek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dockery, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoschl, C.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.2165/00023210-200620050-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.2165%2F00023210-200620050-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=16696579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFyqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=389-409&author=J.+Horacekauthor=V.+Bubenikova-Valesovaauthor=M.+Kopecekauthor=T.+Palenicekauthor=C.+Dockeryauthor=P.+Mohrauthor=C.+Hoschl&title=Mechanism+of+action+of+atypical+antipsychotic+drugs+and+the+neurobiology+of+schizophrenia&doi=10.2165%2F00023210-200620050-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of atypical antipsychotic drugs and the neurobiology and schizophrenia</span></div><div class="casAuthors">Horacek, Jiri; Bubenikova-Valesova, Vera; Kopecek, Milan; Palenicek, Tomas; Dockery, Colleen; Mohr, Pavel; Hoschl, Cyril</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">389-409</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Atypical antipsychotics have greatly enhanced the treatment of schizophrenia.  The mechanisms underlying the effectiveness and adverse effects of these drugs are, to date, not sufficiently explained.  This article summarizes the hypothetical mechanisms of action of atypical antipsychotics with respect to the neurobiol. of schizophrenia.  When considering treatment models for schizophrenia, the role of dopamine receptor blockade and modulation remains dominant.  The optimal occupancy of dopamine D2 receptors seems to be crucial to balancing efficacy and adverse effects - transient D2 receptor antagonism (such as that attained with, for example, quetiapine and clozapine) is sufficient to obtain an antipsychotic effect, while permanent D2 receptor antagonism (as is caused by conventional antipsychotics) increases the risk of adverse effects such as extrapyramidal symptoms.  Partial D2 receptor agonism (induced by aripiprazole) offers the possibility of maintaining optimal blockade and function of D2 receptors.  Balancing presynaptic and post-synaptic D2 receptor antagonism (e.g. induced by amisulpride) is another mechanism that can, through increased release of endogenous dopamine in the striatum, protect against excessive blockade of D2 receptors.  Serotonergic modulation is assocd. with a beneficial increase in striatal dopamine release.  Effects on the neg. and cognitive symptoms of schizophrenia relate to dopamine release in the prefrontal cortex; this can be modulated by combined D2 and serotonin 5-HT2A receptor antagonism (e.g. by olanzapine and risperidone), partial D2 receptor antagonism or the preferential blockade of inhibitory dopamine autoreceptors.  In the context of the neurodevelopmental disconnection hypothesis of schizophrenia, atypical antipsychotics (in contrast to conventional antipsychotics) induce neuronal plasticity and synaptic remodelling, not only in the striatum but also in other brain areas such as the prefrontal cortex and hippocampus.  This mechanism may normalize glutamatergic dysfunction and structural abnormalities and affect the core pathophysiol. substrates for schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7XN_qERk6M7Vg90H21EOLACvtfcHk0lg0n8jdrL0Q9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFyqu78%253D&md5=7110d0f95ae4dfd01395ae371feb59e2</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.2165%2F00023210-200620050-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00023210-200620050-00004%26sid%3Dliteratum%253Aachs%26aulast%3DHoracek%26aufirst%3DJ.%26aulast%3DBubenikova-Valesova%26aufirst%3DV.%26aulast%3DKopecek%26aufirst%3DM.%26aulast%3DPalenicek%26aufirst%3DT.%26aulast%3DDockery%26aufirst%3DC.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DHoschl%26aufirst%3DC.%26atitle%3DMechanism%2520of%2520action%2520of%2520atypical%2520antipsychotic%2520drugs%2520and%2520the%2520neurobiology%2520of%2520schizophrenia%26jtitle%3DCNS%2520Drugs%26date%3D2006%26volume%3D20%26spage%3D389%26epage%3D409%26doi%3D10.2165%2F00023210-200620050-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. M.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic drug development</span>. <i>Curr. Top. Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1007/7854_2010_47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1007%2F7854_2010_47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=21312399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BC3M7osVGhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=123-139&author=D.+H.+Kimauthor=S.+M.+Stahl&title=Antipsychotic+drug+development&doi=10.1007%2F7854_2010_47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic drug development</span></div><div class="casAuthors">Kim Dennis H; Stahl Stephen M</div><div class="citationInfo"><span class="NLM_cas:title">Current topics in behavioral neurosciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">123-39</span>
        ISSN:<span class="NLM_cas:issn">1866-3370</span>.
    </div><div class="casAbstract">Schizophrenia typically manifests itself with a wide array of symptoms--positive, negative, cognitive, and affective--and may also involve neurodevelopmental and neurodegenerative aspects.  Each of these symptom dimensions may be derived from pathology at one or more receptor types, localized in different regions of the brain.  The absence of a single therapeutic target for schizophrenia has therefore prompted the de-emphasis of selective "magic bullets" and a critical re-examination of the intramolecular polypharmacy afforded by antipsychotics.  In this chapter, we present a review of some of the receptor targets that are currently thought to mediate symptoms of schizophrenia, and discuss their possible implications for future antipsychotic drug development.  Therapeutic strategies for schizophrenia that successfully exploit the multifunctionality of antipsychotics will take into account the entire receptor activity "portfolio" of the agent and provide a total therapeutic response that, like the elephant of the Buddhist parable, is greater than the sum of its parts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvsJbrLcyVme98rul4nhSdfW6udTcc2ea2reqx0aVqirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7osVGhtA%253D%253D&md5=3c62f8e750ad3e999847f362585d252a</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1007%2F7854_2010_47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7854_2010_47%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DStahl%26aufirst%3DS.%2BM.%26atitle%3DAntipsychotic%2520drug%2520development%26jtitle%3DCurr.%2520Top.%2520Behav.%2520Neurosci.%26date%3D2010%26volume%3D4%26spage%3D123%26epage%3D139%26doi%3D10.1007%2F7854_2010_47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, B. W.</span></span> <span> </span><span class="NLM_article-title">The role of serotonin receptors in the action of atypical antipsychotic drugs</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2011.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.coph.2011.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=21420906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1Wqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=59-67&author=H.+Y.+Meltzerauthor=B.+W.+Massey&title=The+role+of+serotonin+receptors+in+the+action+of+atypical+antipsychotic+drugs&doi=10.1016%2Fj.coph.2011.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">The role of serotonin receptors in the action of atypical antipsychotic drugs</span></div><div class="casAuthors">Meltzer, H. Y.; Massey, B. W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-67</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  At clin. EDs, these agents produce extensive blockade of serotonin (5-HT)2A receptors, direct or indirect stimulation of 5-HT1A receptors, and to a lesser extent, redn. in dopamine (DA) D2 receptor-mediated neurotransmission.  This contrasts with typical APDs, for example haloperidol and perphenazine, which are mainly DA D2/D3 receptor antagonists and have weaker, if any, potency as 5-HT2A receptor antagonists.  Some, but not all, atypical APDs are also effective 5-HT2C receptor inverse agonists or neutral antagonists, 5-HT6 or 5-HT7 receptor antagonists.  This diverse action on 5-HT receptors may contribute to significant differences in efficacy and tolerability among the atypical APDs.  There is considerable preclin. and some clin. evidence that effects on 5-HT receptors contribute to the low risk of producing extrapyramidal side effects, which is the defining characteristic of an atypical APD, the lack of elevation in plasma prolactin levels (with risperidone and 9-hydroxyrisperidone being exceptions), antipsychotic action, and ability to improve some domains of cognition in patients with schizophrenia.  The serotonergic actions of the atypical APDs, esp. 5-HT2A receptor antagonism, are particularly important to the differential effects of typical and atypical APDs to overcome the effects of acute or subchronic administration of N-methyl-D-aspartate (NMDA) receptor antagonists, such as phencyclidine, ketamine, and dizocipline (MK-801). 5-HT1A receptor stimulation and 5-HT6 and 5-HT7 receptor antagonism may contribute to beneficial effects of these agents on cognition.  In particular, 5-HT7 receptor antagonism may be the basis for the pro-cognitive effects of the atypical APD, amisulpride, a D2/D3 receptor antagonist, which has no effect on other 5-HT receptor. 5-HT2C receptor antagonism appears to contribute to the wt. gain produced by some atypical APDs and may also affect cognition and psychosis via its influence on cortical and limbic dopaminergic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6MORRdD8Py7Vg90H21EOLACvtfcHk0lhr3OkuVtWjag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1Wqs7o%253D&md5=36aeafe6a20307cb009533c6f082a371</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2011.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2011.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DMassey%26aufirst%3DB.%2BW.%26atitle%3DThe%2520role%2520of%2520serotonin%2520receptors%2520in%2520the%2520action%2520of%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2011%26volume%3D11%26spage%3D59%26epage%3D67%26doi%3D10.1016%2Fj.coph.2011.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, Y.</span></span> <span> </span><span class="NLM_article-title">Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders</span>. <i>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">877</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1016/j.pnpbp.2010.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.pnpbp.2010.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=20398719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1KrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=877-881&author=S.+Shimizuauthor=A.+Tataraauthor=J.+Imakiauthor=Y.+Ohno&title=Role+of+cortical+and+striatal+5-HT1A+receptors+in+alleviating+antipsychotic-induced+extrapyramidal+disorders&doi=10.1016%2Fj.pnpbp.2010.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders</span></div><div class="casAuthors">Shimizu, Saki; Tatara, Ayaka; Imaki, Junta; Ohno, Yukihiro</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">877-881</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previous studies have revealed that 5-HT1A agonists ameliorate antipsychotic-induced extrapyramidal symptoms (EPS) through postsynaptic 5-HT1A receptors.  Here, we conducted an intracerebral microinjection study of (±)-8-hydroxy-2-(di-n-propylamino)-tetralin ((±)8-OH-DPAT) to det. the action site of the 5-HT1A agonist in alleviating EPS.  Bilateral microinjection of(±)8-OH-DPAT (5 μg/1 μL per side) either into the primary motor cortex (MC) or the dorsolateral striatum (dlST) significantly attenuated haloperidol-induced catalepsy in rats.  The anticataleptic action of (±)8-OH-DPAT was more prominent with the MC injection than with the dlST injection.  WAY-100135 (a selective 5-HT1A antagonist) completely antagonized the reversal of haloperidol-induced catalepsy both by intracortical and intrastriatal (±)8-OH-DPAT.  Furthermore, lesioning of dopamine neurons with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (30 mg/kg/day, i.p., for 4 days) did not alter the anti-EPS actions of (±)8-OH-DPAT in a mouse pole test.  The present results strongly suggest that 5-HT1A agonist alleviates antipsychotic-induced EPS by activating postsynaptic 5-HT1A receptors in the MC and dlST, probably through non-dopaminergic mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPAjyUQFCgNLVg90H21EOLACvtfcHk0lhr3OkuVtWjag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1KrsbY%253D&md5=87f7b69d93c44b1d9d4dc10a92309493</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2010.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2010.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DS.%26aulast%3DTatara%26aufirst%3DA.%26aulast%3DImaki%26aufirst%3DJ.%26aulast%3DOhno%26aufirst%3DY.%26atitle%3DRole%2520of%2520cortical%2520and%2520striatal%25205-HT1A%2520receptors%2520in%2520alleviating%2520antipsychotic-induced%2520extrapyramidal%2520disorders%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2010%26volume%3D34%26spage%3D877%26epage%3D881%26doi%3D10.1016%2Fj.pnpbp.2010.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, N.</span></span> <span> </span><span class="NLM_article-title">Augmentation of antipsychotic drug action by azapirone 5-HT<sub>1A</sub> receptor partial agonists: a meta-analysis</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1266</span>, <span class="refDoi"> DOI: 10.1017/S1461145713000151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1017%2FS1461145713000151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=23551924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFKisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=1259-1266&author=T.+Kishiauthor=H.+Y.+Meltzerauthor=N.+Iwata&title=Augmentation+of+antipsychotic+drug+action+by+azapirone+5-HT1A+receptor+partial+agonists%3A+a+meta-analysis&doi=10.1017%2FS1461145713000151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis</span></div><div class="casAuthors">Kishi, Taro; Meltzer, Herbert Y.; Iwata, Nakao</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1259-1266</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">The aim of the study was to evaluate the evidence that serotonin1A (5-HT1A) receptor partial agonists of the azapirone class, which are not antipsychotic, have benefits for adjunctive treatment of overall psychopathol., pos. and neg. symptoms for patients with schizophrenia.  We carried out a systematic review of the literature available through PubMed, Cochrane Library, PsycINFO and Google Scholar during Sept. 2012, followed by a meta-anal. of randomized placebo-controlled trials.  Risk ratio (RR), 95% confidence intervals (CI) and standardized mean difference (s.m.d.) were calcd.  Four studies, involving 163 patients with schizophrenia, met inclusion criteria: buspirone: three trials and 137 patients; tandospirone: one trial and 26 patients.  As adjunctive therapy, 5-HT1A partial agonists were significantly superior to placebo for overall improvement in psychopathol. (s.m.d. = -0.46, CI = -0.79 to -0.13, p = 0.006, N = 4, n = 149) and marginally more effective to improve pos. symptoms (s.m.d. = -0.31, CI = -0.64 to 0.01, p = 0.06, N = 4, n = 149).  However, 5-HT1A partial agonists were not more efficacious than placebo as adjunctive therapy for improving neg. symptoms (s.m.d. = -0.09, CI = -0.60 to 0.42, p = 0.72, N = 4, n = 149).  In addn., there was no significant difference in discontinuation rates between 5-HT1A partial agonists and placebo (all cause: RR = 0.98, CI = 0.49-1.98, p = 0.96, N = 4, n = 153, side-effects: RR = 1.96, CI = 0.54-7.19, p = 0.31, N = 4, n = 153). 5-HT1A partial agonists as adjunctive therapy improved overall psychopathol. with a trend to improve pos. symptoms in patients with schizophrenia.  Because the no. of studies was small, addnl. controlled clin. trials with larger nos. of patients are indicated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8Nr1rWMv5CLVg90H21EOLACvtfcHk0lhr3OkuVtWjag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFKisbs%253D&md5=b2ab0cce4b49dc8468bdbdaa092d6860</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1017%2FS1461145713000151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145713000151%26sid%3Dliteratum%253Aachs%26aulast%3DKishi%26aufirst%3DT.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DIwata%26aufirst%3DN.%26atitle%3DAugmentation%2520of%2520antipsychotic%2520drug%2520action%2520by%2520azapirone%25205-HT1A%2520receptor%2520partial%2520agonists%253A%2520a%2520meta-analysis%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2013%26volume%3D16%26spage%3D1259%26epage%3D1266%26doi%3D10.1017%2FS1461145713000151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Harder, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maclean, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alder, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridley, R. M.</span></span> <span> </span><span class="NLM_article-title">The 5-HT<sub>1A</sub> antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset</span>. <i>Psychopharmacology (Berl)</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1007/BF02806000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1007%2FBF02806000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=8912403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADyaK28Xmslyktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=1996&pages=245-254&author=J.+A.+Harderauthor=C.+J.+Macleanauthor=J.+T.+Alderauthor=P.+T.+Francisauthor=R.+M.+Ridley&title=The+5-HT1A+antagonist%2C+WAY+100635%2C+ameliorates+the+cognitive+impairment+induced+by+fornix+transection+in+the+marmoset&doi=10.1007%2FBF02806000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">The 5-HT1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset</span></div><div class="casAuthors">Harder, J. A.; Maclean, C. J.; Alder, J. T.; Francis, P. T.; Ridley, R. M.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">245-254</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Fornix transection in the marmoset produces a specific pattern of cognitive deficits, notably a lack of ability to recall visuospatial tasks learned preoperatively, and a deficit in acquiring new visuospatial tasks following transection.  This learning impairment can be ameliorated by cholinergic agonists, suggesting that it occurs as a consequence of destroying the cholinergic projection from the vertical limb of the diagonal band to the hippocampus which runs through the fornix.  This deficit in new learning can be significantly alleviated by the 5-HT1A antagonist, WAY 100635.  This result supports the suggestion that 5-HT1A projections are inhibitory on the same target cells for which cholinergic projections are excitatory, and that loss of function in the target cells caused by loss of excitatory tone can be compensated by blockade of inhibitory tone.  Since cholinergic loss in the hippocampus (and neocortex) occurs in assocn. with cognitive decline in Alzheimer's disease, these results suggest that 5-HT1A antagonists may have a role in the treatment of some of the cognitive symptoms of dementia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0o7vgliyGkbVg90H21EOLACvtfcHk0lhN30sfq-hExQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xmslyktrw%253D&md5=295d1dcd6e166ea523b9934e18865129</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1007%2FBF02806000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02806000%26sid%3Dliteratum%253Aachs%26aulast%3DHarder%26aufirst%3DJ.%2BA.%26aulast%3DMaclean%26aufirst%3DC.%2BJ.%26aulast%3DAlder%26aufirst%3DJ.%2BT.%26aulast%3DFrancis%26aufirst%3DP.%2BT.%26aulast%3DRidley%26aufirst%3DR.%2BM.%26atitle%3DThe%25205-HT1A%2520antagonist%252C%2520WAY%2520100635%252C%2520ameliorates%2520the%2520cognitive%2520impairment%2520induced%2520by%2520fornix%2520transection%2520in%2520the%2520marmoset%26jtitle%3DPsychopharmacology%2520%2528Berl%2529%26date%3D1996%26volume%3D127%26spage%3D245%26epage%3D254%26doi%3D10.1007%2FBF02806000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>1A</sub> receptor, an old target for new therapeutic agents</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1024</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.2174/156802608785161385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.2174%2F156802608785161385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=18691130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Ohtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1024-1034&author=E.+Lacivitaauthor=M.+Leopoldoauthor=F.+Berardiauthor=R.+Perrone&title=5-HT1A+receptor%2C+an+old+target+for+new+therapeutic+agents&doi=10.2174%2F156802608785161385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT1A receptor, an old target for new therapeutic agents</span></div><div class="casAuthors">Lacivita, Enza; Leopoldo, Marcello; Berardi, Francesco; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1024-1034</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The serotonin receptor subtype 5-HT1A was one of the first serotonin receptor subtypes pharmacol. characterized.  Over the last twenty years the 5-HT1A receptor has been the object of intense research efforts as witnessed by the 5-HT1A acting drugs marketed as anxiolytics.  In recent years, several new chem. entities targeting the 5-HT1A receptor (alone or in combination with other mol. targets) have been proposed for novel therapeutic indications (neuroprotection, cognitive impairment, Parkinson Disease and related disorders, pain treatment).  The present review will focus on those 5-HT1A receptor agents that entered preclin. trials starting from 2000.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquGiFKFKnqLrVg90H21EOLACvtfcHk0lhN30sfq-hExQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Ohtb4%253D&md5=cd19fc17c1edcfec3977fffe3920480d</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.2174%2F156802608785161385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608785161385%26sid%3Dliteratum%253Aachs%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3D5-HT1A%2520receptor%252C%2520an%2520old%2520target%2520for%2520new%2520therapeutic%2520agents%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1024%26epage%3D1034%26doi%3D10.2174%2F156802608785161385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, W. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havran, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asselin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicksler, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosu, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abou-Gharbia, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A. C.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleintop, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magolda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathias, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabb, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andree, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aschmies, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comery, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig-Lipson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukoff-Rizzo, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adedoyin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huselton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, W. D.</span></span> <span> </span><span class="NLM_article-title">The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT<sub>1A</sub> antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4066</span>– <span class="NLM_lpage">4084</span>, <span class="refDoi"> DOI: 10.1021/jm1000908</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1000908" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4066-4084&author=W.+E.+Childersauthor=L.+M.+Havranauthor=M.+Asselinauthor=J.+J.+Bickslerauthor=D.+C.+Chongauthor=G.+T.+Grosuauthor=Z.+Shenauthor=M.+A.+Abou-Gharbiaauthor=A.+C.+Bachauthor=B.+L.+Harrisonauthor=N.+Kaganauthor=T.+Kleintopauthor=R.+Magoldaauthor=V.+Marathiasauthor=A.+J.+Robichaudauthor=A.+L.+Sabbauthor=M.+Y.+Zhangauthor=T.+H.+Andreeauthor=S.+H.+Aschmiesauthor=C.+Beyerauthor=T.+A.+Comeryauthor=M.+Dayauthor=S.+M.+Grauerauthor=Z.+A.+Hughesauthor=S.+Rosenzweig-Lipsonauthor=B.+Plattauthor=C.+Pulicicchioauthor=D.+E.+Smithauthor=S.+J.+Sukoff-Rizzoauthor=K.+M.+Sullivanauthor=A.+Adedoyinauthor=C.+Huseltonauthor=W.+D.+Hirst&title=The+synthesis+and+biological+evaluation+of+quinolyl-piperazinyl+piperidines+as+potent+serotonin+5-HT1A+antagonists&doi=10.1021%2Fjm1000908"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1021%2Fjm1000908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1000908%26sid%3Dliteratum%253Aachs%26aulast%3DChilders%26aufirst%3DW.%2BE.%26aulast%3DHavran%26aufirst%3DL.%2BM.%26aulast%3DAsselin%26aufirst%3DM.%26aulast%3DBicksler%26aufirst%3DJ.%2BJ.%26aulast%3DChong%26aufirst%3DD.%2BC.%26aulast%3DGrosu%26aufirst%3DG.%2BT.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DAbou-Gharbia%26aufirst%3DM.%2BA.%26aulast%3DBach%26aufirst%3DA.%2BC.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DKagan%26aufirst%3DN.%26aulast%3DKleintop%26aufirst%3DT.%26aulast%3DMagolda%26aufirst%3DR.%26aulast%3DMarathias%26aufirst%3DV.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26aulast%3DSabb%26aufirst%3DA.%2BL.%26aulast%3DZhang%26aufirst%3DM.%2BY.%26aulast%3DAndree%26aufirst%3DT.%2BH.%26aulast%3DAschmies%26aufirst%3DS.%2BH.%26aulast%3DBeyer%26aufirst%3DC.%26aulast%3DComery%26aufirst%3DT.%2BA.%26aulast%3DDay%26aufirst%3DM.%26aulast%3DGrauer%26aufirst%3DS.%2BM.%26aulast%3DHughes%26aufirst%3DZ.%2BA.%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26aulast%3DPlatt%26aufirst%3DB.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DD.%2BE.%26aulast%3DSukoff-Rizzo%26aufirst%3DS.%2BJ.%26aulast%3DSullivan%26aufirst%3DK.%2BM.%26aulast%3DAdedoyin%26aufirst%3DA.%26aulast%3DHuselton%26aufirst%3DC.%26aulast%3DHirst%26aufirst%3DW.%2BD.%26atitle%3DThe%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520quinolyl-piperazinyl%2520piperidines%2520as%2520potent%2520serotonin%25205-HT1A%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4066%26epage%3D4084%26doi%3D10.1021%2Fjm1000908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sumiyoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, Y.</span></span> <span> </span><span class="NLM_article-title">Facilitative effect of 5-HT<sub>1A</sub> receptor agonists on cognition in patients with schizophrenia</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.2174/0929867311320030006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.2174%2F0929867311320030006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=23157627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtFegurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=357-362&author=T.+Sumiyoshiauthor=Y.+Higuchi&title=Facilitative+effect+of+5-HT1A+receptor+agonists+on+cognition+in+patients+with+schizophrenia&doi=10.2174%2F0929867311320030006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14dR"><div class="casContent"><span class="casTitleNuber">14d</span><div class="casTitle"><span class="NLM_cas:atitle">Facilitative effect of serotonin1A receptor agonists on cognition in patients with schizophrenia</span></div><div class="casAuthors">Sumiyoshi, T.; Higuchi, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">357-362</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Disturbances of cognitive function are considered to largely affect the outcome in patients with schizophrenia.  There is much attention to the role of psychotropic compds. acting on serotonin (5-HT) receptors in ameliorating cognitive deficits of the disease.  Among the 5-HT receptor subtypes, the 5-HT1A receptor is attracting particular interests as a potential target for enhancing cognition, based on preclin. and clin. evidence.  The neural network underlying the ability of 5-HT1A agonists to treat cognitive impairments of schizophrenia likely includes dopamine, glutamate, and gamma-aminobutyric acid neurons.  Recent advances of electrophysiol. measures, such as event-related potentials, have provided insights into facilitative effects on cognition of some atypical antipsychotic drugs or related compds. acting directly or indirectly on 5-HT1A receptors.  These considerations are expected to promote the development of novel therapeutics for the betterment of functional outcome in people suffering from schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFiyYjZ1O_WrVg90H21EOLACvtfcHk0lj1WbntOlEYEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtFegurs%253D&md5=1416dd6cfe539860da0147748669e65c</span></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=10.2174%2F0929867311320030006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320030006%26sid%3Dliteratum%253Aachs%26aulast%3DSumiyoshi%26aufirst%3DT.%26aulast%3DHiguchi%26aufirst%3DY.%26atitle%3DFacilitative%2520effect%2520of%25205-HT1A%2520receptor%2520agonists%2520on%2520cognition%2520in%2520patients%2520with%2520schizophrenia%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D357%26epage%3D362%26doi%3D10.2174%2F0929867311320030006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Opler, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medalia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opler, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacotherapy of cognitive deficits in schizophrenia</span>. <i>CNS. Spectr.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">142</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1017/S1092852913000771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1017%2FS1092852913000771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=24229725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BC2c7msFejtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=142-156&author=L.+A.+Oplerauthor=A.+Medaliaauthor=M.+G.+Oplerauthor=S.+M.+Stahl&title=Pharmacotherapy+of+cognitive+deficits+in+schizophrenia&doi=10.1017%2FS1092852913000771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14eR"><div class="casContent"><span class="casTitleNuber">14e</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacotherapy of cognitive deficits in schizophrenia</span></div><div class="casAuthors">Opler Lewis A; Medalia Alice; Opler Mark G; Stahl Stephen M</div><div class="citationInfo"><span class="NLM_cas:title">CNS spectrums</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">142-56</span>
        ISSN:<span class="NLM_cas:issn">1092-8529</span>.
    </div><div class="casAbstract">While second-generation antipsychotics treat negative as well as positive symptoms, recovery for persons with schizophrenia remains elusive, in part because there are no FDA-approved medications that treat the cognitive deficits of schizophrenia (CDS).  Recent work has identified agents that, when added to antipsychotics, improve cognition in schizophrenia.  This work and hypothesized mechanisms of action will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVEc91WN9nEJotVjB3IRIyfW6udTcc2eayarEhmGkgz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7msFejtQ%253D%253D&md5=5a7e00ac36651448a6d903baa15daa78</span></div><a href="/servlet/linkout?suffix=cit14e&amp;dbid=16384&amp;doi=10.1017%2FS1092852913000771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1092852913000771%26sid%3Dliteratum%253Aachs%26aulast%3DOpler%26aufirst%3DL.%2BA.%26aulast%3DMedalia%26aufirst%3DA.%26aulast%3DOpler%26aufirst%3DM.%2BG.%26aulast%3DStahl%26aufirst%3DS.%2BM.%26atitle%3DPharmacotherapy%2520of%2520cognitive%2520deficits%2520in%2520schizophrenia%26jtitle%3DCNS.%2520Spectr.%26date%3D2014%26volume%3D19%26spage%3D142%26epage%3D156%26doi%3D10.1017%2FS1092852913000771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richtand, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welge, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logue, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, P. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strakowski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, R. K.</span></span> <span> </span><span class="NLM_article-title">Dopamine and serotonin receptor binding and antipsychotic efficacy</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1715</span>– <span class="NLM_lpage">1726</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1301305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1038%2Fsj.npp.1301305" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=1715-1726&author=N.+M.+Richtandauthor=J.+A.+Welgeauthor=A.+D.+Logueauthor=P.+E.+Keckauthor=S.+M.+Strakowskiauthor=R.+K.+McNamara&title=Dopamine+and+serotonin+receptor+binding+and+antipsychotic+efficacy&doi=10.1038%2Fsj.npp.1301305"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301305%26sid%3Dliteratum%253Aachs%26aulast%3DRichtand%26aufirst%3DN.%2BM.%26aulast%3DWelge%26aufirst%3DJ.%2BA.%26aulast%3DLogue%26aufirst%3DA.%2BD.%26aulast%3DKeck%26aufirst%3DP.%2BE.%26aulast%3DStrakowski%26aufirst%3DS.%2BM.%26aulast%3DMcNamara%26aufirst%3DR.%2BK.%26atitle%3DDopamine%2520and%2520serotonin%2520receptor%2520binding%2520and%2520antipsychotic%2520efficacy%26jtitle%3DNeuropsychopharmacology%26date%3D2007%26volume%3D32%26spage%3D1715%26epage%3D1726%26doi%3D10.1038%2Fsj.npp.1301305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ames, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr-Lopez, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakib, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yudofsky, L. M.</span></span> <span> </span><span class="NLM_article-title">Detecting and managing adverse effects of antipsychotic medications: Current State of Play</span>. <i>Psychiatr. Clin. North. Am.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1016/j.psc.2016.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.psc.2016.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=27216904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FivFaqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2016&pages=275-311&author=D.+Amesauthor=S.+M.+Carr-Lopezauthor=M.+A.+Gutierrezauthor=J.+M.+Pierreauthor=J.+A.+Rosenauthor=S.+Shakibauthor=L.+M.+Yudofsky&title=Detecting+and+managing+adverse+effects+of+antipsychotic+medications%3A+Current+State+of+Play&doi=10.1016%2Fj.psc.2016.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Detecting and Managing Adverse Effects of Antipsychotic Medications: Current State of Play</span></div><div class="casAuthors">Ames Donna; Carr-Lopez Sian M; Gutierrez Mary A; Pierre Joseph M; Rosen Jennifer A; Shakib Susan; Yudofsky Lynn M</div><div class="citationInfo"><span class="NLM_cas:title">The Psychiatric clinics of North America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-311</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antipsychotics are some of the most frequently prescribed medications not only for psychotic disorders and symptoms but also for a wide range of on-label and off-label indications.  Because second-generation antipsychotics have largely replaced first-generation antipsychotics as first-line options due to their substantially decreased risk of extrapyramidal side effects, attention has shifted to other clinically concerning adverse events associated with antipsychotic therapy.  The focus of this article is to update the nonextrapyramidal side effects associated with second-generation antipsychotics.  Issues surrounding diagnosis and monitoring as well as clinical management are addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYhiE3R9PpBkg6wdEZmT2rfW6udTcc2eayarEhmGkgz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FivFaqtA%253D%253D&md5=b955fec4c21555a7045b9d202d7f8255</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.psc.2016.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.psc.2016.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DAmes%26aufirst%3DD.%26aulast%3DCarr-Lopez%26aufirst%3DS.%2BM.%26aulast%3DGutierrez%26aufirst%3DM.%2BA.%26aulast%3DPierre%26aufirst%3DJ.%2BM.%26aulast%3DRosen%26aufirst%3DJ.%2BA.%26aulast%3DShakib%26aufirst%3DS.%26aulast%3DYudofsky%26aufirst%3DL.%2BM.%26atitle%3DDetecting%2520and%2520managing%2520adverse%2520effects%2520of%2520antipsychotic%2520medications%253A%2520Current%2520State%2520of%2520Play%26jtitle%3DPsychiatr.%2520Clin.%2520North.%2520Am.%26date%3D2016%26volume%3D39%26spage%3D275%26epage%3D311%26doi%3D10.1016%2Fj.psc.2016.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, S. L.</span></span> <span> </span><span class="NLM_article-title">Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2009.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.pharmthera.2009.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19931306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFyiu77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2010&pages=169-179&author=G.+P.+Reynoldsauthor=S.+L.+Kirk&title=Metabolic+side+effects+of+antipsychotic+drug+treatment%2D%2Dpharmacological+mechanisms&doi=10.1016%2Fj.pharmthera.2009.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms</span></div><div class="casAuthors">Reynolds, Gavin P.; Kirk, Shona L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">169-179</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Obesity and metabolic syndrome, with increased risk of eventual cardiovascular disease and type II diabetes, are significant problems for patients receiving antipsychotic drugs and are likely contribute to their decreased life expectancy.  Several drug-related mechanisms may contribute to these problems, including effects both influencing food intake and on glucose and lipid metab.  The metabolic consequences of different antipsychotic drugs vary substantially; these variations reflect differences in receptor pharmacol. and provide clues as to the underlying pharmacol. mechanisms.  The two drugs with the greatest effects on body wt., olanzapine and clozapine, also have high affinity for the 5-HT2C and histamine H1 receptors, which implicate these receptors in antipsychotic-induced wt. gain, while peripheral M3 muscarinic receptor antagonism as well as central 5-HT2C effects may contribute to obesity-independent diabetes.  Other receptor mechanisms may have additive or synergistic effects; dopamine D2 receptor antagonism can enhance 5-HT2C-mediated effects on food intake, as well as influencing lipid and glucose metab. via disinhibition of prolactin secretion.  Pharmacogenetic assocns. of drug-induced wt. gain with 5-HT2C receptor and leptin gene polymorphisms, among others, have provided further clues.  Elevated leptin secretion in the absence of a decrease in food intake indicates drug-induced leptin insensitivity in the hypothalamus.  The minimal wt. gain seen with ziprasidone and aripiprazole may reflect their having further pharmacol. effects that protect against changes in food intake and related metabolic factors.  Understanding the pharmacol. of metabolic consequences of current antipsychotic drug treatment is clearly the key to developing improved pharmacotherapies that avoid these problematic and limiting adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt7JyuRcCdILVg90H21EOLACvtfcHk0lhrU14xeX4JmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFyiu77E&md5=548d49d2cca697e4405549be6ba0dd6f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DG.%2BP.%26aulast%3DKirk%26aufirst%3DS.%2BL.%26atitle%3DMetabolic%2520side%2520effects%2520of%2520antipsychotic%2520drug%2520treatment--pharmacological%2520mechanisms%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D125%26spage%3D169%26epage%3D179%26doi%3D10.1016%2Fj.pharmthera.2009.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weston-Green, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. F.</span></span> <span> </span><span class="NLM_article-title">The role of histaminergic H<sub>1</sub> and H<sub>3</sub> receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?</span>. <i>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1016/j.pnpbp.2009.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.pnpbp.2009.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19922755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsl2kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=1-4&author=C.+Dengauthor=K.+Weston-Greenauthor=X.+F.+Huang&title=The+role+of+histaminergic+H1+and+H3+receptors+in+food+intake%3A+a+mechanism+for+atypical+antipsychotic-induced+weight+gain%3F&doi=10.1016%2Fj.pnpbp.2009.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain?</span></div><div class="casAuthors">Deng, Chao; Weston-Green, Katrina; Huang, Xu-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-4</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Atypical antipsychotics such as olanzapine and clozapine are effective at treating the multiple domains of schizophrenia, with a low risk of extra-pyramidal side-effects.  However a major downfall to their use is metabolic side-effects particularly wt. gain/obesity, which occurs by unknown mechanisms.  The present paper explores the potential candidature of histaminergic neurotransmission in the mechanisms of atypical antipsychotic-induced wt. gain, with a focus on the histaminergic H1 and H3 receptors.  Olanzapine and clozapine have a high affinity for the H1 receptor, and meta-analyses show a strong correlation between risk of wt. gain and H1 receptor affinity.  In addn., olanzapine treatment decreases H1 receptor binding and mRNA expression in the rat hypothalamus.  Furthermore, a complex role is emerging for the histamine H3 receptor in the control of hunger.  The H3 receptor is a pre-synaptic autoreceptor that inhibits the synthesis and release of histamine, and a heteroreceptor that inhibits other neurotransmitters such as serotonin (5-HT), noradrenaline (NA) and acetylcholine (ACh), which are also implicated in the regulation of food intake.  Thus, the H3 receptor is in a prime position to regulate food intake, both through its control of histamine and its influence on other feeding pathways.  We proposed that a mechanism for atypical antipsychotic-induced wt. gain may be partly through the H3 receptor, as a drug-induced decrease in H1 receptor activity may decrease histamine tone through the H3 autoreceptors, compounding the wt. gain problem.  In addn., atypical antipsychotics may affect food intake by influencing 5-HT, NA and ACh release via interactions with the H3 heteroreceptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRPtyjEiBxobVg90H21EOLACvtfcHk0lhrU14xeX4JmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsl2kuw%253D%253D&md5=8ee52c313f7e12534d2cf4016f06b6b4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2009.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2009.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DC.%26aulast%3DWeston-Green%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DX.%2BF.%26atitle%3DThe%2520role%2520of%2520histaminergic%2520H1%2520and%2520H3%2520receptors%2520in%2520food%2520intake%253A%2520a%2520mechanism%2520for%2520atypical%2520antipsychotic-induced%2520weight%2520gain%253F%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2010%26volume%3D34%26spage%3D1%26epage%3D4%26doi%3D10.1016%2Fj.pnpbp.2009.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glazebrook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neill, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, G. P.</span></span> <span> </span><span class="NLM_article-title">Olanzapine-induced weight gain in the rat: role of 5-HT<sub>2C</sub> and histamine H<sub>1</sub> receptors</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>207</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1007/s00213-009-1639-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1007%2Fs00213-009-1639-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19688201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVSiurfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=2009&pages=119-125&author=S.+L.+Kirkauthor=J.+Glazebrookauthor=B.+Graysonauthor=J.+C.+Neillauthor=G.+P.+Reynolds&title=Olanzapine-induced+weight+gain+in+the+rat%3A+role+of+5-HT2C+and+histamine+H1+receptors&doi=10.1007%2Fs00213-009-1639-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors</span></div><div class="casAuthors">Kirk, Shona L.; Glazebrook, John; Grayson, Ben; Neill, Joanna C.; Reynolds, Gavin P.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">207</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-125</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Substantial increases in body wt. can be induced by several antipsychotic drugs, most notably olanzapine and clozapine.  Antagonism at certain receptors, particularly 5-HT2C and histamine H1 receptors, is implicated in this effect.  We have investigated the contribution of effects at these receptors to olanzapine-induced wt. gain occurring over 5 days following daily i.p. drug injections in groups of eight female rats.  Olanzapine (2 mg/kg) and the 5-HT2C antagonist SB 243213 (1 mg/kg), but not the histamine H1 antagonist mepyramine (1 mg/kg), produced significant increases in percentage body wt. above vehicle; olanzapine showed a significantly greater effect than SB 243213.  Haloperidol (0.1 mg/kg) alone or with mepyramine had no significant effects on wt. gain, while with SB 243213 and with both SB 243213 and mepyramine, it showed olanzapine-like increases in wt.  These results suggest that 5-HT2C receptor antagonism or inverse agonism, in the presence of D2 receptor antagonism, may contribute to olanzapine-induced wt. gain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmjmVRL8e4w7Vg90H21EOLACvtfcHk0lhrU14xeX4JmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVSiurfE&md5=3874fc5b7ab395710a52b045599ef5e2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00213-009-1639-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-009-1639-8%26sid%3Dliteratum%253Aachs%26aulast%3DKirk%26aufirst%3DS.%2BL.%26aulast%3DGlazebrook%26aufirst%3DJ.%26aulast%3DGrayson%26aufirst%3DB.%26aulast%3DNeill%26aufirst%3DJ.%2BC.%26aulast%3DReynolds%26aufirst%3DG.%2BP.%26atitle%3DOlanzapine-induced%2520weight%2520gain%2520in%2520the%2520rat%253A%2520role%2520of%25205-HT2C%2520and%2520histamine%2520H1%2520receptors%26jtitle%3DPsychopharmacology%26date%3D2009%26volume%3D207%26spage%3D119%26epage%3D125%26doi%3D10.1007%2Fs00213-009-1639-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Da
Silva Costa-Aze, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauphin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulouard, M.</span></span> <span> </span><span class="NLM_article-title">Serotonin 5-HT<sub>6</sub> receptor blockade reverses the age-related deficits of recognition memory and working memory in mice</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>222</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2011.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.bbr.2011.03.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=2011&pages=134-140&author=V.+Da%0ASilva+Costa-Azeauthor=F.+Dauphinauthor=M.+Boulouard&title=Serotonin+5-HT6+receptor+blockade+reverses+the+age-related+deficits+of+recognition+memory+and+working+memory+in+mice&doi=10.1016%2Fj.bbr.2011.03.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2011.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2011.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DDa%2BSilva%2BCosta-Aze%26aufirst%3DV.%26aulast%3DDauphin%26aufirst%3DF.%26aulast%3DBoulouard%26aufirst%3DM.%26atitle%3DSerotonin%25205-HT6%2520receptor%2520blockade%2520reverses%2520the%2520age-related%2520deficits%2520of%2520recognition%2520memory%2520and%2520working%2520memory%2520in%2520mice%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2011%26volume%3D222%26spage%3D134%26epage%3D140%26doi%3D10.1016%2Fj.bbr.2011.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidbreder, C. A.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>6</sub> receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1002/syn.10288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1002%2Fsyn.10288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=14618683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BD3srjvVWrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2004&pages=158-164&author=L.+P.+Lacroixauthor=L.+A.+Dawsonauthor=J.+J.+Haganauthor=C.+A.+Heidbreder&title=5-HT6+receptor+antagonist+SB-271046+enhances+extracellular+levels+of+monoamines+in+the+rat+medial+prefrontal+cortex&doi=10.1002%2Fsyn.10288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex</span></div><div class="casAuthors">Lacroix Laurent P; Dawson Lee A; Hagan Jim J; Heidbreder Christian A</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">158-64</span>
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    </div><div class="casAbstract">The present study investigated the neurochemical effects of the selective 5-HT(6) receptor antagonist SB-271046 in the rat medial prefrontal cortex (mPFC).  The effect of SB-271046 on extracellular levels of dopamine (DA), norepinephrine (NE), and serotonin (5-HT) in the mPFC was examined using in vivo microdialysis in the freely moving rat.  SB-271046 (10 mg/kg, p.o.) produced a significant increase in extracellular levels of both DA and NE without altering 5-HT neurotransmission.  These results further support the rationale for the use of 5-HT(6) receptor antagonists in the treatment of cognitive dysfunction associated with psychiatric diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfdX5-PKOb2t0Q2ypr7jHkfW6udTcc2eaVCAJGxNgPC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srjvVWrtg%253D%253D&md5=dce6fb05bddd0c003712fdd645444bd4</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1002%2Fsyn.10288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.10288%26sid%3Dliteratum%253Aachs%26aulast%3DLacroix%26aufirst%3DL.%2BP.%26aulast%3DDawson%26aufirst%3DL.%2BA.%26aulast%3DHagan%26aufirst%3DJ.%2BJ.%26aulast%3DHeidbreder%26aufirst%3DC.%2BA.%26atitle%3D5-HT6%2520receptor%2520antagonist%2520SB-271046%2520enhances%2520extracellular%2520levels%2520of%2520monoamines%2520in%2520the%2520rat%2520medial%2520prefrontal%2520cortex%26jtitle%3DSynapse%26date%3D2004%26volume%3D51%26spage%3D158%26epage%3D164%26doi%3D10.1002%2Fsyn.10288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tassone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madeo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirinzi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vita, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puglisi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponterio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonsi, P.</span></span> <span> </span><span class="NLM_article-title">Activation of 5-HT<sub>6</sub> receptors inhibits corticostriatal glutamatergic transmission</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">632</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2011.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.neuropharm.2011.05.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2011&pages=632-637&author=A.+Tassoneauthor=G.+Madeoauthor=T.+Schirinziauthor=D.+Vitaauthor=F.+Puglisiauthor=G.+Ponterioauthor=F.+Borsiniauthor=A.+Pisaniauthor=P.+Bonsi&title=Activation+of+5-HT6+receptors+inhibits+corticostriatal+glutamatergic+transmission&doi=10.1016%2Fj.neuropharm.2011.05.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2011.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2011.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DTassone%26aufirst%3DA.%26aulast%3DMadeo%26aufirst%3DG.%26aulast%3DSchirinzi%26aufirst%3DT.%26aulast%3DVita%26aufirst%3DD.%26aulast%3DPuglisi%26aufirst%3DF.%26aulast%3DPonterio%26aufirst%3DG.%26aulast%3DBorsini%26aufirst%3DF.%26aulast%3DPisani%26aufirst%3DA.%26aulast%3DBonsi%26aufirst%3DP.%26atitle%3DActivation%2520of%25205-HT6%2520receptors%2520inhibits%2520corticostriatal%2520glutamatergic%2520transmission%26jtitle%3DNeuropharmacology%26date%3D2011%26volume%3D61%26spage%3D632%26epage%3D637%26doi%3D10.1016%2Fj.neuropharm.2011.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fone, K. C.</span></span> <span> </span><span class="NLM_article-title">An update on the role of the 5-HT<sub>6</sub> receptor in cognitive function</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2008.06.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.neuropharm.2008.06.061" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2008&pages=1015-1022&author=K.+C.+Fone&title=An+update+on+the+role+of+the+5-HT6+receptor+in+cognitive+function&doi=10.1016%2Fj.neuropharm.2008.06.061"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2008.06.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2008.06.061%26sid%3Dliteratum%253Aachs%26aulast%3DFone%26aufirst%3DK.%2BC.%26atitle%3DAn%2520update%2520on%2520the%2520role%2520of%2520the%25205-HT6%2520receptor%2520in%2520cognitive%2520function%26jtitle%3DNeuropharmacology%26date%3D2008%26volume%3D55%26spage%3D1015%26epage%3D1022%26doi%3D10.1016%2Fj.neuropharm.2008.06.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arnt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang-Andersen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bymaster, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLapp, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giethlen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreilgaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinzie, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neill, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witten, L. M.</span></span> <span> </span><span class="NLM_article-title">Lu AE58054, a 5-HT<sub>6</sub> antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1033</span>, <span class="refDoi"> DOI: 10.1017/S1461145710000659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1017%2FS1461145710000659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=20569520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCksLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=1021-1033&author=J.+Arntauthor=B.+Bang-Andersenauthor=B.+Graysonauthor=F.+P.+Bymasterauthor=M.+P.+Cohenauthor=N.+W.+DeLappauthor=B.+Giethlenauthor=M.+Kreilgaardauthor=D.+L.+McKinzieauthor=J.+C.+Neillauthor=D.+L.+Nelsonauthor=S.+M.+Nielsenauthor=M.+N.+Poulsenauthor=J.+M.+Schausauthor=L.+M.+Witten&title=Lu+AE58054%2C+a+5-HT6+antagonist%2C+reverses+cognitive+impairment+induced+by+subchronic+phencyclidine+in+a+novel+object+recognition+test+in+rats&doi=10.1017%2FS1461145710000659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats</span></div><div class="casAuthors">Arnt, Jorn; Bang-Andersen, Benny; Grayson, Ben; Bymaster, Franklin P.; Cohen, Michael P.; De Lapp, Neil W.; Giethlen, Bruno; Kreilgaard, Mads; McKinzie, David L.; Neill, Joanna C.; Nelson, David L.; Nielsen, Soren M.; Poulsen, Mette N.; Schaus, John M.; Witten, Louise M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1021-1033</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">The in-vitro potency and selectivity, in-vivo binding affinity and effect of the 5-HT6R antagonist Lu AE58054 ([2-(6-fluoro-1H-indol-3-yl)-ethyl]-[3-(2,2,3,3-tetrafluoropropoxy)-benzyl]-amine) on impaired cognition were evaluated.  Lu AE58054 displayed high affinity to the human 5-HT6 receptor (5-HT6R) with a Ki of 0.83 nm.  In a 5-HT6 GTPγS efficacy assay Lu AE58054 showed no agonist activity, but demonstrated potent inhibition of 5-HT-mediated activation.  Besides medium affinity to adrenergic α1A- and α1B-adrenoreceptors, Lu AE58054 demonstrated >50-fold selectivity for more than 70 targets examd.  Orally administered Lu AE58054 potently inhibited striatal in-vivo binding of the 5-HT6 antagonist radioligand [3H]Lu AE60157 ([3H]8-(4-methylpiperazin-1-yl)-3-phenylsulfonylquinoline), with an ED50 of 2.7 mg/kg.  Steady-state modeling of an acute pharmacokinetic/5-HT6R occupancy time-course expt. indicated a plasma EC50 value of 20 ng/mL.  Administration of Lu AE58054 in a dose range (5-20 mg/kg p.o.) leading to above 65% striatal 5-HT6R binding occupancy in vivo, reversed cognitive impairment in a rat novel object recognition task induced after subchronic treatment for 7 d with phencyclidine (PCP 2 mg/kg b.i.d., i.p. for 7 d, followed by 7 d drug free).  The results indicate that Lu AE58054 is a selective antagonist of 5-HT6Rs with good oral bioavailability and robust efficacy in a rat model of cognitive impairment in schizophrenia.  Lu AE58054 may be useful for the pharmacotherapy of cognitive dysfunction in disease states such as schizophrenia and Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk_dkkVdbZyLVg90H21EOLACvtfcHk0lghtdbiGcRzLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCksLnK&md5=dfe5d1110dbcbc295af9a886635320aa</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1017%2FS1461145710000659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145710000659%26sid%3Dliteratum%253Aachs%26aulast%3DArnt%26aufirst%3DJ.%26aulast%3DBang-Andersen%26aufirst%3DB.%26aulast%3DGrayson%26aufirst%3DB.%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DCohen%26aufirst%3DM.%2BP.%26aulast%3DDeLapp%26aufirst%3DN.%2BW.%26aulast%3DGiethlen%26aufirst%3DB.%26aulast%3DKreilgaard%26aufirst%3DM.%26aulast%3DMcKinzie%26aufirst%3DD.%2BL.%26aulast%3DNeill%26aufirst%3DJ.%2BC.%26aulast%3DNelson%26aufirst%3DD.%2BL.%26aulast%3DNielsen%26aufirst%3DS.%2BM.%26aulast%3DPoulsen%26aufirst%3DM.%2BN.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26aulast%3DWitten%26aufirst%3DL.%2BM.%26atitle%3DLu%2520AE58054%252C%2520a%25205-HT6%2520antagonist%252C%2520reverses%2520cognitive%2520impairment%2520induced%2520by%2520subchronic%2520phencyclidine%2520in%2520a%2520novel%2520object%2520recognition%2520test%2520in%2520rats%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2010%26volume%3D13%26spage%3D1021%26epage%3D1033%26doi%3D10.1017%2FS1461145710000659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bucki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinkowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sniecikowska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieckowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gluch-Lutwin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grybos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pytka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jastrzebska-Wiesek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partyka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesolowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mierzejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolaczkowski, M.</span></span> <span> </span><span class="NLM_article-title">Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1<i>H</i>-indole-based multifunctional ligands with antipsychotic-Like, mood-modulating, and procognitive activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7483</span>– <span class="NLM_lpage">7501</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00839</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00839" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1KrtbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7483-7501&author=A.+Buckiauthor=M.+Marcinkowskaauthor=J.+Sniecikowskaauthor=K.+Wieckowskiauthor=M.+Pawlowskiauthor=M.+Gluch-Lutwinauthor=A.+Grybosauthor=A.+Siwekauthor=K.+Pytkaauthor=M.+Jastrzebska-Wiesekauthor=A.+Partykaauthor=A.+Wesolowskaauthor=P.+Mierzejewskiauthor=M.+Kolaczkowski&title=Novel+3-%281%2C2%2C3%2C6-Tetrahydropyridin-4-yl%29-1H-indole-based+multifunctional+ligands+with+antipsychotic-Like%2C+mood-modulating%2C+and+procognitive+activity&doi=10.1021%2Facs.jmedchem.7b00839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22cR"><div class="casContent"><span class="casTitleNuber">22c</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity</span></div><div class="casAuthors">Bucki, Adam; Marcinkowska, Monika; Sniecikowska, Joanna; Wieckowski, Krzysztof; Pawlowski, Maciej; Gluch-Lutwin, Monika; Grybos, Anna; Siwek, Agata; Pytka, Karolina; Jastrzebska-Wiesek, Magdalena; Partyka, Anna; Wesolowska, Anna; Mierzejewski, Pawel; Kolaczkowski, Marcin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7483-7501</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The most troublesome aspects of behavioral and psychol. symptoms of dementia (BPSD) are nowadays addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label.  Considering their modest effectiveness in dementia patients, the increased risk of adverse events and cognitive decline, there is an unmet need for well-tolerated and effective therapy of BPSD.  We designed and synthesized multifunctional ligands characterized in vitro as high-affinity partial agonists of D2R, antagonists of 5-HT6R, and blockers of SERT.  Moreover, the mols. activated 5-HT1AR and blocked 5-HT7R while having no relevant affinity for off-target M1R and hERG channel.  Compd. I, (N-{2-[4-(5-chloro-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}-3-methylbenzene-1-sulfonamide), exhibited a broad antipsychotic-, antidepressant-, and anxiolytic-like activity, not eliciting motor impairments in mice.  Most importantly, I showed memory-enhancing properties and it ameliorated memory deficits induced by scopolamine.  The mol. outperformed most important comparators in selected tests, indicating its potential in the treatment of both cognitive and noncognitive (behavioral and psychol.) symptoms of dementia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_i47_Akgt17Vg90H21EOLACvtfcHk0ljp86h8QIKiAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1KrtbbF&md5=9bb21d4918f0c0575aeef817b89b9b19</span></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00839%26sid%3Dliteratum%253Aachs%26aulast%3DBucki%26aufirst%3DA.%26aulast%3DMarcinkowska%26aufirst%3DM.%26aulast%3DSniecikowska%26aufirst%3DJ.%26aulast%3DWieckowski%26aufirst%3DK.%26aulast%3DPawlowski%26aufirst%3DM.%26aulast%3DGluch-Lutwin%26aufirst%3DM.%26aulast%3DGrybos%26aufirst%3DA.%26aulast%3DSiwek%26aufirst%3DA.%26aulast%3DPytka%26aufirst%3DK.%26aulast%3DJastrzebska-Wiesek%26aufirst%3DM.%26aulast%3DPartyka%26aufirst%3DA.%26aulast%3DWesolowska%26aufirst%3DA.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DKolaczkowski%26aufirst%3DM.%26atitle%3DNovel%25203-%25281%252C2%252C3%252C6-Tetrahydropyridin-4-yl%2529-1H-indole-based%2520multifunctional%2520ligands%2520with%2520antipsychotic-Like%252C%2520mood-modulating%252C%2520and%2520procognitive%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7483%26epage%3D7501%26doi%3D10.1021%2Facs.jmedchem.7b00839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casado, V.</span></span> <span> </span><span class="NLM_article-title">Targeting the dopamine D<sub>3</sub> receptor: an overview of drug design strategies</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1185413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1080%2F17460441.2016.1185413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=27135354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFOrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=641-664&author=A.+Cortesauthor=E.+Morenoauthor=M.+Rodriguez-Ruizauthor=E.+I.+Canelaauthor=V.+Casado&title=Targeting+the+dopamine+D3+receptor%3A+an+overview+of+drug+design+strategies&doi=10.1080%2F17460441.2016.1185413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dopamine D3 receptor: an overview of drug design strategies</span></div><div class="casAuthors">Cortes, Antoni; Moreno, Estefania; Rodriguez-Ruiz, Mar; Canela, Enric I.; Casado, Vicent</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">641-664</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter widely distributed in both the periphery and the central nervous system (CNS).  Its physiol. effects are mediated by five closely related G protein-coupled receptors (GPCRs) that are divided into two major subclasses: the D1-like (D1, D5) and the D2-like (D2, D3, D4) receptors.  D3 receptors (D3Rs) have the highest d. in the limbic areas of the brain, which are assocd. with cognitive and emotional functions.  These receptors are therefore attractive targets for therapeutic management.  This review summarizes the functional and pharmacol. characteristics of D3Rs, including the design and clin. relevance of full agonists, partial agonists and antagonists, as well as the capacity of these receptors to form active homodimers, heterodimers or higher order receptor complexes as pharmacol. targets in several neurol. and neurodegenerative disorders.  The high sequence homol. between D3R and the D2-type challenges the development of D3R-selective compds.  The design of new D3R-preferential ligands with improved physicochem. properties should provide a better pharmacokinetic/bioavailability profile and lesser toxicity than is found with existing D3R ligands.  It is also essential to optimize D3R affinity and, esp., D3R vs.  D2-type binding and functional selectivity ratios.  Developing allosteric and bitopic ligands should help to improve the D3R selectivity of these drugs.  As most evidence points to the ability of GPCRs to form homomers and heteromers, the most promising therapeutic strategy in the future is likely to involve the application of heteromer-selective drugs.  These selective ligands would display different affinities for a given receptor depending on the receptor partners within the heteromer.  Therefore, designing novel compds. that specifically target and modulate D1R-D3R heteromers would be an interesting approach for the treatment of levodopa (L-DOPA)-induced dyskinesias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE412vMxQCZ7Vg90H21EOLACvtfcHk0ljp86h8QIKiAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFOrsL4%253D&md5=eda2d0b52e03bbca2d62f1b27b193360</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1185413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1185413%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DRodriguez-Ruiz%26aufirst%3DM.%26aulast%3DCanela%26aufirst%3DE.%2BI.%26aulast%3DCasado%26aufirst%3DV.%26atitle%3DTargeting%2520the%2520dopamine%2520D3%2520receptor%253A%2520an%2520overview%2520of%2520drug%2520design%2520strategies%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D641%26epage%3D664%26doi%3D10.1080%2F17460441.2016.1185413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryoo, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. N.</span></span> <span> </span><span class="NLM_article-title">Localization of dopamine D<sub>3</sub> receptors to mesolimbic and D<sub>2</sub> receptors to mesostriatal regions of human forebrain</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">11271</span>– <span class="NLM_lpage">11275</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.23.11271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1073%2Fpnas.91.23.11271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=7972046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFems70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=11271-11275&author=A.+M.+Murrayauthor=H.+L.+Ryooauthor=E.+Gurevichauthor=J.+N.+Joyce&title=Localization+of+dopamine+D3+receptors+to+mesolimbic+and+D2+receptors+to+mesostriatal+regions+of+human+forebrain&doi=10.1073%2Fpnas.91.23.11271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24a</span><div class="casTitle"><span class="NLM_cas:atitle">Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain</span></div><div class="casAuthors">Murray, Angela M.; Ryoo, Han L.; Gurevich, Eugenia; Joyce, Jeffrey N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11271-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We characterized the binding of [125I]epidepride to dopamine D2-like and D3-like receptors in tissue sections of human striatum.  The competition for binding of [125I]epidepride by domperidone, quinpirole, and 7-hydroxy-N,N-di(1-propyl)-2-aminotetralin (7-OH-DPAT) was best fit by assuming one site in the caudate but two sites in nucleus accumbens.  Guanosine 5'-[β,γ-imido]triphosphate showed a large modulatory influence in agonist inhibition of [125I]epidepride binding in caudate but not in nucleus accumbens.  The binding of [125I]epidepride in the presence of 7-OH-DPAT (1000-fold selective for D3-like vs. D2-like sites) and domperidone (20-fold selective for D2 vs. D3-like sites) was used to quantify the nos. of D2-like and D3-like receptors in areas of human brain.  The distribution of D2-like and D3-like receptors was largely nonoverlapping.  Binding of [125I]epidepride to D3-like receptors was negligible in the dorsal striatum but was concd. in islands of dense binding in the nucleus accumbens and ventral putamen that aligned with acetylcholinesterase-poor striosomes.  Binding to D3-like receptors was also enriched in the internal globus pallidus, ventral palladium, septum, islands of Calleja, nucleus basalis, amygdalostriatal transition nucleus of the amygdala, central nucleus of the amygdala, and ventral tegmental area.  Binding of [125I]epidepride to D2 but not D3 receptors was detected in cortex and hippocampus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXhwrtC4swVrVg90H21EOLACvtfcHk0ljp86h8QIKiAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFems70%253D&md5=229c93d0b8695eb673e9c7265a1d574f</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.23.11271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.23.11271%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DA.%2BM.%26aulast%3DRyoo%26aufirst%3DH.%2BL.%26aulast%3DGurevich%26aufirst%3DE.%26aulast%3DJoyce%26aufirst%3DJ.%2BN.%26atitle%3DLocalization%2520of%2520dopamine%2520D3%2520receptors%2520to%2520mesolimbic%2520and%2520D2%2520receptors%2520to%2520mesostriatal%2520regions%2520of%2520human%2520forebrain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D11271%26epage%3D11275%26doi%3D10.1073%2Fpnas.91.23.11271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure of the human dopamine D<sub>3</sub> receptor in complex with a D<sub>2</sub>/D<sub>3</sub> selective antagonist</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+W.+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+human+dopamine+D3+receptor+in+complex+with+a+D2%2FD3+selective+antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0lgMl2_esfC2Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520human%2520dopamine%2520D3%2520receptor%2520in%2520complex%2520with%2520a%2520D2%252FD3%2520selective%2520antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordalski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warszycki, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogendorf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojarski, A. J.</span></span> <span> </span><span class="NLM_article-title">Pyrano[2,3,4-cd]indole as a scaffold for selective nonbasic 5-HT<sub>6</sub>R ligands</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00482</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00482" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=390-394&author=J.+Staronauthor=S.+Mordalskiauthor=D.+Warszyckiauthor=G.+Satalaauthor=A.+Hogendorfauthor=A.+J.+Bojarski&title=Pyrano%5B2%2C3%2C4-cd%5Dindole+as+a+scaffold+for+selective+nonbasic+5-HT6R+ligands&doi=10.1021%2Facsmedchemlett.6b00482"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00482%26sid%3Dliteratum%253Aachs%26aulast%3DStaron%26aufirst%3DJ.%26aulast%3DMordalski%26aufirst%3DS.%26aulast%3DWarszycki%26aufirst%3DD.%26aulast%3DSatala%26aufirst%3DG.%26aulast%3DHogendorf%26aufirst%3DA.%26aulast%3DBojarski%26aufirst%3DA.%2BJ.%26atitle%3DPyrano%255B2%252C3%252C4-cd%255Dindole%2520as%2520a%2520scaffold%2520for%2520selective%2520nonbasic%25205-HT6R%2520ligands%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D390%26epage%3D394%26doi%3D10.1021%2Facsmedchemlett.6b00482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. W.</span></span> <span> </span><span class="NLM_article-title">Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-<i>ij</i>]quinolin-4-one derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2307</span>– <span class="NLM_lpage">2319</span>, <span class="refDoi"> DOI: 10.1021/jm101470k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101470k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVChuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2307-2319&author=S.+Lucasauthor=M.+Negriauthor=R.+Heimauthor=C.+Zimmerauthor=R.+W.+Hartmann&title=Fine-tuning+the+selectivity+of+aldosterone+synthase+inhibitors%3A+structure-activity+and+structure-selectivity+insights+from+studies+of+heteroaryl+substituted+1%2C2%2C5%2C6-tetrahydropyrrolo%5B3%2C2%2C1-ij%5Dquinolin-4-one+derivatives&doi=10.1021%2Fjm101470k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Fine-Tuning the Selectivity of Aldosterone Synthase Inhibitors: Structure-Activity and Structure-Selectivity Insights from Studies of Heteroaryl Substituted 1,2,5,6-Tetrahydropyrrolo[3,2,1-ij]quinolin-4-one Derivatives</span></div><div class="casAuthors">Lucas, Simon; Negri, Matthias; Heim, Ralf; Zimmer, Christina; Hartmann, Rolf W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2307-2319</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyridine substituted 3,4-dihydro-1H-quinolin-2-ones (e.g., 1-3) constitute a class of highly potent and selective inhibitors of aldosterone synthase (CYP11B2), a promising target for the treatment of hyperaldosteronism, congestive heart failure, and myocardial fibrosis.  Among these, ethyl-substituted 3 possesses high selectivity against CYP1A2.  Rigidification of 3 by incorporation of the Et group into a 5- or 6-membered ring affords compds. with a pyrroloquinolinone or pyridoquinolinone mol. scaffold (e.g., 4 and 5).  It was found that these mols. are even more potent and selective CYP11B2 inhibitors than their corresponding open-chain analogs.  Moreover, pyrroloquinolinone 4 exhibits no inhibition of the six most important hepatic CYP enzymes as well as a bioavailability in the range of the marketed drug fadrozole.  The SAR studies disclose that subtle changes in the heterocyclic moiety are responsible for either a strong or a weak inhibition of the highly homologous 11β-hydroxylase (CYP11B1).  These results are not only important for fine-tuning the selectivity of CYP11B2 inhibitors but also for the development of selective CYP11B1 inhibitors that are of interest for the treatment of Cushing's syndrome and metabolic syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobbs5KsMMQUrVg90H21EOLACvtfcHk0lgMl2_esfC2Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVChuro%253D&md5=8c1515e12a059bf5fb125b75d419e1ca</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Fjm101470k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101470k%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DS.%26aulast%3DNegri%26aufirst%3DM.%26aulast%3DHeim%26aufirst%3DR.%26aulast%3DZimmer%26aufirst%3DC.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DFine-tuning%2520the%2520selectivity%2520of%2520aldosterone%2520synthase%2520inhibitors%253A%2520structure-activity%2520and%2520structure-selectivity%2520insights%2520from%2520studies%2520of%2520heteroaryl%2520substituted%25201%252C2%252C5%252C6-tetrahydropyrrolo%255B3%252C2%252C1-ij%255Dquinolin-4-one%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2307%26epage%3D2319%26doi%3D10.1021%2Fjm101470k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmaier, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. W.</span></span> <span> </span><span class="NLM_article-title">Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydro pyrrolo[3,2,1-<i>ij</i>]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing’s syndrome</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6629</span>– <span class="NLM_lpage">6633</span>, <span class="refDoi"> DOI: 10.1021/jm3003872</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003872" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6629-6633&author=L.+Yinauthor=S.+Lucasauthor=F.+Maurerauthor=U.+Kazmaierauthor=Q.+Huauthor=R.+W.+Hartmann&title=Novel+imidazol-1-ylmethyl+substituted+1%2C2%2C5%2C6-tetrahydro+pyrrolo%5B3%2C2%2C1-ij%5Dquinolin-4-ones+as+potent+and+selective+CYP11B1+inhibitors+for+the+treatment+of+Cushing%E2%80%99s+syndrome&doi=10.1021%2Fjm3003872"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1021%2Fjm3003872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003872%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DF.%26aulast%3DKazmaier%26aufirst%3DU.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DNovel%2520imidazol-1-ylmethyl%2520substituted%25201%252C2%252C5%252C6-tetrahydro%2520pyrrolo%255B3%252C2%252C1-ij%255Dquinolin-4-ones%2520as%2520potent%2520and%2520selective%2520CYP11B1%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Cushing%25E2%2580%2599s%2520syndrome%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6629%26epage%3D6633%26doi%3D10.1021%2Fjm3003872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, A. K.</span>; <span class="NLM_string-name">Cho, S. S. Y.</span>; <span class="NLM_string-name">Graham, J. M.</span>; <span class="NLM_string-name">Nikam, S. S.</span></span> <span> </span><span class="NLM_article-title">Fused tricycle heterocycles for the treatment of schizophrenia</span>. WO Patent <span class="NLM_patent">WO 2008015516 A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=A.+K.+Awasthi&author=S.+S.+Y.+Cho&author=J.+M.+Graham&author=S.+S.+Nikam&title=Fused+tricycle+heterocycles+for+the+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAwasthi%26aufirst%3DA.%2BK.%26atitle%3DFused%2520tricycle%2520heterocycles%2520for%2520the%2520treatment%2520of%2520schizophrenia%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D<sub>2</sub> receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4924</span>– <span class="NLM_lpage">4939</span>, <span class="refDoi"> DOI: 10.1021/jm500457x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500457x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVans70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4924-4939&author=M.+Szaboauthor=C.+Klein+Herenbrinkauthor=A.+Christopoulosauthor=J.+R.+Laneauthor=B.+Capuano&title=Structure-activity+relationships+of+privileged+structures+lead+to+the+discovery+of+novel+biased+ligands+at+the+dopamine+D2+receptor&doi=10.1021%2Fjm500457x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships of Privileged Structures Lead to the Discovery of Novel Biased Ligands at the Dopamine D2 Receptor</span></div><div class="casAuthors">Szabo, Monika; Klein Herenbrink, Carmen; Christopoulos, Arthur; Lane, J. Robert; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4924-4939</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biased agonism at GPCRs highlights the potential for the discovery and design of pathway-selective ligands and may confer therapeutic advantages to ligands targeting the dopamine D2 receptor (D2R).  We investigated the determinants of efficacy, affinity, and bias for three privileged structures for the D2R, exploring changes to linker length and incorporation of a heterocyclic unit.  Profiling the compds. in two signaling assays (cAMP and pERK1/2) allowed us to identify and quantify determinants of biased agonism at the D2R.  Substitution on the phenylpiperazine privileged structures (2-methoxy vs 2,3-dichloro) influenced bias when the thienopyridine heterocycle was absent.  Upon inclusion of the thienopyridine unit, the substitution pattern (4,6-di-Me vs 5-chloro-6-methoxy-4-methyl) had a significant effect on bias that overruled the effect of the phenylpiperazine substitution pattern.  This latter observation could be reconciled with an extended binding mode for these compds., whereby the interaction of the heterocycle with a secondary binding pocket may engender bias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvED1_D7mzdLVg90H21EOLACvtfcHk0lgv4rNj4t3njA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVans70%253D&md5=944e53ea2b1abf220e4c76a7d33d6f15</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1021%2Fjm500457x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500457x%26sid%3Dliteratum%253Aachs%26aulast%3DSzabo%26aufirst%3DM.%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DStructure-activity%2520relationships%2520of%2520privileged%2520structures%2520lead%2520to%2520the%2520discovery%2520of%2520novel%2520biased%2520ligands%2520at%2520the%2520dopamine%2520D2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4924%26epage%3D4939%26doi%3D10.1021%2Fjm500457x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4671</span>– <span class="NLM_lpage">4690</span>, <span class="refDoi"> DOI: 10.1021/jm400408r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400408r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslWmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4671-4690&author=Y.+Chenauthor=S.+Wangauthor=X.+Xuauthor=X.+Liuauthor=M.+Yuauthor=S.+Zhaoauthor=S.+Liuauthor=Y.+Qiuauthor=T.+Zhangauthor=B.+F.+Liuauthor=G.+Zhang&title=Synthesis+and+biological+investigation+of+coumarin+piperazine+%28piperidine%29+derivatives+as+potential+multireceptor+atypical+antipsychotics&doi=10.1021%2Fjm400408r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Investigation of Coumarin Piperazine (Piperidine) Derivatives as Potential Multireceptor Atypical Antipsychotics</span></div><div class="casAuthors">Chen, Yin; Wang, Songlin; Xu, Xiangqing; Liu, Xin; Yu, Minquan; Zhao, Song; Liu, Shicheng; Qiu, Yinli; Zhang, Tan; Liu, Bi-Feng; Zhang, Guisen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4671-4690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and synthesis of potential and novel antipsychotic coumarin derivs., assocd. with potent dopamine D2, D3, and serotonin 5-HT1A and 5-HT2A receptor properties, are the focus of the present article.  The most-promising deriv. was 7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl)butoxy)-4-methyl-8-chloro-2H-chromen-2-one (I).  This deriv. possesses unique pharmacol. features, including high affinity for dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors.  Moreover, it possesses low affinity for 5-HT2C and H1 receptors (to reduce the risk of obesity assocd. with chronic treatment) and hERG channels (to reduce the incidence of torsade de pointes).  In animal models, compd. I inhibited apomorphine-induced climbing behavior, MK-801-induced hyperactivity, and the conditioned avoidance response without observable catalepsy at the highest dose tested.  Further, fewer preclin. adverse events were noted with I compared with risperidone in assays that measured prolactin secretion and wt. gain.  Acceptable pharmacokinetic properties were also noted with I.  Taken together, I may constitute a novel class of drugs for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoByJHAgVuYCLVg90H21EOLACvtfcHk0lgv4rNj4t3njA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslWmtbw%253D&md5=5862884cd1ca8f74276d266757689334</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1021%2Fjm400408r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400408r%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520investigation%2520of%2520coumarin%2520piperazine%2520%2528piperidine%2529%2520derivatives%2520as%2520potential%2520multireceptor%2520atypical%2520antipsychotics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4671%26epage%3D4690%26doi%3D10.1021%2Fjm400408r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit28c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of new 6-hydroxypyridazinone benzisoxazoles: Potential multi-receptor-targeting atypical antipsychotics</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">728</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.ejmech.2016.09.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=713-728&author=X.+Caoauthor=Y.+Chenauthor=Y.+Zhangauthor=Y.+Qiuauthor=M.+Yuauthor=X.+Xuauthor=X.+Liuauthor=B.+F.+Liuauthor=G.+Zhang&title=Synthesis+and+biological+evaluation+of+new+6-hydroxypyridazinone+benzisoxazoles%3A+Potential+multi-receptor-targeting+atypical+antipsychotics&doi=10.1016%2Fj.ejmech.2016.09.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28c&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520new%25206-hydroxypyridazinone%2520benzisoxazoles%253A%2520Potential%2520multi-receptor-targeting%2520atypical%2520antipsychotics%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D124%26spage%3D713%26epage%3D728%26doi%3D10.1016%2Fj.ejmech.2016.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span> <span> </span><span class="NLM_article-title">Proof of concept study for designed multiple ligands targeting the dopamine D<sub>2</sub>, serotonin 5-HT<sub>2A</sub>, and muscarinic M<sub>1</sub> acetylcholine receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1550</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1021/jm5013243</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5013243" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVygug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1550-1555&author=M.+Szaboauthor=H.+D.+Limauthor=C.+Klein+Herenbrinkauthor=A.+Christopoulosauthor=J.+R.+Laneauthor=B.+Capuano&title=Proof+of+concept+study+for+designed+multiple+ligands+targeting+the+dopamine+D2%2C+serotonin+5-HT2A%2C+and+muscarinic+M1+acetylcholine+receptors&doi=10.1021%2Fjm5013243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Proof of Concept Study for Designed Multiple Ligands Targeting the Dopamine D2, Serotonin 5-HT2A, and Muscarinic M1 Acetylcholine Receptors</span></div><div class="casAuthors">Szabo, Monika; Lim, Herman D.; Klein Herenbrink, Carmen; Christopoulos, Arthur; Lane, J. Robert; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1550-1555</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors describe the hybridization of a benzoxazinone M1 scaffold with D2 privileged structures derived from putative and clin. relevant antipsychotics to develop designed multiple ligands.  The M1 mAChR is an attractive target for the cognitive deficits in key CNS disorders.  Moreover, activity at D2 and 5-HT2A receptors has proven useful for antipsychotic efficacy.  The authors identified 9 which retained functional activity at the target M1 mAChR and D2R and demonstrated high affinity for the 5-HT2AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJqxxyfgdbsbVg90H21EOLACvtfcHk0ljQOufZ9FVDIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVygug%253D%253D&md5=9aebec84dcc8ce782a4ef4d53cf773e0</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm5013243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5013243%26sid%3Dliteratum%253Aachs%26aulast%3DSzabo%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DH.%2BD.%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DProof%2520of%2520concept%2520study%2520for%2520designed%2520multiple%2520ligands%2520targeting%2520the%2520dopamine%2520D2%252C%2520serotonin%25205-HT2A%252C%2520and%2520muscarinic%2520M1%2520acetylcholine%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1550%26epage%3D1555%26doi%3D10.1021%2Fjm5013243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uto, Y.</span></span> <span> </span><span class="NLM_article-title">1,2-Benzisoxazole compounds: a patent review (2009 - 2014)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1517/13543776.2015.1027192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1517%2F13543776.2015.1027192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=25800253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVKitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=643-662&author=Y.+Uto&title=1%2C2-Benzisoxazole+compounds%3A+a+patent+review+%282009+-+2014%29&doi=10.1517%2F13543776.2015.1027192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">1,2-Benzisoxazole compounds: a patent review (2009 - 2014)</span></div><div class="casAuthors">Uto, Yoshikazu</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">643-662</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Benzisoxazoles represent a class of heterocyclic compds. of great importance for the prepn. of biol. active compds.  Benzisoxazoles are an important structure and some benzisoxazole-based medicines have been approved for human clin. use, including atypical antipsychotics (risperidone, paliperidone and iloperidone) and an anticonvulsant (zonisamide).  Areas covered: This review puts emphasis on the recent progress in therapeutically attractive benzisoxazole derivs. esp. 1,2-benzisoxazoles, which were published in the patent literature between 2009 and 2014.  As for the class of medicines, the main focus is on atypical antipsychotics and potential therapeutic treatments for other CNS disorders.  This review also covers the examples of benzisoxazole-based kinase inhibitors.  Moreover, novel benzisoxazoles with significant therapeutic interest are also mentioned.  Expert opinion: More recent examples of structural modification of existing drugs led to the discovery of some promising benzisoxazoles for antipsychotic use.  The design of multi-target ligands is important for the manipulation of pharmacol. properties and safety profiles for the use of antipsychotics.  Benzisoxazoles have been widely used as pharmacophores in the search for novel drug candidates in a variety of therapeutic area.  It is fair to assume that the wide and frequent use of benzisoxazoles in drug discovery and development will continue into the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX3RQJQGkOeLVg90H21EOLACvtfcHk0ljQOufZ9FVDIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVKitLY%253D&md5=26cb45757932db9ebb537b205cb66914</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1517%2F13543776.2015.1027192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2015.1027192%26sid%3Dliteratum%253Aachs%26aulast%3DUto%26aufirst%3DY.%26atitle%3D1%252C2-Benzisoxazole%2520compounds%253A%2520a%2520patent%2520review%2520%25282009%2520-%25202014%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2015%26volume%3D25%26spage%3D643%26epage%3D662%26doi%3D10.1517%2F13543776.2015.1027192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H. Y.</span></span> <span> </span><span class="NLM_article-title">Update on typical and atypical antipsychotic drugs</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-050911-161504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1146%2Fannurev-med-050911-161504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=23020880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFKltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=393-406&author=H.+Y.+Meltzer&title=Update+on+typical+and+atypical+antipsychotic+drugs&doi=10.1146%2Fannurev-med-050911-161504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Update on typical and atypical antipsychotic drugs</span></div><div class="casAuthors">Meltzer, Herbert Y.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">393-406</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Antipsychotic drugs (APDs) are best classified as typical or atypical.  The distinction is based solely on their ability to cause extrapyramidal side effects (EPS), including tardive dyskinesia (TD).  The two classes differ in mechanism of action, with atypical APDs providing important modulation of serotonergic neurotransmission.  TD increases the death rate and can be minimized by limiting use of typical APDs.  Clozapine is unique among the atypical APDs in its efficacy for ameliorating psychosis in patients with treatment-resistant schizophrenia (TRS), for redn. of suicide, and for improving longevity.  The typical and atypical APDs do not differ in improving psychopathol. in non-TRS.  The atypicals vary in metabolic side effects: some have little burden.  Cognitive benefits of the atypical APDs may be superior for some domains of cognition and require less use of anticholinergic drugs, which impair memory, for treatment of EPS.  Overall, choosing among the atypical APDs as first-line treatment represents the best course for schizophrenia and most likely other disorders for which APDs are used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK6NegaTYH_7Vg90H21EOLACvtfcHk0ljQOufZ9FVDIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFKltL8%253D&md5=cb4d64f893e34f0cf66b92ba97723081</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-050911-161504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-050911-161504%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DUpdate%2520on%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2013%26volume%3D64%26spage%3D393%26epage%3D406%26doi%3D10.1146%2Fannurev-med-050911-161504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newcomer, J. W.</span></span> <span> </span><span class="NLM_article-title">Metabolic considerations in the use of antipsychotic medications: a review of recent evidence</span>. <i>J. Clin. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">27</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=17286524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislWks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2007&pages=20-27&author=J.+W.+Newcomer&title=Metabolic+considerations+in+the+use+of+antipsychotic+medications%3A+a+review+of+recent+evidence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic considerations in the use of antipsychotic medications: a review of recent evidence</span></div><div class="casAuthors">Newcomer, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry (Memphis, TN, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">20-27</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press, Inc.</span>)
        </div><div class="casAbstract">A review.  Compared with the general population, persons with schizophrenia have up to a 20% shorter lifespan, with cardiovascular disease as the leading cause of death.  In addn., persons with schizophrenia have increased prevalence of the metabolic syndrome (obesity, insulin resistance, dyslipidemia, impaired glucose tolerance, and hypertension), increased prevalence of risk factors such as smoking, poverty, and poor nutrition, and reduced access to medical care.  Results from the recent Clin. Antipsychotic Trials of Intervention Effectiveness (CATIE) provide further evidence of the metabolic risk assocd. with different atypical antipsychotics.  Based on this study and a growing no. of other randomized clin. trials, clozapine and olanzapine treatment can produce substantial mean changes in wt. and an increased risk of assocd. metabolic disturbances.  Risperidone and quetiapine treatment can produce intermediate changes in mean wt. in comparison to treatment with other atypical antipsychotics, with discrepant results with respect to metabolic risk.  Aripiprazole and ziprasidone treatment induced the lowest mean changes in wt. gain and had no effect on risk for adverse metabolic changes, among currently available atypical agents.  Considerable evidence indicates that mentally ill patients often do not receive adequate recognition of, monitoring of, or care for their medical illnesses.  There is a crit. need for psychiatrists and primary care professionals to increase awareness of and attention to the phys. health problems of persons with mental illness, including appropriate management of metabolic adverse events assocd. with psychiatric medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsY5iWytM627Vg90H21EOLACvtfcHk0ljQOufZ9FVDIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislWks7s%253D&md5=e64a954d4fb7e0eea1599393bc61112f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNewcomer%26aufirst%3DJ.%2BW.%26atitle%3DMetabolic%2520considerations%2520in%2520the%2520use%2520of%2520antipsychotic%2520medications%253A%2520a%2520review%2520of%2520recent%2520evidence%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2007%26volume%3D68%26spage%3D20%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vohora, D.</span></span> <span> </span><span class="NLM_article-title">Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia</span>. <i>Curr. Opin. Investig. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">538</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=531-538&author=D.+Vohora&title=Atypical+antipsychotic+drugs%3A+current+issues+of+safety+and+efficacy+in+the+management+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVohora%26aufirst%3DD.%26atitle%3DAtypical%2520antipsychotic%2520drugs%253A%2520current%2520issues%2520of%2520safety%2520and%2520efficacy%2520in%2520the%2520management%2520of%2520schizophrenia%26jtitle%3DCurr.%2520Opin.%2520Investig.%2520Drugs%26date%3D2007%26volume%3D8%26spage%3D531%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, C. G.</span></span> <span> </span><span class="NLM_article-title">Schizophrenia: a review</span>. <i>Am. Fam. Physician</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1821</span>– <span class="NLM_lpage">1829</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=17619525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BD2svgt1Wrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2007&pages=1821-1829&author=S.+H.+Schultzauthor=S.+W.+Northauthor=C.+G.+Shields&title=Schizophrenia%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia: a review</span></div><div class="casAuthors">Schultz Stephen H; North Stephen W; Shields Cleveland G</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1821-9</span>
        ISSN:<span class="NLM_cas:issn">0002-838X</span>.
    </div><div class="casAbstract">Schizophrenia is a debilitating mental illness that affects 1 percent of the population in all cultures.  It affects equal numbers of men and women, but the onset is often later in women than in men.  Schizophrenia is characterized by positive and negative symptoms.  Positive symptoms include hallucinations, voices that converse with or about the patient, and delusions that are often paranoid.  Negative symptoms include flattened affect, loss of a sense of pleasure, loss of will or drive, and social withdrawal.  Both types of symptoms affect patients' families; therefore, it is important for physicians to provide guidance to all persons affected by the disease.  Psychosocial and family interventions can improve outcomes.  Medications can control symptoms, but virtually all antipsychotics have neurologic or physical side effects (e.g., weight gain, hypercholesterolemia, diabetes).  There is a 10 percent lifetime risk of suicide in patients with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSsiLzV1XkxGMjl5L8hwNX0fW6udTcc2eY9kAz0pIY_h7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svgt1Wrug%253D%253D&md5=f1bff146f01c38a5a1c819966d2e2434</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchultz%26aufirst%3DS.%2BH.%26aulast%3DNorth%26aufirst%3DS.%2BW.%26aulast%3DShields%26aufirst%3DC.%2BG.%26atitle%3DSchizophrenia%253A%2520a%2520review%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2007%26volume%3D75%26spage%3D1821%26epage%3D1829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit33c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Leucht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komossa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rummel-Kluge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corves, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asenjo Lobos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. M.</span></span> <span> </span><span class="NLM_article-title">A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.2008.08030368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1176%2Fappi.ajp.2008.08030368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19015230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BD1M7ht1yktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2009&pages=152-163&author=S.+Leuchtauthor=K.+Komossaauthor=C.+Rummel-Klugeauthor=C.+Corvesauthor=H.+Hungerauthor=F.+Schmidauthor=C.+Asenjo+Lobosauthor=S.+Schwarzauthor=J.+M.+Davis&title=A+meta-analysis+of+head-to-head+comparisons+of+second-generation+antipsychotics+in+the+treatment+of+schizophrenia&doi=10.1176%2Fappi.ajp.2008.08030368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33cR"><div class="casContent"><span class="casTitleNuber">33c</span><div class="casTitle"><span class="NLM_cas:atitle">A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia</span></div><div class="casAuthors">Leucht Stefan; Komossa Katja; Rummel-Kluge Christine; Corves Caroline; Hunger Heike; Schmid Franziska; Asenjo Lobos Claudia; Schwarz Sandra; Davis John M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Whether there are differences in efficacy among second-generation antipsychotics in the treatment of schizophrenia is a matter of heated debate.  The authors conducted a systematic review and meta-analysis of blinded studies comparing second-generation antipsychotics head-to-head.  METHOD:  Searches of the Cochrane Schizophrenia Group's register (May 2007) and MEDLINE (September 2007) were conducted for randomized, blinded studies comparing two or more of nine second-generation antipsychotics in the treatment of schizophrenia.  All data were extracted by at least three reviewers independently.  The primary outcome measure was change in total score on the Positive and Negative Syndrome Scale; secondary outcome measures were positive and negative symptom subscores and rate of dropout due to inefficacy.  The results were combined in a meta-analysis.  Various sensitivity analyses and metaregressions were used to examine bias.  RESULTS:  The analysis included 78 studies with 167 relevant arms and 13,558 participants.  Olanzapine proved superior to aripiprazole, quetiapine, risperidone, and ziprasidone.  Risperidone was more efficacious than quetiapine and ziprasidone.  Clozapine proved superior to zotepine and, in doses >400 mg/day, to risperidone.  These differences were due to improvement in positive symptoms rather than negative symptoms.  The results were rather robust with regard to the effects of industry sponsorship, study quality, dosages, and trial duration.  CONCLUSIONS:  The findings suggest that some second-generation antipsychotics may be somewhat more efficacious than others, but the limitations of meta-analysis must be considered.  In tailoring drug treatment to the individual patient, small efficacy superiorities must be weighed against large differences in side effects and cost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyN-UZrbWZdWBAiYWy6n3SfW6udTcc2eY9kAz0pIY_h7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7ht1yktA%253D%253D&md5=323f4fe01e2e21fd261043307f734607</span></div><a href="/servlet/linkout?suffix=cit33c&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2008.08030368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2008.08030368%26sid%3Dliteratum%253Aachs%26aulast%3DLeucht%26aufirst%3DS.%26aulast%3DKomossa%26aufirst%3DK.%26aulast%3DRummel-Kluge%26aufirst%3DC.%26aulast%3DCorves%26aufirst%3DC.%26aulast%3DHunger%26aufirst%3DH.%26aulast%3DSchmid%26aufirst%3DF.%26aulast%3DAsenjo%2BLobos%26aufirst%3DC.%26aulast%3DSchwarz%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26atitle%3DA%2520meta-analysis%2520of%2520head-to-head%2520comparisons%2520of%2520second-generation%2520antipsychotics%2520in%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2009%26volume%3D166%26spage%3D152%26epage%3D163%26doi%3D10.1176%2Fappi.ajp.2008.08030368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snowman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teuscher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, S. H.</span></span> <span> </span><span class="NLM_article-title">From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H<sub>1</sub> receptor-linked activation of hypothalamic AMP-kinase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">3456</span>– <span class="NLM_lpage">3459</span>, <span class="refDoi"> DOI: 10.1073/pnas.0611417104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1073%2Fpnas.0611417104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=3456-3459&author=S.+F.+Kimauthor=A.+S.+Huangauthor=A.+M.+Snowmanauthor=C.+Teuscherauthor=S.+H.+Snyder&title=From+the+Cover%3A+Antipsychotic+drug-induced+weight+gain+mediated+by+histamine+H1+receptor-linked+activation+of+hypothalamic+AMP-kinase&doi=10.1073%2Fpnas.0611417104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0611417104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0611417104%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BF.%26aulast%3DHuang%26aufirst%3DA.%2BS.%26aulast%3DSnowman%26aufirst%3DA.%2BM.%26aulast%3DTeuscher%26aufirst%3DC.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DFrom%2520the%2520Cover%253A%2520Antipsychotic%2520drug-induced%2520weight%2520gain%2520mediated%2520by%2520histamine%2520H1%2520receptor-linked%2520activation%2520of%2520hypothalamic%2520AMP-kinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D3456%26epage%3D3459%26doi%3D10.1073%2Fpnas.0611417104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poluzzi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, F.</span></span> <span> </span><span class="NLM_article-title">QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1002/med.20019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1002%2Fmed.20019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=15389727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlWhs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=133-166&author=M.+Recanatiniauthor=E.+Poluzziauthor=M.+Masettiauthor=A.+Cavalliauthor=F.+De+Ponti&title=QT+prolongation+through+hERG+K%28%2B%29+channel+blockade%3A+current+knowledge+and+strategies+for+the+early+prediction+during+drug+development&doi=10.1002%2Fmed.20019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35aR"><div class="casContent"><span class="casTitleNuber">35a</span><div class="casTitle"><span class="NLM_cas:atitle">QT prolongation through hERG K+ channel blockade: current knowledge and strategies for the early prediction during drug development</span></div><div class="casAuthors">Recanatini, Maurizio; Poluzzi, Elisabetta; Masetti, Matteo; Cavalli, Andrea; de Ponti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-166</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Prolongation of the QT interval of the ECG is a typical effect of Class III antiarrhythmic drugs, achieved through blockade of potassium channels.  In the past decade, evidence has accrued that several classes of drugs used for non-cardiovascular indications may prolong the QT interval with the same mechanism (namely, human ether-a-go-go-related gene (hERG) K+ channel blockade).  The great interest in QT prolongation is because of several reasons.  First, drug-induced QT prolongation increases the likelihood of a polymorphous ventricular arrhythmia (namely, torsades de pointes, TdP), which may cause syncope and degenerate into ventricular fibrillation and sudden death.  Second, the fact that several classes of drugs, such as antihistamines, fluoroquinolones, macrolides, and neuroleptics may cause the long QT syndrome (LQTS) raises the question whether this is a class effect (e.g., shared by all agents of a given pharmacol. class) or a specific effect of single agents within a class.  There is now consensus that, in most cases, only a few agents within a therapeutic class share the ability to significantly affect hERG K+ channels.  These compds. should be identified as early as possible during drug development.  Third, QT prolongation and interaction with hERG K+ channels have become surrogate markers of cardiotoxicity and have received increasing regulatory attention.  This review briefly outlines the mechanisms leading to QT prolongation and the different strategies that can be followed to predict this unwanted effect.  In particular, it will focus on the approaches recently proposed for the in silico screening of new compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO7B-6DBAFeLVg90H21EOLACvtfcHk0lgjAe8Ld4gLfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlWhs7Y%253D&md5=aa5aea37c667b4f35546259cc2593c6d</span></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.1002%2Fmed.20019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20019%26sid%3Dliteratum%253Aachs%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DMasetti%26aufirst%3DM.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26atitle%3DQT%2520prolongation%2520through%2520hERG%2520K%2528%252B%2529%2520channel%2520blockade%253A%2520current%2520knowledge%2520and%2520strategies%2520for%2520the%2520early%2520prediction%2520during%2520drug%2520development%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2005%26volume%3D25%26spage%3D133%26epage%3D166%26doi%3D10.1002%2Fmed.20019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit35b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Raschi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceccarini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span> <span> </span><span class="NLM_article-title">hERG-related drug toxicity and models for predicting hERG liability and QT prolongation</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1021</span>, <span class="refDoi"> DOI: 10.1517/17425250903055070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1517%2F17425250903055070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19572824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWhsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=1005-1021&author=E.+Raschiauthor=L.+Ceccariniauthor=F.+De+Pontiauthor=M.+Recanatini&title=hERG-related+drug+toxicity+and+models+for+predicting+hERG+liability+and+QT+prolongation&doi=10.1517%2F17425250903055070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35bR"><div class="casContent"><span class="casTitleNuber">35b</span><div class="casTitle"><span class="NLM_cas:atitle">hERG-related drug toxicity and models for predicting hERG liability and QT prolongation</span></div><div class="casAuthors">Raschi, Emanuel; Ceccarini, Luisa; De Ponti, Fabrizio; Recanatini, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1005-1021</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: hERG K+ channels have been recognized as a primary antitarget in safety pharmacol.  Their blockade, caused by several drugs with different therapeutic indications, may lead to QT prolongation and, eventually, to potentially fatal arrhythmia, namely torsade de pointes.  Therefore, a no. of preclin. models have been developed to predict hERG liability early in the drug development process.  Objective: The aim of this review is to outline the present state of the art on drug-induced hERG blockade, providing insights on the predictive value of in vitro and in silico models for hERG liability.  Methods: On the basis of latest reports, high-throughput preclin. models have been discussed outlining advantages and limitations.  Conclusion: Although no single model has an abs. value, an integrated risk assessment is recommended to predict the pro-arrhythmic risk of a given drug.  This prediction requires expertise from different areas and should encompass emerging issues such as interference with hERG trafficking and QT shortening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCQa-hX-BiQ7Vg90H21EOLACvtfcHk0lgjAe8Ld4gLfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWhsLnK&md5=93e148db825611c7e086f75e50b8953c</span></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1517%2F17425250903055070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250903055070%26sid%3Dliteratum%253Aachs%26aulast%3DRaschi%26aufirst%3DE.%26aulast%3DCeccarini%26aufirst%3DL.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26aulast%3DRecanatini%26aufirst%3DM.%26atitle%3DhERG-related%2520drug%2520toxicity%2520and%2520models%2520for%2520predicting%2520hERG%2520liability%2520and%2520QT%2520prolongation%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D1005%26epage%3D1021%26doi%3D10.1517%2F17425250903055070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mannel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Hydroxy-Substituted heteroarylpiperazines: novel scaffolds for beta-arrestin-biased D<sub>2</sub>R agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4693</span>– <span class="NLM_lpage">4713</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00363</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00363" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4693-4713&author=B.+Mannelauthor=D.+Denglerauthor=J.+Shonbergauthor=H.+Hubnerauthor=D.+M%C3%B6llerauthor=P.+Gmeiner&title=Hydroxy-Substituted+heteroarylpiperazines%3A+novel+scaffolds+for+beta-arrestin-biased+D2R+agonists&doi=10.1021%2Facs.jmedchem.7b00363"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00363%26sid%3Dliteratum%253Aachs%26aulast%3DMannel%26aufirst%3DB.%26aulast%3DDengler%26aufirst%3DD.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DHubner%26aufirst%3DH.%26aulast%3DM%25C3%25B6ller%26aufirst%3DD.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DHydroxy-Substituted%2520heteroarylpiperazines%253A%2520novel%2520scaffolds%2520for%2520beta-arrestin-biased%2520D2R%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4693%26epage%3D4713%26doi%3D10.1021%2Facs.jmedchem.7b00363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattorusso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalanotti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagnotto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mereghetti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennini, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Cesare, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastroianni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scafetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galletti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castorina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacifici, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vertechy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Serio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghirardi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carminati, P.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1021/jm0309811</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0309811" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=143-157&author=G.+Campianiauthor=S.+Butiniauthor=C.+Fattorussoauthor=B.+Catalanottiauthor=S.+Gemmaauthor=V.+Nacciauthor=E.+Morelliauthor=A.+Cagnottoauthor=I.+Mereghettiauthor=T.+Menniniauthor=M.+Carliauthor=P.+Minettiauthor=M.+A.+Di+Cesareauthor=D.+Mastroianniauthor=N.+Scafettaauthor=B.+Gallettiauthor=M.+A.+Stasiauthor=M.+Castorinaauthor=L.+Pacificiauthor=M.+Vertechyauthor=S.+Di+Serioauthor=O.+Ghirardiauthor=O.+Tintiauthor=P.+Carminati&title=Pyrrolo%5B1%2C3%5Dbenzothiazepine-based+serotonin+and+dopamine+receptor+antagonists.+Molecular+modeling%2C+further+structure-activity+relationship+studies%2C+and+identification+of+novel+atypical+antipsychotic+agents&doi=10.1021%2Fjm0309811"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm0309811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0309811%26sid%3Dliteratum%253Aachs%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DFattorusso%26aufirst%3DC.%26aulast%3DCatalanotti%26aufirst%3DB.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DNacci%26aufirst%3DV.%26aulast%3DMorelli%26aufirst%3DE.%26aulast%3DCagnotto%26aufirst%3DA.%26aulast%3DMereghetti%26aufirst%3DI.%26aulast%3DMennini%26aufirst%3DT.%26aulast%3DCarli%26aufirst%3DM.%26aulast%3DMinetti%26aufirst%3DP.%26aulast%3DDi%2BCesare%26aufirst%3DM.%2BA.%26aulast%3DMastroianni%26aufirst%3DD.%26aulast%3DScafetta%26aufirst%3DN.%26aulast%3DGalletti%26aufirst%3DB.%26aulast%3DStasi%26aufirst%3DM.%2BA.%26aulast%3DCastorina%26aufirst%3DM.%26aulast%3DPacifici%26aufirst%3DL.%26aulast%3DVertechy%26aufirst%3DM.%26aulast%3DDi%2BSerio%26aufirst%3DS.%26aulast%3DGhirardi%26aufirst%3DO.%26aulast%3DTinti%26aufirst%3DO.%26aulast%3DCarminati%26aufirst%3DP.%26atitle%3DPyrrolo%255B1%252C3%255Dbenzothiazepine-based%2520serotonin%2520and%2520dopamine%2520receptor%2520antagonists.%2520Molecular%2520modeling%252C%2520further%2520structure-activity%2520relationship%2520studies%252C%2520and%2520identification%2520of%2520novel%2520atypical%2520antipsychotic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D143%26epage%3D157%26doi%3D10.1021%2Fjm0309811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, Y.</span></span> <span> </span><span class="NLM_article-title">Therapeutic role of 5-HT<sub>1A</sub> receptors in the treatment of schizophrenia and Parkinson’s disease</span>. <i>CNS Neurosci. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1111/j.1755-5949.2010.00211.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1111%2Fj.1755-5949.2010.00211.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=21091640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVCnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=58-65&author=Y.+Ohno&title=Therapeutic+role+of+5-HT1A+receptors+in+the+treatment+of+schizophrenia+and+Parkinson%E2%80%99s+disease&doi=10.1111%2Fj.1755-5949.2010.00211.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38aR"><div class="casContent"><span class="casTitleNuber">38a</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease</span></div><div class="casAuthors">Ohno, Yukihiro</div><div class="citationInfo"><span class="NLM_cas:title">CNS Neuroscience & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-65</span>CODEN:
                <span class="NLM_cas:coden">CNTNAB</span>;
        ISSN:<span class="NLM_cas:issn">1755-5930</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  5-HT1A receptors have long been implicated in the pathogenesis and treatment of anxiety and depressive disorders.  Recently, several lines of studies have revealed new insights into the therapeutic role of 5-HT1A receptors in treating schizophrenia and Parkinson's disease.  Specifically, 5-HT1A receptors seem to be a promising target for alleviating antipsychotic-induced extrapyramidal side effects (EPS) and cognitive/affective disorders in schizophrenia.  In the treatment of patients with Parkinson's disease, 5-HT1A agonists are expected to improve not only affective symptoms (e.g., anxiety and depression), but also the core parkinsonian symptoms as well as antiparkinsonian agents-induced side effects (e.g., L-DOPA-induced dyskinesia).  Here, the therapeutic mechanisms mediated by 5-HT1A receptors in schizophrenia and Parkinson's disease are reviewed.  This evidence should encourage discovery of new 5-HT1A ligands, which can resolve the unmet clin. needs in the current therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMhhzTRrq3R7Vg90H21EOLACvtfcHk0lg1OX7aONBB4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVCnurc%253D&md5=d70ebb228afb20826693e9ed48d287c2</span></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.1111%2Fj.1755-5949.2010.00211.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1755-5949.2010.00211.x%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DY.%26atitle%3DTherapeutic%2520role%2520of%25205-HT1A%2520receptors%2520in%2520the%2520treatment%2520of%2520schizophrenia%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCNS%2520Neurosci.%2520Ther.%26date%3D2011%26volume%3D17%26spage%3D58%26epage%3D65%26doi%3D10.1111%2Fj.1755-5949.2010.00211.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit38b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, C. R.</span></span> <span> </span><span class="NLM_article-title">Return of D<sub>4</sub> dopamine receptor antagonists in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7233</span>– <span class="NLM_lpage">7243</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00151</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00151" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsVWrt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7233-7243&author=C.+W.+Lindsleyauthor=C.+R.+Hopkins&title=Return+of+D4+dopamine+receptor+antagonists+in+drug+discovery&doi=10.1021%2Facs.jmedchem.7b00151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38bR"><div class="casContent"><span class="casTitleNuber">38b</span><div class="casTitle"><span class="NLM_cas:atitle">Return of D4 Dopamine Receptor Antagonists in Drug Discovery</span></div><div class="casAuthors">Lindsley, Craig W.; Hopkins, Corey R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7233-7243</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D4 receptor garnered a great deal of interest in the early 1990s when studies showed the atypical antipsychotic clozapine possessed higher affinity for D4, relative to other dopamine receptor subtypes, and that this activity might underlie the unique clin. efficacy of clozapine.  Unfortunately, D4 antagonists that were developed for schizophrenia failed in the clinic.  Thus, D4 fell out of favor as a therapeutic target, and work in this area was silent for decades.  Recently, D4 ligands with improved selectivity for D4 against not only D1-3,5 but also other biogenic amine targets have emerged, and D4 is once again in the spotlight as a novel target for both addiction and Parkinson's disease (PD), as well as other emerging diseases.  This report will review the historical data for D4, review the known D4 ligands, and then highlight new data supporting a role for D4 inhibition in addiction, PD, and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqspfOt_2Te-LVg90H21EOLACvtfcHk0lg1OX7aONBB4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsVWrt7o%253D&md5=6d58ae979689c79d9c4dfe4e0802f195</span></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00151%26sid%3Dliteratum%253Aachs%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26atitle%3DReturn%2520of%2520D4%2520dopamine%2520receptor%2520antagonists%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7233%26epage%3D7243%26doi%3D10.1021%2Facs.jmedchem.7b00151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Maeso, J.</span></span> <span> </span><span class="NLM_article-title">Preclinical models of antipsychotic drug action</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2131</span>– <span class="NLM_lpage">2144</span>, <span class="refDoi"> DOI: 10.1017/S1461145713000606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1017%2FS1461145713000606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=23745738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOisbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=2131-2144&author=J.+L.+Morenoauthor=J.+Gonzalez-Maeso&title=Preclinical+models+of+antipsychotic+drug+action&doi=10.1017%2FS1461145713000606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical models of antipsychotic drug action</span></div><div class="casAuthors">Moreno, Jose L.; Gonzalez-Maeso, Javier</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2131-2144</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review.  One of the main obstacles faced by translational neuroscience is the development of animal models of psychiatric disorders.  Behavioral pharmacol. studies indicate that psychedelic drugs, such as lysergic acid diethylamide (LSD) and dissociative drugs, such as phencyclidine (PCP), induce in healthy human volunteers psychotic and cognitive symptoms that resemble some of those obsd. in schizophrenia patients.  Serotonin 5-HT2A and metabotropic glutamate 2 receptors have been involved in the mechanism of action of psychedelic and dissociative drugs.  Here we review recent advances using LSD-like and PCP-like drugs in rodent models that implicate these receptors in the neurobiol. of schizophrenia and its treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAGcPjQnLWFLVg90H21EOLACvtfcHk0lg2JKEnFimvdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOisbfK&md5=1c0df24addc20d894c142b2cc6168d65</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1017%2FS1461145713000606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145713000606%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno%26aufirst%3DJ.%2BL.%26aulast%3DGonzalez-Maeso%26aufirst%3DJ.%26atitle%3DPreclinical%2520models%2520of%2520antipsychotic%2520drug%2520action%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2013%26volume%3D16%26spage%3D2131%26epage%3D2144%26doi%3D10.1017%2FS1461145713000606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porsolt, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagne, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virley, D.</span></span> <span> </span><span class="NLM_article-title">Nonhuman primates: translational models for predicting antipsychotic-induced movement disorders</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.207209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1124%2Fjpet.113.207209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=24030013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyiu7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=542-546&author=R.+D.+Porsoltauthor=V.+Castagneauthor=E.+Hayesauthor=D.+Virley&title=Nonhuman+primates%3A+translational+models+for+predicting+antipsychotic-induced+movement+disorders&doi=10.1124%2Fjpet.113.207209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Nonhuman primates: translational models for predicting antipsychotic-induced movement disorders</span></div><div class="casAuthors">Porsolt, Roger D.; Castagne, Vincent; Hayes, Eric; Virley, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">542-546</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Repeated haloperidol treatment administered to nonhuman primates (NHPs) over several months or even years leads to the gradual appearance of drug-induced dystonic reactions in the orofacial region (mouth opening, tongue protrusion or retraction, bar biting) and in the whole body (writhing of the limbs and trunk, bar grasping).  The propensity of antipsychotics to induce dystonia in NHPs is not correlated with their propensity to induce catalepsy in rodents, suggesting that the two types of effects are dissocd. and may represent distinct aspects of the extrapyramidal symptoms induced by antipsychotics.  In view of the clear homol. to clin. obsd. phenomena, antipsychotic-induced dystonias in antipsychotic-primed NHPs would appear to possess a high degree of translational validity.  These NHP phenomena could therefore serve as a useful model for predicting the occurrence of similar abnormal movements with novel substances developed for the treatment of schizophrenia or other psychotic disorders.  Moreover, the NHP dystonia model could possibly serve as a biomarker for substances that will eventually cause tardive dyskinesia in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKr94MjRXldbVg90H21EOLACvtfcHk0lg2JKEnFimvdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyiu7vM&md5=1d8f0efe43009f91ea25005ae3920fe9</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207209%26sid%3Dliteratum%253Aachs%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26aulast%3DCastagne%26aufirst%3DV.%26aulast%3DHayes%26aufirst%3DE.%26aulast%3DVirley%26aufirst%3DD.%26atitle%3DNonhuman%2520primates%253A%2520translational%2520models%2520for%2520predicting%2520antipsychotic-induced%2520movement%2520disorders%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D542%26epage%3D546%26doi%3D10.1124%2Fjpet.113.207209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiberas, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinot, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artiges, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loc'h, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maziere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paillere-Martinot, M.
L.</span></span> <span> </span><span class="NLM_article-title">Extrastriatal and striatal D<sub>2</sub> dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia</span>. <i>Br. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">503</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1192/bjp.179.6.503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1192%2Fbjp.179.6.503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=11731352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BD3MnosVKgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2001&pages=503-508&author=X.+Xiberasauthor=J.+L.+Martinotauthor=L.+Malletauthor=E.+Artigesauthor=H.+C.+Loc%27hauthor=B.+Maziereauthor=M.%0AL.+Paillere-Martinot&title=Extrastriatal+and+striatal+D2+dopamine+receptor+blockade+with+haloperidol+or+new+antipsychotic+drugs+in+patients+with+schizophrenia&doi=10.1192%2Fbjp.179.6.503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia</span></div><div class="casAuthors">Xiberas X; Martinot J L; Mallet L; Artiges E; Loc'H C; Maziere B; Paillere-Martinot M L</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of psychiatry : the journal of mental science</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">503-8</span>
        ISSN:<span class="NLM_cas:issn">0007-1250</span>.
    </div><div class="casAbstract">BACKGROUND:  Both traditional and atypical antipsychotics have been hypothesised to be effective in schizophrenia through limbic and cortical D(2) dopamine receptor blockade.  AIMS:  To investigate this hypothesis with the D(2)/D(3)-selective positron emission tomography (PET) probe [(76)Br]-FLB457.  METHOD:  PET scans were performed on 6 controls and 18 patients with schizophrenia treated with haloperidol or with risperidone, clozapine, amisulpride or olanzapine.  RESULTS:  The D(2) dopamine receptor blockade was high in the temporal cortex with both haloperidol and atypical antipsychotics.  The atypicals, however, induced a significantly lower D(2) binding index than haloperidol in the thalamus and in the striatum.  CONCLUSIONS:  Results suggest that cortical D(2) dopamine receptors are a common target of traditional and atypical antipsychotics for therapeutic action.  Higher in vivo binding to the D(2) receptors in the cortex than in the basal ganglia is suggested as an indicator of favourable profile for a putative antipsychotic compound.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbBFlCBiZZKZI8NvIb08rbfW6udTcc2eYqNO71DGlWA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnosVKgsA%253D%253D&md5=3da69371e0d4fa0af919eaba133cd908</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1192%2Fbjp.179.6.503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1192%252Fbjp.179.6.503%26sid%3Dliteratum%253Aachs%26aulast%3DXiberas%26aufirst%3DX.%26aulast%3DMartinot%26aufirst%3DJ.%2BL.%26aulast%3DMallet%26aufirst%3DL.%26aulast%3DArtiges%26aufirst%3DE.%26aulast%3DLoc%2527h%26aufirst%3DH.%2BC.%26aulast%3DMaziere%26aufirst%3DB.%26aulast%3DPaillere-Martinot%26aufirst%3DM.%2BL.%26atitle%3DExtrastriatal%2520and%2520striatal%2520D2%2520dopamine%2520receptor%2520blockade%2520with%2520haloperidol%2520or%2520new%2520antipsychotic%2520drugs%2520in%2520patients%2520with%2520schizophrenia%26jtitle%3DBr.%2520J.%2520Psychiatry%26date%3D2001%26volume%3D179%26spage%3D503%26epage%3D508%26doi%3D10.1192%2Fbjp.179.6.503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arnt, J.</span></span> <span> </span><span class="NLM_article-title">Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade</span>. <i>Acta Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1111/j.1600-0773.1982.tb01032.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1111%2Fj.1600-0773.1982.tb01032.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=6129770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADyaL3sXmsFehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1982&pages=321-329&author=J.+Arnt&title=Pharmacological+specificity+of+conditioned+avoidance+response+inhibition+in+rats%3A+inhibition+by+neuroleptics+and+correlation+to+dopamine+receptor+blockade&doi=10.1111%2Fj.1600-0773.1982.tb01032.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42aR"><div class="casContent"><span class="casTitleNuber">42a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological specificity of conditioned avoidance response inhibition in rats:  inhibition by neuroleptics and correlation to dopamine receptor blockade</span></div><div class="casAuthors">Arnt, Joern</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica et Toxicologica</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">321-9</span>CODEN:
                <span class="NLM_cas:coden">APTOA6</span>;
        ISSN:<span class="NLM_cas:issn">0001-6683</span>.
    </div><div class="casAbstract">The inhibitory effect of 36 neuroleptic compds. on conditioned avoidance response (CAR) and unconditioned escape response (UER) has been studied in rats.  All neuroleptics antagonized CAR in doses below those inhibiting UER and below those inducing catalepsy.  Stereospecificity was shown in 2 cases.  Significant correlation was found between CAR inhibitory and cataleptogenic potency.  Also inhibition of amphetamine-induced stereotypy, affinity to 3H-haloperidol binding in vitro, and clin. potency was significantly correlated to CAR inhibition.  CAR and UER inhibition induced by cis(Z)-flupentixol (I)  [53772-82-0] and haloperidol  [52-86-8] was attenuated by scopolamine, but was only weakly influenced by methysergide and prazosin.  Among a wide range of other CNS active compds. tested, CAR was inhibited by α1-adrenergic antagonists, benzodiazepines, a barbiturate, GABA agonists, morphine, and a serotonin agonist, but in doses inducing other motor disturbances.  Thus, CAR inhibition is a sensitive test for dopamine receptor antagonists.  However, addnl. α-adrenergic activity found for some neuroleptics (e.g. clozapine  [5786-21-0], chlorprothixene  [113-59-7]) may contribute to the CAR inhibitory potency.  Addnl. antimuscarinic activity of neuroleptics may moderately attenuate CAR inhibition whereas serotonin receptor blockade is of minor importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcjmAjdj8YybVg90H21EOLACvtfcHk0ljPhIgPLRSU-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXmsFehug%253D%253D&md5=3c6a8cdc6e90e5a481b017c61b84d39c</span></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0773.1982.tb01032.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0773.1982.tb01032.x%26sid%3Dliteratum%253Aachs%26aulast%3DArnt%26aufirst%3DJ.%26atitle%3DPharmacological%2520specificity%2520of%2520conditioned%2520avoidance%2520response%2520inhibition%2520in%2520rats%253A%2520inhibition%2520by%2520neuroleptics%2520and%2520correlation%2520to%2520dopamine%2520receptor%2520blockade%26jtitle%3DActa%2520Pharmacol.%2520Toxicol.%26date%3D1982%26volume%3D51%26spage%3D321%26epage%3D329%26doi%3D10.1111%2Fj.1600-0773.1982.tb01032.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit42b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bundgaard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreilgaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennum, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D<sub>2</sub> receptor occupancy and behavioural conditioned avoidance response</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1002/bdd.656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1002%2Fbdd.656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19475539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFyhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=209-220&author=C.+Bundgaardauthor=F.+Larsenauthor=M.+Kreilgaardauthor=L.+T.+Brennumauthor=C.+K.+Olsen&title=Pharmacokinetics+of+sertindole+and+its+metabolite+dehydrosertindole+in+rats+and+characterization+of+their+comparative+pharmacodynamics+based+on+in+vivo+D2+receptor+occupancy+and+behavioural+conditioned+avoidance+response&doi=10.1002%2Fbdd.656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42bR"><div class="casContent"><span class="casTitleNuber">42b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response</span></div><div class="casAuthors">Bundgaard, Christoffer; Larsen, Frank; Kreilgaard, Mads; Brennum, Lise T.; Olsen, Christina Kurre</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">209-220</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The objectives of this study were to characterize the pharmacokinetics of sertindole and its active metabolite dehydrosertindole in rats and to evaluate the central modulatory and behavioral pharmacodynamics including a competitive interaction model between the compds.  Following oral administration of sertindole or dehydrosertindole, the plasma concn.-time courses were detd. in conjunction with striatal dopamine D2 receptor binding.  In addn., the behavioral effects were recorded in the conditioned avoidance response (CAR) paradigm.  A one-compartment model with Michaelis-Menten elimination best described the pharmacokinetics of sertindole.  Formation of dehydrosertindole was incorporated into the pharmacokinetic model and exhibited first-order elimination.  PK/PD modeling after administration of dehydrosertindole resulted in potency ests. of 165 and 424 ng/mL for D2-occupancy (Kd) and CAR measurements (EC50), resp.  The pharmacokinetics of the parent-metabolite system was integrated into a competitive pharmacodynamic Emax model to quantitate the potency of sertindole with the pharmacodynamic parameters of the metabolite taken into account.  Based on this approach, effect compartment concns. of sertindole needed to attain 50% occupancy and half-maximal effect in the CAR paradigm were 133 and 338 ng/mL, resp.  The corresponding potency-ests. obtained after conventional modeling of the sertindole data without accounting for the metabolite amounted to 102 and 345 ng/mL.  Based on competitive PK/PD anal. of the parent-metabolite interaction, the relative contribution of dehydrosertindole to the overall pharmacol. effect after sertindole administration in rats appeared to be of minor significance.  This could mainly be ascribed to the relatively low extent of bioconversion of sertindole into dehydrosertindole in this species.  Copyright © 2009 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbQ03cTJ7XSLVg90H21EOLACvtfcHk0ljPhIgPLRSU-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFyhsLs%253D&md5=2680510cf2c7a41a3770f592f91d86e1</span></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=10.1002%2Fbdd.656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.656%26sid%3Dliteratum%253Aachs%26aulast%3DBundgaard%26aufirst%3DC.%26aulast%3DLarsen%26aufirst%3DF.%26aulast%3DKreilgaard%26aufirst%3DM.%26aulast%3DBrennum%26aufirst%3DL.%2BT.%26aulast%3DOlsen%26aufirst%3DC.%2BK.%26atitle%3DPharmacokinetics%2520of%2520sertindole%2520and%2520its%2520metabolite%2520dehydrosertindole%2520in%2520rats%2520and%2520characterization%2520of%2520their%2520comparative%2520pharmacodynamics%2520based%2520on%2520in%2520vivo%2520D2%2520receptor%2520occupancy%2520and%2520behavioural%2520conditioned%2520avoidance%2520response%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2009%26volume%3D30%26spage%3D209%26epage%3D220%26doi%3D10.1002%2Fbdd.656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schlumberger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietraszek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gravius, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danysz, W.</span></span> <span> </span><span class="NLM_article-title">Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2009.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.pbb.2009.12.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2010&pages=23-30&author=C.+Schlumbergerauthor=M.+Pietraszekauthor=A.+Graviusauthor=W.+Danysz&title=Effects+of+a+positive+allosteric+modulator+of+mGluR5+ADX47273+on+conditioned+avoidance+response+and+PCP-induced+hyperlocomotion+in+the+rat+as+models+for+schizophrenia&doi=10.1016%2Fj.pbb.2009.12.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2009.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2009.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DSchlumberger%26aufirst%3DC.%26aulast%3DPietraszek%26aufirst%3DM.%26aulast%3DGravius%26aufirst%3DA.%26aulast%3DDanysz%26aufirst%3DW.%26atitle%3DEffects%2520of%2520a%2520positive%2520allosteric%2520modulator%2520of%2520mGluR5%2520ADX47273%2520on%2520conditioned%2520avoidance%2520response%2520and%2520PCP-induced%2520hyperlocomotion%2520in%2520the%2520rat%2520as%2520models%2520for%2520schizophrenia%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2010%26volume%3D95%26spage%3D23%26epage%3D30%26doi%3D10.1016%2Fj.pbb.2009.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit43b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wadenberg, M. L.</span></span> <span> </span><span class="NLM_article-title">Conditioned avoidance response in the development of new antipsychotics</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.2174/138161210790170085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.2174%2F138161210790170085" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=358-370&author=M.+L.+Wadenberg&title=Conditioned+avoidance+response+in+the+development+of+new+antipsychotics&doi=10.2174%2F138161210790170085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=10.2174%2F138161210790170085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210790170085%26sid%3Dliteratum%253Aachs%26aulast%3DWadenberg%26aufirst%3DM.%2BL.%26atitle%3DConditioned%2520avoidance%2520response%2520in%2520the%2520development%2520of%2520new%2520antipsychotics%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2010%26volume%3D16%26spage%3D358%26epage%3D370%26doi%3D10.2174%2F138161210790170085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathiasen, J. R.</span>; <span class="NLM_string-name">DiCamillo, A.</span></span> <span> </span><span class="NLM_article-title">Novel object recognition in the rat: a facile assay for cognitive function</span>. In  <i>Current Protocols in Pharmacology</i>; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2010</span>; pp  <span class="NLM_fpage">5.59.1</span>– <span class="NLM_lpage">5.59.15</span>, <span class="refDoi"> DOI: 10.1002/0471141755.ph0559s49</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1002%2F0471141755.ph0559s49" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=5.59.1-5.59.15&author=J.+R.+Mathiasen&author=A.+DiCamillo&title=Current+Protocols+in+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44a&amp;dbid=16384&amp;doi=10.1002%2F0471141755.ph0559s49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471141755.ph0559s49%26sid%3Dliteratum%253Aachs%26aulast%3DMathiasen%26aufirst%3DJ.%2BR.%26atitle%3DNovel%2520object%2520recognition%2520in%2520the%2520rat%253A%2520a%2520facile%2520assay%2520for%2520cognitive%2520function%26btitle%3DCurrent%2520Protocols%2520in%2520Pharmacology%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2010%26spage%3D5.59.1%26epage%3D5.59.15%26doi%3D10.1002%2F0471141755.ph0559s49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit44b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Millan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buccafusco, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loiseau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decamp, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fone, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomasson-Perret, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mocaer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J. S.</span></span> <span> </span><span class="NLM_article-title">The dopamine D<sub>3</sub> receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1035</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1017/S1461145710000775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1017%2FS1461145710000775" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=20663270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCksLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=1035-1051&author=M.+J.+Millanauthor=J.+J.+Buccafuscoauthor=F.+Loiseauauthor=D.+J.+Watsonauthor=E.+Decampauthor=K.+C.+Foneauthor=N.+Thomasson-Perretauthor=M.+Hillauthor=E.+Mocaerauthor=J.+S.+Schneider&title=The+dopamine+D3+receptor+antagonist%2C+S33138%2C+counters+cognitive+impairment+in+a+range+of+rodent+and+primate+procedures&doi=10.1017%2FS1461145710000775"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44bR"><div class="casContent"><span class="casTitleNuber">44b</span><div class="casTitle"><span class="NLM_cas:atitle">The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures</span></div><div class="casAuthors">Millan, Mark J.; Buccafusco, Jerry J.; Loiseau, Florence; Watson, David J. G.; Decamp, Emmanuel; Fone, Kevin C. F.; Thomasson-Perret, Nitza; Hill, Michael; Mocaer, Elisabeth; Schneider, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1035-1051</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Although dopamine D3 receptor antagonists have been shown to enhance frontocortical cholinergic transmission and improve cognitive performance in rodents, data are limited and their effects have never been examd. in primates.  Accordingly, we characterized the actions of the D3 receptor antagonist, S33138, in rats and rhesus monkeys using a suite of procedures in which cognitive performance was disrupted by several contrasting manipulations.  S33138 dose-dependently (0.01-0.63 mg/kg s.c.) blocked a delay-induced impairment of novel object recognition in rats, a model of visual learning and memory.  Further, S33138 (0.16-2.5 mg/kg s.c.) similarly reduced a delay-induced deficit in social novelty discrimination in rats, a procedure principally based on olfactory cues.  Adult rhesus monkeys were trained to perform cognitive procedures, then chronically exposed to low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine which produced cognitive impairment without motor disruption.  In an attentional set-shifting task of cognitive flexibility involving an extra-dimensional shift, deficits were reversed by S33138 (0.04 and 0.16 mg/kg p.o.).  S33138 also significantly improved accuracy (0.04 and 0.16 mg/kg p.o.) at short (but not long) delays in a variable delayed-response task of attention and working memory.  Finally, in a sep. set of expts. performed in monkeys displaying age-related deficits, S33138 significantly (0.16 and 0.63 mg/kg p.o.) improved task accuracies for long delay intervals in a delayed matching-to-sample task of working memory.  In conclusion, S33138 improved performance in several rat and primate procedures of cognitive impairment.  These data underpin interest in D3 receptor blockade as a strategy for improving cognitive performance in CNS disorders like schizophrenia and Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAOsVc2rbr1bVg90H21EOLACvtfcHk0lgg1VYeM4YhMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCksLbO&md5=7903a09e0a4b9218dae0b89a60170305</span></div><a href="/servlet/linkout?suffix=cit44b&amp;dbid=16384&amp;doi=10.1017%2FS1461145710000775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145710000775%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26aulast%3DBuccafusco%26aufirst%3DJ.%2BJ.%26aulast%3DLoiseau%26aufirst%3DF.%26aulast%3DWatson%26aufirst%3DD.%2BJ.%26aulast%3DDecamp%26aufirst%3DE.%26aulast%3DFone%26aufirst%3DK.%2BC.%26aulast%3DThomasson-Perret%26aufirst%3DN.%26aulast%3DHill%26aufirst%3DM.%26aulast%3DMocaer%26aufirst%3DE.%26aulast%3DSchneider%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520dopamine%2520D3%2520receptor%2520antagonist%252C%2520S33138%252C%2520counters%2520cognitive%2520impairment%2520in%2520a%2520range%2520of%2520rodent%2520and%2520primate%2520procedures%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2010%26volume%3D13%26spage%3D1035%26epage%3D1051%26doi%3D10.1017%2FS1461145710000775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit44c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerretsen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravaggio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Foll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulsant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff-Guerrero, A.</span></span> <span> </span><span class="NLM_article-title">The potential role of dopamine D<sub>3</sub> receptor neurotransmission in cognition</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1016/j.euroneuro.2013.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.euroneuro.2013.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=23791072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVyrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=799-813&author=S.+Nakajimaauthor=P.+Gerretsenauthor=H.+Takeuchiauthor=F.+Caravaggioauthor=T.+Chowauthor=B.+Le+Follauthor=B.+Mulsantauthor=B.+Pollockauthor=A.+Graff-Guerrero&title=The+potential+role+of+dopamine+D3+receptor+neurotransmission+in+cognition&doi=10.1016%2Fj.euroneuro.2013.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44cR"><div class="casContent"><span class="casTitleNuber">44c</span><div class="casTitle"><span class="NLM_cas:atitle">The potential role of dopamine D3 receptor neurotransmission in cognition</span></div><div class="casAuthors">Nakajima, Shinichiro; Gerretsen, Philip; Takeuchi, Hiroyoshi; Caravaggio, Fernando; Chow, Tiffany; Le Foll, Bernard; Mulsant, Benoit; Pollock, Bruce; Graff-Guerrero, Ariel</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">799-813</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Currently available treatments have limited pro-cognitive effects for neuropsychiatric disorders, such as schizophrenia, Parkinson's disease and Alzheimer's disease.  The primary objective of this work is to review the literature on the role of dopamine D3 receptors in cognition, and propose dopamine D3 receptor antagonists as possible cognitive enhancers for neuropsychiatric disorders.  A literature search was performed to identify animal and human studies on D3 receptors and cognition using PubMed, MEDLINE and EMBASE.  The search terms included "dopamine D3 receptor" and "cognition".  The literature search identified 164 articles.  The results revealed: (1) D3 receptors are assocd. with cognitive functioning in both healthy individuals and those with neuropsychiatric disorders; (2) D3 receptor blockade appears to enhance while D3 receptor agonism seems to impair cognitive function, including memory, attention, learning, processing speed, social recognition and executive function independent of age; and (3) D3 receptor antagonists may exert their pro-cognitive effect by enhancing the release of acetylcholine in the prefrontal cortex, disinhibiting the activity of dopamine neurons projecting to the nucleus accumbens or prefrontal cortex, or activating CREB signaling in the hippocampus.  These findings suggest that D3 receptor blockade may enhance cognitive performance in healthy individuals and treat cognitive dysfunction in individuals with a neuropsychiatric disorder.  Clin. trials are needed to confirm these effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSUxqVZeIzYLVg90H21EOLACvtfcHk0lgg1VYeM4YhMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVyrtLc%253D&md5=3d42c98b759d0d27039345dbee2ae73e</span></div><a href="/servlet/linkout?suffix=cit44c&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2013.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2013.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DNakajima%26aufirst%3DS.%26aulast%3DGerretsen%26aufirst%3DP.%26aulast%3DTakeuchi%26aufirst%3DH.%26aulast%3DCaravaggio%26aufirst%3DF.%26aulast%3DChow%26aufirst%3DT.%26aulast%3DLe%2BFoll%26aufirst%3DB.%26aulast%3DMulsant%26aufirst%3DB.%26aulast%3DPollock%26aufirst%3DB.%26aulast%3DGraff-Guerrero%26aufirst%3DA.%26atitle%3DThe%2520potential%2520role%2520of%2520dopamine%2520D3%2520receptor%2520neurotransmission%2520in%2520cognition%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2013%26volume%3D23%26spage%3D799%26epage%3D813%26doi%3D10.1016%2Fj.euroneuro.2013.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit44d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Benhamu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Fontecha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Villa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Rodriguez, M. L.</span></span> <span> </span><span class="NLM_article-title">Serotonin 5-HT<sub>6</sub> receptor antagonists for the treatment of cognitive deficiency in Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7160</span>– <span class="NLM_lpage">7181</span>, <span class="refDoi"> DOI: 10.1021/jm5003952</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5003952" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVWjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7160-7181&author=B.+Benhamuauthor=M.+Martin-Fontechaauthor=H.+Vazquez-Villaauthor=L.+Pardoauthor=M.+L.+Lopez-Rodriguez&title=Serotonin+5-HT6+receptor+antagonists+for+the+treatment+of+cognitive+deficiency+in+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm5003952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44dR"><div class="casContent"><span class="casTitleNuber">44d</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin 5-HT6 Receptor Antagonists for the Treatment of Cognitive Deficiency in Alzheimer's Disease</span></div><div class="casAuthors">Benhamu, Bellinda; Martin-Fontecha, Mar; Vazquez-Villa, Henar; Pardo, Leonardo; Lopez-Rodriguez, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7160-7181</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is one of the most frequent causes of death and disability worldwide and has a significant clin. and socioeconomic impact.  In the search for novel therapeutic strategies, serotonin 5-HT6 receptor (5-HT6R) has been proposed as a promising drug target for cognition enhancement in AD.  This manuscript reviews the compelling evidence for the implication of this receptor in learning and memory processes.  We have summarized the current status of the medicinal chem. of 5-HT6R antagonists and the encouraging preclin. findings that demonstrate their significant procognitive behavioral effects in a no. of learning paradigms, probably acting through modulation of multiple neurotransmitter systems and signaling pathways.  The results of the ongoing clin. trials are eagerly awaited to shed some light on the validation of 5-HT6R antagonists as a new drug class for the treatment of symptomatic cognitive impairment in AD, either as stand-alone therapy or in combination with established agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeTO6_2THvaLVg90H21EOLACvtfcHk0lgg1VYeM4YhMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVWjs7c%253D&md5=bf8d2cba73f72e04a5caf8b295647064</span></div><a href="/servlet/linkout?suffix=cit44d&amp;dbid=16384&amp;doi=10.1021%2Fjm5003952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5003952%26sid%3Dliteratum%253Aachs%26aulast%3DBenhamu%26aufirst%3DB.%26aulast%3DMartin-Fontecha%26aufirst%3DM.%26aulast%3DVazquez-Villa%26aufirst%3DH.%26aulast%3DPardo%26aufirst%3DL.%26aulast%3DLopez-Rodriguez%26aufirst%3DM.%2BL.%26atitle%3DSerotonin%25205-HT6%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520cognitive%2520deficiency%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7160%26epage%3D7181%26doi%3D10.1021%2Fjm5003952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massari, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freestone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarrick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoder, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadbent, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barido, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmelzer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neul, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aertgeerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabatabaei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitenbucher, J. G.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel and selective phosphodiesterase 2 (PDE2a) inhibitors for the treatment of memory disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2037</span>– <span class="NLM_lpage">2051</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01793</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01793" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1Sjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2037-2051&author=L.+Gomezauthor=M.+E.+Massariauthor=T.+Vickersauthor=G.+Freestoneauthor=W.+Vernierauthor=K.+Lyauthor=R.+Xuauthor=M.+McCarrickauthor=T.+Marroneauthor=M.+Metzauthor=Y.+G.+Yanauthor=Z.+W.+Yoderauthor=R.+Lemusauthor=N.+J.+Broadbentauthor=R.+Baridoauthor=N.+Warrenauthor=K.+Schmelzerauthor=D.+Neulauthor=D.+Leeauthor=C.+B.+Andersenauthor=K.+Sebringauthor=K.+Aertgeertsauthor=X.+Zhouauthor=A.+Tabatabaeiauthor=M.+Petersauthor=J.+G.+Breitenbucher&title=Design+and+synthesis+of+novel+and+selective+phosphodiesterase+2+%28PDE2a%29+inhibitors+for+the+treatment+of+memory+disorders&doi=10.1021%2Facs.jmedchem.6b01793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45aR"><div class="casContent"><span class="casTitleNuber">45a</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders</span></div><div class="casAuthors">Gomez, Laurent; Massari, Mark Eben; Vickers, Troy; Freestone, Graeme; Vernier, William; Ly, Kiev; Xu, Rui; McCarrick, Margaret; Marrone, Tami; Metz, Markus; Yan, Yingzhou G.; Yoder, Zachary W.; Lemus, Robert; Broadbent, Nicola J.; Barido, Richard; Warren, Noelle; Schmelzer, Kara; Neul, David; Lee, Dong; Andersen, Carsten B.; Sebring, Kristen; Aertgeerts, Kathleen; Zhou, Xianbo; Tabatabaei, Ali; Peters, Marco; Breitenbucher, J. Guy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2037-2051</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of potent and selective [1,2,4]triazolo[1,5-a]pyrimidine PDE2a inhibitors is reported.  The design and improvement of the binding properties of this series was achieved using X-ray crystal structures in conjunction with careful anal. of electronic and structural requirements for the PDE2a enzyme.  One of the lead compds., compd. I (DNS-8254), was identified as a potent and highly selective PDE2a enzyme inhibitor with favorable rat pharmacokinetic properties.  Interestingly, the increased potency of compd. I was facilitated by the formation of a halogen bond with the oxygen of Tyr827 present in the PDE2a active site.  In vivo, compd. I demonstrated significant memory enhancing effects in a rat model of novel object recognition.  Taken together, these data suggest that compd. I may be a useful tool to explore the pharmacol. of selective PDE2a inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6ML_QxZhnWLVg90H21EOLACvtfcHk0ljRWmUvi-TpvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1Sjuro%253D&md5=fe8df71fbd1f61423352dfcb862d9d53</span></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01793%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DL.%26aulast%3DMassari%26aufirst%3DM.%2BE.%26aulast%3DVickers%26aufirst%3DT.%26aulast%3DFreestone%26aufirst%3DG.%26aulast%3DVernier%26aufirst%3DW.%26aulast%3DLy%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DMcCarrick%26aufirst%3DM.%26aulast%3DMarrone%26aufirst%3DT.%26aulast%3DMetz%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DY.%2BG.%26aulast%3DYoder%26aufirst%3DZ.%2BW.%26aulast%3DLemus%26aufirst%3DR.%26aulast%3DBroadbent%26aufirst%3DN.%2BJ.%26aulast%3DBarido%26aufirst%3DR.%26aulast%3DWarren%26aufirst%3DN.%26aulast%3DSchmelzer%26aufirst%3DK.%26aulast%3DNeul%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DAndersen%26aufirst%3DC.%2BB.%26aulast%3DSebring%26aufirst%3DK.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DTabatabaei%26aufirst%3DA.%26aulast%3DPeters%26aufirst%3DM.%26aulast%3DBreitenbucher%26aufirst%3DJ.%2BG.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520and%2520selective%2520phosphodiesterase%25202%2520%2528PDE2a%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520memory%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2037%26epage%3D2051%26doi%3D10.1021%2Facs.jmedchem.6b01793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit45b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mikami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokubo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of clinical candidate N-((1S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2, 3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): a highly potent, selective, and brain-penetrating phosphodiesterase 2A inhibitor for the treatment of cognitive disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7677</span>– <span class="NLM_lpage">7702</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00807</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00807" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSmtL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7677-7702&author=S.+Mikamiauthor=S.+Nakamuraauthor=T.+Ashizawaauthor=I.+Nomuraauthor=M.+Kawasakiauthor=S.+Sasakiauthor=H.+Okiauthor=H.+Kokuboauthor=I.+D.+Hoffmanauthor=H.+Zouauthor=N.+Uchiyamaauthor=K.+Nakashimaauthor=N.+Kamiguchiauthor=H.+Imadaauthor=N.+Suzukiauthor=H.+Iwashitaauthor=T.+Taniguchi&title=Discovery+of+clinical+candidate+N-%28%281S%29-1-%283-fluoro-4-%28trifluoromethoxy%29phenyl%29-2-methoxyethyl%29-7-methoxy-2-oxo-2%2C+3-dihydropyrido%5B2%2C3-b%5Dpyrazine-4%281H%29-carboxamide+%28TAK-915%29%3A+a+highly+potent%2C+selective%2C+and+brain-penetrating+phosphodiesterase+2A+inhibitor+for+the+treatment+of+cognitive+disorders&doi=10.1021%2Facs.jmedchem.7b00807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45bR"><div class="casContent"><span class="casTitleNuber">45b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders</span></div><div class="casAuthors">Mikami, Satoshi; Nakamura, Shinji; Ashizawa, Tomoko; Nomura, Izumi; Kawasaki, Masanori; Sasaki, Shigekazu; Oki, Hideyuki; Kokubo, Hironori; Hoffman, Isaac D.; Zou, Hua; Uchiyama, Noriko; Nakashima, Kosuke; Kamiguchi, Naomi; Imada, Haruka; Suzuki, Noriko; Iwashita, Hiroki; Taniguchi, Takahiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7677-7702</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) 2A inhibitors have emerged as a novel mechanism with potential therapeutic option to ameliorate cognitive dysfunction in schizophrenia or Alzheimer's disease through upregulation of cyclic nucleotides in the brain, and thereby achieve potentiation of cyclic nucleotide signaling pathways.  This article details the expedited optimization of the authors' recently disclosed pyrazolo[1,5-a]pyrimidine lead compd. 4b, leading to the discovery of clin. candidate 36 (I) (TAK-915), which demonstrates an appropriate combination of potency, PDE selectivity, and favorable pharmacokinetic (PK) properties, including brain penetration.  Successful identification of 36 was realized through application of structure-based drug design (SBDD) to further improve potency and PDE selectivity, coupled with prospective design focused on physicochem. properties to deliver brain penetration.  Oral administration of 36 demonstrated significant elevation of 3',5'-cGMP levels in mouse brains, and improved cognitive performance in a novel object recognition task in rats.  Consequently, compd. 36 was advanced into human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCUw5grC_66rVg90H21EOLACvtfcHk0ljRWmUvi-TpvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSmtL3I&md5=f87cb3ac86b6299fc90e336b88ea2a21</span></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00807%26sid%3Dliteratum%253Aachs%26aulast%3DMikami%26aufirst%3DS.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DAshizawa%26aufirst%3DT.%26aulast%3DNomura%26aufirst%3DI.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DOki%26aufirst%3DH.%26aulast%3DKokubo%26aufirst%3DH.%26aulast%3DHoffman%26aufirst%3DI.%2BD.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DUchiyama%26aufirst%3DN.%26aulast%3DNakashima%26aufirst%3DK.%26aulast%3DKamiguchi%26aufirst%3DN.%26aulast%3DImada%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DIwashita%26aufirst%3DH.%26aulast%3DTaniguchi%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%2520N-%2528%25281S%2529-1-%25283-fluoro-4-%2528trifluoromethoxy%2529phenyl%2529-2-methoxyethyl%2529-7-methoxy-2-oxo-2%252C%25203-dihydropyrido%255B2%252C3-b%255Dpyrazine-4%25281H%2529-carboxamide%2520%2528TAK-915%2529%253A%2520a%2520highly%2520potent%252C%2520selective%252C%2520and%2520brain-penetrating%2520phosphodiesterase%25202A%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cognitive%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7677%26epage%3D7702%26doi%3D10.1021%2Facs.jmedchem.7b00807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit45c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Santora, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almos, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barido, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellows, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bookser, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitenbucher, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadbent, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabebe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crickard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danks, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freestone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitnick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmaster, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limberis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masatsugu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neul, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikpur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petroski, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevidal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabatabaei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoder, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zook, D.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel and selective glycine transporter-1 (GlyT1) inhibitors with memory enhancing properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6018</span>– <span class="NLM_lpage">6033</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00372</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00372" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6018-6033&author=V.+J.+Santoraauthor=T.+A.+Almosauthor=R.+Baridoauthor=J.+Basingerauthor=C.+L.+Bellowsauthor=B.+C.+Bookserauthor=J.+G.+Breitenbucherauthor=N.+J.+Broadbentauthor=C.+Cabebeauthor=C.+K.+Chaiauthor=M.+Chenauthor=S.+Chowauthor=M.+Chungauthor=L.+Crickardauthor=A.+M.+Danksauthor=G.+Freestoneauthor=D.+Gitnickauthor=V.+Guptaauthor=C.+Hoffmasterauthor=A.+R.+Hudsonauthor=A.+P.+Kaplanauthor=M.+R.+Kennedyauthor=D.+Leeauthor=J.+Limberisauthor=K.+Lyauthor=C.+C.+Makauthor=B.+Masatsuguauthor=A.+C.+Morseauthor=J.+Naauthor=D.+Neulauthor=J.+Nikpurauthor=M.+Petersauthor=R.+E.+Petroskiauthor=J.+Renickauthor=K.+Sebringauthor=S.+Sevidalauthor=A.+Tabatabaeiauthor=J.+Wenauthor=Y.+Yanauthor=Z.+W.+Yoderauthor=D.+Zook&title=Design+and+synthesis+of+novel+and+selective+glycine+transporter-1+%28GlyT1%29+inhibitors+with+memory+enhancing+properties&doi=10.1021%2Facs.jmedchem.8b00372"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00372%26sid%3Dliteratum%253Aachs%26aulast%3DSantora%26aufirst%3DV.%2BJ.%26aulast%3DAlmos%26aufirst%3DT.%2BA.%26aulast%3DBarido%26aufirst%3DR.%26aulast%3DBasinger%26aufirst%3DJ.%26aulast%3DBellows%26aufirst%3DC.%2BL.%26aulast%3DBookser%26aufirst%3DB.%2BC.%26aulast%3DBreitenbucher%26aufirst%3DJ.%2BG.%26aulast%3DBroadbent%26aufirst%3DN.%2BJ.%26aulast%3DCabebe%26aufirst%3DC.%26aulast%3DChai%26aufirst%3DC.%2BK.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DChow%26aufirst%3DS.%26aulast%3DChung%26aufirst%3DM.%26aulast%3DCrickard%26aufirst%3DL.%26aulast%3DDanks%26aufirst%3DA.%2BM.%26aulast%3DFreestone%26aufirst%3DG.%26aulast%3DGitnick%26aufirst%3DD.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DHoffmaster%26aufirst%3DC.%26aulast%3DHudson%26aufirst%3DA.%2BR.%26aulast%3DKaplan%26aufirst%3DA.%2BP.%26aulast%3DKennedy%26aufirst%3DM.%2BR.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DLimberis%26aufirst%3DJ.%26aulast%3DLy%26aufirst%3DK.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMasatsugu%26aufirst%3DB.%26aulast%3DMorse%26aufirst%3DA.%2BC.%26aulast%3DNa%26aufirst%3DJ.%26aulast%3DNeul%26aufirst%3DD.%26aulast%3DNikpur%26aufirst%3DJ.%26aulast%3DPeters%26aufirst%3DM.%26aulast%3DPetroski%26aufirst%3DR.%2BE.%26aulast%3DRenick%26aufirst%3DJ.%26aulast%3DSebring%26aufirst%3DK.%26aulast%3DSevidal%26aufirst%3DS.%26aulast%3DTabatabaei%26aufirst%3DA.%26aulast%3DWen%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DYoder%26aufirst%3DZ.%2BW.%26aulast%3DZook%26aufirst%3DD.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520and%2520selective%2520glycine%2520transporter-1%2520%2528GlyT1%2529%2520inhibitors%2520with%2520memory%2520enhancing%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6018%26epage%3D6033%26doi%3D10.1021%2Facs.jmedchem.8b00372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishihara, Y.</span>; <span class="NLM_string-name">Ishichi, Y.</span>; <span class="NLM_string-name">Doi, T.</span>; <span class="NLM_string-name">Nagabukuro, H.</span>; <span class="NLM_string-name">Kanzaki, N.</span>; <span class="NLM_string-name">Ikeuchi, M.</span></span> <span> </span><span class="NLM_article-title">Preventives/remedies for urinary disturbance</span>. <span class="NLM_year">2001</span>, European Patent <span class="NLM_patent">EP 1466625 A1</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=Y.+Ishihara&author=Y.+Ishichi&author=T.+Doi&author=H.+Nagabukuro&author=N.+Kanzaki&author=M.+Ikeuchi&title=Preventives%2Fremedies+for+urinary+disturbance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIshihara%26aufirst%3DY.%26atitle%3DPreventives%252Fremedies%2520for%2520urinary%2520disturbance%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccaro, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conder, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins-West, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span> <span> </span><span class="NLM_article-title">Dihydropyrazolopyrimidine inhibitors of K<sub>v</sub>1.5 (<i>I</i><sub>Kur</sub>)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">6381</span>– <span class="NLM_lpage">6385</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.10.099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.bmcl.2008.10.099" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6381-6385&author=W.+Vaccaroauthor=T.+Huynhauthor=J.+Lloydauthor=K.+Atwalauthor=H.+J.+Finlayauthor=P.+Levesqueauthor=M.+L.+Conderauthor=T.+Jenkins-Westauthor=H.+Shiauthor=L.+Sun&title=Dihydropyrazolopyrimidine+inhibitors+of+Kv1.5+%28IKur%29&doi=10.1016%2Fj.bmcl.2008.10.099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.10.099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.10.099%26sid%3Dliteratum%253Aachs%26aulast%3DVaccaro%26aufirst%3DW.%26aulast%3DHuynh%26aufirst%3DT.%26aulast%3DLloyd%26aufirst%3DJ.%26aulast%3DAtwal%26aufirst%3DK.%26aulast%3DFinlay%26aufirst%3DH.%2BJ.%26aulast%3DLevesque%26aufirst%3DP.%26aulast%3DConder%26aufirst%3DM.%2BL.%26aulast%3DJenkins-West%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26atitle%3DDihydropyrazolopyrimidine%2520inhibitors%2520of%2520Kv1.5%2520%2528IKur%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6381%26epage%3D6385%26doi%3D10.1016%2Fj.bmcl.2008.10.099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit47b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Maiti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturdy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegan, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzuto, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushman, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1873</span>– <span class="NLM_lpage">1884</span>, <span class="refDoi"> DOI: 10.1021/jm801335z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801335z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisl2kur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1873-1884&author=A.+Maitiauthor=P.+V.+Reddyauthor=M.+Sturdyauthor=L.+Marlerauthor=S.+D.+Peganauthor=A.+D.+Mesecarauthor=J.+M.+Pezzutoauthor=M.+Cushman&title=Synthesis+of+casimiroin+and+optimization+of+its+quinone+reductase+2+and+aromatase+inhibitory+activities&doi=10.1021%2Fjm801335z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47bR"><div class="casContent"><span class="casTitleNuber">47b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Casimiroin and Optimization of Its Quinone Reductase 2 and Aromatase Inhibitory Activities</span></div><div class="casAuthors">Maiti, Arup; Reddy, P. V. Narasimha; Sturdy, Megan; Marler, Laura; Pegan, Scott D.; Mesecar, Andrew D.; Pezzuto, John M.; Cushman, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1873-1884</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient method has been developed to synthesize casimiroin (I), a component of the edible fruit of Casimiroa edulis, on a multigram scale in good overall yield.  The route was versatile enough to provide an array of I's analogs that were evaluated as QR2 and aromatase inhibitors.  In addn., X-ray crystallog. studies of QR2 in complex with I and one of its more potent analog II has provided insight into the mechanism of action of this new series of QR2 inhibitors.  The initial biol. investigations suggest that I and its analogs merit further investigation as potential chemopreventive or chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxfer9QooPoLVg90H21EOLACvtfcHk0lhybNZJ7OHU0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisl2kur8%253D&md5=e1fdf097ef37bff1b3d167f9d834c427</span></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.1021%2Fjm801335z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801335z%26sid%3Dliteratum%253Aachs%26aulast%3DMaiti%26aufirst%3DA.%26aulast%3DReddy%26aufirst%3DP.%2BV.%26aulast%3DSturdy%26aufirst%3DM.%26aulast%3DMarler%26aufirst%3DL.%26aulast%3DPegan%26aufirst%3DS.%2BD.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26aulast%3DPezzuto%26aufirst%3DJ.%2BM.%26aulast%3DCushman%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520casimiroin%2520and%2520optimization%2520of%2520its%2520quinone%2520reductase%25202%2520and%2520aromatase%2520inhibitory%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1873%26epage%3D1884%26doi%3D10.1021%2Fjm801335z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alabaster, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddock, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuels, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefaniak, M. H.</span></span> <span> </span><span class="NLM_article-title">2(1H)-quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.1021/jm00123a011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00123a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1989&pages=575-583&author=C.+T.+Alabasterauthor=A.+S.+Bellauthor=S.+F.+Campbellauthor=P.+Ellisauthor=C.+G.+Hendersonauthor=D.+S.+Morrisauthor=D.+A.+Robertsauthor=K.+S.+Ruddockauthor=G.+M.+Samuelsauthor=M.+H.+Stefaniak&title=2%281H%29-quinolinones+with+cardiac+stimulant+activity.+2.+Synthesis+and+biological+activities+of+6-%28N-linked%2C+five-membered+heteroaryl%29+derivatives&doi=10.1021%2Fjm00123a011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm00123a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00123a011%26sid%3Dliteratum%253Aachs%26aulast%3DAlabaster%26aufirst%3DC.%2BT.%26aulast%3DBell%26aufirst%3DA.%2BS.%26aulast%3DCampbell%26aufirst%3DS.%2BF.%26aulast%3DEllis%26aufirst%3DP.%26aulast%3DHenderson%26aufirst%3DC.%2BG.%26aulast%3DMorris%26aufirst%3DD.%2BS.%26aulast%3DRoberts%26aufirst%3DD.%2BA.%26aulast%3DRuddock%26aufirst%3DK.%2BS.%26aulast%3DSamuels%26aufirst%3DG.%2BM.%26aulast%3DStefaniak%26aufirst%3DM.%2BH.%26atitle%3D2%25281H%2529-quinolinones%2520with%2520cardiac%2520stimulant%2520activity.%25202.%2520Synthesis%2520and%2520biological%2520activities%2520of%25206-%2528N-linked%252C%2520five-membered%2520heteroaryl%2529%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1989%26volume%3D32%26spage%3D575%26epage%3D583%26doi%3D10.1021%2Fjm00123a011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel σ<sub>1</sub> Receptor ligands for treating neuropathic pain: 6-hydroxypyridazinones</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2942</span>– <span class="NLM_lpage">2961</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01416</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01416" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2942-2961&author=X.+Caoauthor=Y.+Chenauthor=Y.+Zhangauthor=Y.+Lanauthor=J.+Zhangauthor=X.+Xuauthor=Y.+Qiuauthor=S.+Zhaoauthor=X.+Liuauthor=B.+F.+Liuauthor=G.+Zhang&title=Synthesis+and+biological+evaluation+of+novel+%CF%831+Receptor+ligands+for+treating+neuropathic+pain%3A+6-hydroxypyridazinones&doi=10.1021%2Facs.jmedchem.5b01416"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01416%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520%25CF%25831%2520Receptor%2520ligands%2520for%2520treating%2520neuropathic%2520pain%253A%25206-hydroxypyridazinones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2942%26epage%3D2961%26doi%3D10.1021%2Facs.jmedchem.5b01416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H.</span></span> <span> </span><span class="NLM_article-title">A rabbit model for evaluation of chlorpromazine-induced orthostatic hypotension</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1248/bpb.22.457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1248%2Fbpb.22.457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10375164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADyaK1MXjsFShtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1999&pages=457-462&author=Y.+Takataauthor=J.+Kuriharaauthor=S.+Suzukiauthor=Y.+Okuboauthor=H.+Kato&title=A+rabbit+model+for+evaluation+of+chlorpromazine-induced+orthostatic+hypotension&doi=10.1248%2Fbpb.22.457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A rabbit model for evaluation of chlorpromazine-induced orthostatic hypotension</span></div><div class="casAuthors">Takata, Yoshinobu; Kurihara, Junichi; Suzuki, Shigeto; Okubo, Yoko; Kato, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">457-462</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">The present study was conducted to develop an exptl. model for evaluation of chlorpromazine-induced orthostatic hypotension in rabbits.  In addn., the α-adrenoceptor blocking effect of chlorpromazine was investigated in isolated rabbit aorta and saphenous vein in comparison with prazosin.  Chlorpromazine (0.1 and 1 mg/kg, i.v.) potentiated significantly a decrease in mean blood pressure at 1 min after the onset of head-up tilt in rabbits anesthetized with urethane alone, urethane + α-chloralose or NO alone, but not in conscious and morphine + urethane + α-chloralose-anesthetized rabbits.  There was a neg. correlation (r = -0.986, p< 0.01) between the extent of chlorpromazine-induced orthostatic hypotension and the amplitude of tilt-induced reflex tachycardia before chlorpromazine treatment.  Both prazosin and pentolinium elicited orthostatic hypotension under all four anesthetic conditions.  The pA2 value for chlorpromazine to antagonize norepinephrine-induced contraction in aorta was significantly larger than that in saphenous vein, whereas prazosin blocked aortic and venous contractions to a similar extent.  These results suggest that a rabbit under an anesthesia which impairs tilt-induced reflex tachycardia may be useful for evaluation of orthostatic hypotension by chlorpromazine.  The relatively low potential of chlorpromazine to produce orthostatic hypotension may be partly due to its weak venodilating action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodayjeh8xWn7Vg90H21EOLACvtfcHk0ljxsDiyDE0Fzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsFShtbg%253D&md5=f95e99f3f6c8e68db64dd2cbefec22a2</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1248%2Fbpb.22.457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.22.457%26sid%3Dliteratum%253Aachs%26aulast%3DTakata%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DOkubo%26aufirst%3DY.%26aulast%3DKato%26aufirst%3DH.%26atitle%3DA%2520rabbit%2520model%2520for%2520evaluation%2520of%2520chlorpromazine-induced%2520orthostatic%2520hypotension%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D1999%26volume%3D22%26spage%3D457%26epage%3D462%26doi%3D10.1248%2Fbpb.22.457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2'],'ref3':['cit3a','cit3b'],'ref4':['cit4'],'ref5':['cit5a','cit5b','cit5c','cit5d'],'ref6':['cit6a','cit6b'],'ref7':['cit7'],'ref8':['cit8a','cit8b'],'ref9':['cit9'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12a','cit12b','cit12c','cit12d'],'ref13':['cit13a','cit13b'],'ref14':['cit14a','cit14b','cit14c','cit14d','cit14e'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22a','cit22b','cit22c'],'ref23':['cit23'],'ref24':['cit24a','cit24b'],'ref25':['cit25'],'ref26':['cit26a','cit26b'],'ref27':['cit27'],'ref28':['cit28a','cit28b','cit28c'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33a','cit33b','cit33c'],'ref34':['cit34'],'ref35':['cit35a','cit35b'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38a','cit38b'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42a','cit42b'],'ref43':['cit43a','cit43b'],'ref44':['cit44a','cit44b','cit44c','cit44d'],'ref45':['cit45a','cit45b','cit45c'],'ref46':['cit46'],'ref47':['cit47a','cit47b'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhongtang Li, Guanxing Cai, Fan Fang, Wenchao Li, Minghua Fan, Jingjing Lian, Yinli Qiu, Xiangqing Xu, Xuehui Lv, Yiyan Li, Ruqiu Zheng, Yuxi Wang, Zhongjun Li, Guisen Zhang, Zhenming Liu, Zhuo Huang, <span class="NLM_string-name hlFld-ContribAuthor">Liangren Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel and Potent N-Methyl-d-aspartate Receptor Positive Allosteric Modulators with Antidepressant-like Activity in Rodent Models. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (9)
                                     , 5551-5576. <a href="https://doi.org/10.1021/acs.jmedchem.0c02018" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02018%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252Band%252BPotent%252BN-Methyl-d-aspartate%252BReceptor%252BPositive%252BAllosteric%252BModulators%252Bwith%252BAntidepressant-like%252BActivity%252Bin%252BRodent%252BModels%26aulast%3DLi%26aufirst%3DZhongtang%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D21112020%26date%3D03052021%26volume%3D64%26issue%3D9%26spage%3D5551%26epage%3D5576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Vimala</span>, <span class="hlFld-ContribAuthor ">S. Stella  Mary</span>, <span class="hlFld-ContribAuthor ">R.  Ramalakshmi</span>, <span class="hlFld-ContribAuthor ">S.  Muthu</span>. </span><span class="cited-content_cbyCitation_article-title">Theoretical description of green solvents effect on electronic property and reactivity of Tert-butyl 4-formylpiperidine-1-carboxylate. </span><span class="cited-content_cbyCitation_journal-name">Computational and Theoretical Chemistry</span><span> <strong>2021,</strong> <em>1201 </em>, 113255. <a href="https://doi.org/10.1016/j.comptc.2021.113255" title="DOI URL">https://doi.org/10.1016/j.comptc.2021.113255</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.comptc.2021.113255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.comptc.2021.113255%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520and%2520Theoretical%2520Chemistry%26atitle%3DTheoretical%252Bdescription%252Bof%252Bgreen%252Bsolvents%252Beffect%252Bon%252Belectronic%252Bproperty%252Band%252Breactivity%252Bof%252BTert-butyl%252B4-formylpiperidine-1-carboxylate%26aulast%3DVimala%26aufirst%3DM.%26date%3D2021%26volume%3D1201%26spage%3D113255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lanchang  Gao</span>, <span class="hlFld-ContribAuthor ">Chao  Hao</span>, <span class="hlFld-ContribAuthor ">Ru  Ma</span>, <span class="hlFld-ContribAuthor ">Jiali  Chen</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhang</span>, <span class="hlFld-ContribAuthor ">Yin  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of a new class of multi-target heterocycle piperazine derivatives as potential antipsychotics. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2021,</strong> <em>11 </em>
                                    (28)
                                     , 16931-16941. <a href="https://doi.org/10.1039/D1RA02426D" title="DOI URL">https://doi.org/10.1039/D1RA02426D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1RA02426D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1RA02426D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Ba%252Bnew%252Bclass%252Bof%252Bmulti-target%252Bheterocycle%252Bpiperazine%252Bderivatives%252Bas%252Bpotential%252Bantipsychotics%26aulast%3DGao%26aufirst%3DLanchang%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D28%26spage%3D16931%26epage%3D16941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lanchang  Gao</span>, <span class="hlFld-ContribAuthor ">Chao  Hao</span>, <span class="hlFld-ContribAuthor ">Jiali  Chen</span>, <span class="hlFld-ContribAuthor ">Ru  Ma</span>, <span class="hlFld-ContribAuthor ">Lu  Zheng</span>, <span class="hlFld-ContribAuthor ">Qingkun  Wu</span>, <span class="hlFld-ContribAuthor ">Xin  Liu</span>, <span class="hlFld-ContribAuthor ">Bi-Feng  Liu</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhang</span>, <span class="hlFld-ContribAuthor ">Yin  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>40 </em>, 127909. <a href="https://doi.org/10.1016/j.bmcl.2021.127909" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127909</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127909%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252Bnew%252Bclass%252Bof%252Bmulti-target%252Bheterocycle%252Bpiperidine%252Bderivatives%252Bas%252Bpotential%252Bantipsychotics%252Bwith%252Bpro-cognitive%252Beffect%26aulast%3DGao%26aufirst%3DLanchang%26date%3D2021%26volume%3D40%26spage%3D127909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristina  Cosi</span>, <span class="hlFld-ContribAuthor ">Jean-Claude  Martel</span>, <span class="hlFld-ContribAuthor ">Agnès L.  Auclair</span>, <span class="hlFld-ContribAuthor ">Ginetta  Collo</span>, <span class="hlFld-ContribAuthor ">Laura  Cavalleri</span>, <span class="hlFld-ContribAuthor ">Peter  Heusler</span>, <span class="hlFld-ContribAuthor ">Ludovic  Leriche</span>, <span class="hlFld-ContribAuthor ">Florence  Gaudoux</span>, <span class="hlFld-ContribAuthor ">Pierre  Sokoloff</span>, <span class="hlFld-ContribAuthor ">Paul C.  Moser</span>, <span class="hlFld-ContribAuthor ">Silvia  Gatti-McArthur</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2021,</strong> <em>890 </em>, 173635. <a href="https://doi.org/10.1016/j.ejphar.2020.173635" title="DOI URL">https://doi.org/10.1016/j.ejphar.2020.173635</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2020.173635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2020.173635%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DPharmacology%252Bprofile%252Bof%252BF17464%25252C%252Ba%252Bdopamine%252BD3%252Breceptor%252Bpreferential%252Bantagonist%26aulast%3DCosi%26aufirst%3DCristina%26date%3D2021%26volume%3D890%26spage%3D173635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Run-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong-Yan  Guo</span>, <span class="hlFld-ContribAuthor ">Hao  Deng</span>, <span class="hlFld-ContribAuthor ">Jinzi  Li</span>, <span class="hlFld-ContribAuthor ">Zhe-Shan  Quan</span>. </span><span class="cited-content_cbyCitation_article-title">Piperazine skeleton in the structural modification of natural products: a review. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>
                                    (1)
                                     , 1165-1197. <a href="https://doi.org/10.1080/14756366.2021.1931861" title="DOI URL">https://doi.org/10.1080/14756366.2021.1931861</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2021.1931861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2021.1931861%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DPiperazine%252Bskeleton%252Bin%252Bthe%252Bstructural%252Bmodification%252Bof%252Bnatural%252Bproducts%25253A%252Ba%252Breview%26aulast%3DZhang%26aufirst%3DRun-Hui%26date%3D2021%26date%3D2021%26volume%3D36%26issue%3D1%26spage%3D1165%26epage%3D1197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling  Huang</span>, <span class="hlFld-ContribAuthor ">Lanchang  Gao</span>, <span class="hlFld-ContribAuthor ">Xiaohua  Zhang</span>, <span class="hlFld-ContribAuthor ">Lei  Yin</span>, <span class="hlFld-ContribAuthor ">Jintao  Hu</span>, <span class="hlFld-ContribAuthor ">Ting  Song</span>, <span class="hlFld-ContribAuthor ">Yin  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and pharmacological evaluation of piperidine (piperazine)-amide substituted derivatives as multi-target antipsychotics. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (20)
                                     , 127506. <a href="https://doi.org/10.1016/j.bmcl.2020.127506" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127506</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127506%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bpharmacological%252Bevaluation%252Bof%252Bpiperidine%252B%252528piperazine%252529-amide%252Bsubstituted%252Bderivatives%252Bas%252Bmulti-target%252Bantipsychotics%26aulast%3DHuang%26aufirst%3DLing%26date%3D2020%26volume%3D30%26issue%3D20%26spage%3D127506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongguang  Ma</span>, <span class="hlFld-ContribAuthor ">Boshi  Huang</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (9)
                                     , 1682-1692. <a href="https://doi.org/10.1016/j.drudis.2020.07.004" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.07.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.07.004%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DRecent%252Badvances%252Bin%252Bmultitarget-directed%252Bligands%252Btargeting%252BG-protein-coupled%252Breceptors%26aulast%3DMa%26aufirst%3DHongguang%26date%3D2020%26volume%3D25%26issue%3D9%26spage%3D1682%26epage%3D1692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lanchang  Gao</span>, <span class="hlFld-ContribAuthor ">Zhengge  Yang</span>, <span class="hlFld-ContribAuthor ">Jiaying  Xiong</span>, <span class="hlFld-ContribAuthor ">Chao  Hao</span>, <span class="hlFld-ContribAuthor ">Ru  Ma</span>, <span class="hlFld-ContribAuthor ">Xin  Liu</span>, <span class="hlFld-ContribAuthor ">Bi-Feng  Liu</span>, <span class="hlFld-ContribAuthor ">Jian  Jin</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhang</span>, <span class="hlFld-ContribAuthor ">Yin  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Investigation of Flavone Derivatives as Potential Multi-Receptor Atypical Antipsychotics. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (18)
                                     , 4107. <a href="https://doi.org/10.3390/molecules25184107" title="DOI URL">https://doi.org/10.3390/molecules25184107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25184107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25184107%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BInvestigation%252Bof%252BFlavone%252BDerivatives%252Bas%252BPotential%252BMulti-Receptor%252BAtypical%252BAntipsychotics%26aulast%3DGao%26aufirst%3DLanchang%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D18%26spage%3D4107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kosuke  Yasui</span>, <span class="hlFld-ContribAuthor ">Miharu  Kamitani</span>, <span class="hlFld-ContribAuthor ">Mamoru  Tobisu</span>. </span><span class="cited-content_cbyCitation_article-title">N‐Heterocyclic Carbene Catalyzed Concerted Nucleophilic Aromatic Substitution of Aryl Fluorides Bearing α,β‐Unsaturated Amides. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2019,</strong> <em>131 </em>
                                    (40)
                                     , 14295-14299. <a href="https://doi.org/10.1002/ange.201907837" title="DOI URL">https://doi.org/10.1002/ange.201907837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201907837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201907837%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DN%2525E2%252580%252590Heterocyclic%252BCarbene%252BCatalyzed%252BConcerted%252BNucleophilic%252BAromatic%252BSubstitution%252Bof%252BAryl%252BFluorides%252BBearing%252B%2525CE%2525B1%25252C%2525CE%2525B2%2525E2%252580%252590Unsaturated%252BAmides%26aulast%3DYasui%26aufirst%3DKosuke%26date%3D2019%26date%3D2019%26volume%3D131%26issue%3D40%26spage%3D14295%26epage%3D14299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kosuke  Yasui</span>, <span class="hlFld-ContribAuthor ">Miharu  Kamitani</span>, <span class="hlFld-ContribAuthor ">Mamoru  Tobisu</span>. </span><span class="cited-content_cbyCitation_article-title">N‐Heterocyclic Carbene Catalyzed Concerted Nucleophilic Aromatic Substitution of Aryl Fluorides Bearing α,β‐Unsaturated Amides. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2019,</strong> <em>58 </em>
                                    (40)
                                     , 14157-14161. <a href="https://doi.org/10.1002/anie.201907837" title="DOI URL">https://doi.org/10.1002/anie.201907837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201907837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201907837%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DN%2525E2%252580%252590Heterocyclic%252BCarbene%252BCatalyzed%252BConcerted%252BNucleophilic%252BAromatic%252BSubstitution%252Bof%252BAryl%252BFluorides%252BBearing%252B%2525CE%2525B1%25252C%2525CE%2525B2%2525E2%252580%252590Unsaturated%252BAmides%26aulast%3DYasui%26aufirst%3DKosuke%26date%3D2019%26date%3D2019%26volume%3D58%26issue%3D40%26spage%3D14157%26epage%3D14161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michele  Montaruli</span>, <span class="hlFld-ContribAuthor ">Domenico  Alberga</span>, <span class="hlFld-ContribAuthor ">Fulvio  Ciriaco</span>, <span class="hlFld-ContribAuthor ">Daniela  Trisciuzzi</span>, <span class="hlFld-ContribAuthor ">Anna Rita  Tondo</span>, <span class="hlFld-ContribAuthor ">Giuseppe Felice  Mangiatordi</span>, <span class="hlFld-ContribAuthor ">Orazio  Nicolotti</span>. </span><span class="cited-content_cbyCitation_article-title">Accelerating Drug Discovery by Early Protein Drug Target Prediction Based on a Multi-Fingerprint Similarity Search †. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (12)
                                     , 2233. <a href="https://doi.org/10.3390/molecules24122233" title="DOI URL">https://doi.org/10.3390/molecules24122233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24122233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24122233%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DAccelerating%252BDrug%252BDiscovery%252Bby%252BEarly%252BProtein%252BDrug%252BTarget%252BPrediction%252BBased%252Bon%252Ba%252BMulti-Fingerprint%252BSimilarity%252BSearch%252B%2525E2%252580%2525A0%26aulast%3DMontaruli%26aufirst%3DMichele%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D12%26spage%3D2233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representaive antipyschotics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of <b>1</b> highlighting common dopaminergic D<sub>2</sub> structural characteristics: a motif containing features of common privileged structures, an aliphatic spacer/linker, and a heterocyclic group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design of multifunctional ligands. On the basis of the compound <b>1</b>, the privileged structures (phenylpiperazines and heterocyclicpiperazines(piperidines)) were introduced by replacement of 3-(piperidin-4-yl)-1<i>H</i>-indole. The appropriate linker between the privileged structures and the fused tricyclic heterocycles and the substituent of fused tricyclic heterocycles for the new compounds were investigated for the binding to the multireceptors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 3-chloropropanoyl chloride, acetone, reflux; (ii) AlCl<sub>3</sub>, 110 °C; (iii) appropriate chloroalkyl chloride, AlCl<sub>3</sub>, DCE; (iv) appropriate phenylpiperazines or heterocyclicpiperazines (piperidines), K<sub>2</sub>CO<sub>3</sub>, KI, acetonitrile, reflux; (v) Et<sub>3</sub>SiH, TFA, room tempreture; (vi) NaBH<sub>4</sub>, MeOH, room tempreture.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) ethyl acetoacetate, toluene, reflux overnight; (ii) H<sub>2</sub>SO<sub>4</sub> (conc), 100 °C, 6 h; (iii) Pd/C, H<sub>2</sub>; (iv) 4-chlorobutanoyl chloride, AlCl<sub>3</sub>, DCE; (v) 6-fluoro-3-(piperidin-4-yl)benzo[<i>d</i>]isoxazole hydrochloride, K<sub>2</sub>CO<sub>3</sub>, KI, acetonitrile, reflux; (vi) Et<sub>3</sub>SiH, TFA, room temperature.</p></p></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Summary of the results of SAR studies performed on different regions of the synthesized derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of compound <b>47</b> administered po on APO (apomorphine)-induced climbing in mice (10/group). Results are expressed as means ± SEM of the score. Statistical significances of drug effects were analyzed by the nonparametric two-tailed Mann–Whitney U-test: #, <i>p</i> < 0.05 versus vehicle treatment; **, <i>p</i> < 0.01 and *, <i>p</i> < 0.05 versus apomorphine treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of compound <b>47</b> administered po on MK-801-induced hyperactivity in mice (10/group). Results are expressed as the means ± SEM of distance traveled. Statistical evaluation was performed by two-way ANOVA followed by Tukey’s test for multiple comparisons. #, <i>p</i> < 0.05 versus vehicle treatment; **, <i>p</i> < 0.01 and *, <i>p</i> < 0.05 versus MK-801 treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of risperidone (10/group) and compound <b>47</b> (10/group) on the performance of conditioned avoidance response in rats 90 min after single oral administration. The animals served as their own controls using a within-subject design. Values of percentage inhibition of avoidance are expressed as mean ± SEM. The avoidance values were analyzed in a repeated measures analysis of variance with dose (resperidone and compound <b>47</b>) as a within-subject factor for each drug separately. Post hoc comparisons were performed using the Bonferroni adjustment for multiple comparisons, and the level of significance indicated in the figure is that with respect to vehicle treatment (**, <i>P</i> < 0.05) and all statistical analysis were carried out using SPSS software.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Influence of <b>47</b> and risperidone on weight gain. Each value is the mean ± SEM of 10 mice per group. Student’s <i>t</i> test: ##, <i>p</i> < 0.01 versus vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Serum prolactin (PRL) multiple (28 days) administration of compound <b>47</b> and risperidone in mice. Each value is the mean ± SEM of 10 mice per group. Student’s <i>t</i> test: ##, <i>p</i> < 0.01 versus vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/medium/jm-2018-01096m_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effects of <b>47</b> on a novel object recognition task in rats. Vehicle or <b>47</b> (0.03, 0.1, and 0.3 mg/kg), rivastigmine (0.3 mg/kg), and risperidone (0.2 mg/kg) was orally administered 1 h prior to the acquisition trials. (A) Exploration times in the acquisition trial and (B) the retention trial (performed 24 h after the acquisition trial) were scored. (C) Novelty discrimination index (NDI) in the retention trial was calculated as novel object interaction time/total interaction time ×100 (%). Data are presented as the mean ± SEM, <i>n</i> = 9 for 0.03 mg/kg, <i>n</i> = 10 for the other groups; **, <i>p</i> < 0.01 vs familiar object by paired <i>t</i> test; #, <i>p</i> < 0.025 vs vehicle by one-tailed Williams’ test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01096/20181119/images/large/jm-2018-01096m_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01096&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i122">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17514" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17514" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 50 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, R.</span></span> <span> </span><span class="NLM_article-title">Schizophrenia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">1738</span>– <span class="NLM_lpage">1749</span>, <span class="refDoi"> DOI: 10.1056/NEJMra035458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1056%2FNEJMra035458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=14585943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Smsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2003&pages=1738-1749&author=R.+Freedman&title=Schizophrenia&doi=10.1056%2FNEJMra035458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia</span></div><div class="casAuthors">Freedman, Robert</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1738-1749</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on the clin. features, pathophysiol., and treatment of schizophrenia.  A new generation of medications and recent developments in neuropathol., brain imaging, and mol. genetics have led to a greater understanding of the pathophysiol. of schizophrenia and to improved treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmsEOcFuK4KLVg90H21EOLACvtfcHk0lgBRcBmsvslJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Smsbc%253D&md5=9b6c07fce84e996e44820ee4b4531b59</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1056%2FNEJMra035458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra035458%26sid%3Dliteratum%253Aachs%26aulast%3DFreedman%26aufirst%3DR.%26atitle%3DSchizophrenia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D349%26spage%3D1738%26epage%3D1749%26doi%3D10.1056%2FNEJMra035458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Perala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvisaari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saarni, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuoppasalmi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isometsa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirkola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partonen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuulio-Henriksson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hintikka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieseppa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harkanen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koskinen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonnqvist, J.</span></span> <span> </span><span class="NLM_article-title">Lifetime prevalence of psychotic and bipolar I disorders in a general population</span>. <i>Arch. Gen. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1001/archpsyc.64.1.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1001%2Farchpsyc.64.1.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=17199051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FitVOjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2007&pages=19-28&author=J.+Peralaauthor=J.+Suvisaariauthor=S.+I.+Saarniauthor=K.+Kuoppasalmiauthor=E.+Isometsaauthor=S.+Pirkolaauthor=T.+Partonenauthor=A.+Tuulio-Henrikssonauthor=J.+Hintikkaauthor=T.+Kieseppaauthor=T.+Harkanenauthor=S.+Koskinenauthor=J.+Lonnqvist&title=Lifetime+prevalence+of+psychotic+and+bipolar+I+disorders+in+a+general+population&doi=10.1001%2Farchpsyc.64.1.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Lifetime prevalence of psychotic and bipolar I disorders in a general population</span></div><div class="casAuthors">Perala Jonna; Suvisaari Jaana; Saarni Samuli I; Kuoppasalmi Kimmo; Isometsa Erkki; Pirkola Sami; Partonen Timo; Tuulio-Henriksson Annamari; Hintikka Jukka; Kieseppa Tuula; Harkanen Tommi; Koskinen Seppo; Lonnqvist Jouko</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-28</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">CONTEXT:  Recent general population surveys of psychotic disorders have found low lifetime prevalences.  However, this may be owing to methodological problems.  Few studies have reported the prevalences of all specific psychotic disorders.  OBJECTIVE:  To provide reliable estimates of the lifetime prevalences of specific psychotic disorders.  DESIGN:  General population survey.  SETTING AND PARTICIPANTS:  A nationally representative sample of 8028 persons 30 years or older was screened for psychotic and bipolar I disorders using the Composite International Diagnostic Interview, self-reported diagnoses, medical examination, and national registers.  Those selected by the screens were then re-interviewed with the Structured Clinical Interview for DSM-IV.  Best-estimate DSM-IV diagnoses were formed by combining the interview and case note data.  Register diagnoses were used to estimate the effect of the nonresponders.  MAIN OUTCOME MEASURES:  Diagnosis of any psychotic or bipolar I disorder according to the DSM-IV criteria.  RESULTS:  The lifetime prevalence of all psychotic disorders was 3.06% and rose to 3.48% when register diagnoses of the nonresponder group were included.  Lifetime prevalences were as follows: 0.87% for schizophrenia, 0.32% for schizoaffective disorder, 0.07% for schizophreniform disorder, 0.18% for delusional disorder, 0.24% for bipolar I disorder, 0.35% for major depressive disorder with psychotic features, 0.42% for substance-induced psychotic disorders, and 0.21% for psychotic disorders due to a general medical condition.  The National Hospital Discharge Register was the most reliable of the screens (kappa = 0.80).  Case notes supplementing the interviews were essential for specific diagnoses of psychotic disorders.  CONCLUSIONS:  Multiple sources of information are essential for accurate estimation of lifetime prevalences of psychotic disorders.  The use of comprehensive methods reveals that their lifetime prevalence exceeds 3%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKNfedLYPE38ERNNga7KD-fW6udTcc2eYm9RC62SnkwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FitVOjtw%253D%253D&md5=c092fedf94e477bc7c329ef994ab8e8b</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.64.1.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.64.1.19%26sid%3Dliteratum%253Aachs%26aulast%3DPerala%26aufirst%3DJ.%26aulast%3DSuvisaari%26aufirst%3DJ.%26aulast%3DSaarni%26aufirst%3DS.%2BI.%26aulast%3DKuoppasalmi%26aufirst%3DK.%26aulast%3DIsometsa%26aufirst%3DE.%26aulast%3DPirkola%26aufirst%3DS.%26aulast%3DPartonen%26aufirst%3DT.%26aulast%3DTuulio-Henriksson%26aufirst%3DA.%26aulast%3DHintikka%26aufirst%3DJ.%26aulast%3DKieseppa%26aufirst%3DT.%26aulast%3DHarkanen%26aufirst%3DT.%26aulast%3DKoskinen%26aufirst%3DS.%26aulast%3DLonnqvist%26aufirst%3DJ.%26atitle%3DLifetime%2520prevalence%2520of%2520psychotic%2520and%2520bipolar%2520I%2520disorders%2520in%2520a%2520general%2520population%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2007%26volume%3D64%26spage%3D19%26epage%3D28%26doi%3D10.1001%2Farchpsyc.64.1.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasrallah, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keshavan, M. S.</span></span> <span> </span><span class="NLM_article-title">Schizophrenia, ″just the facts″ 4. Clinical features and conceptualization</span>. <i>Schizophr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.schres.2009.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.schres.2009.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19328655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BD1M3ps12mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2009&pages=1-23&author=R.+Tandonauthor=H.+A.+Nasrallahauthor=M.+S.+Keshavan&title=Schizophrenia%2C+%E2%80%B3just+the+facts%E2%80%B3+4.+Clinical+features+and+conceptualization&doi=10.1016%2Fj.schres.2009.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia, "just the facts" 4. Clinical features and conceptualization</span></div><div class="casAuthors">Tandon Rajiv; Nasrallah Henry A; Keshavan Matcheri S</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">1-23</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Although dementia praecox or schizophrenia has been considered a unique disease entity for the past century, its definitions and boundaries have continued to vary over this period.  At any given time, the changing concept of schizophrenia has been influenced by available diagnostic tools and treatments, related conditions from which it most needs to be distinguished, extant knowledge and scientific paradigms.  There is significant heterogeneity in the etiopathology, symptomatology, and course of schizophrenia.  It is characterized by an admixture of positive, negative, cognitive, mood, and motor symptoms whose severity varies across patients and through the course of the illness.  Positive symptoms usually first begin in adolescence or early adulthood, but are often preceded by varying degrees of negative and cognitive symptomatology.  Schizophrenia tends to be a chronic and relapsing disorder with generally incomplete remissions, variable degrees of functional impairment and social disability, frequent comorbid substance abuse, and decreased longevity.  Although schizophrenia may not represent a single disease with a unitary etiology or pathogenetic process, alternative approaches have thus far been unsuccessful in better defining this syndrome or its component entities.  The symptomatologic, course, and etio-pathological heterogeneity can usefully be addressed by a dimensional approach to psychopathology, a clinical staging approach to illness course, and by elucidating endophenotypes and markers of illness progression, respectively.  This will allow an approach to the deconstruction of schizophrenia into its multiple component parts and strategies to reconfigure these components in a more meaningful manner.  Possible implications for DSM-V and ICD-11 definitions of schizophrenia are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvnCea0e_JZZotVjB3IRIyfW6udTcc2eYm9RC62SnkwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3ps12mtw%253D%253D&md5=8ed68c03937fb30924537e7cbe9f624e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2009.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2009.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DTandon%26aufirst%3DR.%26aulast%3DNasrallah%26aufirst%3DH.%2BA.%26aulast%3DKeshavan%26aufirst%3DM.%2BS.%26atitle%3DSchizophrenia%252C%2520%25E2%2580%25B3just%2520the%2520facts%25E2%2580%25B3%25204.%2520Clinical%2520features%2520and%2520conceptualization%26jtitle%3DSchizophr.%2520Res.%26date%3D2009%26volume%3D110%26spage%3D1%26epage%3D23%26doi%3D10.1016%2Fj.schres.2009.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaebel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barch, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bustillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gur, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malaspina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Os, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, W.</span></span> <span> </span><span class="NLM_article-title">Definition and description of schizophrenia in the DSM-5</span>. <i>Schizophr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.schres.2013.05.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.schres.2013.05.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=23800613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BC3sjlsVKhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2013&pages=3-10&author=R.+Tandonauthor=W.+Gaebelauthor=D.+M.+Barchauthor=J.+Bustilloauthor=R.+E.+Gurauthor=S.+Heckersauthor=D.+Malaspinaauthor=M.+J.+Owenauthor=S.+Schultzauthor=M.+Tsuangauthor=J.+Van+Osauthor=W.+Carpenter&title=Definition+and+description+of+schizophrenia+in+the+DSM-5&doi=10.1016%2Fj.schres.2013.05.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Definition and description of schizophrenia in the DSM-5</span></div><div class="casAuthors">Tandon Rajiv; Gaebel Wolfgang; Barch Deanna M; Bustillo Juan; Gur Raquel E; Heckers Stephan; Malaspina Dolores; Owen Michael J; Schultz Susan; Tsuang Ming; Van Os Jim; Carpenter William</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although dementia praecox or schizophrenia has been considered a unique disease for over a century, its definitions and boundaries have changed over this period and its etiology and pathophysiology remain elusive.  Despite changing definitions, DSM-IV schizophrenia is reliably diagnosed, has fair validity and conveys useful clinical information.  Therefore, the essence of the broad DSM-IV definition of schizophrenia is retained in DSM-5.  The clinical manifestations are extremely diverse, however, with this heterogeneity being poorly explained by the DSM-IV clinical subtypes and course specifiers.  Additionally, the boundaries of schizophrenia are imprecisely demarcated from schizoaffective disorder and other diagnostic categories and its special emphasis on Schneiderian "first-rank" symptoms appears misplaced.  Changes in the definition of schizophrenia in DSM-5 seek to address these shortcomings and incorporate the new information about the nature of the disorder accumulated over the past two decades.  Specific changes in its definition include elimination of the classic subtypes, addition of unique psychopathological dimensions, clarification of cross-sectional and longitudinal course specifiers, elimination of special treatment of Schneiderian 'first-rank symptoms', better delineation of schizophrenia from schizoaffective disorder, and clarification of the relationship of schizophrenia to catatonia.  These changes should improve diagnosis and characterization of individuals with schizophrenia and facilitate measurement-based treatment and concurrently provide a more useful platform for research that will elucidate its nature and permit a more precise future delineation of the 'schizophrenias'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSl9hdo7Fq4FT0SWnHPWbmmfW6udTcc2eYm9RC62SnkwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjlsVKhsw%253D%253D&md5=7b84bfba8cb8e6882ae727f29947d6a2</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2013.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2013.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DTandon%26aufirst%3DR.%26aulast%3DGaebel%26aufirst%3DW.%26aulast%3DBarch%26aufirst%3DD.%2BM.%26aulast%3DBustillo%26aufirst%3DJ.%26aulast%3DGur%26aufirst%3DR.%2BE.%26aulast%3DHeckers%26aufirst%3DS.%26aulast%3DMalaspina%26aufirst%3DD.%26aulast%3DOwen%26aufirst%3DM.%2BJ.%26aulast%3DSchultz%26aufirst%3DS.%26aulast%3DTsuang%26aufirst%3DM.%26aulast%3DVan%2BOs%26aufirst%3DJ.%26aulast%3DCarpenter%26aufirst%3DW.%26atitle%3DDefinition%2520and%2520description%2520of%2520schizophrenia%2520in%2520the%2520DSM-5%26jtitle%3DSchizophr.%2520Res.%26date%3D2013%26volume%3D150%26spage%3D3%26epage%3D10%26doi%3D10.1016%2Fj.schres.2013.05.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peshin, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, docking and pharmacological evaluation of novel indole based potential atypical antipsychotics</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.09.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.ejmech.2013.09.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=477-490&author=A.+Baliauthor=U.+Senauthor=T.+Peshin&title=Synthesis%2C+docking+and+pharmacological+evaluation+of+novel+indole+based+potential+atypical+antipsychotics&doi=10.1016%2Fj.ejmech.2013.09.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.09.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.09.020%26sid%3Dliteratum%253Aachs%26aulast%3DBali%26aufirst%3DA.%26aulast%3DSen%26aufirst%3DU.%26aulast%3DPeshin%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520docking%2520and%2520pharmacological%2520evaluation%2520of%2520novel%2520indole%2520based%2520potential%2520atypical%2520antipsychotics%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D74%26spage%3D477%26epage%3D490%26doi%3D10.1016%2Fj.ejmech.2013.09.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beard, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrick, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanover, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mates, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennogle, L. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2670</span>– <span class="NLM_lpage">2682</span>, <span class="refDoi"> DOI: 10.1021/jm401958n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401958n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFOhu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2670-2682&author=P.+Liauthor=Q.+Zhangauthor=A.+J.+Robichaudauthor=T.+Leeauthor=J.+Tomeschauthor=W.+Yaoauthor=J.+D.+Beardauthor=G.+L.+Snyderauthor=H.+Zhuauthor=Y.+Pengauthor=J.+P.+Hendrickauthor=K.+E.+Vanoverauthor=R.+E.+Davisauthor=S.+Matesauthor=L.+P.+Wennogle&title=Discovery+of+a+tetracyclic+quinoxaline+derivative+as+a+potent+and+orally+active+multifunctional+drug+candidate+for+the+treatment+of+neuropsychiatric+and+neurological+disorders&doi=10.1021%2Fjm401958n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders</span></div><div class="casAuthors">Li, Peng; Zhang, Qiang; Robichaud, Albert J.; Lee, Taekyu; Tomesch, John; Yao, Wei; Beard, J. David; Snyder, Gretchen L.; Zhu, Hongwen; Peng, Youyi; Hendrick, Joseph P.; Vanover, Kimberly E.; Davis, Robert E.; Mates, Sharon; Wennogle, Lawrence P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2670-2682</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the synthesis and structure-activity relationships of a class of tetracyclic butyrophenones that exhibit potent binding affinities to serotonin 5-HT2A and dopamine D2 receptors.  This work has led to the discovery of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 4-methylbenzenesulfonate (ITI-007, I.TsOH), which is a potent 5-HT2A antagonist, postsynaptic D2 antagonist, and inhibitor of serotonin transporter.  This multifunctional drug candidate is orally bioavailable and exhibits good antipsychotic efficacy in vivo.  Currently, this investigational new drug is under clin. development for the treatment of neuropsychiatric and neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozLklhmBkFo7Vg90H21EOLACvtfcHk0liMEfAlGX3FTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFOhu7o%253D&md5=318c9a3df9d79a2ac593c40015021015</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm401958n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401958n%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DTomesch%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DBeard%26aufirst%3DJ.%2BD.%26aulast%3DSnyder%26aufirst%3DG.%2BL.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DHendrick%26aufirst%3DJ.%2BP.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DMates%26aufirst%3DS.%26aulast%3DWennogle%26aufirst%3DL.%2BP.%26atitle%3DDiscovery%2520of%2520a%2520tetracyclic%2520quinoxaline%2520derivative%2520as%2520a%2520potent%2520and%2520orally%2520active%2520multifunctional%2520drug%2520candidate%2520for%2520the%2520treatment%2520of%2520neuropsychiatric%2520and%2520neurological%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2670%26epage%3D2682%26doi%3D10.1021%2Fjm401958n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Remington, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foussias, G.</span></span> <span> </span><span class="NLM_article-title">Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1586/ern.10.191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1586%2Fern.10.191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=21469931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlyqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=589-607&author=G.+Remingtonauthor=O.+Agidauthor=G.+Foussias&title=Schizophrenia+as+a+disorder+of+too+little+dopamine%3A+implications+for+symptoms+and+treatment&doi=10.1586%2Fern.10.191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment</span></div><div class="casAuthors">Remington, Gary; Agid, Ofer; Foussias, George</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-607</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Antipsychotics represent the first effective therapy for schizophrenia, with their benefits linked to dopamine D2 blockade.  Schizophrenia was soon identified as a hyperdopaminergic disorder, and antipsychotics proved to be reasonably effective in controlling pos. symptoms.  However, over the years, schizophrenia has been reconceptualized more broadly, now defined as a heterogeneous disorder with multiple symptom domains.  Neg. and cognitive features, not particularly responsive to antipsychotic therapy, have taken on increased importance -- current thinking suggests that these domains predate the onset of pos. symptoms and are more closely tied to functional outcome.  That they are better understood in the context of decreased dopamine activity suggests that schizophrenia may fundamentally represent a hypodopaminergic disorder.  This shift in thinking has important theor. implications from the standpoint of etiol. and pathophysiol., but also clin. in terms of treatment and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKxDPNplr2yrVg90H21EOLACvtfcHk0liMEfAlGX3FTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlyqtbo%253D&md5=65a8003827406d9e7ba57f1a60222940</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1586%2Fern.10.191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fern.10.191%26sid%3Dliteratum%253Aachs%26aulast%3DRemington%26aufirst%3DG.%26aulast%3DAgid%26aufirst%3DO.%26aulast%3DFoussias%26aufirst%3DG.%26atitle%3DSchizophrenia%2520as%2520a%2520disorder%2520of%2520too%2520little%2520dopamine%253A%2520implications%2520for%2520symptoms%2520and%2520treatment%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2011%26volume%3D11%26spage%3D589%26epage%3D607%26doi%3D10.1586%2Fern.10.191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maneen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. M.</span></span> <span> </span><span class="NLM_article-title">Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.nurt.2008.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.nurt.2008.10.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=78-85&author=D.+H.+Kimauthor=M.+J.+Maneenauthor=S.+M.+Stahl&title=Building+a+better+antipsychotic%3A+receptor+targets+for+the+treatment+of+multiple+symptom+dimensions+of+schizophrenia&doi=10.1016%2Fj.nurt.2008.10.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2008.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2008.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DManeen%26aufirst%3DM.%2BJ.%26aulast%3DStahl%26aufirst%3DS.%2BM.%26atitle%3DBuilding%2520a%2520better%2520antipsychotic%253A%2520receptor%2520targets%2520for%2520the%2520treatment%2520of%2520multiple%2520symptom%2520dimensions%2520of%2520schizophrenia%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26spage%3D78%26epage%3D85%26doi%3D10.1016%2Fj.nurt.2008.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">A new era of rationally designed antipsychotics</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>555</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1038/d41586-018-02328-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1038%2Fd41586-018-02328-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2018&pages=170-172&author=D.+R.+Sibleyauthor=L.+Shi&title=A+new+era+of+rationally+designed+antipsychotics&doi=10.1038%2Fd41586-018-02328-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1038%2Fd41586-018-02328-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41586-018-02328-z%26sid%3Dliteratum%253Aachs%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DA%2520new%2520era%2520of%2520rationally%2520designed%2520antipsychotics%26jtitle%3DNature%26date%3D2018%26volume%3D555%26spage%3D170%26epage%3D172%26doi%3D10.1038%2Fd41586-018-02328-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure of the D<sub>2</sub> dopamine receptor bound to the atypical antipsychotic drug risperidone</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>555</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1038/nature25758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1038%2Fnature25758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=29466326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2018&pages=269-273&author=S.+Wangauthor=T.+Cheauthor=A.+Levitauthor=B.+K.+Shoichetauthor=D.+Wackerauthor=B.+L.+Roth&title=Structure+of+the+D2+dopamine+receptor+bound+to+the+atypical+antipsychotic+drug+risperidone&doi=10.1038%2Fnature25758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span></div><div class="casAuthors">Wang, Sheng; Che, Tao; Levit, Anat; Shoichet, Brian K.; Wacker, Daniel; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">555</span>
        (<span class="NLM_cas:issue">7695</span>),
    <span class="NLM_cas:pages">269-273</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metab. and hormonal secretion.  Correspondingly, dysregulation of the dopaminergic system has been implicated in diseases such as schizophrenia, Parkinson's disease, depression, attention deficit hyperactivity disorder, and nausea and vomiting.  The actions of dopamine are mediated by a family of five G-protein-coupled receptors.  The D2 dopamine receptor (DRD2) is the primary target for both typical and atypical antipsychotic drugs, and for drugs used to treat Parkinson's disease.  Unfortunately, many drugs that target DRD2 cause serious and potentially life-threatening side effects due to promiscuous activities against related receptors.  Accordingly, a mol. understanding of the structure and function of DRD2 could provide a template for the design of safer and more effective medications.  Here we report the crystal structure of DRD2 in complex with the widely prescribed atypical antipsychotic drug risperidone.  The DRD2-risperidone structure reveals an unexpected mode of antipsychotic drug binding to dopamine receptors, and highlights structural determinants that are essential for the actions of risperidone and related drugs at DRD2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeo4Ov49kft7Vg90H21EOLACvtfcHk0lhzYRkeabjuxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D&md5=2842adc1893293ea8dbf98ae3270a1b2</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1038%2Fnature25758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25758%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure%2520of%2520the%2520D2%2520dopamine%2520receptor%2520bound%2520to%2520the%2520atypical%2520antipsychotic%2520drug%2520risperidone%26jtitle%3DNature%26date%3D2018%26volume%3D555%26spage%3D269%26epage%3D273%26doi%3D10.1038%2Fnature25758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Seeman, P.</span></span> <span> </span><span class="NLM_article-title">Targeting the dopamine D<sub>2</sub> receptor in schizophrenia</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1517/14728222.10.4.515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1517%2F14728222.10.4.515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=16848689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1ahtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=515-531&author=P.+Seeman&title=Targeting+the+dopamine+D2+receptor+in+schizophrenia&doi=10.1517%2F14728222.10.4.515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dopamine D2 receptor in schizophrenia</span></div><div class="casAuthors">Seeman, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">515-531</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  After a 12-yr search for the antipsychotic receptor, the binding site was discovered and labeled by [3H]haloperidol in 1975.  Of the various neurotransmitters, dopamine was the most potent in inhibiting the binding of [3H]haloperidol, indicating that the antipsychotic receptor was a dopamine receptor, now named the dopamine D2 receptor, a major targeting site in schizophrenia.  All antipsychotic drugs, including traditional and newer antipsychotics, either bind to D2 in direct relation to their clin. potencies or hinder normal dopamine neurotransmission, as in the case of partial dopamine agonists.  In fact, the antipsychotic concns. found in the plasma water of treated patients closely match the predicted therapeutic abs. concns., adjusted for the 60-75% D2 occupancy needed for clin. efficacy.  Antipsychotics that elicit low or no Parkinsonism or prolactinemia are loosely attached to D2 and rapidly dissoc. from D2, whereas those eliciting Parkinsonism stay tightly attached to D2 for many hours.  Because animal models of psychosis (amfetamine sensitization, brain lesions) all show a marked elevation in the no. of high-affinity states of D2, the antipsychotics are thought to specifically target these D2High states in psychosis in general and schizophrenia in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGjVyTQvf6orVg90H21EOLACvtfcHk0lhzYRkeabjuxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1ahtro%253D&md5=4ac073cabc6f50e8d0e3a2ecc631e781</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1517%2F14728222.10.4.515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.10.4.515%26sid%3Dliteratum%253Aachs%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DTargeting%2520the%2520dopamine%2520D2%2520receptor%2520in%2520schizophrenia%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2006%26volume%3D10%26spage%3D515%26epage%3D531%26doi%3D10.1517%2F14728222.10.4.515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanover, K. E.</span></span> <span> </span><span class="NLM_article-title">Dopamine targeting drugs for the treatment of schizophrenia: past, present and future</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3385</span>– <span class="NLM_lpage">3403</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160608084834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.2174%2F1568026616666160608084834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=27291902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKksb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=3385-3403&author=P.+Liauthor=G.+L.+Snyderauthor=K.+E.+Vanover&title=Dopamine+targeting+drugs+for+the+treatment+of+schizophrenia%3A+past%2C+present+and+future&doi=10.2174%2F1568026616666160608084834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future</span></div><div class="casAuthors">Li, Peng; Snyder, Gretchen L.; Vanover, Kimberly E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3385-3403</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting approx. 1% of the world's population.  This disease is assocd. with considerable morbidity placing a major financial burden on society.  Antipsychotics have been the mainstay of the pharmacol. treatment of schizophrenia for decades.  The traditional typical and atypical antipsychotics demonstrate clin. efficacy in treating pos. symptoms, such as hallucinations and delusions, while are largely ineffective and may worsen neg. symptoms, such as blunted affect and social withdrawal, as well as cognitive function.  The inability to treat these latter symptoms may contribute to social function impairment assocd. with schizophrenia.  The dysfunction of multiple neurotransmitter systems in schizophrenia suggests that drugs selectively targeting one neurotransmission pathway are unlikely to meet all the therapeutic needs of this heterogeneous disorder.  Often, however, the unintentional engagement of multiple pharmacol. targets or even the excessive engagement of intended pharmacol. targets can lead to undesired consequences and poor tolerability.  In this article, we will review marketed typical and atypical antipsychotics and new therapeutic agents targeting dopamine receptors and other neurotransmitters for the treatment of schizophrenia.  Representative typical and atypical antipsychotic drugs and new investigational drug candidates will be systematically reviewed and compared by reviewing structure-activity relationships, pharmacokinetic properties, drug metab. and safety, pharmacol. properties, preclin. data in animal models, clin. outcomes and assocd. side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW2CSrOaezH7Vg90H21EOLACvtfcHk0lhzYRkeabjuxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKksb3P&md5=50cf78381bcc8669642112f94fcc26e8</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160608084834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160608084834%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSnyder%26aufirst%3DG.%2BL.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26atitle%3DDopamine%2520targeting%2520drugs%2520for%2520the%2520treatment%2520of%2520schizophrenia%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D3385%26epage%3D3403%26doi%3D10.2174%2F1568026616666160608084834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartolome-Nebreda, J.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Martin, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Viturro, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iturrino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Megens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhoof, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde-Ceide, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4196</span>– <span class="NLM_lpage">4212</span>, <span class="refDoi"> DOI: 10.1021/jm500073h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500073h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4196-4212&author=J.%0AM.+Bartolome-Nebredaauthor=F.+Delgadoauthor=M.+L.+Martin-Martinauthor=C.+M.+Martinez-Viturroauthor=J.+Pastorauthor=H.+M.+Tongauthor=L.+Iturrinoauthor=G.+J.+Macdonaldauthor=W.+Sandersonauthor=A.+Megensauthor=X.+Langloisauthor=M.+Somersauthor=G.+Vanhoofauthor=S.+Conde-Ceide&title=Discovery+of+a+potent%2C+selective%2C+and+orally+active+phosphodiesterase+10A+inhibitor+for+the+potential+treatment+of+schizophrenia&doi=10.1021%2Fjm500073h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm500073h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500073h%26sid%3Dliteratum%253Aachs%26aulast%3DBartolome-Nebreda%26aufirst%3DJ.%2BM.%26aulast%3DDelgado%26aufirst%3DF.%26aulast%3DMartin-Martin%26aufirst%3DM.%2BL.%26aulast%3DMartinez-Viturro%26aufirst%3DC.%2BM.%26aulast%3DPastor%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DH.%2BM.%26aulast%3DIturrino%26aufirst%3DL.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DSanderson%26aufirst%3DW.%26aulast%3DMegens%26aufirst%3DA.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DSomers%26aufirst%3DM.%26aulast%3DVanhoof%26aufirst%3DG.%26aulast%3DConde-Ceide%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520active%2520phosphodiesterase%252010A%2520inhibitor%2520for%2520the%2520potential%2520treatment%2520of%2520schizophrenia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4196%26epage%3D4212%26doi%3D10.1021%2Fjm500073h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Seeman, P.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic drugs, dopamine receptors, and schizophrenia</span>. <i>Clin. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/S1566-2772(00)00007-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2FS1566-2772%2800%2900007-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntlartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=53-60&author=P.+Seeman&title=Antipsychotic+drugs%2C+dopamine+receptors%2C+and+schizophrenia&doi=10.1016%2FS1566-2772%2800%2900007-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic drugs, dopamine receptors, and schizophrenia</span></div><div class="casAuthors">Seeman, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Neuroscience Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">53-60</span>CODEN:
                <span class="NLM_cas:coden">CNRLBU</span>;
        ISSN:<span class="NLM_cas:issn">1566-2772</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The clin. potencies of antipsychotic drugs are directly related to their affinities for the dopamine D2 receptor.  In addn., the concns. of antipsychotic drugs (given at therapeutic maintenance doses) in the plasma water or in the spinal fluid are almost identical to the antipsychotic dissocn. consts. at the dopamine D2 receptor.  A consistent 70-75% of brain D2 receptors are occupied by antipsychotic drugs, as calcd. from the therapeutic concn. and the antipsychotic dissocn. const.  The D3 and D4 dopamine receptors, however, are not consistently occupied by antipsychotic drugs, the occupancies being 0-85% for D3, and 0-95% for D4.  Human brain imaging also reveals that therapeutic doses of antipsychotic drugs occupy ∼70% of D2 receptors.  Between 2 and 4 h after the daily oral dose, clozapine and quetiapine occupy high levels (∼70%) of the dopamine D2 receptors in schizophrenia patients, with lower occupancies at 6 and 12 h.  Although clozapine and quetiapine occupy low levels of D2 receptors many hours after the oral dose, the obsd. fraction of D2 receptors occupied by these drugs, however, depends on the radioligand used, with high occupancy seen when using [11C]raclopride, and low occupancy seen with [11C]methylspiperone (which is tightly bound to D2).  This dependence on the radioligand occurs because clozapine and quetiapine are loosely bound to D2.  The loose binding of clozapine and quetiapine to D2 permits endogenous dopamine to displace these antipsychotic drugs much more quickly than haloperidol.  In addn., the small dose of radioactive raclopride injected (in brain imaging) can displace a little of the D2-bound clozapine.  Hence, the obsd. low level of D2 occupancy by clozapine in patients may arise from a combination of the above three factors - the ligand dependency, the endogenous dopamine, and the displacement by the imaging dose.  Parkinsonism and extrapyramidal effects occur with antipsychotics which have a high affinity for D2 and which are, therefore, tightly bound to D2.  Clozapine and quetiapine have a low affinity for D2, and, being readily displaced by endogenous dopamine, do not give rise to extrapyramidal effects.  Because the loosely bound antipsychotics dissoc. from D2 more rapidly, clin. relapse may occur earlier than that found with the tightly bound traditional antipsychotics.  The dopamine hypothesis of schizophrenia is supported by the fact that D2 is the main target of antipsychotic action, that monomers of D2 appear elevated in schizophrenia, and that the synaptic levels of dopamine in schizophrenia are at least two-fold higher than in control subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQy-mJNj1fZbVg90H21EOLACvtfcHk0li8qUmL1O18Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntlartb0%253D&md5=228879acf06c63cc22c09435352b2be7</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2FS1566-2772%2800%2900007-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1566-2772%252800%252900007-4%26sid%3Dliteratum%253Aachs%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DAntipsychotic%2520drugs%252C%2520dopamine%2520receptors%252C%2520and%2520schizophrenia%26jtitle%3DClin.%2520Neurosci.%2520Res.%26date%3D2001%26volume%3D1%26spage%3D53%26epage%3D60%26doi%3D10.1016%2FS1566-2772%2800%2900007-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Strange, P. G.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">133</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2001&pages=119-133&author=P.+G.+Strange&title=Antipsychotic+drugs%3A+importance+of+dopamine+receptors+for+mechanisms+of+therapeutic+actions+and+side+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStrange%26aufirst%3DP.%2BG.%26atitle%3DAntipsychotic%2520drugs%253A%2520importance%2520of%2520dopamine%2520receptors%2520for%2520mechanisms%2520of%2520therapeutic%2520actions%2520and%2520side%2520effects%26jtitle%3DPharmacol.%2520Rev.%26date%3D2001%26volume%3D53%26spage%3D119%26epage%3D133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muench, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamer, A. M.</span></span> <span> </span><span class="NLM_article-title">Adverse effects of antipsychotic medications</span>. <i>Am. Fam. Physician</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">622</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=20187598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BC3c7ktlynsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2010&pages=617-622&author=J.+Muenchauthor=A.+M.+Hamer&title=Adverse+effects+of+antipsychotic+medications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse effects of antipsychotic medications</span></div><div class="casAuthors">Muench John; Hamer Ann M</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">617-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The use of antipsychotic medications entails a difficult trade-off between the benefit of alleviating psychotic symptoms and the risk of troubling, sometimes life-shortening adverse effects.  There is more variability among specific antipsychotic medications than there is between the first- and second-generation antipsychotic classes.  The newer second-generation antipsychotics, especially clozapine and olanzapine, generally tend to cause more problems relating to metabolic syndrome, such as obesity and type 2 diabetes mellitus.  Also, as a class, the older first-generation antipsychotics are more likely to be associated with movement disorders, but this is primarily true of medications that bind tightly to dopaminergic neuroreceptors, such as haloperidol, and less true of medications that bind weakly, such as chlorpromazine.  Anticholinergic effects are especially prominent with weaker-binding first-generation antipsychotics, as well as with the second-generation antipsychotic clozapine.  All antipsychotic medications are associated with an increased likelihood of sedation, sexual dysfunction, postural hypotension, cardiac arrhythmia, and sudden cardiac death.  Primary care physicians should understand the individual adverse effect profiles of these medications.  They should be vigilant for the occurrence of adverse effects, be willing to adjust or change medications as needed (or work with psychiatric colleagues to do so), and be prepared to treat any resulting medical sequelae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKTaXFsO12OOIHSmpohpd0fW6udTcc2ebL3xAqdVs_fLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7ktlynsQ%253D%253D&md5=2bac8b3c75c7610f7d59f5a34b296723</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuench%26aufirst%3DJ.%26aulast%3DHamer%26aufirst%3DA.%2BM.%26atitle%3DAdverse%2520effects%2520of%2520antipsychotic%2520medications%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2010%26volume%3D81%26spage%3D617%26epage%3D622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designing multiple ligands - medicinal chemistry strategies and challenges</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.2174/138161209787315594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.2174%2F138161209787315594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19199984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=587-600&author=R.+Morphyauthor=Z.+Rankovic&title=Designing+multiple+ligands+-+medicinal+chemistry+strategies+and+challenges&doi=10.2174%2F138161209787315594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multiple ligands - medicinal chemistry strategies and challenges</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  It has been widely recognized over the recent years that parallel modulation of multiple biol. targets can be beneficial for treatment of diseases with complex etiologies such as cancer asthma, and psychiatric disease.  In this article, current strategies for the generation of ligands with a specific multi-target profile (designed multiple ligands or DMLs) are described and a no. of illustrative example are given.  Designing multiple ligands is frequently a challenging endeavor for medicinal chemists, with the need to appropriately balance affinity for 2 or more targets while obtaining physicochem. and pharmacokinetic properties that are consistent with the administration of an oral drug.  Given that the properties of DMLs are influenced to a large extent by the proteomic superfamily to which the targets belong and the lead generation strategy that is pursued, an early assessment of the feasibility of any given DML project is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUo6NjoK5D-LVg90H21EOLACvtfcHk0li8qUmL1O18Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D&md5=fa34039be6e9c3b489f530fc74fd0346</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.2174%2F138161209787315594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209787315594%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigning%2520multiple%2520ligands%2520-%2520medicinal%2520chemistry%2520strategies%2520and%2520challenges%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26spage%3D587%26epage%3D600%26doi%3D10.2174%2F138161209787315594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. an emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+an+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0liuBfzINO1p6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroeze, W. K.</span></span> <span> </span><span class="NLM_article-title">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1038/nrd1346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+shotguns+versus+magic+bullets%3A+selectively+non-selective+drugs+for+mood+disorders+and+schizophrenia&doi=10.1038%2Fnrd1346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0liuBfzINO1p6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520shotguns%2520versus%2520magic%2520bullets%253A%2520selectively%2520non-selective%2520drugs%2520for%2520mood%2520disorders%2520and%2520schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D353%26epage%3D359%26doi%3D10.1038%2Fnrd1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H.
Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. A.</span></span> <span> </span><span class="NLM_article-title">Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin 2 p<i>K</i><sub>i</sub> values</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>251</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">246</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=2571717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADyaL1MXmt1Cksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=251&publication_year=1989&pages=238-246&author=H.%0AY.+Meltzerauthor=S.+Matsubaraauthor=M.+A.+Lee&title=Classification+of+typical+and+atypical+antipsychotic+drugs+on+the+basis+of+dopamine+D-1%2C+D-2%2C+and+serotonin+2+pKi+values"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values</span></div><div class="casAuthors">Meltzer, Herbert Y.; Matsubara, Shigehiro; Lee, Jar Chi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">251</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-46</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The pKi values of 38 typical and atypical antipsychotic drugs (APD) for 5-HT2, D-1 and D-2 binding sites in rat brain have been detd.  Multivariate analytic techniques demonstrate the importance of the D-2 and 5-HT2 affinities for detg. whether a drug which can block the conditioned avoidance response will have atypical properties as an antipsychotic.  A 5-HT2/D-2 ratio ≥1.12 is characteristic of the atypical APD.  These results may be useful in drug screening programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqCUl6xIvXorVg90H21EOLACvtfcHk0liuBfzINO1p6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmt1Cksb4%253D&md5=0f46fdcc98abf7d93d7ea102ac30df84</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DMatsubara%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.%2BA.%26atitle%3DClassification%2520of%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%2520on%2520the%2520basis%2520of%2520dopamine%2520D-1%252C%2520D-2%252C%2520and%2520serotonin%25202%2520pKi%2520values%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1989%26volume%3D251%26spage%3D238%26epage%3D246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Horacek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubenikova-Valesova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palenicek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dockery, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoschl, C.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.2165/00023210-200620050-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.2165%2F00023210-200620050-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=16696579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFyqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=389-409&author=J.+Horacekauthor=V.+Bubenikova-Valesovaauthor=M.+Kopecekauthor=T.+Palenicekauthor=C.+Dockeryauthor=P.+Mohrauthor=C.+Hoschl&title=Mechanism+of+action+of+atypical+antipsychotic+drugs+and+the+neurobiology+of+schizophrenia&doi=10.2165%2F00023210-200620050-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of atypical antipsychotic drugs and the neurobiology and schizophrenia</span></div><div class="casAuthors">Horacek, Jiri; Bubenikova-Valesova, Vera; Kopecek, Milan; Palenicek, Tomas; Dockery, Colleen; Mohr, Pavel; Hoschl, Cyril</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">389-409</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Atypical antipsychotics have greatly enhanced the treatment of schizophrenia.  The mechanisms underlying the effectiveness and adverse effects of these drugs are, to date, not sufficiently explained.  This article summarizes the hypothetical mechanisms of action of atypical antipsychotics with respect to the neurobiol. of schizophrenia.  When considering treatment models for schizophrenia, the role of dopamine receptor blockade and modulation remains dominant.  The optimal occupancy of dopamine D2 receptors seems to be crucial to balancing efficacy and adverse effects - transient D2 receptor antagonism (such as that attained with, for example, quetiapine and clozapine) is sufficient to obtain an antipsychotic effect, while permanent D2 receptor antagonism (as is caused by conventional antipsychotics) increases the risk of adverse effects such as extrapyramidal symptoms.  Partial D2 receptor agonism (induced by aripiprazole) offers the possibility of maintaining optimal blockade and function of D2 receptors.  Balancing presynaptic and post-synaptic D2 receptor antagonism (e.g. induced by amisulpride) is another mechanism that can, through increased release of endogenous dopamine in the striatum, protect against excessive blockade of D2 receptors.  Serotonergic modulation is assocd. with a beneficial increase in striatal dopamine release.  Effects on the neg. and cognitive symptoms of schizophrenia relate to dopamine release in the prefrontal cortex; this can be modulated by combined D2 and serotonin 5-HT2A receptor antagonism (e.g. by olanzapine and risperidone), partial D2 receptor antagonism or the preferential blockade of inhibitory dopamine autoreceptors.  In the context of the neurodevelopmental disconnection hypothesis of schizophrenia, atypical antipsychotics (in contrast to conventional antipsychotics) induce neuronal plasticity and synaptic remodelling, not only in the striatum but also in other brain areas such as the prefrontal cortex and hippocampus.  This mechanism may normalize glutamatergic dysfunction and structural abnormalities and affect the core pathophysiol. substrates for schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7XN_qERk6M7Vg90H21EOLACvtfcHk0liuBfzINO1p6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFyqu78%253D&md5=7110d0f95ae4dfd01395ae371feb59e2</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.2165%2F00023210-200620050-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00023210-200620050-00004%26sid%3Dliteratum%253Aachs%26aulast%3DHoracek%26aufirst%3DJ.%26aulast%3DBubenikova-Valesova%26aufirst%3DV.%26aulast%3DKopecek%26aufirst%3DM.%26aulast%3DPalenicek%26aufirst%3DT.%26aulast%3DDockery%26aufirst%3DC.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DHoschl%26aufirst%3DC.%26atitle%3DMechanism%2520of%2520action%2520of%2520atypical%2520antipsychotic%2520drugs%2520and%2520the%2520neurobiology%2520of%2520schizophrenia%26jtitle%3DCNS%2520Drugs%26date%3D2006%26volume%3D20%26spage%3D389%26epage%3D409%26doi%3D10.2165%2F00023210-200620050-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. M.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic drug development</span>. <i>Curr. Top. Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1007/7854_2010_47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1007%2F7854_2010_47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=21312399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BC3M7osVGhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=123-139&author=D.+H.+Kimauthor=S.+M.+Stahl&title=Antipsychotic+drug+development&doi=10.1007%2F7854_2010_47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic drug development</span></div><div class="casAuthors">Kim Dennis H; Stahl Stephen M</div><div class="citationInfo"><span class="NLM_cas:title">Current topics in behavioral neurosciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">123-39</span>
        ISSN:<span class="NLM_cas:issn">1866-3370</span>.
    </div><div class="casAbstract">Schizophrenia typically manifests itself with a wide array of symptoms--positive, negative, cognitive, and affective--and may also involve neurodevelopmental and neurodegenerative aspects.  Each of these symptom dimensions may be derived from pathology at one or more receptor types, localized in different regions of the brain.  The absence of a single therapeutic target for schizophrenia has therefore prompted the de-emphasis of selective "magic bullets" and a critical re-examination of the intramolecular polypharmacy afforded by antipsychotics.  In this chapter, we present a review of some of the receptor targets that are currently thought to mediate symptoms of schizophrenia, and discuss their possible implications for future antipsychotic drug development.  Therapeutic strategies for schizophrenia that successfully exploit the multifunctionality of antipsychotics will take into account the entire receptor activity "portfolio" of the agent and provide a total therapeutic response that, like the elephant of the Buddhist parable, is greater than the sum of its parts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvsJbrLcyVme98rul4nhSdfW6udTcc2eaGDjtk1T11bbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7osVGhtA%253D%253D&md5=3c62f8e750ad3e999847f362585d252a</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1007%2F7854_2010_47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7854_2010_47%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DStahl%26aufirst%3DS.%2BM.%26atitle%3DAntipsychotic%2520drug%2520development%26jtitle%3DCurr.%2520Top.%2520Behav.%2520Neurosci.%26date%3D2010%26volume%3D4%26spage%3D123%26epage%3D139%26doi%3D10.1007%2F7854_2010_47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, B. W.</span></span> <span> </span><span class="NLM_article-title">The role of serotonin receptors in the action of atypical antipsychotic drugs</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2011.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.coph.2011.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=21420906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1Wqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=59-67&author=H.+Y.+Meltzerauthor=B.+W.+Massey&title=The+role+of+serotonin+receptors+in+the+action+of+atypical+antipsychotic+drugs&doi=10.1016%2Fj.coph.2011.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">The role of serotonin receptors in the action of atypical antipsychotic drugs</span></div><div class="casAuthors">Meltzer, H. Y.; Massey, B. W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-67</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  At clin. EDs, these agents produce extensive blockade of serotonin (5-HT)2A receptors, direct or indirect stimulation of 5-HT1A receptors, and to a lesser extent, redn. in dopamine (DA) D2 receptor-mediated neurotransmission.  This contrasts with typical APDs, for example haloperidol and perphenazine, which are mainly DA D2/D3 receptor antagonists and have weaker, if any, potency as 5-HT2A receptor antagonists.  Some, but not all, atypical APDs are also effective 5-HT2C receptor inverse agonists or neutral antagonists, 5-HT6 or 5-HT7 receptor antagonists.  This diverse action on 5-HT receptors may contribute to significant differences in efficacy and tolerability among the atypical APDs.  There is considerable preclin. and some clin. evidence that effects on 5-HT receptors contribute to the low risk of producing extrapyramidal side effects, which is the defining characteristic of an atypical APD, the lack of elevation in plasma prolactin levels (with risperidone and 9-hydroxyrisperidone being exceptions), antipsychotic action, and ability to improve some domains of cognition in patients with schizophrenia.  The serotonergic actions of the atypical APDs, esp. 5-HT2A receptor antagonism, are particularly important to the differential effects of typical and atypical APDs to overcome the effects of acute or subchronic administration of N-methyl-D-aspartate (NMDA) receptor antagonists, such as phencyclidine, ketamine, and dizocipline (MK-801). 5-HT1A receptor stimulation and 5-HT6 and 5-HT7 receptor antagonism may contribute to beneficial effects of these agents on cognition.  In particular, 5-HT7 receptor antagonism may be the basis for the pro-cognitive effects of the atypical APD, amisulpride, a D2/D3 receptor antagonist, which has no effect on other 5-HT receptor. 5-HT2C receptor antagonism appears to contribute to the wt. gain produced by some atypical APDs and may also affect cognition and psychosis via its influence on cortical and limbic dopaminergic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6MORRdD8Py7Vg90H21EOLACvtfcHk0lhhvKRDYJBHYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1Wqs7o%253D&md5=36aeafe6a20307cb009533c6f082a371</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2011.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2011.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DMassey%26aufirst%3DB.%2BW.%26atitle%3DThe%2520role%2520of%2520serotonin%2520receptors%2520in%2520the%2520action%2520of%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2011%26volume%3D11%26spage%3D59%26epage%3D67%26doi%3D10.1016%2Fj.coph.2011.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, Y.</span></span> <span> </span><span class="NLM_article-title">Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders</span>. <i>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">877</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1016/j.pnpbp.2010.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.pnpbp.2010.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=20398719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1KrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=877-881&author=S.+Shimizuauthor=A.+Tataraauthor=J.+Imakiauthor=Y.+Ohno&title=Role+of+cortical+and+striatal+5-HT1A+receptors+in+alleviating+antipsychotic-induced+extrapyramidal+disorders&doi=10.1016%2Fj.pnpbp.2010.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders</span></div><div class="casAuthors">Shimizu, Saki; Tatara, Ayaka; Imaki, Junta; Ohno, Yukihiro</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">877-881</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previous studies have revealed that 5-HT1A agonists ameliorate antipsychotic-induced extrapyramidal symptoms (EPS) through postsynaptic 5-HT1A receptors.  Here, we conducted an intracerebral microinjection study of (±)-8-hydroxy-2-(di-n-propylamino)-tetralin ((±)8-OH-DPAT) to det. the action site of the 5-HT1A agonist in alleviating EPS.  Bilateral microinjection of(±)8-OH-DPAT (5 μg/1 μL per side) either into the primary motor cortex (MC) or the dorsolateral striatum (dlST) significantly attenuated haloperidol-induced catalepsy in rats.  The anticataleptic action of (±)8-OH-DPAT was more prominent with the MC injection than with the dlST injection.  WAY-100135 (a selective 5-HT1A antagonist) completely antagonized the reversal of haloperidol-induced catalepsy both by intracortical and intrastriatal (±)8-OH-DPAT.  Furthermore, lesioning of dopamine neurons with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (30 mg/kg/day, i.p., for 4 days) did not alter the anti-EPS actions of (±)8-OH-DPAT in a mouse pole test.  The present results strongly suggest that 5-HT1A agonist alleviates antipsychotic-induced EPS by activating postsynaptic 5-HT1A receptors in the MC and dlST, probably through non-dopaminergic mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPAjyUQFCgNLVg90H21EOLACvtfcHk0lhhvKRDYJBHYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1KrsbY%253D&md5=87f7b69d93c44b1d9d4dc10a92309493</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2010.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2010.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DS.%26aulast%3DTatara%26aufirst%3DA.%26aulast%3DImaki%26aufirst%3DJ.%26aulast%3DOhno%26aufirst%3DY.%26atitle%3DRole%2520of%2520cortical%2520and%2520striatal%25205-HT1A%2520receptors%2520in%2520alleviating%2520antipsychotic-induced%2520extrapyramidal%2520disorders%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2010%26volume%3D34%26spage%3D877%26epage%3D881%26doi%3D10.1016%2Fj.pnpbp.2010.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, N.</span></span> <span> </span><span class="NLM_article-title">Augmentation of antipsychotic drug action by azapirone 5-HT<sub>1A</sub> receptor partial agonists: a meta-analysis</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1266</span>, <span class="refDoi"> DOI: 10.1017/S1461145713000151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1017%2FS1461145713000151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=23551924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFKisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=1259-1266&author=T.+Kishiauthor=H.+Y.+Meltzerauthor=N.+Iwata&title=Augmentation+of+antipsychotic+drug+action+by+azapirone+5-HT1A+receptor+partial+agonists%3A+a+meta-analysis&doi=10.1017%2FS1461145713000151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis</span></div><div class="casAuthors">Kishi, Taro; Meltzer, Herbert Y.; Iwata, Nakao</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1259-1266</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">The aim of the study was to evaluate the evidence that serotonin1A (5-HT1A) receptor partial agonists of the azapirone class, which are not antipsychotic, have benefits for adjunctive treatment of overall psychopathol., pos. and neg. symptoms for patients with schizophrenia.  We carried out a systematic review of the literature available through PubMed, Cochrane Library, PsycINFO and Google Scholar during Sept. 2012, followed by a meta-anal. of randomized placebo-controlled trials.  Risk ratio (RR), 95% confidence intervals (CI) and standardized mean difference (s.m.d.) were calcd.  Four studies, involving 163 patients with schizophrenia, met inclusion criteria: buspirone: three trials and 137 patients; tandospirone: one trial and 26 patients.  As adjunctive therapy, 5-HT1A partial agonists were significantly superior to placebo for overall improvement in psychopathol. (s.m.d. = -0.46, CI = -0.79 to -0.13, p = 0.006, N = 4, n = 149) and marginally more effective to improve pos. symptoms (s.m.d. = -0.31, CI = -0.64 to 0.01, p = 0.06, N = 4, n = 149).  However, 5-HT1A partial agonists were not more efficacious than placebo as adjunctive therapy for improving neg. symptoms (s.m.d. = -0.09, CI = -0.60 to 0.42, p = 0.72, N = 4, n = 149).  In addn., there was no significant difference in discontinuation rates between 5-HT1A partial agonists and placebo (all cause: RR = 0.98, CI = 0.49-1.98, p = 0.96, N = 4, n = 153, side-effects: RR = 1.96, CI = 0.54-7.19, p = 0.31, N = 4, n = 153). 5-HT1A partial agonists as adjunctive therapy improved overall psychopathol. with a trend to improve pos. symptoms in patients with schizophrenia.  Because the no. of studies was small, addnl. controlled clin. trials with larger nos. of patients are indicated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8Nr1rWMv5CLVg90H21EOLACvtfcHk0li5d68_wt2wlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFKisbs%253D&md5=b2ab0cce4b49dc8468bdbdaa092d6860</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1017%2FS1461145713000151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145713000151%26sid%3Dliteratum%253Aachs%26aulast%3DKishi%26aufirst%3DT.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DIwata%26aufirst%3DN.%26atitle%3DAugmentation%2520of%2520antipsychotic%2520drug%2520action%2520by%2520azapirone%25205-HT1A%2520receptor%2520partial%2520agonists%253A%2520a%2520meta-analysis%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2013%26volume%3D16%26spage%3D1259%26epage%3D1266%26doi%3D10.1017%2FS1461145713000151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Harder, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maclean, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alder, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridley, R. M.</span></span> <span> </span><span class="NLM_article-title">The 5-HT<sub>1A</sub> antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset</span>. <i>Psychopharmacology (Berl)</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1007/BF02806000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1007%2FBF02806000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=8912403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADyaK28Xmslyktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=1996&pages=245-254&author=J.+A.+Harderauthor=C.+J.+Macleanauthor=J.+T.+Alderauthor=P.+T.+Francisauthor=R.+M.+Ridley&title=The+5-HT1A+antagonist%2C+WAY+100635%2C+ameliorates+the+cognitive+impairment+induced+by+fornix+transection+in+the+marmoset&doi=10.1007%2FBF02806000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">The 5-HT1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset</span></div><div class="casAuthors">Harder, J. A.; Maclean, C. J.; Alder, J. T.; Francis, P. T.; Ridley, R. M.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">245-254</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Fornix transection in the marmoset produces a specific pattern of cognitive deficits, notably a lack of ability to recall visuospatial tasks learned preoperatively, and a deficit in acquiring new visuospatial tasks following transection.  This learning impairment can be ameliorated by cholinergic agonists, suggesting that it occurs as a consequence of destroying the cholinergic projection from the vertical limb of the diagonal band to the hippocampus which runs through the fornix.  This deficit in new learning can be significantly alleviated by the 5-HT1A antagonist, WAY 100635.  This result supports the suggestion that 5-HT1A projections are inhibitory on the same target cells for which cholinergic projections are excitatory, and that loss of function in the target cells caused by loss of excitatory tone can be compensated by blockade of inhibitory tone.  Since cholinergic loss in the hippocampus (and neocortex) occurs in assocn. with cognitive decline in Alzheimer's disease, these results suggest that 5-HT1A antagonists may have a role in the treatment of some of the cognitive symptoms of dementia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0o7vgliyGkbVg90H21EOLACvtfcHk0li5d68_wt2wlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xmslyktrw%253D&md5=295d1dcd6e166ea523b9934e18865129</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1007%2FBF02806000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02806000%26sid%3Dliteratum%253Aachs%26aulast%3DHarder%26aufirst%3DJ.%2BA.%26aulast%3DMaclean%26aufirst%3DC.%2BJ.%26aulast%3DAlder%26aufirst%3DJ.%2BT.%26aulast%3DFrancis%26aufirst%3DP.%2BT.%26aulast%3DRidley%26aufirst%3DR.%2BM.%26atitle%3DThe%25205-HT1A%2520antagonist%252C%2520WAY%2520100635%252C%2520ameliorates%2520the%2520cognitive%2520impairment%2520induced%2520by%2520fornix%2520transection%2520in%2520the%2520marmoset%26jtitle%3DPsychopharmacology%2520%2528Berl%2529%26date%3D1996%26volume%3D127%26spage%3D245%26epage%3D254%26doi%3D10.1007%2FBF02806000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>1A</sub> receptor, an old target for new therapeutic agents</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1024</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.2174/156802608785161385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.2174%2F156802608785161385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=18691130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Ohtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1024-1034&author=E.+Lacivitaauthor=M.+Leopoldoauthor=F.+Berardiauthor=R.+Perrone&title=5-HT1A+receptor%2C+an+old+target+for+new+therapeutic+agents&doi=10.2174%2F156802608785161385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT1A receptor, an old target for new therapeutic agents</span></div><div class="casAuthors">Lacivita, Enza; Leopoldo, Marcello; Berardi, Francesco; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1024-1034</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The serotonin receptor subtype 5-HT1A was one of the first serotonin receptor subtypes pharmacol. characterized.  Over the last twenty years the 5-HT1A receptor has been the object of intense research efforts as witnessed by the 5-HT1A acting drugs marketed as anxiolytics.  In recent years, several new chem. entities targeting the 5-HT1A receptor (alone or in combination with other mol. targets) have been proposed for novel therapeutic indications (neuroprotection, cognitive impairment, Parkinson Disease and related disorders, pain treatment).  The present review will focus on those 5-HT1A receptor agents that entered preclin. trials starting from 2000.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquGiFKFKnqLrVg90H21EOLACvtfcHk0li5d68_wt2wlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Ohtb4%253D&md5=cd19fc17c1edcfec3977fffe3920480d</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.2174%2F156802608785161385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608785161385%26sid%3Dliteratum%253Aachs%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3D5-HT1A%2520receptor%252C%2520an%2520old%2520target%2520for%2520new%2520therapeutic%2520agents%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1024%26epage%3D1034%26doi%3D10.2174%2F156802608785161385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, W. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havran, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asselin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicksler, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosu, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abou-Gharbia, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A. C.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleintop, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magolda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathias, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabb, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andree, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aschmies, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comery, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig-Lipson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukoff-Rizzo, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adedoyin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huselton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, W. D.</span></span> <span> </span><span class="NLM_article-title">The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT<sub>1A</sub> antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4066</span>– <span class="NLM_lpage">4084</span>, <span class="refDoi"> DOI: 10.1021/jm1000908</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1000908" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4066-4084&author=W.+E.+Childersauthor=L.+M.+Havranauthor=M.+Asselinauthor=J.+J.+Bickslerauthor=D.+C.+Chongauthor=G.+T.+Grosuauthor=Z.+Shenauthor=M.+A.+Abou-Gharbiaauthor=A.+C.+Bachauthor=B.+L.+Harrisonauthor=N.+Kaganauthor=T.+Kleintopauthor=R.+Magoldaauthor=V.+Marathiasauthor=A.+J.+Robichaudauthor=A.+L.+Sabbauthor=M.+Y.+Zhangauthor=T.+H.+Andreeauthor=S.+H.+Aschmiesauthor=C.+Beyerauthor=T.+A.+Comeryauthor=M.+Dayauthor=S.+M.+Grauerauthor=Z.+A.+Hughesauthor=S.+Rosenzweig-Lipsonauthor=B.+Plattauthor=C.+Pulicicchioauthor=D.+E.+Smithauthor=S.+J.+Sukoff-Rizzoauthor=K.+M.+Sullivanauthor=A.+Adedoyinauthor=C.+Huseltonauthor=W.+D.+Hirst&title=The+synthesis+and+biological+evaluation+of+quinolyl-piperazinyl+piperidines+as+potent+serotonin+5-HT1A+antagonists&doi=10.1021%2Fjm1000908"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1021%2Fjm1000908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1000908%26sid%3Dliteratum%253Aachs%26aulast%3DChilders%26aufirst%3DW.%2BE.%26aulast%3DHavran%26aufirst%3DL.%2BM.%26aulast%3DAsselin%26aufirst%3DM.%26aulast%3DBicksler%26aufirst%3DJ.%2BJ.%26aulast%3DChong%26aufirst%3DD.%2BC.%26aulast%3DGrosu%26aufirst%3DG.%2BT.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DAbou-Gharbia%26aufirst%3DM.%2BA.%26aulast%3DBach%26aufirst%3DA.%2BC.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DKagan%26aufirst%3DN.%26aulast%3DKleintop%26aufirst%3DT.%26aulast%3DMagolda%26aufirst%3DR.%26aulast%3DMarathias%26aufirst%3DV.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26aulast%3DSabb%26aufirst%3DA.%2BL.%26aulast%3DZhang%26aufirst%3DM.%2BY.%26aulast%3DAndree%26aufirst%3DT.%2BH.%26aulast%3DAschmies%26aufirst%3DS.%2BH.%26aulast%3DBeyer%26aufirst%3DC.%26aulast%3DComery%26aufirst%3DT.%2BA.%26aulast%3DDay%26aufirst%3DM.%26aulast%3DGrauer%26aufirst%3DS.%2BM.%26aulast%3DHughes%26aufirst%3DZ.%2BA.%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26aulast%3DPlatt%26aufirst%3DB.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DD.%2BE.%26aulast%3DSukoff-Rizzo%26aufirst%3DS.%2BJ.%26aulast%3DSullivan%26aufirst%3DK.%2BM.%26aulast%3DAdedoyin%26aufirst%3DA.%26aulast%3DHuselton%26aufirst%3DC.%26aulast%3DHirst%26aufirst%3DW.%2BD.%26atitle%3DThe%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520quinolyl-piperazinyl%2520piperidines%2520as%2520potent%2520serotonin%25205-HT1A%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4066%26epage%3D4084%26doi%3D10.1021%2Fjm1000908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sumiyoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, Y.</span></span> <span> </span><span class="NLM_article-title">Facilitative effect of 5-HT<sub>1A</sub> receptor agonists on cognition in patients with schizophrenia</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.2174/0929867311320030006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.2174%2F0929867311320030006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=23157627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtFegurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=357-362&author=T.+Sumiyoshiauthor=Y.+Higuchi&title=Facilitative+effect+of+5-HT1A+receptor+agonists+on+cognition+in+patients+with+schizophrenia&doi=10.2174%2F0929867311320030006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14dR"><div class="casContent"><span class="casTitleNuber">14d</span><div class="casTitle"><span class="NLM_cas:atitle">Facilitative effect of serotonin1A receptor agonists on cognition in patients with schizophrenia</span></div><div class="casAuthors">Sumiyoshi, T.; Higuchi, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">357-362</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Disturbances of cognitive function are considered to largely affect the outcome in patients with schizophrenia.  There is much attention to the role of psychotropic compds. acting on serotonin (5-HT) receptors in ameliorating cognitive deficits of the disease.  Among the 5-HT receptor subtypes, the 5-HT1A receptor is attracting particular interests as a potential target for enhancing cognition, based on preclin. and clin. evidence.  The neural network underlying the ability of 5-HT1A agonists to treat cognitive impairments of schizophrenia likely includes dopamine, glutamate, and gamma-aminobutyric acid neurons.  Recent advances of electrophysiol. measures, such as event-related potentials, have provided insights into facilitative effects on cognition of some atypical antipsychotic drugs or related compds. acting directly or indirectly on 5-HT1A receptors.  These considerations are expected to promote the development of novel therapeutics for the betterment of functional outcome in people suffering from schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFiyYjZ1O_WrVg90H21EOLACvtfcHk0lhb5nvsI6hOMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtFegurs%253D&md5=1416dd6cfe539860da0147748669e65c</span></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=10.2174%2F0929867311320030006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320030006%26sid%3Dliteratum%253Aachs%26aulast%3DSumiyoshi%26aufirst%3DT.%26aulast%3DHiguchi%26aufirst%3DY.%26atitle%3DFacilitative%2520effect%2520of%25205-HT1A%2520receptor%2520agonists%2520on%2520cognition%2520in%2520patients%2520with%2520schizophrenia%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D357%26epage%3D362%26doi%3D10.2174%2F0929867311320030006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Opler, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medalia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opler, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacotherapy of cognitive deficits in schizophrenia</span>. <i>CNS. Spectr.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">142</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1017/S1092852913000771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1017%2FS1092852913000771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=24229725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BC2c7msFejtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=142-156&author=L.+A.+Oplerauthor=A.+Medaliaauthor=M.+G.+Oplerauthor=S.+M.+Stahl&title=Pharmacotherapy+of+cognitive+deficits+in+schizophrenia&doi=10.1017%2FS1092852913000771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14eR"><div class="casContent"><span class="casTitleNuber">14e</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacotherapy of cognitive deficits in schizophrenia</span></div><div class="casAuthors">Opler Lewis A; Medalia Alice; Opler Mark G; Stahl Stephen M</div><div class="citationInfo"><span class="NLM_cas:title">CNS spectrums</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">142-56</span>
        ISSN:<span class="NLM_cas:issn">1092-8529</span>.
    </div><div class="casAbstract">While second-generation antipsychotics treat negative as well as positive symptoms, recovery for persons with schizophrenia remains elusive, in part because there are no FDA-approved medications that treat the cognitive deficits of schizophrenia (CDS).  Recent work has identified agents that, when added to antipsychotics, improve cognition in schizophrenia.  This work and hypothesized mechanisms of action will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVEc91WN9nEJotVjB3IRIyfW6udTcc2eaCKakjK5K6arntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7msFejtQ%253D%253D&md5=5a7e00ac36651448a6d903baa15daa78</span></div><a href="/servlet/linkout?suffix=cit14e&amp;dbid=16384&amp;doi=10.1017%2FS1092852913000771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1092852913000771%26sid%3Dliteratum%253Aachs%26aulast%3DOpler%26aufirst%3DL.%2BA.%26aulast%3DMedalia%26aufirst%3DA.%26aulast%3DOpler%26aufirst%3DM.%2BG.%26aulast%3DStahl%26aufirst%3DS.%2BM.%26atitle%3DPharmacotherapy%2520of%2520cognitive%2520deficits%2520in%2520schizophrenia%26jtitle%3DCNS.%2520Spectr.%26date%3D2014%26volume%3D19%26spage%3D142%26epage%3D156%26doi%3D10.1017%2FS1092852913000771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richtand, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welge, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logue, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, P. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strakowski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, R. K.</span></span> <span> </span><span class="NLM_article-title">Dopamine and serotonin receptor binding and antipsychotic efficacy</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1715</span>– <span class="NLM_lpage">1726</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1301305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1038%2Fsj.npp.1301305" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=1715-1726&author=N.+M.+Richtandauthor=J.+A.+Welgeauthor=A.+D.+Logueauthor=P.+E.+Keckauthor=S.+M.+Strakowskiauthor=R.+K.+McNamara&title=Dopamine+and+serotonin+receptor+binding+and+antipsychotic+efficacy&doi=10.1038%2Fsj.npp.1301305"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301305%26sid%3Dliteratum%253Aachs%26aulast%3DRichtand%26aufirst%3DN.%2BM.%26aulast%3DWelge%26aufirst%3DJ.%2BA.%26aulast%3DLogue%26aufirst%3DA.%2BD.%26aulast%3DKeck%26aufirst%3DP.%2BE.%26aulast%3DStrakowski%26aufirst%3DS.%2BM.%26aulast%3DMcNamara%26aufirst%3DR.%2BK.%26atitle%3DDopamine%2520and%2520serotonin%2520receptor%2520binding%2520and%2520antipsychotic%2520efficacy%26jtitle%3DNeuropsychopharmacology%26date%3D2007%26volume%3D32%26spage%3D1715%26epage%3D1726%26doi%3D10.1038%2Fsj.npp.1301305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ames, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr-Lopez, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakib, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yudofsky, L. M.</span></span> <span> </span><span class="NLM_article-title">Detecting and managing adverse effects of antipsychotic medications: Current State of Play</span>. <i>Psychiatr. Clin. North. Am.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1016/j.psc.2016.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.psc.2016.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=27216904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FivFaqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2016&pages=275-311&author=D.+Amesauthor=S.+M.+Carr-Lopezauthor=M.+A.+Gutierrezauthor=J.+M.+Pierreauthor=J.+A.+Rosenauthor=S.+Shakibauthor=L.+M.+Yudofsky&title=Detecting+and+managing+adverse+effects+of+antipsychotic+medications%3A+Current+State+of+Play&doi=10.1016%2Fj.psc.2016.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Detecting and Managing Adverse Effects of Antipsychotic Medications: Current State of Play</span></div><div class="casAuthors">Ames Donna; Carr-Lopez Sian M; Gutierrez Mary A; Pierre Joseph M; Rosen Jennifer A; Shakib Susan; Yudofsky Lynn M</div><div class="citationInfo"><span class="NLM_cas:title">The Psychiatric clinics of North America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-311</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antipsychotics are some of the most frequently prescribed medications not only for psychotic disorders and symptoms but also for a wide range of on-label and off-label indications.  Because second-generation antipsychotics have largely replaced first-generation antipsychotics as first-line options due to their substantially decreased risk of extrapyramidal side effects, attention has shifted to other clinically concerning adverse events associated with antipsychotic therapy.  The focus of this article is to update the nonextrapyramidal side effects associated with second-generation antipsychotics.  Issues surrounding diagnosis and monitoring as well as clinical management are addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYhiE3R9PpBkg6wdEZmT2rfW6udTcc2eaCKakjK5K6arntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FivFaqtA%253D%253D&md5=b955fec4c21555a7045b9d202d7f8255</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.psc.2016.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.psc.2016.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DAmes%26aufirst%3DD.%26aulast%3DCarr-Lopez%26aufirst%3DS.%2BM.%26aulast%3DGutierrez%26aufirst%3DM.%2BA.%26aulast%3DPierre%26aufirst%3DJ.%2BM.%26aulast%3DRosen%26aufirst%3DJ.%2BA.%26aulast%3DShakib%26aufirst%3DS.%26aulast%3DYudofsky%26aufirst%3DL.%2BM.%26atitle%3DDetecting%2520and%2520managing%2520adverse%2520effects%2520of%2520antipsychotic%2520medications%253A%2520Current%2520State%2520of%2520Play%26jtitle%3DPsychiatr.%2520Clin.%2520North.%2520Am.%26date%3D2016%26volume%3D39%26spage%3D275%26epage%3D311%26doi%3D10.1016%2Fj.psc.2016.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, S. L.</span></span> <span> </span><span class="NLM_article-title">Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2009.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.pharmthera.2009.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19931306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFyiu77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2010&pages=169-179&author=G.+P.+Reynoldsauthor=S.+L.+Kirk&title=Metabolic+side+effects+of+antipsychotic+drug+treatment%2D%2Dpharmacological+mechanisms&doi=10.1016%2Fj.pharmthera.2009.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms</span></div><div class="casAuthors">Reynolds, Gavin P.; Kirk, Shona L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">169-179</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Obesity and metabolic syndrome, with increased risk of eventual cardiovascular disease and type II diabetes, are significant problems for patients receiving antipsychotic drugs and are likely contribute to their decreased life expectancy.  Several drug-related mechanisms may contribute to these problems, including effects both influencing food intake and on glucose and lipid metab.  The metabolic consequences of different antipsychotic drugs vary substantially; these variations reflect differences in receptor pharmacol. and provide clues as to the underlying pharmacol. mechanisms.  The two drugs with the greatest effects on body wt., olanzapine and clozapine, also have high affinity for the 5-HT2C and histamine H1 receptors, which implicate these receptors in antipsychotic-induced wt. gain, while peripheral M3 muscarinic receptor antagonism as well as central 5-HT2C effects may contribute to obesity-independent diabetes.  Other receptor mechanisms may have additive or synergistic effects; dopamine D2 receptor antagonism can enhance 5-HT2C-mediated effects on food intake, as well as influencing lipid and glucose metab. via disinhibition of prolactin secretion.  Pharmacogenetic assocns. of drug-induced wt. gain with 5-HT2C receptor and leptin gene polymorphisms, among others, have provided further clues.  Elevated leptin secretion in the absence of a decrease in food intake indicates drug-induced leptin insensitivity in the hypothalamus.  The minimal wt. gain seen with ziprasidone and aripiprazole may reflect their having further pharmacol. effects that protect against changes in food intake and related metabolic factors.  Understanding the pharmacol. of metabolic consequences of current antipsychotic drug treatment is clearly the key to developing improved pharmacotherapies that avoid these problematic and limiting adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt7JyuRcCdILVg90H21EOLACvtfcHk0ljeOGR9V8fXow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFyiu77E&md5=548d49d2cca697e4405549be6ba0dd6f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DG.%2BP.%26aulast%3DKirk%26aufirst%3DS.%2BL.%26atitle%3DMetabolic%2520side%2520effects%2520of%2520antipsychotic%2520drug%2520treatment--pharmacological%2520mechanisms%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D125%26spage%3D169%26epage%3D179%26doi%3D10.1016%2Fj.pharmthera.2009.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weston-Green, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. F.</span></span> <span> </span><span class="NLM_article-title">The role of histaminergic H<sub>1</sub> and H<sub>3</sub> receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?</span>. <i>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1016/j.pnpbp.2009.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.pnpbp.2009.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19922755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsl2kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=1-4&author=C.+Dengauthor=K.+Weston-Greenauthor=X.+F.+Huang&title=The+role+of+histaminergic+H1+and+H3+receptors+in+food+intake%3A+a+mechanism+for+atypical+antipsychotic-induced+weight+gain%3F&doi=10.1016%2Fj.pnpbp.2009.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain?</span></div><div class="casAuthors">Deng, Chao; Weston-Green, Katrina; Huang, Xu-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-4</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Atypical antipsychotics such as olanzapine and clozapine are effective at treating the multiple domains of schizophrenia, with a low risk of extra-pyramidal side-effects.  However a major downfall to their use is metabolic side-effects particularly wt. gain/obesity, which occurs by unknown mechanisms.  The present paper explores the potential candidature of histaminergic neurotransmission in the mechanisms of atypical antipsychotic-induced wt. gain, with a focus on the histaminergic H1 and H3 receptors.  Olanzapine and clozapine have a high affinity for the H1 receptor, and meta-analyses show a strong correlation between risk of wt. gain and H1 receptor affinity.  In addn., olanzapine treatment decreases H1 receptor binding and mRNA expression in the rat hypothalamus.  Furthermore, a complex role is emerging for the histamine H3 receptor in the control of hunger.  The H3 receptor is a pre-synaptic autoreceptor that inhibits the synthesis and release of histamine, and a heteroreceptor that inhibits other neurotransmitters such as serotonin (5-HT), noradrenaline (NA) and acetylcholine (ACh), which are also implicated in the regulation of food intake.  Thus, the H3 receptor is in a prime position to regulate food intake, both through its control of histamine and its influence on other feeding pathways.  We proposed that a mechanism for atypical antipsychotic-induced wt. gain may be partly through the H3 receptor, as a drug-induced decrease in H1 receptor activity may decrease histamine tone through the H3 autoreceptors, compounding the wt. gain problem.  In addn., atypical antipsychotics may affect food intake by influencing 5-HT, NA and ACh release via interactions with the H3 heteroreceptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRPtyjEiBxobVg90H21EOLACvtfcHk0ljeOGR9V8fXow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsl2kuw%253D%253D&md5=8ee52c313f7e12534d2cf4016f06b6b4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2009.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2009.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DC.%26aulast%3DWeston-Green%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DX.%2BF.%26atitle%3DThe%2520role%2520of%2520histaminergic%2520H1%2520and%2520H3%2520receptors%2520in%2520food%2520intake%253A%2520a%2520mechanism%2520for%2520atypical%2520antipsychotic-induced%2520weight%2520gain%253F%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2010%26volume%3D34%26spage%3D1%26epage%3D4%26doi%3D10.1016%2Fj.pnpbp.2009.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glazebrook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neill, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, G. P.</span></span> <span> </span><span class="NLM_article-title">Olanzapine-induced weight gain in the rat: role of 5-HT<sub>2C</sub> and histamine H<sub>1</sub> receptors</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>207</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1007/s00213-009-1639-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1007%2Fs00213-009-1639-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19688201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVSiurfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=2009&pages=119-125&author=S.+L.+Kirkauthor=J.+Glazebrookauthor=B.+Graysonauthor=J.+C.+Neillauthor=G.+P.+Reynolds&title=Olanzapine-induced+weight+gain+in+the+rat%3A+role+of+5-HT2C+and+histamine+H1+receptors&doi=10.1007%2Fs00213-009-1639-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors</span></div><div class="casAuthors">Kirk, Shona L.; Glazebrook, John; Grayson, Ben; Neill, Joanna C.; Reynolds, Gavin P.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">207</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-125</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Substantial increases in body wt. can be induced by several antipsychotic drugs, most notably olanzapine and clozapine.  Antagonism at certain receptors, particularly 5-HT2C and histamine H1 receptors, is implicated in this effect.  We have investigated the contribution of effects at these receptors to olanzapine-induced wt. gain occurring over 5 days following daily i.p. drug injections in groups of eight female rats.  Olanzapine (2 mg/kg) and the 5-HT2C antagonist SB 243213 (1 mg/kg), but not the histamine H1 antagonist mepyramine (1 mg/kg), produced significant increases in percentage body wt. above vehicle; olanzapine showed a significantly greater effect than SB 243213.  Haloperidol (0.1 mg/kg) alone or with mepyramine had no significant effects on wt. gain, while with SB 243213 and with both SB 243213 and mepyramine, it showed olanzapine-like increases in wt.  These results suggest that 5-HT2C receptor antagonism or inverse agonism, in the presence of D2 receptor antagonism, may contribute to olanzapine-induced wt. gain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmjmVRL8e4w7Vg90H21EOLACvtfcHk0ljeOGR9V8fXow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVSiurfE&md5=3874fc5b7ab395710a52b045599ef5e2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00213-009-1639-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-009-1639-8%26sid%3Dliteratum%253Aachs%26aulast%3DKirk%26aufirst%3DS.%2BL.%26aulast%3DGlazebrook%26aufirst%3DJ.%26aulast%3DGrayson%26aufirst%3DB.%26aulast%3DNeill%26aufirst%3DJ.%2BC.%26aulast%3DReynolds%26aufirst%3DG.%2BP.%26atitle%3DOlanzapine-induced%2520weight%2520gain%2520in%2520the%2520rat%253A%2520role%2520of%25205-HT2C%2520and%2520histamine%2520H1%2520receptors%26jtitle%3DPsychopharmacology%26date%3D2009%26volume%3D207%26spage%3D119%26epage%3D125%26doi%3D10.1007%2Fs00213-009-1639-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Da
Silva Costa-Aze, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauphin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulouard, M.</span></span> <span> </span><span class="NLM_article-title">Serotonin 5-HT<sub>6</sub> receptor blockade reverses the age-related deficits of recognition memory and working memory in mice</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>222</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2011.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.bbr.2011.03.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=2011&pages=134-140&author=V.+Da%0ASilva+Costa-Azeauthor=F.+Dauphinauthor=M.+Boulouard&title=Serotonin+5-HT6+receptor+blockade+reverses+the+age-related+deficits+of+recognition+memory+and+working+memory+in+mice&doi=10.1016%2Fj.bbr.2011.03.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2011.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2011.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DDa%2BSilva%2BCosta-Aze%26aufirst%3DV.%26aulast%3DDauphin%26aufirst%3DF.%26aulast%3DBoulouard%26aufirst%3DM.%26atitle%3DSerotonin%25205-HT6%2520receptor%2520blockade%2520reverses%2520the%2520age-related%2520deficits%2520of%2520recognition%2520memory%2520and%2520working%2520memory%2520in%2520mice%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2011%26volume%3D222%26spage%3D134%26epage%3D140%26doi%3D10.1016%2Fj.bbr.2011.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidbreder, C. A.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>6</sub> receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1002/syn.10288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1002%2Fsyn.10288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=14618683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BD3srjvVWrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2004&pages=158-164&author=L.+P.+Lacroixauthor=L.+A.+Dawsonauthor=J.+J.+Haganauthor=C.+A.+Heidbreder&title=5-HT6+receptor+antagonist+SB-271046+enhances+extracellular+levels+of+monoamines+in+the+rat+medial+prefrontal+cortex&doi=10.1002%2Fsyn.10288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex</span></div><div class="casAuthors">Lacroix Laurent P; Dawson Lee A; Hagan Jim J; Heidbreder Christian A</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">158-64</span>
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    </div><div class="casAbstract">The present study investigated the neurochemical effects of the selective 5-HT(6) receptor antagonist SB-271046 in the rat medial prefrontal cortex (mPFC).  The effect of SB-271046 on extracellular levels of dopamine (DA), norepinephrine (NE), and serotonin (5-HT) in the mPFC was examined using in vivo microdialysis in the freely moving rat.  SB-271046 (10 mg/kg, p.o.) produced a significant increase in extracellular levels of both DA and NE without altering 5-HT neurotransmission.  These results further support the rationale for the use of 5-HT(6) receptor antagonists in the treatment of cognitive dysfunction associated with psychiatric diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfdX5-PKOb2t0Q2ypr7jHkfW6udTcc2eZWraj7oovzebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srjvVWrtg%253D%253D&md5=dce6fb05bddd0c003712fdd645444bd4</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1002%2Fsyn.10288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.10288%26sid%3Dliteratum%253Aachs%26aulast%3DLacroix%26aufirst%3DL.%2BP.%26aulast%3DDawson%26aufirst%3DL.%2BA.%26aulast%3DHagan%26aufirst%3DJ.%2BJ.%26aulast%3DHeidbreder%26aufirst%3DC.%2BA.%26atitle%3D5-HT6%2520receptor%2520antagonist%2520SB-271046%2520enhances%2520extracellular%2520levels%2520of%2520monoamines%2520in%2520the%2520rat%2520medial%2520prefrontal%2520cortex%26jtitle%3DSynapse%26date%3D2004%26volume%3D51%26spage%3D158%26epage%3D164%26doi%3D10.1002%2Fsyn.10288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tassone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madeo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirinzi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vita, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puglisi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponterio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonsi, P.</span></span> <span> </span><span class="NLM_article-title">Activation of 5-HT<sub>6</sub> receptors inhibits corticostriatal glutamatergic transmission</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">632</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2011.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.neuropharm.2011.05.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2011&pages=632-637&author=A.+Tassoneauthor=G.+Madeoauthor=T.+Schirinziauthor=D.+Vitaauthor=F.+Puglisiauthor=G.+Ponterioauthor=F.+Borsiniauthor=A.+Pisaniauthor=P.+Bonsi&title=Activation+of+5-HT6+receptors+inhibits+corticostriatal+glutamatergic+transmission&doi=10.1016%2Fj.neuropharm.2011.05.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2011.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2011.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DTassone%26aufirst%3DA.%26aulast%3DMadeo%26aufirst%3DG.%26aulast%3DSchirinzi%26aufirst%3DT.%26aulast%3DVita%26aufirst%3DD.%26aulast%3DPuglisi%26aufirst%3DF.%26aulast%3DPonterio%26aufirst%3DG.%26aulast%3DBorsini%26aufirst%3DF.%26aulast%3DPisani%26aufirst%3DA.%26aulast%3DBonsi%26aufirst%3DP.%26atitle%3DActivation%2520of%25205-HT6%2520receptors%2520inhibits%2520corticostriatal%2520glutamatergic%2520transmission%26jtitle%3DNeuropharmacology%26date%3D2011%26volume%3D61%26spage%3D632%26epage%3D637%26doi%3D10.1016%2Fj.neuropharm.2011.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fone, K. C.</span></span> <span> </span><span class="NLM_article-title">An update on the role of the 5-HT<sub>6</sub> receptor in cognitive function</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2008.06.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.neuropharm.2008.06.061" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2008&pages=1015-1022&author=K.+C.+Fone&title=An+update+on+the+role+of+the+5-HT6+receptor+in+cognitive+function&doi=10.1016%2Fj.neuropharm.2008.06.061"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2008.06.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2008.06.061%26sid%3Dliteratum%253Aachs%26aulast%3DFone%26aufirst%3DK.%2BC.%26atitle%3DAn%2520update%2520on%2520the%2520role%2520of%2520the%25205-HT6%2520receptor%2520in%2520cognitive%2520function%26jtitle%3DNeuropharmacology%26date%3D2008%26volume%3D55%26spage%3D1015%26epage%3D1022%26doi%3D10.1016%2Fj.neuropharm.2008.06.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arnt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang-Andersen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bymaster, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLapp, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giethlen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreilgaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinzie, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neill, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witten, L. M.</span></span> <span> </span><span class="NLM_article-title">Lu AE58054, a 5-HT<sub>6</sub> antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1033</span>, <span class="refDoi"> DOI: 10.1017/S1461145710000659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1017%2FS1461145710000659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=20569520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCksLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=1021-1033&author=J.+Arntauthor=B.+Bang-Andersenauthor=B.+Graysonauthor=F.+P.+Bymasterauthor=M.+P.+Cohenauthor=N.+W.+DeLappauthor=B.+Giethlenauthor=M.+Kreilgaardauthor=D.+L.+McKinzieauthor=J.+C.+Neillauthor=D.+L.+Nelsonauthor=S.+M.+Nielsenauthor=M.+N.+Poulsenauthor=J.+M.+Schausauthor=L.+M.+Witten&title=Lu+AE58054%2C+a+5-HT6+antagonist%2C+reverses+cognitive+impairment+induced+by+subchronic+phencyclidine+in+a+novel+object+recognition+test+in+rats&doi=10.1017%2FS1461145710000659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats</span></div><div class="casAuthors">Arnt, Jorn; Bang-Andersen, Benny; Grayson, Ben; Bymaster, Franklin P.; Cohen, Michael P.; De Lapp, Neil W.; Giethlen, Bruno; Kreilgaard, Mads; McKinzie, David L.; Neill, Joanna C.; Nelson, David L.; Nielsen, Soren M.; Poulsen, Mette N.; Schaus, John M.; Witten, Louise M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1021-1033</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">The in-vitro potency and selectivity, in-vivo binding affinity and effect of the 5-HT6R antagonist Lu AE58054 ([2-(6-fluoro-1H-indol-3-yl)-ethyl]-[3-(2,2,3,3-tetrafluoropropoxy)-benzyl]-amine) on impaired cognition were evaluated.  Lu AE58054 displayed high affinity to the human 5-HT6 receptor (5-HT6R) with a Ki of 0.83 nm.  In a 5-HT6 GTPγS efficacy assay Lu AE58054 showed no agonist activity, but demonstrated potent inhibition of 5-HT-mediated activation.  Besides medium affinity to adrenergic α1A- and α1B-adrenoreceptors, Lu AE58054 demonstrated >50-fold selectivity for more than 70 targets examd.  Orally administered Lu AE58054 potently inhibited striatal in-vivo binding of the 5-HT6 antagonist radioligand [3H]Lu AE60157 ([3H]8-(4-methylpiperazin-1-yl)-3-phenylsulfonylquinoline), with an ED50 of 2.7 mg/kg.  Steady-state modeling of an acute pharmacokinetic/5-HT6R occupancy time-course expt. indicated a plasma EC50 value of 20 ng/mL.  Administration of Lu AE58054 in a dose range (5-20 mg/kg p.o.) leading to above 65% striatal 5-HT6R binding occupancy in vivo, reversed cognitive impairment in a rat novel object recognition task induced after subchronic treatment for 7 d with phencyclidine (PCP 2 mg/kg b.i.d., i.p. for 7 d, followed by 7 d drug free).  The results indicate that Lu AE58054 is a selective antagonist of 5-HT6Rs with good oral bioavailability and robust efficacy in a rat model of cognitive impairment in schizophrenia.  Lu AE58054 may be useful for the pharmacotherapy of cognitive dysfunction in disease states such as schizophrenia and Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk_dkkVdbZyLVg90H21EOLACvtfcHk0liuXIo_rc5Gzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCksLnK&md5=dfe5d1110dbcbc295af9a886635320aa</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1017%2FS1461145710000659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145710000659%26sid%3Dliteratum%253Aachs%26aulast%3DArnt%26aufirst%3DJ.%26aulast%3DBang-Andersen%26aufirst%3DB.%26aulast%3DGrayson%26aufirst%3DB.%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DCohen%26aufirst%3DM.%2BP.%26aulast%3DDeLapp%26aufirst%3DN.%2BW.%26aulast%3DGiethlen%26aufirst%3DB.%26aulast%3DKreilgaard%26aufirst%3DM.%26aulast%3DMcKinzie%26aufirst%3DD.%2BL.%26aulast%3DNeill%26aufirst%3DJ.%2BC.%26aulast%3DNelson%26aufirst%3DD.%2BL.%26aulast%3DNielsen%26aufirst%3DS.%2BM.%26aulast%3DPoulsen%26aufirst%3DM.%2BN.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26aulast%3DWitten%26aufirst%3DL.%2BM.%26atitle%3DLu%2520AE58054%252C%2520a%25205-HT6%2520antagonist%252C%2520reverses%2520cognitive%2520impairment%2520induced%2520by%2520subchronic%2520phencyclidine%2520in%2520a%2520novel%2520object%2520recognition%2520test%2520in%2520rats%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2010%26volume%3D13%26spage%3D1021%26epage%3D1033%26doi%3D10.1017%2FS1461145710000659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bucki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinkowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sniecikowska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieckowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gluch-Lutwin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grybos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pytka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jastrzebska-Wiesek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partyka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesolowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mierzejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolaczkowski, M.</span></span> <span> </span><span class="NLM_article-title">Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1<i>H</i>-indole-based multifunctional ligands with antipsychotic-Like, mood-modulating, and procognitive activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7483</span>– <span class="NLM_lpage">7501</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00839</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00839" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1KrtbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7483-7501&author=A.+Buckiauthor=M.+Marcinkowskaauthor=J.+Sniecikowskaauthor=K.+Wieckowskiauthor=M.+Pawlowskiauthor=M.+Gluch-Lutwinauthor=A.+Grybosauthor=A.+Siwekauthor=K.+Pytkaauthor=M.+Jastrzebska-Wiesekauthor=A.+Partykaauthor=A.+Wesolowskaauthor=P.+Mierzejewskiauthor=M.+Kolaczkowski&title=Novel+3-%281%2C2%2C3%2C6-Tetrahydropyridin-4-yl%29-1H-indole-based+multifunctional+ligands+with+antipsychotic-Like%2C+mood-modulating%2C+and+procognitive+activity&doi=10.1021%2Facs.jmedchem.7b00839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22cR"><div class="casContent"><span class="casTitleNuber">22c</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity</span></div><div class="casAuthors">Bucki, Adam; Marcinkowska, Monika; Sniecikowska, Joanna; Wieckowski, Krzysztof; Pawlowski, Maciej; Gluch-Lutwin, Monika; Grybos, Anna; Siwek, Agata; Pytka, Karolina; Jastrzebska-Wiesek, Magdalena; Partyka, Anna; Wesolowska, Anna; Mierzejewski, Pawel; Kolaczkowski, Marcin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7483-7501</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The most troublesome aspects of behavioral and psychol. symptoms of dementia (BPSD) are nowadays addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label.  Considering their modest effectiveness in dementia patients, the increased risk of adverse events and cognitive decline, there is an unmet need for well-tolerated and effective therapy of BPSD.  We designed and synthesized multifunctional ligands characterized in vitro as high-affinity partial agonists of D2R, antagonists of 5-HT6R, and blockers of SERT.  Moreover, the mols. activated 5-HT1AR and blocked 5-HT7R while having no relevant affinity for off-target M1R and hERG channel.  Compd. I, (N-{2-[4-(5-chloro-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}-3-methylbenzene-1-sulfonamide), exhibited a broad antipsychotic-, antidepressant-, and anxiolytic-like activity, not eliciting motor impairments in mice.  Most importantly, I showed memory-enhancing properties and it ameliorated memory deficits induced by scopolamine.  The mol. outperformed most important comparators in selected tests, indicating its potential in the treatment of both cognitive and noncognitive (behavioral and psychol.) symptoms of dementia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_i47_Akgt17Vg90H21EOLACvtfcHk0liuXIo_rc5Gzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1KrtbbF&md5=9bb21d4918f0c0575aeef817b89b9b19</span></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00839%26sid%3Dliteratum%253Aachs%26aulast%3DBucki%26aufirst%3DA.%26aulast%3DMarcinkowska%26aufirst%3DM.%26aulast%3DSniecikowska%26aufirst%3DJ.%26aulast%3DWieckowski%26aufirst%3DK.%26aulast%3DPawlowski%26aufirst%3DM.%26aulast%3DGluch-Lutwin%26aufirst%3DM.%26aulast%3DGrybos%26aufirst%3DA.%26aulast%3DSiwek%26aufirst%3DA.%26aulast%3DPytka%26aufirst%3DK.%26aulast%3DJastrzebska-Wiesek%26aufirst%3DM.%26aulast%3DPartyka%26aufirst%3DA.%26aulast%3DWesolowska%26aufirst%3DA.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DKolaczkowski%26aufirst%3DM.%26atitle%3DNovel%25203-%25281%252C2%252C3%252C6-Tetrahydropyridin-4-yl%2529-1H-indole-based%2520multifunctional%2520ligands%2520with%2520antipsychotic-Like%252C%2520mood-modulating%252C%2520and%2520procognitive%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7483%26epage%3D7501%26doi%3D10.1021%2Facs.jmedchem.7b00839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casado, V.</span></span> <span> </span><span class="NLM_article-title">Targeting the dopamine D<sub>3</sub> receptor: an overview of drug design strategies</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1185413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1080%2F17460441.2016.1185413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=27135354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFOrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=641-664&author=A.+Cortesauthor=E.+Morenoauthor=M.+Rodriguez-Ruizauthor=E.+I.+Canelaauthor=V.+Casado&title=Targeting+the+dopamine+D3+receptor%3A+an+overview+of+drug+design+strategies&doi=10.1080%2F17460441.2016.1185413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dopamine D3 receptor: an overview of drug design strategies</span></div><div class="casAuthors">Cortes, Antoni; Moreno, Estefania; Rodriguez-Ruiz, Mar; Canela, Enric I.; Casado, Vicent</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">641-664</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter widely distributed in both the periphery and the central nervous system (CNS).  Its physiol. effects are mediated by five closely related G protein-coupled receptors (GPCRs) that are divided into two major subclasses: the D1-like (D1, D5) and the D2-like (D2, D3, D4) receptors.  D3 receptors (D3Rs) have the highest d. in the limbic areas of the brain, which are assocd. with cognitive and emotional functions.  These receptors are therefore attractive targets for therapeutic management.  This review summarizes the functional and pharmacol. characteristics of D3Rs, including the design and clin. relevance of full agonists, partial agonists and antagonists, as well as the capacity of these receptors to form active homodimers, heterodimers or higher order receptor complexes as pharmacol. targets in several neurol. and neurodegenerative disorders.  The high sequence homol. between D3R and the D2-type challenges the development of D3R-selective compds.  The design of new D3R-preferential ligands with improved physicochem. properties should provide a better pharmacokinetic/bioavailability profile and lesser toxicity than is found with existing D3R ligands.  It is also essential to optimize D3R affinity and, esp., D3R vs.  D2-type binding and functional selectivity ratios.  Developing allosteric and bitopic ligands should help to improve the D3R selectivity of these drugs.  As most evidence points to the ability of GPCRs to form homomers and heteromers, the most promising therapeutic strategy in the future is likely to involve the application of heteromer-selective drugs.  These selective ligands would display different affinities for a given receptor depending on the receptor partners within the heteromer.  Therefore, designing novel compds. that specifically target and modulate D1R-D3R heteromers would be an interesting approach for the treatment of levodopa (L-DOPA)-induced dyskinesias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE412vMxQCZ7Vg90H21EOLACvtfcHk0liuXIo_rc5Gzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFOrsL4%253D&md5=eda2d0b52e03bbca2d62f1b27b193360</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1185413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1185413%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DRodriguez-Ruiz%26aufirst%3DM.%26aulast%3DCanela%26aufirst%3DE.%2BI.%26aulast%3DCasado%26aufirst%3DV.%26atitle%3DTargeting%2520the%2520dopamine%2520D3%2520receptor%253A%2520an%2520overview%2520of%2520drug%2520design%2520strategies%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D641%26epage%3D664%26doi%3D10.1080%2F17460441.2016.1185413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryoo, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. N.</span></span> <span> </span><span class="NLM_article-title">Localization of dopamine D<sub>3</sub> receptors to mesolimbic and D<sub>2</sub> receptors to mesostriatal regions of human forebrain</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">11271</span>– <span class="NLM_lpage">11275</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.23.11271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1073%2Fpnas.91.23.11271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=7972046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFems70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=11271-11275&author=A.+M.+Murrayauthor=H.+L.+Ryooauthor=E.+Gurevichauthor=J.+N.+Joyce&title=Localization+of+dopamine+D3+receptors+to+mesolimbic+and+D2+receptors+to+mesostriatal+regions+of+human+forebrain&doi=10.1073%2Fpnas.91.23.11271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24a</span><div class="casTitle"><span class="NLM_cas:atitle">Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain</span></div><div class="casAuthors">Murray, Angela M.; Ryoo, Han L.; Gurevich, Eugenia; Joyce, Jeffrey N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11271-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We characterized the binding of [125I]epidepride to dopamine D2-like and D3-like receptors in tissue sections of human striatum.  The competition for binding of [125I]epidepride by domperidone, quinpirole, and 7-hydroxy-N,N-di(1-propyl)-2-aminotetralin (7-OH-DPAT) was best fit by assuming one site in the caudate but two sites in nucleus accumbens.  Guanosine 5'-[β,γ-imido]triphosphate showed a large modulatory influence in agonist inhibition of [125I]epidepride binding in caudate but not in nucleus accumbens.  The binding of [125I]epidepride in the presence of 7-OH-DPAT (1000-fold selective for D3-like vs. D2-like sites) and domperidone (20-fold selective for D2 vs. D3-like sites) was used to quantify the nos. of D2-like and D3-like receptors in areas of human brain.  The distribution of D2-like and D3-like receptors was largely nonoverlapping.  Binding of [125I]epidepride to D3-like receptors was negligible in the dorsal striatum but was concd. in islands of dense binding in the nucleus accumbens and ventral putamen that aligned with acetylcholinesterase-poor striosomes.  Binding to D3-like receptors was also enriched in the internal globus pallidus, ventral palladium, septum, islands of Calleja, nucleus basalis, amygdalostriatal transition nucleus of the amygdala, central nucleus of the amygdala, and ventral tegmental area.  Binding of [125I]epidepride to D2 but not D3 receptors was detected in cortex and hippocampus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXhwrtC4swVrVg90H21EOLACvtfcHk0lig7xKrsoG4Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFems70%253D&md5=229c93d0b8695eb673e9c7265a1d574f</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.23.11271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.23.11271%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DA.%2BM.%26aulast%3DRyoo%26aufirst%3DH.%2BL.%26aulast%3DGurevich%26aufirst%3DE.%26aulast%3DJoyce%26aufirst%3DJ.%2BN.%26atitle%3DLocalization%2520of%2520dopamine%2520D3%2520receptors%2520to%2520mesolimbic%2520and%2520D2%2520receptors%2520to%2520mesostriatal%2520regions%2520of%2520human%2520forebrain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D11271%26epage%3D11275%26doi%3D10.1073%2Fpnas.91.23.11271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure of the human dopamine D<sub>3</sub> receptor in complex with a D<sub>2</sub>/D<sub>3</sub> selective antagonist</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+W.+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+human+dopamine+D3+receptor+in+complex+with+a+D2%2FD3+selective+antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0lig7xKrsoG4Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520human%2520dopamine%2520D3%2520receptor%2520in%2520complex%2520with%2520a%2520D2%252FD3%2520selective%2520antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordalski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warszycki, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogendorf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojarski, A. J.</span></span> <span> </span><span class="NLM_article-title">Pyrano[2,3,4-cd]indole as a scaffold for selective nonbasic 5-HT<sub>6</sub>R ligands</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00482</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00482" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=390-394&author=J.+Staronauthor=S.+Mordalskiauthor=D.+Warszyckiauthor=G.+Satalaauthor=A.+Hogendorfauthor=A.+J.+Bojarski&title=Pyrano%5B2%2C3%2C4-cd%5Dindole+as+a+scaffold+for+selective+nonbasic+5-HT6R+ligands&doi=10.1021%2Facsmedchemlett.6b00482"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00482%26sid%3Dliteratum%253Aachs%26aulast%3DStaron%26aufirst%3DJ.%26aulast%3DMordalski%26aufirst%3DS.%26aulast%3DWarszycki%26aufirst%3DD.%26aulast%3DSatala%26aufirst%3DG.%26aulast%3DHogendorf%26aufirst%3DA.%26aulast%3DBojarski%26aufirst%3DA.%2BJ.%26atitle%3DPyrano%255B2%252C3%252C4-cd%255Dindole%2520as%2520a%2520scaffold%2520for%2520selective%2520nonbasic%25205-HT6R%2520ligands%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D390%26epage%3D394%26doi%3D10.1021%2Facsmedchemlett.6b00482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. W.</span></span> <span> </span><span class="NLM_article-title">Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-<i>ij</i>]quinolin-4-one derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2307</span>– <span class="NLM_lpage">2319</span>, <span class="refDoi"> DOI: 10.1021/jm101470k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101470k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVChuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2307-2319&author=S.+Lucasauthor=M.+Negriauthor=R.+Heimauthor=C.+Zimmerauthor=R.+W.+Hartmann&title=Fine-tuning+the+selectivity+of+aldosterone+synthase+inhibitors%3A+structure-activity+and+structure-selectivity+insights+from+studies+of+heteroaryl+substituted+1%2C2%2C5%2C6-tetrahydropyrrolo%5B3%2C2%2C1-ij%5Dquinolin-4-one+derivatives&doi=10.1021%2Fjm101470k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Fine-Tuning the Selectivity of Aldosterone Synthase Inhibitors: Structure-Activity and Structure-Selectivity Insights from Studies of Heteroaryl Substituted 1,2,5,6-Tetrahydropyrrolo[3,2,1-ij]quinolin-4-one Derivatives</span></div><div class="casAuthors">Lucas, Simon; Negri, Matthias; Heim, Ralf; Zimmer, Christina; Hartmann, Rolf W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2307-2319</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyridine substituted 3,4-dihydro-1H-quinolin-2-ones (e.g., 1-3) constitute a class of highly potent and selective inhibitors of aldosterone synthase (CYP11B2), a promising target for the treatment of hyperaldosteronism, congestive heart failure, and myocardial fibrosis.  Among these, ethyl-substituted 3 possesses high selectivity against CYP1A2.  Rigidification of 3 by incorporation of the Et group into a 5- or 6-membered ring affords compds. with a pyrroloquinolinone or pyridoquinolinone mol. scaffold (e.g., 4 and 5).  It was found that these mols. are even more potent and selective CYP11B2 inhibitors than their corresponding open-chain analogs.  Moreover, pyrroloquinolinone 4 exhibits no inhibition of the six most important hepatic CYP enzymes as well as a bioavailability in the range of the marketed drug fadrozole.  The SAR studies disclose that subtle changes in the heterocyclic moiety are responsible for either a strong or a weak inhibition of the highly homologous 11β-hydroxylase (CYP11B1).  These results are not only important for fine-tuning the selectivity of CYP11B2 inhibitors but also for the development of selective CYP11B1 inhibitors that are of interest for the treatment of Cushing's syndrome and metabolic syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobbs5KsMMQUrVg90H21EOLACvtfcHk0lhnR750CTrcdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVChuro%253D&md5=8c1515e12a059bf5fb125b75d419e1ca</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Fjm101470k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101470k%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DS.%26aulast%3DNegri%26aufirst%3DM.%26aulast%3DHeim%26aufirst%3DR.%26aulast%3DZimmer%26aufirst%3DC.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DFine-tuning%2520the%2520selectivity%2520of%2520aldosterone%2520synthase%2520inhibitors%253A%2520structure-activity%2520and%2520structure-selectivity%2520insights%2520from%2520studies%2520of%2520heteroaryl%2520substituted%25201%252C2%252C5%252C6-tetrahydropyrrolo%255B3%252C2%252C1-ij%255Dquinolin-4-one%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2307%26epage%3D2319%26doi%3D10.1021%2Fjm101470k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmaier, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. W.</span></span> <span> </span><span class="NLM_article-title">Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydro pyrrolo[3,2,1-<i>ij</i>]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing’s syndrome</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6629</span>– <span class="NLM_lpage">6633</span>, <span class="refDoi"> DOI: 10.1021/jm3003872</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003872" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6629-6633&author=L.+Yinauthor=S.+Lucasauthor=F.+Maurerauthor=U.+Kazmaierauthor=Q.+Huauthor=R.+W.+Hartmann&title=Novel+imidazol-1-ylmethyl+substituted+1%2C2%2C5%2C6-tetrahydro+pyrrolo%5B3%2C2%2C1-ij%5Dquinolin-4-ones+as+potent+and+selective+CYP11B1+inhibitors+for+the+treatment+of+Cushing%E2%80%99s+syndrome&doi=10.1021%2Fjm3003872"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1021%2Fjm3003872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003872%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DF.%26aulast%3DKazmaier%26aufirst%3DU.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26atitle%3DNovel%2520imidazol-1-ylmethyl%2520substituted%25201%252C2%252C5%252C6-tetrahydro%2520pyrrolo%255B3%252C2%252C1-ij%255Dquinolin-4-ones%2520as%2520potent%2520and%2520selective%2520CYP11B1%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Cushing%25E2%2580%2599s%2520syndrome%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6629%26epage%3D6633%26doi%3D10.1021%2Fjm3003872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, A. K.</span>; <span class="NLM_string-name">Cho, S. S. Y.</span>; <span class="NLM_string-name">Graham, J. M.</span>; <span class="NLM_string-name">Nikam, S. S.</span></span> <span> </span><span class="NLM_article-title">Fused tricycle heterocycles for the treatment of schizophrenia</span>. WO Patent <span class="NLM_patent">WO 2008015516 A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=A.+K.+Awasthi&author=S.+S.+Y.+Cho&author=J.+M.+Graham&author=S.+S.+Nikam&title=Fused+tricycle+heterocycles+for+the+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAwasthi%26aufirst%3DA.%2BK.%26atitle%3DFused%2520tricycle%2520heterocycles%2520for%2520the%2520treatment%2520of%2520schizophrenia%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D<sub>2</sub> receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4924</span>– <span class="NLM_lpage">4939</span>, <span class="refDoi"> DOI: 10.1021/jm500457x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500457x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVans70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4924-4939&author=M.+Szaboauthor=C.+Klein+Herenbrinkauthor=A.+Christopoulosauthor=J.+R.+Laneauthor=B.+Capuano&title=Structure-activity+relationships+of+privileged+structures+lead+to+the+discovery+of+novel+biased+ligands+at+the+dopamine+D2+receptor&doi=10.1021%2Fjm500457x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships of Privileged Structures Lead to the Discovery of Novel Biased Ligands at the Dopamine D2 Receptor</span></div><div class="casAuthors">Szabo, Monika; Klein Herenbrink, Carmen; Christopoulos, Arthur; Lane, J. Robert; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4924-4939</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biased agonism at GPCRs highlights the potential for the discovery and design of pathway-selective ligands and may confer therapeutic advantages to ligands targeting the dopamine D2 receptor (D2R).  We investigated the determinants of efficacy, affinity, and bias for three privileged structures for the D2R, exploring changes to linker length and incorporation of a heterocyclic unit.  Profiling the compds. in two signaling assays (cAMP and pERK1/2) allowed us to identify and quantify determinants of biased agonism at the D2R.  Substitution on the phenylpiperazine privileged structures (2-methoxy vs 2,3-dichloro) influenced bias when the thienopyridine heterocycle was absent.  Upon inclusion of the thienopyridine unit, the substitution pattern (4,6-di-Me vs 5-chloro-6-methoxy-4-methyl) had a significant effect on bias that overruled the effect of the phenylpiperazine substitution pattern.  This latter observation could be reconciled with an extended binding mode for these compds., whereby the interaction of the heterocycle with a secondary binding pocket may engender bias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvED1_D7mzdLVg90H21EOLACvtfcHk0lhnR750CTrcdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVans70%253D&md5=944e53ea2b1abf220e4c76a7d33d6f15</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1021%2Fjm500457x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500457x%26sid%3Dliteratum%253Aachs%26aulast%3DSzabo%26aufirst%3DM.%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DStructure-activity%2520relationships%2520of%2520privileged%2520structures%2520lead%2520to%2520the%2520discovery%2520of%2520novel%2520biased%2520ligands%2520at%2520the%2520dopamine%2520D2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4924%26epage%3D4939%26doi%3D10.1021%2Fjm500457x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4671</span>– <span class="NLM_lpage">4690</span>, <span class="refDoi"> DOI: 10.1021/jm400408r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400408r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslWmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4671-4690&author=Y.+Chenauthor=S.+Wangauthor=X.+Xuauthor=X.+Liuauthor=M.+Yuauthor=S.+Zhaoauthor=S.+Liuauthor=Y.+Qiuauthor=T.+Zhangauthor=B.+F.+Liuauthor=G.+Zhang&title=Synthesis+and+biological+investigation+of+coumarin+piperazine+%28piperidine%29+derivatives+as+potential+multireceptor+atypical+antipsychotics&doi=10.1021%2Fjm400408r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Investigation of Coumarin Piperazine (Piperidine) Derivatives as Potential Multireceptor Atypical Antipsychotics</span></div><div class="casAuthors">Chen, Yin; Wang, Songlin; Xu, Xiangqing; Liu, Xin; Yu, Minquan; Zhao, Song; Liu, Shicheng; Qiu, Yinli; Zhang, Tan; Liu, Bi-Feng; Zhang, Guisen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4671-4690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and synthesis of potential and novel antipsychotic coumarin derivs., assocd. with potent dopamine D2, D3, and serotonin 5-HT1A and 5-HT2A receptor properties, are the focus of the present article.  The most-promising deriv. was 7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl)butoxy)-4-methyl-8-chloro-2H-chromen-2-one (I).  This deriv. possesses unique pharmacol. features, including high affinity for dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors.  Moreover, it possesses low affinity for 5-HT2C and H1 receptors (to reduce the risk of obesity assocd. with chronic treatment) and hERG channels (to reduce the incidence of torsade de pointes).  In animal models, compd. I inhibited apomorphine-induced climbing behavior, MK-801-induced hyperactivity, and the conditioned avoidance response without observable catalepsy at the highest dose tested.  Further, fewer preclin. adverse events were noted with I compared with risperidone in assays that measured prolactin secretion and wt. gain.  Acceptable pharmacokinetic properties were also noted with I.  Taken together, I may constitute a novel class of drugs for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoByJHAgVuYCLVg90H21EOLACvtfcHk0lhnR750CTrcdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslWmtbw%253D&md5=5862884cd1ca8f74276d266757689334</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1021%2Fjm400408r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400408r%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520investigation%2520of%2520coumarin%2520piperazine%2520%2528piperidine%2529%2520derivatives%2520as%2520potential%2520multireceptor%2520atypical%2520antipsychotics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4671%26epage%3D4690%26doi%3D10.1021%2Fjm400408r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit28c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of new 6-hydroxypyridazinone benzisoxazoles: Potential multi-receptor-targeting atypical antipsychotics</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">728</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.ejmech.2016.09.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=713-728&author=X.+Caoauthor=Y.+Chenauthor=Y.+Zhangauthor=Y.+Qiuauthor=M.+Yuauthor=X.+Xuauthor=X.+Liuauthor=B.+F.+Liuauthor=G.+Zhang&title=Synthesis+and+biological+evaluation+of+new+6-hydroxypyridazinone+benzisoxazoles%3A+Potential+multi-receptor-targeting+atypical+antipsychotics&doi=10.1016%2Fj.ejmech.2016.09.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28c&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520new%25206-hydroxypyridazinone%2520benzisoxazoles%253A%2520Potential%2520multi-receptor-targeting%2520atypical%2520antipsychotics%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D124%26spage%3D713%26epage%3D728%26doi%3D10.1016%2Fj.ejmech.2016.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span> <span> </span><span class="NLM_article-title">Proof of concept study for designed multiple ligands targeting the dopamine D<sub>2</sub>, serotonin 5-HT<sub>2A</sub>, and muscarinic M<sub>1</sub> acetylcholine receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1550</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1021/jm5013243</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5013243" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVygug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1550-1555&author=M.+Szaboauthor=H.+D.+Limauthor=C.+Klein+Herenbrinkauthor=A.+Christopoulosauthor=J.+R.+Laneauthor=B.+Capuano&title=Proof+of+concept+study+for+designed+multiple+ligands+targeting+the+dopamine+D2%2C+serotonin+5-HT2A%2C+and+muscarinic+M1+acetylcholine+receptors&doi=10.1021%2Fjm5013243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Proof of Concept Study for Designed Multiple Ligands Targeting the Dopamine D2, Serotonin 5-HT2A, and Muscarinic M1 Acetylcholine Receptors</span></div><div class="casAuthors">Szabo, Monika; Lim, Herman D.; Klein Herenbrink, Carmen; Christopoulos, Arthur; Lane, J. Robert; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1550-1555</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors describe the hybridization of a benzoxazinone M1 scaffold with D2 privileged structures derived from putative and clin. relevant antipsychotics to develop designed multiple ligands.  The M1 mAChR is an attractive target for the cognitive deficits in key CNS disorders.  Moreover, activity at D2 and 5-HT2A receptors has proven useful for antipsychotic efficacy.  The authors identified 9 which retained functional activity at the target M1 mAChR and D2R and demonstrated high affinity for the 5-HT2AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJqxxyfgdbsbVg90H21EOLACvtfcHk0li_KjrDwb7UbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVygug%253D%253D&md5=9aebec84dcc8ce782a4ef4d53cf773e0</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm5013243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5013243%26sid%3Dliteratum%253Aachs%26aulast%3DSzabo%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DH.%2BD.%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DProof%2520of%2520concept%2520study%2520for%2520designed%2520multiple%2520ligands%2520targeting%2520the%2520dopamine%2520D2%252C%2520serotonin%25205-HT2A%252C%2520and%2520muscarinic%2520M1%2520acetylcholine%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1550%26epage%3D1555%26doi%3D10.1021%2Fjm5013243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uto, Y.</span></span> <span> </span><span class="NLM_article-title">1,2-Benzisoxazole compounds: a patent review (2009 - 2014)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1517/13543776.2015.1027192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1517%2F13543776.2015.1027192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=25800253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVKitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=643-662&author=Y.+Uto&title=1%2C2-Benzisoxazole+compounds%3A+a+patent+review+%282009+-+2014%29&doi=10.1517%2F13543776.2015.1027192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">1,2-Benzisoxazole compounds: a patent review (2009 - 2014)</span></div><div class="casAuthors">Uto, Yoshikazu</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">643-662</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Benzisoxazoles represent a class of heterocyclic compds. of great importance for the prepn. of biol. active compds.  Benzisoxazoles are an important structure and some benzisoxazole-based medicines have been approved for human clin. use, including atypical antipsychotics (risperidone, paliperidone and iloperidone) and an anticonvulsant (zonisamide).  Areas covered: This review puts emphasis on the recent progress in therapeutically attractive benzisoxazole derivs. esp. 1,2-benzisoxazoles, which were published in the patent literature between 2009 and 2014.  As for the class of medicines, the main focus is on atypical antipsychotics and potential therapeutic treatments for other CNS disorders.  This review also covers the examples of benzisoxazole-based kinase inhibitors.  Moreover, novel benzisoxazoles with significant therapeutic interest are also mentioned.  Expert opinion: More recent examples of structural modification of existing drugs led to the discovery of some promising benzisoxazoles for antipsychotic use.  The design of multi-target ligands is important for the manipulation of pharmacol. properties and safety profiles for the use of antipsychotics.  Benzisoxazoles have been widely used as pharmacophores in the search for novel drug candidates in a variety of therapeutic area.  It is fair to assume that the wide and frequent use of benzisoxazoles in drug discovery and development will continue into the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX3RQJQGkOeLVg90H21EOLACvtfcHk0li_KjrDwb7UbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVKitLY%253D&md5=26cb45757932db9ebb537b205cb66914</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1517%2F13543776.2015.1027192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2015.1027192%26sid%3Dliteratum%253Aachs%26aulast%3DUto%26aufirst%3DY.%26atitle%3D1%252C2-Benzisoxazole%2520compounds%253A%2520a%2520patent%2520review%2520%25282009%2520-%25202014%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2015%26volume%3D25%26spage%3D643%26epage%3D662%26doi%3D10.1517%2F13543776.2015.1027192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H. Y.</span></span> <span> </span><span class="NLM_article-title">Update on typical and atypical antipsychotic drugs</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-050911-161504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1146%2Fannurev-med-050911-161504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=23020880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFKltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=393-406&author=H.+Y.+Meltzer&title=Update+on+typical+and+atypical+antipsychotic+drugs&doi=10.1146%2Fannurev-med-050911-161504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Update on typical and atypical antipsychotic drugs</span></div><div class="casAuthors">Meltzer, Herbert Y.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">393-406</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Antipsychotic drugs (APDs) are best classified as typical or atypical.  The distinction is based solely on their ability to cause extrapyramidal side effects (EPS), including tardive dyskinesia (TD).  The two classes differ in mechanism of action, with atypical APDs providing important modulation of serotonergic neurotransmission.  TD increases the death rate and can be minimized by limiting use of typical APDs.  Clozapine is unique among the atypical APDs in its efficacy for ameliorating psychosis in patients with treatment-resistant schizophrenia (TRS), for redn. of suicide, and for improving longevity.  The typical and atypical APDs do not differ in improving psychopathol. in non-TRS.  The atypicals vary in metabolic side effects: some have little burden.  Cognitive benefits of the atypical APDs may be superior for some domains of cognition and require less use of anticholinergic drugs, which impair memory, for treatment of EPS.  Overall, choosing among the atypical APDs as first-line treatment represents the best course for schizophrenia and most likely other disorders for which APDs are used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK6NegaTYH_7Vg90H21EOLACvtfcHk0li_KjrDwb7UbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFKltL8%253D&md5=cb4d64f893e34f0cf66b92ba97723081</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-050911-161504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-050911-161504%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DUpdate%2520on%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2013%26volume%3D64%26spage%3D393%26epage%3D406%26doi%3D10.1146%2Fannurev-med-050911-161504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newcomer, J. W.</span></span> <span> </span><span class="NLM_article-title">Metabolic considerations in the use of antipsychotic medications: a review of recent evidence</span>. <i>J. Clin. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">27</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=17286524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislWks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2007&pages=20-27&author=J.+W.+Newcomer&title=Metabolic+considerations+in+the+use+of+antipsychotic+medications%3A+a+review+of+recent+evidence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic considerations in the use of antipsychotic medications: a review of recent evidence</span></div><div class="casAuthors">Newcomer, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry (Memphis, TN, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">20-27</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press, Inc.</span>)
        </div><div class="casAbstract">A review.  Compared with the general population, persons with schizophrenia have up to a 20% shorter lifespan, with cardiovascular disease as the leading cause of death.  In addn., persons with schizophrenia have increased prevalence of the metabolic syndrome (obesity, insulin resistance, dyslipidemia, impaired glucose tolerance, and hypertension), increased prevalence of risk factors such as smoking, poverty, and poor nutrition, and reduced access to medical care.  Results from the recent Clin. Antipsychotic Trials of Intervention Effectiveness (CATIE) provide further evidence of the metabolic risk assocd. with different atypical antipsychotics.  Based on this study and a growing no. of other randomized clin. trials, clozapine and olanzapine treatment can produce substantial mean changes in wt. and an increased risk of assocd. metabolic disturbances.  Risperidone and quetiapine treatment can produce intermediate changes in mean wt. in comparison to treatment with other atypical antipsychotics, with discrepant results with respect to metabolic risk.  Aripiprazole and ziprasidone treatment induced the lowest mean changes in wt. gain and had no effect on risk for adverse metabolic changes, among currently available atypical agents.  Considerable evidence indicates that mentally ill patients often do not receive adequate recognition of, monitoring of, or care for their medical illnesses.  There is a crit. need for psychiatrists and primary care professionals to increase awareness of and attention to the phys. health problems of persons with mental illness, including appropriate management of metabolic adverse events assocd. with psychiatric medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsY5iWytM627Vg90H21EOLACvtfcHk0ljfXlXppXBbgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislWks7s%253D&md5=e64a954d4fb7e0eea1599393bc61112f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNewcomer%26aufirst%3DJ.%2BW.%26atitle%3DMetabolic%2520considerations%2520in%2520the%2520use%2520of%2520antipsychotic%2520medications%253A%2520a%2520review%2520of%2520recent%2520evidence%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2007%26volume%3D68%26spage%3D20%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vohora, D.</span></span> <span> </span><span class="NLM_article-title">Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia</span>. <i>Curr. Opin. Investig. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">538</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=531-538&author=D.+Vohora&title=Atypical+antipsychotic+drugs%3A+current+issues+of+safety+and+efficacy+in+the+management+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVohora%26aufirst%3DD.%26atitle%3DAtypical%2520antipsychotic%2520drugs%253A%2520current%2520issues%2520of%2520safety%2520and%2520efficacy%2520in%2520the%2520management%2520of%2520schizophrenia%26jtitle%3DCurr.%2520Opin.%2520Investig.%2520Drugs%26date%3D2007%26volume%3D8%26spage%3D531%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, C. G.</span></span> <span> </span><span class="NLM_article-title">Schizophrenia: a review</span>. <i>Am. Fam. Physician</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1821</span>– <span class="NLM_lpage">1829</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=17619525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BD2svgt1Wrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2007&pages=1821-1829&author=S.+H.+Schultzauthor=S.+W.+Northauthor=C.+G.+Shields&title=Schizophrenia%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia: a review</span></div><div class="casAuthors">Schultz Stephen H; North Stephen W; Shields Cleveland G</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1821-9</span>
        ISSN:<span class="NLM_cas:issn">0002-838X</span>.
    </div><div class="casAbstract">Schizophrenia is a debilitating mental illness that affects 1 percent of the population in all cultures.  It affects equal numbers of men and women, but the onset is often later in women than in men.  Schizophrenia is characterized by positive and negative symptoms.  Positive symptoms include hallucinations, voices that converse with or about the patient, and delusions that are often paranoid.  Negative symptoms include flattened affect, loss of a sense of pleasure, loss of will or drive, and social withdrawal.  Both types of symptoms affect patients' families; therefore, it is important for physicians to provide guidance to all persons affected by the disease.  Psychosocial and family interventions can improve outcomes.  Medications can control symptoms, but virtually all antipsychotics have neurologic or physical side effects (e.g., weight gain, hypercholesterolemia, diabetes).  There is a 10 percent lifetime risk of suicide in patients with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSsiLzV1XkxGMjl5L8hwNX0fW6udTcc2ebPzDMB9_BGFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svgt1Wrug%253D%253D&md5=f1bff146f01c38a5a1c819966d2e2434</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchultz%26aufirst%3DS.%2BH.%26aulast%3DNorth%26aufirst%3DS.%2BW.%26aulast%3DShields%26aufirst%3DC.%2BG.%26atitle%3DSchizophrenia%253A%2520a%2520review%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2007%26volume%3D75%26spage%3D1821%26epage%3D1829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit33c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Leucht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komossa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rummel-Kluge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corves, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asenjo Lobos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. M.</span></span> <span> </span><span class="NLM_article-title">A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.2008.08030368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1176%2Fappi.ajp.2008.08030368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19015230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BD1M7ht1yktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2009&pages=152-163&author=S.+Leuchtauthor=K.+Komossaauthor=C.+Rummel-Klugeauthor=C.+Corvesauthor=H.+Hungerauthor=F.+Schmidauthor=C.+Asenjo+Lobosauthor=S.+Schwarzauthor=J.+M.+Davis&title=A+meta-analysis+of+head-to-head+comparisons+of+second-generation+antipsychotics+in+the+treatment+of+schizophrenia&doi=10.1176%2Fappi.ajp.2008.08030368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33cR"><div class="casContent"><span class="casTitleNuber">33c</span><div class="casTitle"><span class="NLM_cas:atitle">A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia</span></div><div class="casAuthors">Leucht Stefan; Komossa Katja; Rummel-Kluge Christine; Corves Caroline; Hunger Heike; Schmid Franziska; Asenjo Lobos Claudia; Schwarz Sandra; Davis John M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Whether there are differences in efficacy among second-generation antipsychotics in the treatment of schizophrenia is a matter of heated debate.  The authors conducted a systematic review and meta-analysis of blinded studies comparing second-generation antipsychotics head-to-head.  METHOD:  Searches of the Cochrane Schizophrenia Group's register (May 2007) and MEDLINE (September 2007) were conducted for randomized, blinded studies comparing two or more of nine second-generation antipsychotics in the treatment of schizophrenia.  All data were extracted by at least three reviewers independently.  The primary outcome measure was change in total score on the Positive and Negative Syndrome Scale; secondary outcome measures were positive and negative symptom subscores and rate of dropout due to inefficacy.  The results were combined in a meta-analysis.  Various sensitivity analyses and metaregressions were used to examine bias.  RESULTS:  The analysis included 78 studies with 167 relevant arms and 13,558 participants.  Olanzapine proved superior to aripiprazole, quetiapine, risperidone, and ziprasidone.  Risperidone was more efficacious than quetiapine and ziprasidone.  Clozapine proved superior to zotepine and, in doses >400 mg/day, to risperidone.  These differences were due to improvement in positive symptoms rather than negative symptoms.  The results were rather robust with regard to the effects of industry sponsorship, study quality, dosages, and trial duration.  CONCLUSIONS:  The findings suggest that some second-generation antipsychotics may be somewhat more efficacious than others, but the limitations of meta-analysis must be considered.  In tailoring drug treatment to the individual patient, small efficacy superiorities must be weighed against large differences in side effects and cost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyN-UZrbWZdWBAiYWy6n3SfW6udTcc2ebPzDMB9_BGFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7ht1yktA%253D%253D&md5=323f4fe01e2e21fd261043307f734607</span></div><a href="/servlet/linkout?suffix=cit33c&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2008.08030368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2008.08030368%26sid%3Dliteratum%253Aachs%26aulast%3DLeucht%26aufirst%3DS.%26aulast%3DKomossa%26aufirst%3DK.%26aulast%3DRummel-Kluge%26aufirst%3DC.%26aulast%3DCorves%26aufirst%3DC.%26aulast%3DHunger%26aufirst%3DH.%26aulast%3DSchmid%26aufirst%3DF.%26aulast%3DAsenjo%2BLobos%26aufirst%3DC.%26aulast%3DSchwarz%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26atitle%3DA%2520meta-analysis%2520of%2520head-to-head%2520comparisons%2520of%2520second-generation%2520antipsychotics%2520in%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2009%26volume%3D166%26spage%3D152%26epage%3D163%26doi%3D10.1176%2Fappi.ajp.2008.08030368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snowman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teuscher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, S. H.</span></span> <span> </span><span class="NLM_article-title">From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H<sub>1</sub> receptor-linked activation of hypothalamic AMP-kinase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">3456</span>– <span class="NLM_lpage">3459</span>, <span class="refDoi"> DOI: 10.1073/pnas.0611417104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1073%2Fpnas.0611417104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=3456-3459&author=S.+F.+Kimauthor=A.+S.+Huangauthor=A.+M.+Snowmanauthor=C.+Teuscherauthor=S.+H.+Snyder&title=From+the+Cover%3A+Antipsychotic+drug-induced+weight+gain+mediated+by+histamine+H1+receptor-linked+activation+of+hypothalamic+AMP-kinase&doi=10.1073%2Fpnas.0611417104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0611417104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0611417104%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BF.%26aulast%3DHuang%26aufirst%3DA.%2BS.%26aulast%3DSnowman%26aufirst%3DA.%2BM.%26aulast%3DTeuscher%26aufirst%3DC.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DFrom%2520the%2520Cover%253A%2520Antipsychotic%2520drug-induced%2520weight%2520gain%2520mediated%2520by%2520histamine%2520H1%2520receptor-linked%2520activation%2520of%2520hypothalamic%2520AMP-kinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D3456%26epage%3D3459%26doi%3D10.1073%2Fpnas.0611417104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poluzzi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, F.</span></span> <span> </span><span class="NLM_article-title">QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1002/med.20019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1002%2Fmed.20019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=15389727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlWhs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=133-166&author=M.+Recanatiniauthor=E.+Poluzziauthor=M.+Masettiauthor=A.+Cavalliauthor=F.+De+Ponti&title=QT+prolongation+through+hERG+K%28%2B%29+channel+blockade%3A+current+knowledge+and+strategies+for+the+early+prediction+during+drug+development&doi=10.1002%2Fmed.20019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35aR"><div class="casContent"><span class="casTitleNuber">35a</span><div class="casTitle"><span class="NLM_cas:atitle">QT prolongation through hERG K+ channel blockade: current knowledge and strategies for the early prediction during drug development</span></div><div class="casAuthors">Recanatini, Maurizio; Poluzzi, Elisabetta; Masetti, Matteo; Cavalli, Andrea; de Ponti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-166</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Prolongation of the QT interval of the ECG is a typical effect of Class III antiarrhythmic drugs, achieved through blockade of potassium channels.  In the past decade, evidence has accrued that several classes of drugs used for non-cardiovascular indications may prolong the QT interval with the same mechanism (namely, human ether-a-go-go-related gene (hERG) K+ channel blockade).  The great interest in QT prolongation is because of several reasons.  First, drug-induced QT prolongation increases the likelihood of a polymorphous ventricular arrhythmia (namely, torsades de pointes, TdP), which may cause syncope and degenerate into ventricular fibrillation and sudden death.  Second, the fact that several classes of drugs, such as antihistamines, fluoroquinolones, macrolides, and neuroleptics may cause the long QT syndrome (LQTS) raises the question whether this is a class effect (e.g., shared by all agents of a given pharmacol. class) or a specific effect of single agents within a class.  There is now consensus that, in most cases, only a few agents within a therapeutic class share the ability to significantly affect hERG K+ channels.  These compds. should be identified as early as possible during drug development.  Third, QT prolongation and interaction with hERG K+ channels have become surrogate markers of cardiotoxicity and have received increasing regulatory attention.  This review briefly outlines the mechanisms leading to QT prolongation and the different strategies that can be followed to predict this unwanted effect.  In particular, it will focus on the approaches recently proposed for the in silico screening of new compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO7B-6DBAFeLVg90H21EOLACvtfcHk0lhFSNDblTdYiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlWhs7Y%253D&md5=aa5aea37c667b4f35546259cc2593c6d</span></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.1002%2Fmed.20019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20019%26sid%3Dliteratum%253Aachs%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DMasetti%26aufirst%3DM.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26atitle%3DQT%2520prolongation%2520through%2520hERG%2520K%2528%252B%2529%2520channel%2520blockade%253A%2520current%2520knowledge%2520and%2520strategies%2520for%2520the%2520early%2520prediction%2520during%2520drug%2520development%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2005%26volume%3D25%26spage%3D133%26epage%3D166%26doi%3D10.1002%2Fmed.20019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit35b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Raschi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceccarini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span> <span> </span><span class="NLM_article-title">hERG-related drug toxicity and models for predicting hERG liability and QT prolongation</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1021</span>, <span class="refDoi"> DOI: 10.1517/17425250903055070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1517%2F17425250903055070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19572824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWhsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=1005-1021&author=E.+Raschiauthor=L.+Ceccariniauthor=F.+De+Pontiauthor=M.+Recanatini&title=hERG-related+drug+toxicity+and+models+for+predicting+hERG+liability+and+QT+prolongation&doi=10.1517%2F17425250903055070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35bR"><div class="casContent"><span class="casTitleNuber">35b</span><div class="casTitle"><span class="NLM_cas:atitle">hERG-related drug toxicity and models for predicting hERG liability and QT prolongation</span></div><div class="casAuthors">Raschi, Emanuel; Ceccarini, Luisa; De Ponti, Fabrizio; Recanatini, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1005-1021</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: hERG K+ channels have been recognized as a primary antitarget in safety pharmacol.  Their blockade, caused by several drugs with different therapeutic indications, may lead to QT prolongation and, eventually, to potentially fatal arrhythmia, namely torsade de pointes.  Therefore, a no. of preclin. models have been developed to predict hERG liability early in the drug development process.  Objective: The aim of this review is to outline the present state of the art on drug-induced hERG blockade, providing insights on the predictive value of in vitro and in silico models for hERG liability.  Methods: On the basis of latest reports, high-throughput preclin. models have been discussed outlining advantages and limitations.  Conclusion: Although no single model has an abs. value, an integrated risk assessment is recommended to predict the pro-arrhythmic risk of a given drug.  This prediction requires expertise from different areas and should encompass emerging issues such as interference with hERG trafficking and QT shortening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCQa-hX-BiQ7Vg90H21EOLACvtfcHk0lhFSNDblTdYiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWhsLnK&md5=93e148db825611c7e086f75e50b8953c</span></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1517%2F17425250903055070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250903055070%26sid%3Dliteratum%253Aachs%26aulast%3DRaschi%26aufirst%3DE.%26aulast%3DCeccarini%26aufirst%3DL.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26aulast%3DRecanatini%26aufirst%3DM.%26atitle%3DhERG-related%2520drug%2520toxicity%2520and%2520models%2520for%2520predicting%2520hERG%2520liability%2520and%2520QT%2520prolongation%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D1005%26epage%3D1021%26doi%3D10.1517%2F17425250903055070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mannel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Hydroxy-Substituted heteroarylpiperazines: novel scaffolds for beta-arrestin-biased D<sub>2</sub>R agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4693</span>– <span class="NLM_lpage">4713</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00363</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00363" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4693-4713&author=B.+Mannelauthor=D.+Denglerauthor=J.+Shonbergauthor=H.+Hubnerauthor=D.+M%C3%B6llerauthor=P.+Gmeiner&title=Hydroxy-Substituted+heteroarylpiperazines%3A+novel+scaffolds+for+beta-arrestin-biased+D2R+agonists&doi=10.1021%2Facs.jmedchem.7b00363"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00363%26sid%3Dliteratum%253Aachs%26aulast%3DMannel%26aufirst%3DB.%26aulast%3DDengler%26aufirst%3DD.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DHubner%26aufirst%3DH.%26aulast%3DM%25C3%25B6ller%26aufirst%3DD.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DHydroxy-Substituted%2520heteroarylpiperazines%253A%2520novel%2520scaffolds%2520for%2520beta-arrestin-biased%2520D2R%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4693%26epage%3D4713%26doi%3D10.1021%2Facs.jmedchem.7b00363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattorusso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalanotti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagnotto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mereghetti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennini, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Cesare, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastroianni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scafetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galletti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castorina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacifici, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vertechy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Serio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghirardi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carminati, P.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1021/jm0309811</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0309811" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=143-157&author=G.+Campianiauthor=S.+Butiniauthor=C.+Fattorussoauthor=B.+Catalanottiauthor=S.+Gemmaauthor=V.+Nacciauthor=E.+Morelliauthor=A.+Cagnottoauthor=I.+Mereghettiauthor=T.+Menniniauthor=M.+Carliauthor=P.+Minettiauthor=M.+A.+Di+Cesareauthor=D.+Mastroianniauthor=N.+Scafettaauthor=B.+Gallettiauthor=M.+A.+Stasiauthor=M.+Castorinaauthor=L.+Pacificiauthor=M.+Vertechyauthor=S.+Di+Serioauthor=O.+Ghirardiauthor=O.+Tintiauthor=P.+Carminati&title=Pyrrolo%5B1%2C3%5Dbenzothiazepine-based+serotonin+and+dopamine+receptor+antagonists.+Molecular+modeling%2C+further+structure-activity+relationship+studies%2C+and+identification+of+novel+atypical+antipsychotic+agents&doi=10.1021%2Fjm0309811"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm0309811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0309811%26sid%3Dliteratum%253Aachs%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DFattorusso%26aufirst%3DC.%26aulast%3DCatalanotti%26aufirst%3DB.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DNacci%26aufirst%3DV.%26aulast%3DMorelli%26aufirst%3DE.%26aulast%3DCagnotto%26aufirst%3DA.%26aulast%3DMereghetti%26aufirst%3DI.%26aulast%3DMennini%26aufirst%3DT.%26aulast%3DCarli%26aufirst%3DM.%26aulast%3DMinetti%26aufirst%3DP.%26aulast%3DDi%2BCesare%26aufirst%3DM.%2BA.%26aulast%3DMastroianni%26aufirst%3DD.%26aulast%3DScafetta%26aufirst%3DN.%26aulast%3DGalletti%26aufirst%3DB.%26aulast%3DStasi%26aufirst%3DM.%2BA.%26aulast%3DCastorina%26aufirst%3DM.%26aulast%3DPacifici%26aufirst%3DL.%26aulast%3DVertechy%26aufirst%3DM.%26aulast%3DDi%2BSerio%26aufirst%3DS.%26aulast%3DGhirardi%26aufirst%3DO.%26aulast%3DTinti%26aufirst%3DO.%26aulast%3DCarminati%26aufirst%3DP.%26atitle%3DPyrrolo%255B1%252C3%255Dbenzothiazepine-based%2520serotonin%2520and%2520dopamine%2520receptor%2520antagonists.%2520Molecular%2520modeling%252C%2520further%2520structure-activity%2520relationship%2520studies%252C%2520and%2520identification%2520of%2520novel%2520atypical%2520antipsychotic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D143%26epage%3D157%26doi%3D10.1021%2Fjm0309811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, Y.</span></span> <span> </span><span class="NLM_article-title">Therapeutic role of 5-HT<sub>1A</sub> receptors in the treatment of schizophrenia and Parkinson’s disease</span>. <i>CNS Neurosci. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1111/j.1755-5949.2010.00211.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1111%2Fj.1755-5949.2010.00211.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=21091640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVCnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=58-65&author=Y.+Ohno&title=Therapeutic+role+of+5-HT1A+receptors+in+the+treatment+of+schizophrenia+and+Parkinson%E2%80%99s+disease&doi=10.1111%2Fj.1755-5949.2010.00211.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38aR"><div class="casContent"><span class="casTitleNuber">38a</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease</span></div><div class="casAuthors">Ohno, Yukihiro</div><div class="citationInfo"><span class="NLM_cas:title">CNS Neuroscience & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-65</span>CODEN:
                <span class="NLM_cas:coden">CNTNAB</span>;
        ISSN:<span class="NLM_cas:issn">1755-5930</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  5-HT1A receptors have long been implicated in the pathogenesis and treatment of anxiety and depressive disorders.  Recently, several lines of studies have revealed new insights into the therapeutic role of 5-HT1A receptors in treating schizophrenia and Parkinson's disease.  Specifically, 5-HT1A receptors seem to be a promising target for alleviating antipsychotic-induced extrapyramidal side effects (EPS) and cognitive/affective disorders in schizophrenia.  In the treatment of patients with Parkinson's disease, 5-HT1A agonists are expected to improve not only affective symptoms (e.g., anxiety and depression), but also the core parkinsonian symptoms as well as antiparkinsonian agents-induced side effects (e.g., L-DOPA-induced dyskinesia).  Here, the therapeutic mechanisms mediated by 5-HT1A receptors in schizophrenia and Parkinson's disease are reviewed.  This evidence should encourage discovery of new 5-HT1A ligands, which can resolve the unmet clin. needs in the current therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMhhzTRrq3R7Vg90H21EOLACvtfcHk0lgsCslg75eF6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVCnurc%253D&md5=d70ebb228afb20826693e9ed48d287c2</span></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.1111%2Fj.1755-5949.2010.00211.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1755-5949.2010.00211.x%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DY.%26atitle%3DTherapeutic%2520role%2520of%25205-HT1A%2520receptors%2520in%2520the%2520treatment%2520of%2520schizophrenia%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCNS%2520Neurosci.%2520Ther.%26date%3D2011%26volume%3D17%26spage%3D58%26epage%3D65%26doi%3D10.1111%2Fj.1755-5949.2010.00211.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit38b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, C. R.</span></span> <span> </span><span class="NLM_article-title">Return of D<sub>4</sub> dopamine receptor antagonists in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7233</span>– <span class="NLM_lpage">7243</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00151</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00151" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsVWrt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7233-7243&author=C.+W.+Lindsleyauthor=C.+R.+Hopkins&title=Return+of+D4+dopamine+receptor+antagonists+in+drug+discovery&doi=10.1021%2Facs.jmedchem.7b00151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38bR"><div class="casContent"><span class="casTitleNuber">38b</span><div class="casTitle"><span class="NLM_cas:atitle">Return of D4 Dopamine Receptor Antagonists in Drug Discovery</span></div><div class="casAuthors">Lindsley, Craig W.; Hopkins, Corey R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7233-7243</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D4 receptor garnered a great deal of interest in the early 1990s when studies showed the atypical antipsychotic clozapine possessed higher affinity for D4, relative to other dopamine receptor subtypes, and that this activity might underlie the unique clin. efficacy of clozapine.  Unfortunately, D4 antagonists that were developed for schizophrenia failed in the clinic.  Thus, D4 fell out of favor as a therapeutic target, and work in this area was silent for decades.  Recently, D4 ligands with improved selectivity for D4 against not only D1-3,5 but also other biogenic amine targets have emerged, and D4 is once again in the spotlight as a novel target for both addiction and Parkinson's disease (PD), as well as other emerging diseases.  This report will review the historical data for D4, review the known D4 ligands, and then highlight new data supporting a role for D4 inhibition in addiction, PD, and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqspfOt_2Te-LVg90H21EOLACvtfcHk0lgsCslg75eF6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsVWrt7o%253D&md5=6d58ae979689c79d9c4dfe4e0802f195</span></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00151%26sid%3Dliteratum%253Aachs%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26atitle%3DReturn%2520of%2520D4%2520dopamine%2520receptor%2520antagonists%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7233%26epage%3D7243%26doi%3D10.1021%2Facs.jmedchem.7b00151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Maeso, J.</span></span> <span> </span><span class="NLM_article-title">Preclinical models of antipsychotic drug action</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2131</span>– <span class="NLM_lpage">2144</span>, <span class="refDoi"> DOI: 10.1017/S1461145713000606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1017%2FS1461145713000606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=23745738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOisbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=2131-2144&author=J.+L.+Morenoauthor=J.+Gonzalez-Maeso&title=Preclinical+models+of+antipsychotic+drug+action&doi=10.1017%2FS1461145713000606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical models of antipsychotic drug action</span></div><div class="casAuthors">Moreno, Jose L.; Gonzalez-Maeso, Javier</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2131-2144</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review.  One of the main obstacles faced by translational neuroscience is the development of animal models of psychiatric disorders.  Behavioral pharmacol. studies indicate that psychedelic drugs, such as lysergic acid diethylamide (LSD) and dissociative drugs, such as phencyclidine (PCP), induce in healthy human volunteers psychotic and cognitive symptoms that resemble some of those obsd. in schizophrenia patients.  Serotonin 5-HT2A and metabotropic glutamate 2 receptors have been involved in the mechanism of action of psychedelic and dissociative drugs.  Here we review recent advances using LSD-like and PCP-like drugs in rodent models that implicate these receptors in the neurobiol. of schizophrenia and its treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAGcPjQnLWFLVg90H21EOLACvtfcHk0lgsCslg75eF6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOisbfK&md5=1c0df24addc20d894c142b2cc6168d65</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1017%2FS1461145713000606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145713000606%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno%26aufirst%3DJ.%2BL.%26aulast%3DGonzalez-Maeso%26aufirst%3DJ.%26atitle%3DPreclinical%2520models%2520of%2520antipsychotic%2520drug%2520action%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2013%26volume%3D16%26spage%3D2131%26epage%3D2144%26doi%3D10.1017%2FS1461145713000606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porsolt, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagne, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virley, D.</span></span> <span> </span><span class="NLM_article-title">Nonhuman primates: translational models for predicting antipsychotic-induced movement disorders</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.207209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1124%2Fjpet.113.207209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=24030013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyiu7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=542-546&author=R.+D.+Porsoltauthor=V.+Castagneauthor=E.+Hayesauthor=D.+Virley&title=Nonhuman+primates%3A+translational+models+for+predicting+antipsychotic-induced+movement+disorders&doi=10.1124%2Fjpet.113.207209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Nonhuman primates: translational models for predicting antipsychotic-induced movement disorders</span></div><div class="casAuthors">Porsolt, Roger D.; Castagne, Vincent; Hayes, Eric; Virley, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">542-546</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Repeated haloperidol treatment administered to nonhuman primates (NHPs) over several months or even years leads to the gradual appearance of drug-induced dystonic reactions in the orofacial region (mouth opening, tongue protrusion or retraction, bar biting) and in the whole body (writhing of the limbs and trunk, bar grasping).  The propensity of antipsychotics to induce dystonia in NHPs is not correlated with their propensity to induce catalepsy in rodents, suggesting that the two types of effects are dissocd. and may represent distinct aspects of the extrapyramidal symptoms induced by antipsychotics.  In view of the clear homol. to clin. obsd. phenomena, antipsychotic-induced dystonias in antipsychotic-primed NHPs would appear to possess a high degree of translational validity.  These NHP phenomena could therefore serve as a useful model for predicting the occurrence of similar abnormal movements with novel substances developed for the treatment of schizophrenia or other psychotic disorders.  Moreover, the NHP dystonia model could possibly serve as a biomarker for substances that will eventually cause tardive dyskinesia in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKr94MjRXldbVg90H21EOLACvtfcHk0lhIoITQo7yxvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyiu7vM&md5=1d8f0efe43009f91ea25005ae3920fe9</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207209%26sid%3Dliteratum%253Aachs%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26aulast%3DCastagne%26aufirst%3DV.%26aulast%3DHayes%26aufirst%3DE.%26aulast%3DVirley%26aufirst%3DD.%26atitle%3DNonhuman%2520primates%253A%2520translational%2520models%2520for%2520predicting%2520antipsychotic-induced%2520movement%2520disorders%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D542%26epage%3D546%26doi%3D10.1124%2Fjpet.113.207209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiberas, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinot, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artiges, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loc'h, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maziere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paillere-Martinot, M.
L.</span></span> <span> </span><span class="NLM_article-title">Extrastriatal and striatal D<sub>2</sub> dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia</span>. <i>Br. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">503</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1192/bjp.179.6.503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1192%2Fbjp.179.6.503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=11731352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A280%3ADC%252BD3MnosVKgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2001&pages=503-508&author=X.+Xiberasauthor=J.+L.+Martinotauthor=L.+Malletauthor=E.+Artigesauthor=H.+C.+Loc%27hauthor=B.+Maziereauthor=M.%0AL.+Paillere-Martinot&title=Extrastriatal+and+striatal+D2+dopamine+receptor+blockade+with+haloperidol+or+new+antipsychotic+drugs+in+patients+with+schizophrenia&doi=10.1192%2Fbjp.179.6.503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia</span></div><div class="casAuthors">Xiberas X; Martinot J L; Mallet L; Artiges E; Loc'H C; Maziere B; Paillere-Martinot M L</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of psychiatry : the journal of mental science</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">503-8</span>
        ISSN:<span class="NLM_cas:issn">0007-1250</span>.
    </div><div class="casAbstract">BACKGROUND:  Both traditional and atypical antipsychotics have been hypothesised to be effective in schizophrenia through limbic and cortical D(2) dopamine receptor blockade.  AIMS:  To investigate this hypothesis with the D(2)/D(3)-selective positron emission tomography (PET) probe [(76)Br]-FLB457.  METHOD:  PET scans were performed on 6 controls and 18 patients with schizophrenia treated with haloperidol or with risperidone, clozapine, amisulpride or olanzapine.  RESULTS:  The D(2) dopamine receptor blockade was high in the temporal cortex with both haloperidol and atypical antipsychotics.  The atypicals, however, induced a significantly lower D(2) binding index than haloperidol in the thalamus and in the striatum.  CONCLUSIONS:  Results suggest that cortical D(2) dopamine receptors are a common target of traditional and atypical antipsychotics for therapeutic action.  Higher in vivo binding to the D(2) receptors in the cortex than in the basal ganglia is suggested as an indicator of favourable profile for a putative antipsychotic compound.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbBFlCBiZZKZI8NvIb08rbfW6udTcc2ebWateofWhQ17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnosVKgsA%253D%253D&md5=3da69371e0d4fa0af919eaba133cd908</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1192%2Fbjp.179.6.503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1192%252Fbjp.179.6.503%26sid%3Dliteratum%253Aachs%26aulast%3DXiberas%26aufirst%3DX.%26aulast%3DMartinot%26aufirst%3DJ.%2BL.%26aulast%3DMallet%26aufirst%3DL.%26aulast%3DArtiges%26aufirst%3DE.%26aulast%3DLoc%2527h%26aufirst%3DH.%2BC.%26aulast%3DMaziere%26aufirst%3DB.%26aulast%3DPaillere-Martinot%26aufirst%3DM.%2BL.%26atitle%3DExtrastriatal%2520and%2520striatal%2520D2%2520dopamine%2520receptor%2520blockade%2520with%2520haloperidol%2520or%2520new%2520antipsychotic%2520drugs%2520in%2520patients%2520with%2520schizophrenia%26jtitle%3DBr.%2520J.%2520Psychiatry%26date%3D2001%26volume%3D179%26spage%3D503%26epage%3D508%26doi%3D10.1192%2Fbjp.179.6.503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arnt, J.</span></span> <span> </span><span class="NLM_article-title">Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade</span>. <i>Acta Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1111/j.1600-0773.1982.tb01032.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1111%2Fj.1600-0773.1982.tb01032.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=6129770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADyaL3sXmsFehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1982&pages=321-329&author=J.+Arnt&title=Pharmacological+specificity+of+conditioned+avoidance+response+inhibition+in+rats%3A+inhibition+by+neuroleptics+and+correlation+to+dopamine+receptor+blockade&doi=10.1111%2Fj.1600-0773.1982.tb01032.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42aR"><div class="casContent"><span class="casTitleNuber">42a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological specificity of conditioned avoidance response inhibition in rats:  inhibition by neuroleptics and correlation to dopamine receptor blockade</span></div><div class="casAuthors">Arnt, Joern</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica et Toxicologica</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">321-9</span>CODEN:
                <span class="NLM_cas:coden">APTOA6</span>;
        ISSN:<span class="NLM_cas:issn">0001-6683</span>.
    </div><div class="casAbstract">The inhibitory effect of 36 neuroleptic compds. on conditioned avoidance response (CAR) and unconditioned escape response (UER) has been studied in rats.  All neuroleptics antagonized CAR in doses below those inhibiting UER and below those inducing catalepsy.  Stereospecificity was shown in 2 cases.  Significant correlation was found between CAR inhibitory and cataleptogenic potency.  Also inhibition of amphetamine-induced stereotypy, affinity to 3H-haloperidol binding in vitro, and clin. potency was significantly correlated to CAR inhibition.  CAR and UER inhibition induced by cis(Z)-flupentixol (I)  [53772-82-0] and haloperidol  [52-86-8] was attenuated by scopolamine, but was only weakly influenced by methysergide and prazosin.  Among a wide range of other CNS active compds. tested, CAR was inhibited by α1-adrenergic antagonists, benzodiazepines, a barbiturate, GABA agonists, morphine, and a serotonin agonist, but in doses inducing other motor disturbances.  Thus, CAR inhibition is a sensitive test for dopamine receptor antagonists.  However, addnl. α-adrenergic activity found for some neuroleptics (e.g. clozapine  [5786-21-0], chlorprothixene  [113-59-7]) may contribute to the CAR inhibitory potency.  Addnl. antimuscarinic activity of neuroleptics may moderately attenuate CAR inhibition whereas serotonin receptor blockade is of minor importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcjmAjdj8YybVg90H21EOLACvtfcHk0lhIoITQo7yxvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXmsFehug%253D%253D&md5=3c6a8cdc6e90e5a481b017c61b84d39c</span></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0773.1982.tb01032.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0773.1982.tb01032.x%26sid%3Dliteratum%253Aachs%26aulast%3DArnt%26aufirst%3DJ.%26atitle%3DPharmacological%2520specificity%2520of%2520conditioned%2520avoidance%2520response%2520inhibition%2520in%2520rats%253A%2520inhibition%2520by%2520neuroleptics%2520and%2520correlation%2520to%2520dopamine%2520receptor%2520blockade%26jtitle%3DActa%2520Pharmacol.%2520Toxicol.%26date%3D1982%26volume%3D51%26spage%3D321%26epage%3D329%26doi%3D10.1111%2Fj.1600-0773.1982.tb01032.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit42b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bundgaard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreilgaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennum, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D<sub>2</sub> receptor occupancy and behavioural conditioned avoidance response</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1002/bdd.656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1002%2Fbdd.656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=19475539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFyhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=209-220&author=C.+Bundgaardauthor=F.+Larsenauthor=M.+Kreilgaardauthor=L.+T.+Brennumauthor=C.+K.+Olsen&title=Pharmacokinetics+of+sertindole+and+its+metabolite+dehydrosertindole+in+rats+and+characterization+of+their+comparative+pharmacodynamics+based+on+in+vivo+D2+receptor+occupancy+and+behavioural+conditioned+avoidance+response&doi=10.1002%2Fbdd.656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42bR"><div class="casContent"><span class="casTitleNuber">42b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response</span></div><div class="casAuthors">Bundgaard, Christoffer; Larsen, Frank; Kreilgaard, Mads; Brennum, Lise T.; Olsen, Christina Kurre</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">209-220</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The objectives of this study were to characterize the pharmacokinetics of sertindole and its active metabolite dehydrosertindole in rats and to evaluate the central modulatory and behavioral pharmacodynamics including a competitive interaction model between the compds.  Following oral administration of sertindole or dehydrosertindole, the plasma concn.-time courses were detd. in conjunction with striatal dopamine D2 receptor binding.  In addn., the behavioral effects were recorded in the conditioned avoidance response (CAR) paradigm.  A one-compartment model with Michaelis-Menten elimination best described the pharmacokinetics of sertindole.  Formation of dehydrosertindole was incorporated into the pharmacokinetic model and exhibited first-order elimination.  PK/PD modeling after administration of dehydrosertindole resulted in potency ests. of 165 and 424 ng/mL for D2-occupancy (Kd) and CAR measurements (EC50), resp.  The pharmacokinetics of the parent-metabolite system was integrated into a competitive pharmacodynamic Emax model to quantitate the potency of sertindole with the pharmacodynamic parameters of the metabolite taken into account.  Based on this approach, effect compartment concns. of sertindole needed to attain 50% occupancy and half-maximal effect in the CAR paradigm were 133 and 338 ng/mL, resp.  The corresponding potency-ests. obtained after conventional modeling of the sertindole data without accounting for the metabolite amounted to 102 and 345 ng/mL.  Based on competitive PK/PD anal. of the parent-metabolite interaction, the relative contribution of dehydrosertindole to the overall pharmacol. effect after sertindole administration in rats appeared to be of minor significance.  This could mainly be ascribed to the relatively low extent of bioconversion of sertindole into dehydrosertindole in this species.  Copyright © 2009 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbQ03cTJ7XSLVg90H21EOLACvtfcHk0li9CSB57GyaiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFyhsLs%253D&md5=2680510cf2c7a41a3770f592f91d86e1</span></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=10.1002%2Fbdd.656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.656%26sid%3Dliteratum%253Aachs%26aulast%3DBundgaard%26aufirst%3DC.%26aulast%3DLarsen%26aufirst%3DF.%26aulast%3DKreilgaard%26aufirst%3DM.%26aulast%3DBrennum%26aufirst%3DL.%2BT.%26aulast%3DOlsen%26aufirst%3DC.%2BK.%26atitle%3DPharmacokinetics%2520of%2520sertindole%2520and%2520its%2520metabolite%2520dehydrosertindole%2520in%2520rats%2520and%2520characterization%2520of%2520their%2520comparative%2520pharmacodynamics%2520based%2520on%2520in%2520vivo%2520D2%2520receptor%2520occupancy%2520and%2520behavioural%2520conditioned%2520avoidance%2520response%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2009%26volume%3D30%26spage%3D209%26epage%3D220%26doi%3D10.1002%2Fbdd.656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schlumberger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietraszek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gravius, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danysz, W.</span></span> <span> </span><span class="NLM_article-title">Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2009.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.pbb.2009.12.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2010&pages=23-30&author=C.+Schlumbergerauthor=M.+Pietraszekauthor=A.+Graviusauthor=W.+Danysz&title=Effects+of+a+positive+allosteric+modulator+of+mGluR5+ADX47273+on+conditioned+avoidance+response+and+PCP-induced+hyperlocomotion+in+the+rat+as+models+for+schizophrenia&doi=10.1016%2Fj.pbb.2009.12.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2009.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2009.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DSchlumberger%26aufirst%3DC.%26aulast%3DPietraszek%26aufirst%3DM.%26aulast%3DGravius%26aufirst%3DA.%26aulast%3DDanysz%26aufirst%3DW.%26atitle%3DEffects%2520of%2520a%2520positive%2520allosteric%2520modulator%2520of%2520mGluR5%2520ADX47273%2520on%2520conditioned%2520avoidance%2520response%2520and%2520PCP-induced%2520hyperlocomotion%2520in%2520the%2520rat%2520as%2520models%2520for%2520schizophrenia%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2010%26volume%3D95%26spage%3D23%26epage%3D30%26doi%3D10.1016%2Fj.pbb.2009.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit43b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wadenberg, M. L.</span></span> <span> </span><span class="NLM_article-title">Conditioned avoidance response in the development of new antipsychotics</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.2174/138161210790170085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.2174%2F138161210790170085" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=358-370&author=M.+L.+Wadenberg&title=Conditioned+avoidance+response+in+the+development+of+new+antipsychotics&doi=10.2174%2F138161210790170085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=10.2174%2F138161210790170085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210790170085%26sid%3Dliteratum%253Aachs%26aulast%3DWadenberg%26aufirst%3DM.%2BL.%26atitle%3DConditioned%2520avoidance%2520response%2520in%2520the%2520development%2520of%2520new%2520antipsychotics%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2010%26volume%3D16%26spage%3D358%26epage%3D370%26doi%3D10.2174%2F138161210790170085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathiasen, J. R.</span>; <span class="NLM_string-name">DiCamillo, A.</span></span> <span> </span><span class="NLM_article-title">Novel object recognition in the rat: a facile assay for cognitive function</span>. In  <i>Current Protocols in Pharmacology</i>; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2010</span>; pp  <span class="NLM_fpage">5.59.1</span>– <span class="NLM_lpage">5.59.15</span>, <span class="refDoi"> DOI: 10.1002/0471141755.ph0559s49</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1002%2F0471141755.ph0559s49" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=5.59.1-5.59.15&author=J.+R.+Mathiasen&author=A.+DiCamillo&title=Current+Protocols+in+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44a&amp;dbid=16384&amp;doi=10.1002%2F0471141755.ph0559s49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471141755.ph0559s49%26sid%3Dliteratum%253Aachs%26aulast%3DMathiasen%26aufirst%3DJ.%2BR.%26atitle%3DNovel%2520object%2520recognition%2520in%2520the%2520rat%253A%2520a%2520facile%2520assay%2520for%2520cognitive%2520function%26btitle%3DCurrent%2520Protocols%2520in%2520Pharmacology%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2010%26spage%3D5.59.1%26epage%3D5.59.15%26doi%3D10.1002%2F0471141755.ph0559s49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit44b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Millan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buccafusco, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loiseau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decamp, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fone, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomasson-Perret, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mocaer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J. S.</span></span> <span> </span><span class="NLM_article-title">The dopamine D<sub>3</sub> receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1035</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1017/S1461145710000775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1017%2FS1461145710000775" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=20663270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCksLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=1035-1051&author=M.+J.+Millanauthor=J.+J.+Buccafuscoauthor=F.+Loiseauauthor=D.+J.+Watsonauthor=E.+Decampauthor=K.+C.+Foneauthor=N.+Thomasson-Perretauthor=M.+Hillauthor=E.+Mocaerauthor=J.+S.+Schneider&title=The+dopamine+D3+receptor+antagonist%2C+S33138%2C+counters+cognitive+impairment+in+a+range+of+rodent+and+primate+procedures&doi=10.1017%2FS1461145710000775"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44bR"><div class="casContent"><span class="casTitleNuber">44b</span><div class="casTitle"><span class="NLM_cas:atitle">The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures</span></div><div class="casAuthors">Millan, Mark J.; Buccafusco, Jerry J.; Loiseau, Florence; Watson, David J. G.; Decamp, Emmanuel; Fone, Kevin C. F.; Thomasson-Perret, Nitza; Hill, Michael; Mocaer, Elisabeth; Schneider, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1035-1051</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Although dopamine D3 receptor antagonists have been shown to enhance frontocortical cholinergic transmission and improve cognitive performance in rodents, data are limited and their effects have never been examd. in primates.  Accordingly, we characterized the actions of the D3 receptor antagonist, S33138, in rats and rhesus monkeys using a suite of procedures in which cognitive performance was disrupted by several contrasting manipulations.  S33138 dose-dependently (0.01-0.63 mg/kg s.c.) blocked a delay-induced impairment of novel object recognition in rats, a model of visual learning and memory.  Further, S33138 (0.16-2.5 mg/kg s.c.) similarly reduced a delay-induced deficit in social novelty discrimination in rats, a procedure principally based on olfactory cues.  Adult rhesus monkeys were trained to perform cognitive procedures, then chronically exposed to low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine which produced cognitive impairment without motor disruption.  In an attentional set-shifting task of cognitive flexibility involving an extra-dimensional shift, deficits were reversed by S33138 (0.04 and 0.16 mg/kg p.o.).  S33138 also significantly improved accuracy (0.04 and 0.16 mg/kg p.o.) at short (but not long) delays in a variable delayed-response task of attention and working memory.  Finally, in a sep. set of expts. performed in monkeys displaying age-related deficits, S33138 significantly (0.16 and 0.63 mg/kg p.o.) improved task accuracies for long delay intervals in a delayed matching-to-sample task of working memory.  In conclusion, S33138 improved performance in several rat and primate procedures of cognitive impairment.  These data underpin interest in D3 receptor blockade as a strategy for improving cognitive performance in CNS disorders like schizophrenia and Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAOsVc2rbr1bVg90H21EOLACvtfcHk0li9CSB57GyaiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCksLbO&md5=7903a09e0a4b9218dae0b89a60170305</span></div><a href="/servlet/linkout?suffix=cit44b&amp;dbid=16384&amp;doi=10.1017%2FS1461145710000775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145710000775%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26aulast%3DBuccafusco%26aufirst%3DJ.%2BJ.%26aulast%3DLoiseau%26aufirst%3DF.%26aulast%3DWatson%26aufirst%3DD.%2BJ.%26aulast%3DDecamp%26aufirst%3DE.%26aulast%3DFone%26aufirst%3DK.%2BC.%26aulast%3DThomasson-Perret%26aufirst%3DN.%26aulast%3DHill%26aufirst%3DM.%26aulast%3DMocaer%26aufirst%3DE.%26aulast%3DSchneider%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520dopamine%2520D3%2520receptor%2520antagonist%252C%2520S33138%252C%2520counters%2520cognitive%2520impairment%2520in%2520a%2520range%2520of%2520rodent%2520and%2520primate%2520procedures%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2010%26volume%3D13%26spage%3D1035%26epage%3D1051%26doi%3D10.1017%2FS1461145710000775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit44c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerretsen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravaggio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Foll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulsant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff-Guerrero, A.</span></span> <span> </span><span class="NLM_article-title">The potential role of dopamine D<sub>3</sub> receptor neurotransmission in cognition</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1016/j.euroneuro.2013.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.euroneuro.2013.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=23791072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVyrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=799-813&author=S.+Nakajimaauthor=P.+Gerretsenauthor=H.+Takeuchiauthor=F.+Caravaggioauthor=T.+Chowauthor=B.+Le+Follauthor=B.+Mulsantauthor=B.+Pollockauthor=A.+Graff-Guerrero&title=The+potential+role+of+dopamine+D3+receptor+neurotransmission+in+cognition&doi=10.1016%2Fj.euroneuro.2013.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44cR"><div class="casContent"><span class="casTitleNuber">44c</span><div class="casTitle"><span class="NLM_cas:atitle">The potential role of dopamine D3 receptor neurotransmission in cognition</span></div><div class="casAuthors">Nakajima, Shinichiro; Gerretsen, Philip; Takeuchi, Hiroyoshi; Caravaggio, Fernando; Chow, Tiffany; Le Foll, Bernard; Mulsant, Benoit; Pollock, Bruce; Graff-Guerrero, Ariel</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">799-813</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Currently available treatments have limited pro-cognitive effects for neuropsychiatric disorders, such as schizophrenia, Parkinson's disease and Alzheimer's disease.  The primary objective of this work is to review the literature on the role of dopamine D3 receptors in cognition, and propose dopamine D3 receptor antagonists as possible cognitive enhancers for neuropsychiatric disorders.  A literature search was performed to identify animal and human studies on D3 receptors and cognition using PubMed, MEDLINE and EMBASE.  The search terms included "dopamine D3 receptor" and "cognition".  The literature search identified 164 articles.  The results revealed: (1) D3 receptors are assocd. with cognitive functioning in both healthy individuals and those with neuropsychiatric disorders; (2) D3 receptor blockade appears to enhance while D3 receptor agonism seems to impair cognitive function, including memory, attention, learning, processing speed, social recognition and executive function independent of age; and (3) D3 receptor antagonists may exert their pro-cognitive effect by enhancing the release of acetylcholine in the prefrontal cortex, disinhibiting the activity of dopamine neurons projecting to the nucleus accumbens or prefrontal cortex, or activating CREB signaling in the hippocampus.  These findings suggest that D3 receptor blockade may enhance cognitive performance in healthy individuals and treat cognitive dysfunction in individuals with a neuropsychiatric disorder.  Clin. trials are needed to confirm these effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSUxqVZeIzYLVg90H21EOLACvtfcHk0lhlEd_MvwwC4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVyrtLc%253D&md5=3d42c98b759d0d27039345dbee2ae73e</span></div><a href="/servlet/linkout?suffix=cit44c&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2013.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2013.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DNakajima%26aufirst%3DS.%26aulast%3DGerretsen%26aufirst%3DP.%26aulast%3DTakeuchi%26aufirst%3DH.%26aulast%3DCaravaggio%26aufirst%3DF.%26aulast%3DChow%26aufirst%3DT.%26aulast%3DLe%2BFoll%26aufirst%3DB.%26aulast%3DMulsant%26aufirst%3DB.%26aulast%3DPollock%26aufirst%3DB.%26aulast%3DGraff-Guerrero%26aufirst%3DA.%26atitle%3DThe%2520potential%2520role%2520of%2520dopamine%2520D3%2520receptor%2520neurotransmission%2520in%2520cognition%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2013%26volume%3D23%26spage%3D799%26epage%3D813%26doi%3D10.1016%2Fj.euroneuro.2013.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit44d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Benhamu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Fontecha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Villa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Rodriguez, M. L.</span></span> <span> </span><span class="NLM_article-title">Serotonin 5-HT<sub>6</sub> receptor antagonists for the treatment of cognitive deficiency in Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7160</span>– <span class="NLM_lpage">7181</span>, <span class="refDoi"> DOI: 10.1021/jm5003952</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5003952" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVWjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7160-7181&author=B.+Benhamuauthor=M.+Martin-Fontechaauthor=H.+Vazquez-Villaauthor=L.+Pardoauthor=M.+L.+Lopez-Rodriguez&title=Serotonin+5-HT6+receptor+antagonists+for+the+treatment+of+cognitive+deficiency+in+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm5003952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44dR"><div class="casContent"><span class="casTitleNuber">44d</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin 5-HT6 Receptor Antagonists for the Treatment of Cognitive Deficiency in Alzheimer's Disease</span></div><div class="casAuthors">Benhamu, Bellinda; Martin-Fontecha, Mar; Vazquez-Villa, Henar; Pardo, Leonardo; Lopez-Rodriguez, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7160-7181</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is one of the most frequent causes of death and disability worldwide and has a significant clin. and socioeconomic impact.  In the search for novel therapeutic strategies, serotonin 5-HT6 receptor (5-HT6R) has been proposed as a promising drug target for cognition enhancement in AD.  This manuscript reviews the compelling evidence for the implication of this receptor in learning and memory processes.  We have summarized the current status of the medicinal chem. of 5-HT6R antagonists and the encouraging preclin. findings that demonstrate their significant procognitive behavioral effects in a no. of learning paradigms, probably acting through modulation of multiple neurotransmitter systems and signaling pathways.  The results of the ongoing clin. trials are eagerly awaited to shed some light on the validation of 5-HT6R antagonists as a new drug class for the treatment of symptomatic cognitive impairment in AD, either as stand-alone therapy or in combination with established agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeTO6_2THvaLVg90H21EOLACvtfcHk0lhlEd_MvwwC4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVWjs7c%253D&md5=bf8d2cba73f72e04a5caf8b295647064</span></div><a href="/servlet/linkout?suffix=cit44d&amp;dbid=16384&amp;doi=10.1021%2Fjm5003952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5003952%26sid%3Dliteratum%253Aachs%26aulast%3DBenhamu%26aufirst%3DB.%26aulast%3DMartin-Fontecha%26aufirst%3DM.%26aulast%3DVazquez-Villa%26aufirst%3DH.%26aulast%3DPardo%26aufirst%3DL.%26aulast%3DLopez-Rodriguez%26aufirst%3DM.%2BL.%26atitle%3DSerotonin%25205-HT6%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520cognitive%2520deficiency%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7160%26epage%3D7181%26doi%3D10.1021%2Fjm5003952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massari, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freestone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarrick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoder, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadbent, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barido, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmelzer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neul, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aertgeerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabatabaei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitenbucher, J. G.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel and selective phosphodiesterase 2 (PDE2a) inhibitors for the treatment of memory disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2037</span>– <span class="NLM_lpage">2051</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01793</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01793" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1Sjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2037-2051&author=L.+Gomezauthor=M.+E.+Massariauthor=T.+Vickersauthor=G.+Freestoneauthor=W.+Vernierauthor=K.+Lyauthor=R.+Xuauthor=M.+McCarrickauthor=T.+Marroneauthor=M.+Metzauthor=Y.+G.+Yanauthor=Z.+W.+Yoderauthor=R.+Lemusauthor=N.+J.+Broadbentauthor=R.+Baridoauthor=N.+Warrenauthor=K.+Schmelzerauthor=D.+Neulauthor=D.+Leeauthor=C.+B.+Andersenauthor=K.+Sebringauthor=K.+Aertgeertsauthor=X.+Zhouauthor=A.+Tabatabaeiauthor=M.+Petersauthor=J.+G.+Breitenbucher&title=Design+and+synthesis+of+novel+and+selective+phosphodiesterase+2+%28PDE2a%29+inhibitors+for+the+treatment+of+memory+disorders&doi=10.1021%2Facs.jmedchem.6b01793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45aR"><div class="casContent"><span class="casTitleNuber">45a</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders</span></div><div class="casAuthors">Gomez, Laurent; Massari, Mark Eben; Vickers, Troy; Freestone, Graeme; Vernier, William; Ly, Kiev; Xu, Rui; McCarrick, Margaret; Marrone, Tami; Metz, Markus; Yan, Yingzhou G.; Yoder, Zachary W.; Lemus, Robert; Broadbent, Nicola J.; Barido, Richard; Warren, Noelle; Schmelzer, Kara; Neul, David; Lee, Dong; Andersen, Carsten B.; Sebring, Kristen; Aertgeerts, Kathleen; Zhou, Xianbo; Tabatabaei, Ali; Peters, Marco; Breitenbucher, J. Guy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2037-2051</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of potent and selective [1,2,4]triazolo[1,5-a]pyrimidine PDE2a inhibitors is reported.  The design and improvement of the binding properties of this series was achieved using X-ray crystal structures in conjunction with careful anal. of electronic and structural requirements for the PDE2a enzyme.  One of the lead compds., compd. I (DNS-8254), was identified as a potent and highly selective PDE2a enzyme inhibitor with favorable rat pharmacokinetic properties.  Interestingly, the increased potency of compd. I was facilitated by the formation of a halogen bond with the oxygen of Tyr827 present in the PDE2a active site.  In vivo, compd. I demonstrated significant memory enhancing effects in a rat model of novel object recognition.  Taken together, these data suggest that compd. I may be a useful tool to explore the pharmacol. of selective PDE2a inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6ML_QxZhnWLVg90H21EOLACvtfcHk0liyDQ5Yhb_zmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1Sjuro%253D&md5=fe8df71fbd1f61423352dfcb862d9d53</span></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01793%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DL.%26aulast%3DMassari%26aufirst%3DM.%2BE.%26aulast%3DVickers%26aufirst%3DT.%26aulast%3DFreestone%26aufirst%3DG.%26aulast%3DVernier%26aufirst%3DW.%26aulast%3DLy%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DMcCarrick%26aufirst%3DM.%26aulast%3DMarrone%26aufirst%3DT.%26aulast%3DMetz%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DY.%2BG.%26aulast%3DYoder%26aufirst%3DZ.%2BW.%26aulast%3DLemus%26aufirst%3DR.%26aulast%3DBroadbent%26aufirst%3DN.%2BJ.%26aulast%3DBarido%26aufirst%3DR.%26aulast%3DWarren%26aufirst%3DN.%26aulast%3DSchmelzer%26aufirst%3DK.%26aulast%3DNeul%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DAndersen%26aufirst%3DC.%2BB.%26aulast%3DSebring%26aufirst%3DK.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DTabatabaei%26aufirst%3DA.%26aulast%3DPeters%26aufirst%3DM.%26aulast%3DBreitenbucher%26aufirst%3DJ.%2BG.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520and%2520selective%2520phosphodiesterase%25202%2520%2528PDE2a%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520memory%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2037%26epage%3D2051%26doi%3D10.1021%2Facs.jmedchem.6b01793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit45b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mikami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokubo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of clinical candidate N-((1S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2, 3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): a highly potent, selective, and brain-penetrating phosphodiesterase 2A inhibitor for the treatment of cognitive disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7677</span>– <span class="NLM_lpage">7702</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00807</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00807" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSmtL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7677-7702&author=S.+Mikamiauthor=S.+Nakamuraauthor=T.+Ashizawaauthor=I.+Nomuraauthor=M.+Kawasakiauthor=S.+Sasakiauthor=H.+Okiauthor=H.+Kokuboauthor=I.+D.+Hoffmanauthor=H.+Zouauthor=N.+Uchiyamaauthor=K.+Nakashimaauthor=N.+Kamiguchiauthor=H.+Imadaauthor=N.+Suzukiauthor=H.+Iwashitaauthor=T.+Taniguchi&title=Discovery+of+clinical+candidate+N-%28%281S%29-1-%283-fluoro-4-%28trifluoromethoxy%29phenyl%29-2-methoxyethyl%29-7-methoxy-2-oxo-2%2C+3-dihydropyrido%5B2%2C3-b%5Dpyrazine-4%281H%29-carboxamide+%28TAK-915%29%3A+a+highly+potent%2C+selective%2C+and+brain-penetrating+phosphodiesterase+2A+inhibitor+for+the+treatment+of+cognitive+disorders&doi=10.1021%2Facs.jmedchem.7b00807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45bR"><div class="casContent"><span class="casTitleNuber">45b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders</span></div><div class="casAuthors">Mikami, Satoshi; Nakamura, Shinji; Ashizawa, Tomoko; Nomura, Izumi; Kawasaki, Masanori; Sasaki, Shigekazu; Oki, Hideyuki; Kokubo, Hironori; Hoffman, Isaac D.; Zou, Hua; Uchiyama, Noriko; Nakashima, Kosuke; Kamiguchi, Naomi; Imada, Haruka; Suzuki, Noriko; Iwashita, Hiroki; Taniguchi, Takahiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7677-7702</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) 2A inhibitors have emerged as a novel mechanism with potential therapeutic option to ameliorate cognitive dysfunction in schizophrenia or Alzheimer's disease through upregulation of cyclic nucleotides in the brain, and thereby achieve potentiation of cyclic nucleotide signaling pathways.  This article details the expedited optimization of the authors' recently disclosed pyrazolo[1,5-a]pyrimidine lead compd. 4b, leading to the discovery of clin. candidate 36 (I) (TAK-915), which demonstrates an appropriate combination of potency, PDE selectivity, and favorable pharmacokinetic (PK) properties, including brain penetration.  Successful identification of 36 was realized through application of structure-based drug design (SBDD) to further improve potency and PDE selectivity, coupled with prospective design focused on physicochem. properties to deliver brain penetration.  Oral administration of 36 demonstrated significant elevation of 3',5'-cGMP levels in mouse brains, and improved cognitive performance in a novel object recognition task in rats.  Consequently, compd. 36 was advanced into human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCUw5grC_66rVg90H21EOLACvtfcHk0liyDQ5Yhb_zmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSmtL3I&md5=f87cb3ac86b6299fc90e336b88ea2a21</span></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00807%26sid%3Dliteratum%253Aachs%26aulast%3DMikami%26aufirst%3DS.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DAshizawa%26aufirst%3DT.%26aulast%3DNomura%26aufirst%3DI.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DOki%26aufirst%3DH.%26aulast%3DKokubo%26aufirst%3DH.%26aulast%3DHoffman%26aufirst%3DI.%2BD.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DUchiyama%26aufirst%3DN.%26aulast%3DNakashima%26aufirst%3DK.%26aulast%3DKamiguchi%26aufirst%3DN.%26aulast%3DImada%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DIwashita%26aufirst%3DH.%26aulast%3DTaniguchi%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%2520N-%2528%25281S%2529-1-%25283-fluoro-4-%2528trifluoromethoxy%2529phenyl%2529-2-methoxyethyl%2529-7-methoxy-2-oxo-2%252C%25203-dihydropyrido%255B2%252C3-b%255Dpyrazine-4%25281H%2529-carboxamide%2520%2528TAK-915%2529%253A%2520a%2520highly%2520potent%252C%2520selective%252C%2520and%2520brain-penetrating%2520phosphodiesterase%25202A%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cognitive%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7677%26epage%3D7702%26doi%3D10.1021%2Facs.jmedchem.7b00807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit45c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Santora, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almos, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barido, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellows, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bookser, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitenbucher, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadbent, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabebe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crickard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danks, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freestone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitnick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmaster, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limberis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masatsugu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neul, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikpur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petroski, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevidal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabatabaei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoder, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zook, D.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel and selective glycine transporter-1 (GlyT1) inhibitors with memory enhancing properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6018</span>– <span class="NLM_lpage">6033</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00372</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00372" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6018-6033&author=V.+J.+Santoraauthor=T.+A.+Almosauthor=R.+Baridoauthor=J.+Basingerauthor=C.+L.+Bellowsauthor=B.+C.+Bookserauthor=J.+G.+Breitenbucherauthor=N.+J.+Broadbentauthor=C.+Cabebeauthor=C.+K.+Chaiauthor=M.+Chenauthor=S.+Chowauthor=M.+Chungauthor=L.+Crickardauthor=A.+M.+Danksauthor=G.+Freestoneauthor=D.+Gitnickauthor=V.+Guptaauthor=C.+Hoffmasterauthor=A.+R.+Hudsonauthor=A.+P.+Kaplanauthor=M.+R.+Kennedyauthor=D.+Leeauthor=J.+Limberisauthor=K.+Lyauthor=C.+C.+Makauthor=B.+Masatsuguauthor=A.+C.+Morseauthor=J.+Naauthor=D.+Neulauthor=J.+Nikpurauthor=M.+Petersauthor=R.+E.+Petroskiauthor=J.+Renickauthor=K.+Sebringauthor=S.+Sevidalauthor=A.+Tabatabaeiauthor=J.+Wenauthor=Y.+Yanauthor=Z.+W.+Yoderauthor=D.+Zook&title=Design+and+synthesis+of+novel+and+selective+glycine+transporter-1+%28GlyT1%29+inhibitors+with+memory+enhancing+properties&doi=10.1021%2Facs.jmedchem.8b00372"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00372%26sid%3Dliteratum%253Aachs%26aulast%3DSantora%26aufirst%3DV.%2BJ.%26aulast%3DAlmos%26aufirst%3DT.%2BA.%26aulast%3DBarido%26aufirst%3DR.%26aulast%3DBasinger%26aufirst%3DJ.%26aulast%3DBellows%26aufirst%3DC.%2BL.%26aulast%3DBookser%26aufirst%3DB.%2BC.%26aulast%3DBreitenbucher%26aufirst%3DJ.%2BG.%26aulast%3DBroadbent%26aufirst%3DN.%2BJ.%26aulast%3DCabebe%26aufirst%3DC.%26aulast%3DChai%26aufirst%3DC.%2BK.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DChow%26aufirst%3DS.%26aulast%3DChung%26aufirst%3DM.%26aulast%3DCrickard%26aufirst%3DL.%26aulast%3DDanks%26aufirst%3DA.%2BM.%26aulast%3DFreestone%26aufirst%3DG.%26aulast%3DGitnick%26aufirst%3DD.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DHoffmaster%26aufirst%3DC.%26aulast%3DHudson%26aufirst%3DA.%2BR.%26aulast%3DKaplan%26aufirst%3DA.%2BP.%26aulast%3DKennedy%26aufirst%3DM.%2BR.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DLimberis%26aufirst%3DJ.%26aulast%3DLy%26aufirst%3DK.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMasatsugu%26aufirst%3DB.%26aulast%3DMorse%26aufirst%3DA.%2BC.%26aulast%3DNa%26aufirst%3DJ.%26aulast%3DNeul%26aufirst%3DD.%26aulast%3DNikpur%26aufirst%3DJ.%26aulast%3DPeters%26aufirst%3DM.%26aulast%3DPetroski%26aufirst%3DR.%2BE.%26aulast%3DRenick%26aufirst%3DJ.%26aulast%3DSebring%26aufirst%3DK.%26aulast%3DSevidal%26aufirst%3DS.%26aulast%3DTabatabaei%26aufirst%3DA.%26aulast%3DWen%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DYoder%26aufirst%3DZ.%2BW.%26aulast%3DZook%26aufirst%3DD.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520and%2520selective%2520glycine%2520transporter-1%2520%2528GlyT1%2529%2520inhibitors%2520with%2520memory%2520enhancing%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6018%26epage%3D6033%26doi%3D10.1021%2Facs.jmedchem.8b00372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishihara, Y.</span>; <span class="NLM_string-name">Ishichi, Y.</span>; <span class="NLM_string-name">Doi, T.</span>; <span class="NLM_string-name">Nagabukuro, H.</span>; <span class="NLM_string-name">Kanzaki, N.</span>; <span class="NLM_string-name">Ikeuchi, M.</span></span> <span> </span><span class="NLM_article-title">Preventives/remedies for urinary disturbance</span>. <span class="NLM_year">2001</span>, European Patent <span class="NLM_patent">EP 1466625 A1</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=Y.+Ishihara&author=Y.+Ishichi&author=T.+Doi&author=H.+Nagabukuro&author=N.+Kanzaki&author=M.+Ikeuchi&title=Preventives%2Fremedies+for+urinary+disturbance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIshihara%26aufirst%3DY.%26atitle%3DPreventives%252Fremedies%2520for%2520urinary%2520disturbance%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccaro, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conder, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins-West, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span> <span> </span><span class="NLM_article-title">Dihydropyrazolopyrimidine inhibitors of K<sub>v</sub>1.5 (<i>I</i><sub>Kur</sub>)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">6381</span>– <span class="NLM_lpage">6385</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.10.099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1016%2Fj.bmcl.2008.10.099" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6381-6385&author=W.+Vaccaroauthor=T.+Huynhauthor=J.+Lloydauthor=K.+Atwalauthor=H.+J.+Finlayauthor=P.+Levesqueauthor=M.+L.+Conderauthor=T.+Jenkins-Westauthor=H.+Shiauthor=L.+Sun&title=Dihydropyrazolopyrimidine+inhibitors+of+Kv1.5+%28IKur%29&doi=10.1016%2Fj.bmcl.2008.10.099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.10.099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.10.099%26sid%3Dliteratum%253Aachs%26aulast%3DVaccaro%26aufirst%3DW.%26aulast%3DHuynh%26aufirst%3DT.%26aulast%3DLloyd%26aufirst%3DJ.%26aulast%3DAtwal%26aufirst%3DK.%26aulast%3DFinlay%26aufirst%3DH.%2BJ.%26aulast%3DLevesque%26aufirst%3DP.%26aulast%3DConder%26aufirst%3DM.%2BL.%26aulast%3DJenkins-West%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26atitle%3DDihydropyrazolopyrimidine%2520inhibitors%2520of%2520Kv1.5%2520%2528IKur%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6381%26epage%3D6385%26doi%3D10.1016%2Fj.bmcl.2008.10.099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit47b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Maiti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturdy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegan, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzuto, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushman, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1873</span>– <span class="NLM_lpage">1884</span>, <span class="refDoi"> DOI: 10.1021/jm801335z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801335z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisl2kur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1873-1884&author=A.+Maitiauthor=P.+V.+Reddyauthor=M.+Sturdyauthor=L.+Marlerauthor=S.+D.+Peganauthor=A.+D.+Mesecarauthor=J.+M.+Pezzutoauthor=M.+Cushman&title=Synthesis+of+casimiroin+and+optimization+of+its+quinone+reductase+2+and+aromatase+inhibitory+activities&doi=10.1021%2Fjm801335z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47bR"><div class="casContent"><span class="casTitleNuber">47b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Casimiroin and Optimization of Its Quinone Reductase 2 and Aromatase Inhibitory Activities</span></div><div class="casAuthors">Maiti, Arup; Reddy, P. V. Narasimha; Sturdy, Megan; Marler, Laura; Pegan, Scott D.; Mesecar, Andrew D.; Pezzuto, John M.; Cushman, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1873-1884</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient method has been developed to synthesize casimiroin (I), a component of the edible fruit of Casimiroa edulis, on a multigram scale in good overall yield.  The route was versatile enough to provide an array of I's analogs that were evaluated as QR2 and aromatase inhibitors.  In addn., X-ray crystallog. studies of QR2 in complex with I and one of its more potent analog II has provided insight into the mechanism of action of this new series of QR2 inhibitors.  The initial biol. investigations suggest that I and its analogs merit further investigation as potential chemopreventive or chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxfer9QooPoLVg90H21EOLACvtfcHk0lgs9xqJhYigwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisl2kur8%253D&md5=e1fdf097ef37bff1b3d167f9d834c427</span></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.1021%2Fjm801335z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801335z%26sid%3Dliteratum%253Aachs%26aulast%3DMaiti%26aufirst%3DA.%26aulast%3DReddy%26aufirst%3DP.%2BV.%26aulast%3DSturdy%26aufirst%3DM.%26aulast%3DMarler%26aufirst%3DL.%26aulast%3DPegan%26aufirst%3DS.%2BD.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26aulast%3DPezzuto%26aufirst%3DJ.%2BM.%26aulast%3DCushman%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520casimiroin%2520and%2520optimization%2520of%2520its%2520quinone%2520reductase%25202%2520and%2520aromatase%2520inhibitory%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1873%26epage%3D1884%26doi%3D10.1021%2Fjm801335z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alabaster, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddock, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuels, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefaniak, M. H.</span></span> <span> </span><span class="NLM_article-title">2(1H)-quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.1021/jm00123a011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00123a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1989&pages=575-583&author=C.+T.+Alabasterauthor=A.+S.+Bellauthor=S.+F.+Campbellauthor=P.+Ellisauthor=C.+G.+Hendersonauthor=D.+S.+Morrisauthor=D.+A.+Robertsauthor=K.+S.+Ruddockauthor=G.+M.+Samuelsauthor=M.+H.+Stefaniak&title=2%281H%29-quinolinones+with+cardiac+stimulant+activity.+2.+Synthesis+and+biological+activities+of+6-%28N-linked%2C+five-membered+heteroaryl%29+derivatives&doi=10.1021%2Fjm00123a011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm00123a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00123a011%26sid%3Dliteratum%253Aachs%26aulast%3DAlabaster%26aufirst%3DC.%2BT.%26aulast%3DBell%26aufirst%3DA.%2BS.%26aulast%3DCampbell%26aufirst%3DS.%2BF.%26aulast%3DEllis%26aufirst%3DP.%26aulast%3DHenderson%26aufirst%3DC.%2BG.%26aulast%3DMorris%26aufirst%3DD.%2BS.%26aulast%3DRoberts%26aufirst%3DD.%2BA.%26aulast%3DRuddock%26aufirst%3DK.%2BS.%26aulast%3DSamuels%26aufirst%3DG.%2BM.%26aulast%3DStefaniak%26aufirst%3DM.%2BH.%26atitle%3D2%25281H%2529-quinolinones%2520with%2520cardiac%2520stimulant%2520activity.%25202.%2520Synthesis%2520and%2520biological%2520activities%2520of%25206-%2528N-linked%252C%2520five-membered%2520heteroaryl%2529%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1989%26volume%3D32%26spage%3D575%26epage%3D583%26doi%3D10.1021%2Fjm00123a011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel σ<sub>1</sub> Receptor ligands for treating neuropathic pain: 6-hydroxypyridazinones</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2942</span>– <span class="NLM_lpage">2961</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01416</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01416" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2942-2961&author=X.+Caoauthor=Y.+Chenauthor=Y.+Zhangauthor=Y.+Lanauthor=J.+Zhangauthor=X.+Xuauthor=Y.+Qiuauthor=S.+Zhaoauthor=X.+Liuauthor=B.+F.+Liuauthor=G.+Zhang&title=Synthesis+and+biological+evaluation+of+novel+%CF%831+Receptor+ligands+for+treating+neuropathic+pain%3A+6-hydroxypyridazinones&doi=10.1021%2Facs.jmedchem.5b01416"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01416%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520%25CF%25831%2520Receptor%2520ligands%2520for%2520treating%2520neuropathic%2520pain%253A%25206-hydroxypyridazinones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2942%26epage%3D2961%26doi%3D10.1021%2Facs.jmedchem.5b01416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H.</span></span> <span> </span><span class="NLM_article-title">A rabbit model for evaluation of chlorpromazine-induced orthostatic hypotension</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1248/bpb.22.457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10.1248%2Fbpb.22.457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=10375164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;key=1%3ACAS%3A528%3ADyaK1MXjsFShtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1999&pages=457-462&author=Y.+Takataauthor=J.+Kuriharaauthor=S.+Suzukiauthor=Y.+Okuboauthor=H.+Kato&title=A+rabbit+model+for+evaluation+of+chlorpromazine-induced+orthostatic+hypotension&doi=10.1248%2Fbpb.22.457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A rabbit model for evaluation of chlorpromazine-induced orthostatic hypotension</span></div><div class="casAuthors">Takata, Yoshinobu; Kurihara, Junichi; Suzuki, Shigeto; Okubo, Yoko; Kato, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">457-462</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">The present study was conducted to develop an exptl. model for evaluation of chlorpromazine-induced orthostatic hypotension in rabbits.  In addn., the α-adrenoceptor blocking effect of chlorpromazine was investigated in isolated rabbit aorta and saphenous vein in comparison with prazosin.  Chlorpromazine (0.1 and 1 mg/kg, i.v.) potentiated significantly a decrease in mean blood pressure at 1 min after the onset of head-up tilt in rabbits anesthetized with urethane alone, urethane + α-chloralose or NO alone, but not in conscious and morphine + urethane + α-chloralose-anesthetized rabbits.  There was a neg. correlation (r = -0.986, p< 0.01) between the extent of chlorpromazine-induced orthostatic hypotension and the amplitude of tilt-induced reflex tachycardia before chlorpromazine treatment.  Both prazosin and pentolinium elicited orthostatic hypotension under all four anesthetic conditions.  The pA2 value for chlorpromazine to antagonize norepinephrine-induced contraction in aorta was significantly larger than that in saphenous vein, whereas prazosin blocked aortic and venous contractions to a similar extent.  These results suggest that a rabbit under an anesthesia which impairs tilt-induced reflex tachycardia may be useful for evaluation of orthostatic hypotension by chlorpromazine.  The relatively low potential of chlorpromazine to produce orthostatic hypotension may be partly due to its weak venodilating action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodayjeh8xWn7Vg90H21EOLACvtfcHk0lhCF5iDUkPrwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsFShtbg%253D&md5=f95e99f3f6c8e68db64dd2cbefec22a2</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1248%2Fbpb.22.457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.22.457%26sid%3Dliteratum%253Aachs%26aulast%3DTakata%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DOkubo%26aufirst%3DY.%26aulast%3DKato%26aufirst%3DH.%26atitle%3DA%2520rabbit%2520model%2520for%2520evaluation%2520of%2520chlorpromazine-induced%2520orthostatic%2520hypotension%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D1999%26volume%3D22%26spage%3D457%26epage%3D462%26doi%3D10.1248%2Fbpb.22.457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i118"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01096">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_37733"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01096">10.1021/acs.jmedchem.8b01096</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional receptors binding affinities of compound <b>47</b>; <sup>1</sup>H NMR, <sup>13</sup>C NMR, HRMS, and HPLC of compound <b>47</b>; <sup>13</sup>C NMR and HPLC of compound <b>44</b>, <b>50</b>, <b>53</b>, and <b>54</b>; LR-MS of the intermediates <b>3b</b>, <b>4b</b>, <b>5</b>, <b>6c</b>, and <b>7a</b>; D<sub>1</sub>, D<sub>2L</sub>, D<sub>3</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>6</sub> receptors functional activity of compound <b>47</b>; dose–response curve of hERG of compound <b>47</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01096/suppl_file/jm8b01096_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01096/suppl_file/jm8b01096_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01096/suppl_file/jm8b01096_si_001.csv">jm8b01096_si_001.csv (4.8 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01096/suppl_file/jm8b01096_si_002.pdf">jm8b01096_si_002.pdf (1.18 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01096&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-22%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01096%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01096" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994c7e4d093cbe","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
